CA2690557A1 - Imidazopyrazines as protein kinase inhibitors - Google Patents
Imidazopyrazines as protein kinase inhibitors Download PDFInfo
- Publication number
- CA2690557A1 CA2690557A1 CA2690557A CA2690557A CA2690557A1 CA 2690557 A1 CA2690557 A1 CA 2690557A1 CA 2690557 A CA2690557 A CA 2690557A CA 2690557 A CA2690557 A CA 2690557A CA 2690557 A1 CA2690557 A1 CA 2690557A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- heteroaryl
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000005235 imidazopyrazines Chemical class 0.000 title abstract description 8
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 7
- 239000003909 protein kinase inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 337
- 238000000034 method Methods 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 19
- 108060006633 protein kinase Proteins 0.000 claims abstract description 19
- 102000003989 Aurora kinases Human genes 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 108090000433 Aurora kinases Proteins 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 230000005764 inhibitory process Effects 0.000 claims abstract description 5
- -1 heterocyclenyl Chemical group 0.000 claims description 296
- 125000000217 alkyl group Chemical group 0.000 claims description 255
- 125000001072 heteroaryl group Chemical group 0.000 claims description 133
- 125000000623 heterocyclic group Chemical group 0.000 claims description 124
- 125000003118 aryl group Chemical group 0.000 claims description 122
- 150000003839 salts Chemical class 0.000 claims description 108
- 239000012453 solvate Substances 0.000 claims description 95
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 94
- 150000002148 esters Chemical class 0.000 claims description 92
- 125000004122 cyclic group Chemical group 0.000 claims description 84
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 80
- 229940002612 prodrug Drugs 0.000 claims description 63
- 239000000651 prodrug Substances 0.000 claims description 63
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 61
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 57
- 125000003342 alkenyl group Chemical group 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- 125000001475 halogen functional group Chemical group 0.000 claims description 38
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 125000000304 alkynyl group Chemical group 0.000 claims description 29
- 108091000080 Phosphotransferase Proteins 0.000 claims description 26
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 26
- 102000020233 phosphotransferase Human genes 0.000 claims description 26
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 25
- 150000001408 amides Chemical class 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 21
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 21
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 108091007914 CDKs Proteins 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 17
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 10
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 10
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 claims description 9
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 125000006682 monohaloalkyl group Chemical group 0.000 claims description 8
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 8
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 7
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 7
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 7
- 150000003230 pyrimidines Chemical group 0.000 claims description 7
- 229930192474 thiophene Chemical group 0.000 claims description 7
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 229960000473 altretamine Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960002258 fulvestrant Drugs 0.000 claims description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 6
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 6
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 6
- 229960001101 ifosfamide Drugs 0.000 claims description 6
- 229960003881 letrozole Drugs 0.000 claims description 6
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 6
- 229960001924 melphalan Drugs 0.000 claims description 6
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- 229960004641 rituximab Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 claims description 5
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 5
- 229940120638 avastin Drugs 0.000 claims description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims description 3
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 3
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 3
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- 229960001220 amsacrine Drugs 0.000 claims description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002932 anastrozole Drugs 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229940112129 campath Drugs 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002559 chlorotrianisene Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 3
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 3
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 claims description 3
- 229950004683 drostanolone propionate Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 3
- 229940082789 erbitux Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001842 estramustine Drugs 0.000 claims description 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960000961 floxuridine Drugs 0.000 claims description 3
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims description 3
- 229960001751 fluoxymesterone Drugs 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 229940080856 gleevec Drugs 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- 229940022353 herceptin Drugs 0.000 claims description 3
- 229960002899 hydroxyprogesterone Drugs 0.000 claims description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 229940084651 iressa Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 229960001614 levamisole Drugs 0.000 claims description 3
- 229960002247 lomustine Drugs 0.000 claims description 3
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 3
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
- 229960004296 megestrol acetate Drugs 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 229960001566 methyltestosterone Drugs 0.000 claims description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 229960000350 mitotane Drugs 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims description 3
- 229960000952 pipobroman Drugs 0.000 claims description 3
- 229960003171 plicamycin Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960001052 streptozocin Drugs 0.000 claims description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229940120982 tarceva Drugs 0.000 claims description 3
- 229940063683 taxotere Drugs 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 3
- 229960005353 testolactone Drugs 0.000 claims description 3
- 229960003604 testosterone Drugs 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 3
- 229960005026 toremifene Drugs 0.000 claims description 3
- 229960005267 tositumomab Drugs 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 claims description 3
- 229950001353 tretamine Drugs 0.000 claims description 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 3
- 229960005294 triamcinolone Drugs 0.000 claims description 3
- 229940086984 trisenox Drugs 0.000 claims description 3
- 229960001055 uracil mustard Drugs 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 229940099039 velcade Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- 229940053867 xeloda Drugs 0.000 claims description 3
- WHMXDBPHBVLYRC-OFVILXPXSA-N 3-chloro-n-[(2s)-1-[[2-(dimethylamino)acetyl]amino]-3-[4-[8-[(1s)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C(=O)N[C@H](CNC(=O)CN(C)C)CC1=CC=C(C=2N=C3C([C@H](C)O)=CC=CN3C=2)C=C1 WHMXDBPHBVLYRC-OFVILXPXSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 102100028845 Biogenesis of lysosome-related organelles complex 1 subunit 2 Human genes 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101150050673 CHK1 gene Proteins 0.000 claims description 2
- 102100025832 Centromere-associated protein E Human genes 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 2
- 101000935458 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 2 Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102000042838 JAK family Human genes 0.000 claims description 2
- 108091082332 JAK family Proteins 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- QJZRFPJCWMNVAV-HHHXNRCGSA-N N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methylbenzamide Chemical compound NCCCN([C@H](C(C)C)C=1N(C(=O)C2=CC=C(Cl)C=C2N=1)CC=1C=CC=CC=1)C(=O)C1=CC=C(C)C=C1 QJZRFPJCWMNVAV-HHHXNRCGSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 102000001332 SRC Human genes 0.000 claims description 2
- 108060006706 SRC Proteins 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000005124 aminocycloalkyl group Chemical group 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 108010031379 centromere protein E Proteins 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 230000002548 cytokinetic effect Effects 0.000 claims description 2
- 229940115080 doxil Drugs 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229950007344 ispinesib Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229940068117 sprycel Drugs 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229940034785 sutent Drugs 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229940094060 tykerb Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- XPYQFIISZQCINN-QVXDJYSKSA-N 4-amino-1-[(2r,3e,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrate Chemical compound O.O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 XPYQFIISZQCINN-QVXDJYSKSA-N 0.000 claims 2
- OLCWFLWEHWLBTO-HSZRJFAPSA-N BMS-214662 Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 claims 2
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 claims 2
- 229940120655 eloxatin Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960005526 triapine Drugs 0.000 claims 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 claims 1
- 101150115851 Tff2 gene Proteins 0.000 claims 1
- MSLJYSGFUMYUDX-UHFFFAOYSA-N Trimidox Chemical compound ON=C(N)C1=CC(O)=C(O)C(O)=C1 MSLJYSGFUMYUDX-UHFFFAOYSA-N 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229950006410 tezacitabine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- 239000000243 solution Substances 0.000 description 129
- 238000006243 chemical reaction Methods 0.000 description 125
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 116
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 116
- 239000000203 mixture Substances 0.000 description 109
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- 229910052757 nitrogen Inorganic materials 0.000 description 91
- 239000007787 solid Substances 0.000 description 72
- 235000019439 ethyl acetate Nutrition 0.000 description 68
- 238000005481 NMR spectroscopy Methods 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 60
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- 229910052938 sodium sulfate Inorganic materials 0.000 description 52
- 235000011152 sodium sulphate Nutrition 0.000 description 52
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 49
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- 238000000746 purification Methods 0.000 description 42
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 41
- 239000012044 organic layer Substances 0.000 description 40
- 239000012267 brine Substances 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 37
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 33
- 230000002829 reductive effect Effects 0.000 description 33
- 229920006395 saturated elastomer Polymers 0.000 description 33
- 239000007832 Na2SO4 Substances 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 125000004093 cyano group Chemical group *C#N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 239000012043 crude product Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 20
- 229910000104 sodium hydride Inorganic materials 0.000 description 20
- 229910052717 sulfur Inorganic materials 0.000 description 20
- 150000001412 amines Chemical class 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 150000002431 hydrogen Chemical class 0.000 description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 229910052740 iodine Inorganic materials 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000006413 ring segment Chemical group 0.000 description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 125000002757 morpholinyl group Chemical group 0.000 description 13
- 125000004193 piperazinyl group Chemical group 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 13
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 12
- 229910052681 coesite Inorganic materials 0.000 description 12
- 229910052906 cristobalite Inorganic materials 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000012279 sodium borohydride Substances 0.000 description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 description 12
- 229910052682 stishovite Inorganic materials 0.000 description 12
- 229910052905 tridymite Inorganic materials 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 10
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 150000003457 sulfones Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091008794 FGF receptors Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000005038 alkynylalkyl group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000005441 aurora Substances 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000006369 cell cycle progression Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- PXRKEAMNOWAPFZ-UHFFFAOYSA-N 2-[[4-(6-bromo-8-methylsulfonylimidazo[1,2-a]pyrazin-3-yl)pyrazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C1=NN(COCC[Si](C)(C)C)C=C1C1=CN=C2N1C=C(Br)N=C2S(C)(=O)=O PXRKEAMNOWAPFZ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101150006084 CHKB gene Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 241000534944 Thia Species 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 150000005236 imidazo[1,2-a]pyrazines Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- WXRTUDXQAJRAJL-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-1,3-thiazol-5-amine Chemical compound S1C(N)=CN=C1CN1CCOCC1 WXRTUDXQAJRAJL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical class CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 2
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 2
- 230000012746 DNA damage checkpoint Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 102100030011 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 2
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 2
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 2
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 2
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 2
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100028651 Tenascin-N Human genes 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 239000003719 aurora kinase inhibitor Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 108091071773 flk family Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- ABZADCFISYAIKF-UHFFFAOYSA-N n-[6-methyl-3-[1-(2-trimethylsilylethoxymethyl)pyrazol-4-yl]imidazo[1,2-a]pyrazin-8-yl]-3-(pyrrolidin-1-ylmethyl)-1,2-thiazol-5-amine Chemical compound N=1C(C)=CN2C(C3=CN(COCC[Si](C)(C)C)N=C3)=CN=C2C=1NC(SN=1)=CC=1CN1CCCC1 ABZADCFISYAIKF-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000002923 oximes Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- TZGODTCAKVHMFG-UHFFFAOYSA-N sulfanylmethoxymethanethiol Chemical compound SCOCS TZGODTCAKVHMFG-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DXTQRJCFSNCPMD-UHFFFAOYSA-N tert-butyl n-(2-bromo-1,3-thiazol-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(Br)S1 DXTQRJCFSNCPMD-UHFFFAOYSA-N 0.000 description 2
- ZMEFZKPZWCCIFC-UHFFFAOYSA-N tert-butyl n-(2-ethenyl-1,3-thiazol-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(C=C)S1 ZMEFZKPZWCCIFC-UHFFFAOYSA-N 0.000 description 2
- KWXOOGNVKPJYBG-UHFFFAOYSA-N tert-butyl n-[2-(morpholin-4-ylmethyl)-1,3-thiazol-5-yl]carbamate Chemical compound S1C(NC(=O)OC(C)(C)C)=CN=C1CN1CCOCC1 KWXOOGNVKPJYBG-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000005845 (C2-C12)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- GGMQZPIDPNAGFP-UHFFFAOYSA-N 1,1-dibromo-1,2,2,2-tetrachloroethane Chemical class ClC(Cl)(Cl)C(Cl)(Br)Br GGMQZPIDPNAGFP-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- IYCKMNAVTMOAKD-UHFFFAOYSA-N 1,2-thiazol-3-amine Chemical compound NC=1C=CSN=1 IYCKMNAVTMOAKD-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- CSSRPHVEMPFHEN-UHFFFAOYSA-N 1-[[(4,6-dimethylpyrimidin-2-yl)amino]-piperidin-1-ylmethylidene]-3-phenylthiourea Chemical compound CC1=CC(C)=NC(NC(=NC(=S)NC=2C=CC=CC=2)N2CCCCC2)=N1 CSSRPHVEMPFHEN-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- YTRAWJPYNVGDGP-UHFFFAOYSA-N 2-(6-methyl-8-methylsulfonylimidazo[1,2-a]pyrazin-3-yl)-1,3-thiazole Chemical compound C=1N=C2C(S(C)(=O)=O)=NC(C)=CN2C=1C1=NC=CS1 YTRAWJPYNVGDGP-UHFFFAOYSA-N 0.000 description 1
- BESGTWHUMYHYEQ-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=C(Br)S1 BESGTWHUMYHYEQ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XXXOBNJIIZQSPT-UHFFFAOYSA-N 2-methyl-4-nitrobenzoic acid Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C(O)=O XXXOBNJIIZQSPT-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
- NBYIALQCACHGPF-UHFFFAOYSA-N 3-(azidomethyl)-n-[6-methyl-3-[1-(2-trimethylsilylethoxymethyl)pyrazol-4-yl]imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N=1C(C)=CN2C(C3=CN(COCC[Si](C)(C)C)N=C3)=CN=C2C=1NC1=CC(CN=[N+]=[N-])=NS1 NBYIALQCACHGPF-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- VLKKMLRPWBSMSG-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-n-[6-methyl-3-[1-(2-trimethylsilylethoxymethyl)pyrazol-4-yl]imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound S1N=C(CN(C)C)C=C1NC1=NC(C)=CN2C1=NC=C2C1=CN(COCC[Si](C)(C)C)N=C1 VLKKMLRPWBSMSG-UHFFFAOYSA-N 0.000 description 1
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical compound Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WNYFVEFUHMDIRQ-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCOCC1 WNYFVEFUHMDIRQ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SJDHQBPIYARAPS-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]thiophene-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C(O)=O)S1 SJDHQBPIYARAPS-UHFFFAOYSA-N 0.000 description 1
- VNJUNWUOAKEIKG-UHFFFAOYSA-N 5-nitrothiophene-3-carboxylic acid Chemical compound OC(=O)C1=CSC([N+]([O-])=O)=C1 VNJUNWUOAKEIKG-UHFFFAOYSA-N 0.000 description 1
- DQAGMDUVKQKYRR-UHFFFAOYSA-N 6-methyl-8-methylsulfonyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazine Chemical compound C=1N=C2C(S(C)(=O)=O)=NC(C)=CN2C=1C=1C=NNC=1 DQAGMDUVKQKYRR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XUOBFFPGZFFAIT-UHFFFAOYSA-N 8-azaspiro[4.5]dec-2-ene Chemical compound C1C=CCC11CCNCC1 XUOBFFPGZFFAIT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 101100490184 Drosophila melanogaster Ack gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102100026379 Neurofibromin Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100042258 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sem-1 gene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710087911 Tenascin-N Proteins 0.000 description 1
- 102100030141 Testis-specific serine/threonine-protein kinase 6 Human genes 0.000 description 1
- 101710116860 Testis-specific serine/threonine-protein kinase 6 Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 101150006213 ackA gene Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 150000001503 aryl iodides Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- BRTALTYTFFNPAC-UHFFFAOYSA-N boroxin Chemical compound B1OBOBO1 BRTALTYTFFNPAC-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- DKWNQFONVOHKSU-UHFFFAOYSA-N ethyl 3-(chloromethyl)-4-cyanobut-3-enoate Chemical compound CCOC(=O)CC(CCl)=CC#N DKWNQFONVOHKSU-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- OIQQZGUOQIDZAC-UHFFFAOYSA-N ethyl 5-amino-3-(morpholin-4-ylmethyl)thiophene-2-carboxylate Chemical compound S1C(N)=CC(CN2CCOCC2)=C1C(=O)OCC OIQQZGUOQIDZAC-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- GWUSNYRBRMGJEV-IHWYPQMZSA-N methyl (2z)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)acetate Chemical compound COC(=O)\C=C1/SC(=O)NC1=O GWUSNYRBRMGJEV-IHWYPQMZSA-N 0.000 description 1
- NRTWXBXJSGGTTE-UHFFFAOYSA-N methyl 4-amino-2-methylbenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1C NRTWXBXJSGGTTE-UHFFFAOYSA-N 0.000 description 1
- QSKZNCJAOORQCA-UHFFFAOYSA-N methyl 5-[[6-methyl-3-[1-(2-trimethylsilylethoxymethyl)pyrazol-4-yl]imidazo[1,2-a]pyrazin-8-yl]amino]-1,2-thiazole-3-carboxylate Chemical compound S1N=C(C(=O)OC)C=C1NC1=NC(C)=CN2C1=NC=C2C1=CN(COCC[Si](C)(C)C)N=C1 QSKZNCJAOORQCA-UHFFFAOYSA-N 0.000 description 1
- YRGYIZCDBMJMGM-UHFFFAOYSA-N methyl 5-amino-1,2-thiazole-3-carboxylate Chemical compound COC(=O)C=1C=C(N)SN=1 YRGYIZCDBMJMGM-UHFFFAOYSA-N 0.000 description 1
- GFERXXPZQYBEBF-UHFFFAOYSA-N methyl 5-aminothiophene-3-carboxylate Chemical compound COC(=O)C1=CSC(N)=C1 GFERXXPZQYBEBF-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PCZLPJBOJQBSGK-UHFFFAOYSA-N n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-2-(morpholin-4-ylmethyl)-1,3-thiazol-5-amine Chemical compound N=1C(C)=CN2C(C3=CNN=C3)=CN=C2C=1NC(S1)=CN=C1CN1CCOCC1 PCZLPJBOJQBSGK-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- YILVGKATEXTLMW-UHFFFAOYSA-N spiro[4.4]nona-2,7-diene Chemical compound C1C=CCC11CC=CC1 YILVGKATEXTLMW-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- GOAYIIHFCXVBQW-UHFFFAOYSA-N tert-butyl n-(2-formyl-1,3-thiazol-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(C=O)S1 GOAYIIHFCXVBQW-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- YCGAZNXXGKTASZ-UHFFFAOYSA-N thiophene-2,5-dicarboxylic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)S1 YCGAZNXXGKTASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- GFDGUBWLQCCAFT-UHFFFAOYSA-N trimethyl-[2-[[4-(6-methyl-8-methylsulfonylimidazo[1,2-a]pyrazin-3-yl)pyrazol-1-yl]methoxy]ethyl]silane Chemical compound C=1N=C2C(S(C)(=O)=O)=NC(C)=CN2C=1C=1C=NN(COCC[Si](C)(C)C)C=1 GFDGUBWLQCCAFT-UHFFFAOYSA-N 0.000 description 1
- ZSZKZHGOGZUANO-UHFFFAOYSA-N trimethyl-[2-[[4-(8-methylsulfonylimidazo[1,2-a]pyrazin-3-yl)pyrazol-1-yl]methoxy]ethyl]silane Chemical compound C1=NN(COCC[Si](C)(C)C)C=C1C1=CN=C2N1C=CN=C2S(C)(=O)=O ZSZKZHGOGZUANO-UHFFFAOYSA-N 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
Description
IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
Field of the Invention The present invention relates to imidazo[1,2-a]pyrazine compounds useful as protein kinase inhibitors, regulators or modulators, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases. The present compounds are especially useful as Aurora kinase inhibitors.
Background of the Invention Protein kinases are a family of enzymes that catalyze phosphorylation of proteins, in particular the hydroxyl group of specific tyrosine, serine, or threonine residues in proteins. Protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolism, cell proliferation, cell differentiation, and cell survival. Uncontrolled proliferation is a hallmark of cancer cells, and can be manifested by a deregulation of the cell division cycle in one of two ways -making stimulatory genes hyperactive or inhibitory genes inactive. Protein kinase inhibitors, regulators or modulators alter the function of kinases such as cyclin-dependent kinases (CDKs), mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), Checkpoint (Chk) (e.g., CHK-1, CHK-2 etc.) kinases, AKT
kinases, JNK, and the like. Examples of protein kinase inhibitors are described in W002/22610 Al and by Y. Mettey et al in J. Med. Chem., (2003) 46 222-236.
The cyclin-dependent kinases are serine/threonine protein kinases, which are the driving force behind the cell cycle and cell proliferation. Misregulation of CDK
function ocdurs with high frequency in many important solid tumors. Individual CDK's, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either Gl, S, or G2M phase enzymes. CDK2 and CDK4 are of particular interest because their activities are frequently misregulated in a wide variety of human cancers.
Field of the Invention The present invention relates to imidazo[1,2-a]pyrazine compounds useful as protein kinase inhibitors, regulators or modulators, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases. The present compounds are especially useful as Aurora kinase inhibitors.
Background of the Invention Protein kinases are a family of enzymes that catalyze phosphorylation of proteins, in particular the hydroxyl group of specific tyrosine, serine, or threonine residues in proteins. Protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolism, cell proliferation, cell differentiation, and cell survival. Uncontrolled proliferation is a hallmark of cancer cells, and can be manifested by a deregulation of the cell division cycle in one of two ways -making stimulatory genes hyperactive or inhibitory genes inactive. Protein kinase inhibitors, regulators or modulators alter the function of kinases such as cyclin-dependent kinases (CDKs), mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), Checkpoint (Chk) (e.g., CHK-1, CHK-2 etc.) kinases, AKT
kinases, JNK, and the like. Examples of protein kinase inhibitors are described in W002/22610 Al and by Y. Mettey et al in J. Med. Chem., (2003) 46 222-236.
The cyclin-dependent kinases are serine/threonine protein kinases, which are the driving force behind the cell cycle and cell proliferation. Misregulation of CDK
function ocdurs with high frequency in many important solid tumors. Individual CDK's, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8 and the like, perform distinct roles in cell cycle progression and can be classified as either Gl, S, or G2M phase enzymes. CDK2 and CDK4 are of particular interest because their activities are frequently misregulated in a wide variety of human cancers.
activity is required for progression through G1 to the S phase of the cell cycle, and CDK2 is one of the key components of the G1 checkpoint. Checkpoints serve to maintain the proper sequence of cell cycle events and allow the cell to respond to insults or to proliferative signals, while the loss of proper checkpoint control in cancer cells contributes to tumorgenesis. The CDK2 pathway influences tumorgenesis at the level of tumor suppressor function (e.g. p52, RB, and p27) and oncogene activation (cyclin E). Many reports have demonstrated that both the coactivator, cyclin E, and the inhibitor, p27, of CDK2 are either over- or underexpressed, respectively, in breast, colon, nonsmall cell lung, gastric, prostate, bladder, non-Hodgkin's lymphoma, ovarian, and other cancers. Their altered expression has been shown to correlate with increased CDK2 activity levels and poor overall survival. This observation makes CDK2 and its regulatory pathways compelling targets for the development of cancer treatments.
A number of adenosine 5'-triphosphate (ATP) competitive small organic molecules as well as peptides have been reported in the literature as CDK
inhibitors for the potential treatment of cancers. U.S. 6,413,974, col. 1, line 23- col.
15, line 10 offers a good description of the various CDKs and their relationship to various types of cancer. Flavopiridol (shown below) is a nonselective CDK inhibitor that is currently undergoing human clinical trials, A. M. Senderowicz et al, J. Clin. Onco/.
(1998) 16, 2986-2999.
N
HO~~~``, HO O
I \ I
cl Other known inhibitors of CDKs include, for example, olomoucine (J. Vesely et al, Eur. J. Biochem., (1994) 224, 771-786) and roscovitine (I. Meijer et al, Eur. J.
Biochem., (1997) 243, 527-536). U.S. 6,107,305 describes certain pyrazolo[3,4-b]
A number of adenosine 5'-triphosphate (ATP) competitive small organic molecules as well as peptides have been reported in the literature as CDK
inhibitors for the potential treatment of cancers. U.S. 6,413,974, col. 1, line 23- col.
15, line 10 offers a good description of the various CDKs and their relationship to various types of cancer. Flavopiridol (shown below) is a nonselective CDK inhibitor that is currently undergoing human clinical trials, A. M. Senderowicz et al, J. Clin. Onco/.
(1998) 16, 2986-2999.
N
HO~~~``, HO O
I \ I
cl Other known inhibitors of CDKs include, for example, olomoucine (J. Vesely et al, Eur. J. Biochem., (1994) 224, 771-786) and roscovitine (I. Meijer et al, Eur. J.
Biochem., (1997) 243, 527-536). U.S. 6,107,305 describes certain pyrazolo[3,4-b]
pyridine compounds as CDK inhibitors. An illustrative compound from the '305 patent is:
I \
/
"
N N
H
K. S. Kim et al, J. Med. Chem. 45 (2002) 3905-3927 and WO 02/10162 disclose certain aminothiazole compounds as CDK inhibitors.
Imidazopyrazines are known. For example, U.S. 6,919,341 (the disclosure of which is incorporated herein by reference) and US2005/0009832 disclose various imidazopyrazines. Also being mentioned are the following: W02005/047290;
US2005/095616; W02005/039393; W02005/019220; W02004/072081;
W02005/014599; W02005/009354; W02005/005429; W02005/085252;
US2005/009832; US2004/220189; W02004/074289; W02004/026877;
W02004/02631 0; W02004/022562; W02003/089434; W02003/084959;
W02003/051346; US2003/022898; W02002/060492; W02002/060386;
W02002/028860; JP (1986)61-057587; J. Burke et al., J. Biological Chem., Vol.
278(3), 1450-1456 (2003); and F. Bondavalli et al, J. Med. Chem., Vol. 45 (22), 4875-4887 (2002).
Also made reference to are US 2004/0220189 (published November 4, 2004);
US 2005/0009832 (published January 13, 2005); US 2006/0084650 (published April 20, 2006) which describe kinase inhibitors, and US 2006/0106023 (published May 18, 2006) which describe imidazopyrazines as cyclin dependent kinase inhibitors. In addition, US 2007/0117804 (published May 24, 2007), describes imidazopyrazines as protein kinase inhibitors of the following structure:
A compound of the Formula:
I \
/
"
N N
H
K. S. Kim et al, J. Med. Chem. 45 (2002) 3905-3927 and WO 02/10162 disclose certain aminothiazole compounds as CDK inhibitors.
Imidazopyrazines are known. For example, U.S. 6,919,341 (the disclosure of which is incorporated herein by reference) and US2005/0009832 disclose various imidazopyrazines. Also being mentioned are the following: W02005/047290;
US2005/095616; W02005/039393; W02005/019220; W02004/072081;
W02005/014599; W02005/009354; W02005/005429; W02005/085252;
US2005/009832; US2004/220189; W02004/074289; W02004/026877;
W02004/02631 0; W02004/022562; W02003/089434; W02003/084959;
W02003/051346; US2003/022898; W02002/060492; W02002/060386;
W02002/028860; JP (1986)61-057587; J. Burke et al., J. Biological Chem., Vol.
278(3), 1450-1456 (2003); and F. Bondavalli et al, J. Med. Chem., Vol. 45 (22), 4875-4887 (2002).
Also made reference to are US 2004/0220189 (published November 4, 2004);
US 2005/0009832 (published January 13, 2005); US 2006/0084650 (published April 20, 2006) which describe kinase inhibitors, and US 2006/0106023 (published May 18, 2006) which describe imidazopyrazines as cyclin dependent kinase inhibitors. In addition, US 2007/0117804 (published May 24, 2007), describes imidazopyrazines as protein kinase inhibitors of the following structure:
A compound of the Formula:
R' R2 R
1\~
NY`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, -C(O)NR5R6, -N(R5)C(O)R6, heterocyclyl, heteroaryl substituted with (CH2)1_3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6;
R' is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CH2OR5, -C(O)NR5R6, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5 and -OR5;
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein:
- said alkyl shown above for R3 can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, alkoxy, heteroaryl, and -NR5R6;
- said aryl shown above for R3 is unsubstituted, or optionally substituted, or optionally fused, with halo, heteroaryl, heterocyclyl, cycloalkyl or 5 heteroarylalkyl, wherein each of said heteroaryl, heterocyclyl, cycloalkyl and heteroarylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different each moiety being independently selected from alkyl, -OR5, -N(R5R6) and -S(O2)R5; and - said heteroaryl shown above for R3 can be unsubstituted or optionally substituted, or optionally fused, with one or more moieties which can be the same or different with each moiety being independently selected from the group consisting of halo, amino, alkoxycarbonyl, -OR5, alkyl, -CHO, - NR5R6, -S(02)N(R5R6), -C(O)N(R5R6), -SR5, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclenyl, and heterocyclyl;
R5 is H, alkyl, aminoalkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; and R6 is H, alkyl, aryl, arylalkyl, heteroaryl, heterocyclyl or cycloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring.
Another series of protein kinases are those that play an important role as a checkpoint in cell cycle progression. Checkpoints prevent cell cycle progression at inappropriate times, such as in response to DNA damage, and maintain the metabolic balance of cells while the cell is arrested, and in some instances can induce apoptosis (programmed cell death) when the requirements of the checkpoint have not been met.
Checkpoint control can occur in the G1 phase (prior to DNA synthesis) and in G2, prior to entry into mitosis.
One series of checkpoints monitors the integrity of the genome and, upon sensing DNA damage, these "DNA damage checkpoints" block cell cycle progression in G, & G2 phases, and slow progression through S phase. This action enables DNA
repair processes to complete their tasks before replication of the genome and subsequent separation of this genetic material into new daughter cells takes place.
Inactivation of CHK1 has been shown to transduce signals from the DNA-damage sensory complex to inhibit activation of the cyclin B/Cdc2 kinase, which promotes mitotic entry, and abrogate G2 arrest induced by DNA damage inflicted by anticancer agents or endogenous DNA damage, as well as result in preferential killing of the resulting checkpoint defective cells. See, e.g., Peng et al., Science, 277, 1501-1505 (1997); Sanchez et al., Science, 277, 1497-1501 (1997), Nurse, Cell, 91, 867 (1997); Weinert, Science, 277, 1450-1451 (1997); Walworth et al., Nature, 363, 368-371 (1993); and Al-Khodairy et al., Molec. Biol. Cell., 5, 147-160 (1994).
Selective manipulation of checkpoint control in cancer cells could afford broad utilization in cancer chemotherapeutic and radiotherapy regimens and may, in addition, offer a common hallmark of human cancer "genomic instability" to be exploited as the selective basis for the destruction of cancer cells. A number of factors place CHK1 as a pivotal target in DNA-damage checkpoint control. The elucidation of inhibitors of this and functionally related kinases such as CDS1/CHK2, a kinase recently discovered to cooperate with CHK1 in regulating S phase progression (see Zeng et al., Nature, 395, 507-510 (1998); Matsuoka, Science, 282, 1893-(1998)), could provide valuable new therapeutic entities for the treatment of cancer.
Another group of kinases are the tyrosine kinases. Tyrosine kinases can be of the receptor type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified. One tyrosine kinase subfamily, designated the HER subfamily, is comprised of EGFR (HER1), HER2, HER3 and HER4. Ligands of this subfamily of receptors identified so far include epithelial growth factor, TGF-alpha, amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR, IR, and IR-R.
The PDGF subfamily includes the PDGF-alpha and beta receptors, CSFIR, c-kit and FLK-II. The FLK family is comprised of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1). For detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., DN&P 7(6): 334-339, 1994.
At least one of the non-receptor protein tyrosine kinases, namely, LCK, is believed to mediate the transduction in T-cells of a signal from the interaction of a cell-surface protein (Cd4) with a cross-linked anti-Cd4 antibody. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, Oncogene, 8, 2031 (1993). The non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, AbI, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is further sub-divided into varying receptors. For example, the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. For a more detailed discussion of the non-receptor type of tyrosine kinases, see Bolen, Oncogene, 8:2025-2031 (1993).
In addition to its role in cell-cycle control, protein kinases also play a crucial role in angiogenesis, which is the mechanism by which new capillaries are formed from existing vessels. When required, the vascular system has the potential to generate new capillary networks in order to maintain the proper functioning of tissues and organs. In the adult, however, angiogenesis is fairly limited, occurring only in the process of wound healing and neovascularization of the endometrium during menstruation. On the other hand, unwanted angiogenesis is a hallmark of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, age-related macular degeneration, and cancer (solid tumors). Protein kinases which have been shown to be involved in the angiogenic process include three members of the growth factor receptor tyrosine kinase family; VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (kinase insert domain receptor) and as FLK 1); FGF-R
(fibroblast growth factor receptor); and TEK (also known as Tie-2).
VEGF-R2, which is expressed only on endothelial cells, binds the potent angiogenic growth factor VEGF and mediates the subsequent signal transduction through activation of its intracellular kinase activity. Thus, it is expected that direct inhibition of the kinase activity of VEGF-R2 will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al, Cancer Research, 56, 3540-3545 (1996)), as has been shown with mutants of VEGF-R2 which fail to mediate signal transduction. Millauer et al, Cancer Research, 56, 1615-1620 (1996).
Furthermore, VEGF-R2 appears to have no function in the adult beyond that of mediating the angiogenic activity of VEGF. Therefore, a selective inhibitor of the kinase activity of VEGF-R2 would be expected to exhibit little toxicity.
Similarly, FGFR binds the angiogenic growth factors aFGF and bFGF and mediates subsequent intracellular signal transduction. Recently, it has been suggested that growth factors such as bFGF may play a critical role in inducing angiogenesis in solid tumors that have reached a certain size. Yoshiji et al., Cancer Research, 57, 3924-3928 (1997). Unlike VEGF-R2, however, FGF-R is expressed in a number of different cell types throughout the body and may or may not play important roles in other normal physiological processes in the adult.
Nonetheless, systemic administration of a small molecule inhibitor of the kinase activity of FGF-R
has been reported to block bFGF-induced angiogenesis in mice without apparent toxicity. Mohammad et al., EMBO Journal, 17, 5996-5904 (1998).
TEK (also known as Tie-2) is another receptor tyrosine kinase expressed only on endothelial cells which has been shown to play a role in angiogenesis. The binding of the factor angiopoietin-1 results in autophosphorylation of the kinase domain of TEK and results in a signal transduction process which appears to mediate the interaction of endothelial cells with peri-endothelial support cells, thereby facilitating the maturation of newly formed blood vessels. The factor angiopoietin-2, on the other hand, appears to antagonize the action of angiopoietin-1 on TEK and disrupts angiogenesis. Maisonpierre et al., Science, 277, 55-60 (1997).
The kinase, JNK, belongs to the mitogen-activated protein kinase (MAPK) superfamily. JNK plays a crucial role in inflammatory responses, stress responses, cell proliferation, apoptosis, and tumorigenesis. JNK kinase activity can be activated by various stimuli, including the proinflammatory cytokines (TNF-alpha and interleukin-1), lymphocyte costimulatory receptors (CD28 and CD40), DNA-damaging chemicals, radiation, and Fas signaling. Results from the JNK knockout mice indicate that JNK is involved in apoptosis induction and T helper cell differentiation.
Pim-1 is a small serine/threonine kinase. Elevated expression levels of Pim-1 have been detected in lymphoid and myeloid malignancies, and recently Pim-1 was identified as a prognostic marker in prostate cancer. K. Peltola, "Signaling in Cancer:
1\~
NY`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, -C(O)NR5R6, -N(R5)C(O)R6, heterocyclyl, heteroaryl substituted with (CH2)1_3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6;
R' is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CH2OR5, -C(O)NR5R6, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5 and -OR5;
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is H, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein:
- said alkyl shown above for R3 can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, alkoxy, heteroaryl, and -NR5R6;
- said aryl shown above for R3 is unsubstituted, or optionally substituted, or optionally fused, with halo, heteroaryl, heterocyclyl, cycloalkyl or 5 heteroarylalkyl, wherein each of said heteroaryl, heterocyclyl, cycloalkyl and heteroarylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different each moiety being independently selected from alkyl, -OR5, -N(R5R6) and -S(O2)R5; and - said heteroaryl shown above for R3 can be unsubstituted or optionally substituted, or optionally fused, with one or more moieties which can be the same or different with each moiety being independently selected from the group consisting of halo, amino, alkoxycarbonyl, -OR5, alkyl, -CHO, - NR5R6, -S(02)N(R5R6), -C(O)N(R5R6), -SR5, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclenyl, and heterocyclyl;
R5 is H, alkyl, aminoalkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; and R6 is H, alkyl, aryl, arylalkyl, heteroaryl, heterocyclyl or cycloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring.
Another series of protein kinases are those that play an important role as a checkpoint in cell cycle progression. Checkpoints prevent cell cycle progression at inappropriate times, such as in response to DNA damage, and maintain the metabolic balance of cells while the cell is arrested, and in some instances can induce apoptosis (programmed cell death) when the requirements of the checkpoint have not been met.
Checkpoint control can occur in the G1 phase (prior to DNA synthesis) and in G2, prior to entry into mitosis.
One series of checkpoints monitors the integrity of the genome and, upon sensing DNA damage, these "DNA damage checkpoints" block cell cycle progression in G, & G2 phases, and slow progression through S phase. This action enables DNA
repair processes to complete their tasks before replication of the genome and subsequent separation of this genetic material into new daughter cells takes place.
Inactivation of CHK1 has been shown to transduce signals from the DNA-damage sensory complex to inhibit activation of the cyclin B/Cdc2 kinase, which promotes mitotic entry, and abrogate G2 arrest induced by DNA damage inflicted by anticancer agents or endogenous DNA damage, as well as result in preferential killing of the resulting checkpoint defective cells. See, e.g., Peng et al., Science, 277, 1501-1505 (1997); Sanchez et al., Science, 277, 1497-1501 (1997), Nurse, Cell, 91, 867 (1997); Weinert, Science, 277, 1450-1451 (1997); Walworth et al., Nature, 363, 368-371 (1993); and Al-Khodairy et al., Molec. Biol. Cell., 5, 147-160 (1994).
Selective manipulation of checkpoint control in cancer cells could afford broad utilization in cancer chemotherapeutic and radiotherapy regimens and may, in addition, offer a common hallmark of human cancer "genomic instability" to be exploited as the selective basis for the destruction of cancer cells. A number of factors place CHK1 as a pivotal target in DNA-damage checkpoint control. The elucidation of inhibitors of this and functionally related kinases such as CDS1/CHK2, a kinase recently discovered to cooperate with CHK1 in regulating S phase progression (see Zeng et al., Nature, 395, 507-510 (1998); Matsuoka, Science, 282, 1893-(1998)), could provide valuable new therapeutic entities for the treatment of cancer.
Another group of kinases are the tyrosine kinases. Tyrosine kinases can be of the receptor type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified. One tyrosine kinase subfamily, designated the HER subfamily, is comprised of EGFR (HER1), HER2, HER3 and HER4. Ligands of this subfamily of receptors identified so far include epithelial growth factor, TGF-alpha, amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR, IR, and IR-R.
The PDGF subfamily includes the PDGF-alpha and beta receptors, CSFIR, c-kit and FLK-II. The FLK family is comprised of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1). For detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., DN&P 7(6): 334-339, 1994.
At least one of the non-receptor protein tyrosine kinases, namely, LCK, is believed to mediate the transduction in T-cells of a signal from the interaction of a cell-surface protein (Cd4) with a cross-linked anti-Cd4 antibody. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, Oncogene, 8, 2031 (1993). The non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, AbI, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is further sub-divided into varying receptors. For example, the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. For a more detailed discussion of the non-receptor type of tyrosine kinases, see Bolen, Oncogene, 8:2025-2031 (1993).
In addition to its role in cell-cycle control, protein kinases also play a crucial role in angiogenesis, which is the mechanism by which new capillaries are formed from existing vessels. When required, the vascular system has the potential to generate new capillary networks in order to maintain the proper functioning of tissues and organs. In the adult, however, angiogenesis is fairly limited, occurring only in the process of wound healing and neovascularization of the endometrium during menstruation. On the other hand, unwanted angiogenesis is a hallmark of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, age-related macular degeneration, and cancer (solid tumors). Protein kinases which have been shown to be involved in the angiogenic process include three members of the growth factor receptor tyrosine kinase family; VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (kinase insert domain receptor) and as FLK 1); FGF-R
(fibroblast growth factor receptor); and TEK (also known as Tie-2).
VEGF-R2, which is expressed only on endothelial cells, binds the potent angiogenic growth factor VEGF and mediates the subsequent signal transduction through activation of its intracellular kinase activity. Thus, it is expected that direct inhibition of the kinase activity of VEGF-R2 will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al, Cancer Research, 56, 3540-3545 (1996)), as has been shown with mutants of VEGF-R2 which fail to mediate signal transduction. Millauer et al, Cancer Research, 56, 1615-1620 (1996).
Furthermore, VEGF-R2 appears to have no function in the adult beyond that of mediating the angiogenic activity of VEGF. Therefore, a selective inhibitor of the kinase activity of VEGF-R2 would be expected to exhibit little toxicity.
Similarly, FGFR binds the angiogenic growth factors aFGF and bFGF and mediates subsequent intracellular signal transduction. Recently, it has been suggested that growth factors such as bFGF may play a critical role in inducing angiogenesis in solid tumors that have reached a certain size. Yoshiji et al., Cancer Research, 57, 3924-3928 (1997). Unlike VEGF-R2, however, FGF-R is expressed in a number of different cell types throughout the body and may or may not play important roles in other normal physiological processes in the adult.
Nonetheless, systemic administration of a small molecule inhibitor of the kinase activity of FGF-R
has been reported to block bFGF-induced angiogenesis in mice without apparent toxicity. Mohammad et al., EMBO Journal, 17, 5996-5904 (1998).
TEK (also known as Tie-2) is another receptor tyrosine kinase expressed only on endothelial cells which has been shown to play a role in angiogenesis. The binding of the factor angiopoietin-1 results in autophosphorylation of the kinase domain of TEK and results in a signal transduction process which appears to mediate the interaction of endothelial cells with peri-endothelial support cells, thereby facilitating the maturation of newly formed blood vessels. The factor angiopoietin-2, on the other hand, appears to antagonize the action of angiopoietin-1 on TEK and disrupts angiogenesis. Maisonpierre et al., Science, 277, 55-60 (1997).
The kinase, JNK, belongs to the mitogen-activated protein kinase (MAPK) superfamily. JNK plays a crucial role in inflammatory responses, stress responses, cell proliferation, apoptosis, and tumorigenesis. JNK kinase activity can be activated by various stimuli, including the proinflammatory cytokines (TNF-alpha and interleukin-1), lymphocyte costimulatory receptors (CD28 and CD40), DNA-damaging chemicals, radiation, and Fas signaling. Results from the JNK knockout mice indicate that JNK is involved in apoptosis induction and T helper cell differentiation.
Pim-1 is a small serine/threonine kinase. Elevated expression levels of Pim-1 have been detected in lymphoid and myeloid malignancies, and recently Pim-1 was identified as a prognostic marker in prostate cancer. K. Peltola, "Signaling in Cancer:
Pim-1 Kinase and its Partners", Annales Universitatis Turkuensis, Sarja - Ser.
D Osa - Tom. 616, (August 30, 2005), http://kiriasto.utu.fi/iulkaisupalvelut/annaalit/2004/D616.html. Pim-1 acts as a cell survival factor and may prevent apoptosis in malignant cells. K. Petersen Shay et al., Molecular Cancer Research 3:170-181 (2005).
Yet another group of kinases are Aurora kinases. Aurora kinases (Aurora-A, Aurora-B, Aurora-C) are serine/threonine protein kinases that have been implicated in human cancer, such as colon, breast and other solid tumors. Aurora-A (also sometimes referred to as AIK) is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-A may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, Aurora-A, Aurora-B, Aurora-C have been found to be over-expressed (see, Bischoff et al., EMBO J., 17:3052-3065 (1998); Schumacher et al., J. Cell Biol.
143:1635-1646 (1998); Kimura et al., J. Biol. Chem., 272:13766-13771 (1997)).
There is a need for effective inhibitors of protein kinases, especially Aurora kinases, in order to treat or prevent disease states associated with abnormal cell proliferation. Moreover, it is desirable to have kinase inhibitors, especially small-molecule compounds that may be readily synthesized.
Summary of the Invention In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with protein kinases using such compounds or pharmaceutical compositions.
In one aspect, the present invention provides compounds represented by Formula I:
R' R2 R~N
1\~
NN
R3.IN.H
Formula I
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, 5 -C(O)NR5R6, -N(R5)C(O)Rs, heterocyclyl, heteroaryl substituted with (CH2)1_3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6;
D Osa - Tom. 616, (August 30, 2005), http://kiriasto.utu.fi/iulkaisupalvelut/annaalit/2004/D616.html. Pim-1 acts as a cell survival factor and may prevent apoptosis in malignant cells. K. Petersen Shay et al., Molecular Cancer Research 3:170-181 (2005).
Yet another group of kinases are Aurora kinases. Aurora kinases (Aurora-A, Aurora-B, Aurora-C) are serine/threonine protein kinases that have been implicated in human cancer, such as colon, breast and other solid tumors. Aurora-A (also sometimes referred to as AIK) is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-A may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, Aurora-A, Aurora-B, Aurora-C have been found to be over-expressed (see, Bischoff et al., EMBO J., 17:3052-3065 (1998); Schumacher et al., J. Cell Biol.
143:1635-1646 (1998); Kimura et al., J. Biol. Chem., 272:13766-13771 (1997)).
There is a need for effective inhibitors of protein kinases, especially Aurora kinases, in order to treat or prevent disease states associated with abnormal cell proliferation. Moreover, it is desirable to have kinase inhibitors, especially small-molecule compounds that may be readily synthesized.
Summary of the Invention In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with protein kinases using such compounds or pharmaceutical compositions.
In one aspect, the present invention provides compounds represented by Formula I:
R' R2 R~N
1\~
NN
R3.IN.H
Formula I
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, 5 -C(O)NR5R6, -N(R5)C(O)Rs, heterocyclyl, heteroaryl substituted with (CH2)1_3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6;
10 R' is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CH2OR5, -C(O)NR5R6, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5 and -OR5;
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR'R8)n-X, heterocyclenyi-(CR'R$)n-X, heteroaryl-(CR7 R$)õ-X or aryl-(CR'R$)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONRSR6, -OR5 and alkyl, n is 1-6, X is selected from the group consisting of -NR5R6, -OR5, -SO-R5, -SR5, S02R5, heteroaryl, heterocyclyl and aryl, wherein said heteroaryl or aryl can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -0-alkyl, alkyl, halo, or NR5R6;
R' and R 8 are each independently hydrogen, alkyl, heterocyclyl, aryl, heteroaryl or cycloalkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl, wherein each of said alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryI, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyi, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryi, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl,can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, amino, aminodialkyl, aminocycloalkyl, halo, trihaloalkyl, dihaloalkyl, and monohaloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, heterocyclenyl, halo, trihaloalkyl, dihaloalkyl, CN and monohaloalkyl.
The compounds of Formula I can be useful as protein kinase inhibitors. The compounds of Formula I can also be useful as Aurora kinase inhibitors. The compounds of Formula I can be useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis, neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
Detailed Description In an embodiment, the present invention provides imidazopyrazine compounds, especially imidazo[1,2-a]pyrazine compounds which are represented by structural Formula I, or pharmaceutically acceptable salts, solvates, esters or prodrug thereof, wherein the various moieties are as described above.
In another embodiment, the present invention provides compounds represented by Formula I:
R' R2 R~N
~1\
N Y`N
R3.IN.H
Formula I
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkenyl, heterocyclenyl, -C(O)NR5R6, -N(R5)C(O)R6, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5 and -NR5R6;
R' is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(O)NR5R6 and -OR5;
R2 is H, halo, or heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR'R8),-X, heterocyclenyl-(CR'R$)n-X, heteroaryl-(CR'R$)n-X or aryI-(CR'R$)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONR5R6, -OR5 and alkyl, n is 1, X is selected from the group consisting of, -NR5R6, -OR5, -SO-R5 and -SR5, R' and R 8 are each independently hydrogen or alkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalky;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl can be unsubstituted or substituted with one or 5 more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
10 further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of 15 hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In an embodiment, R, R' and R2 are not all H simultaneously.
In another embodiment, in Formula I, R2 is unsubstituted heteroaryl or heteroaryl substituted with alkyl.
In another embodiment, in Formula I, R2 is heteroaryl substituted with alkyl.
In another embodiment, in Formula I, R2 is pyrazolyl.
In another embodiment, in Formula I, R2 is pyrazolyl substituted with alkyl.
In another embodiment, in Formula I, R2 is 1-methyl-pyrazol-4-yl.
In another embodiment, in Formula I, R is H.
In another embodiment, in Formula I, R is CN.
In another embodiment, in Formula I, R is -C(O)NR5R6.
In another embodiment, in Formula I, R is -C(O)NH2.
In another embodiment, in Formula I, R is heterocyclenyl.
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR'R8)n-X, heterocyclenyi-(CR'R$)n-X, heteroaryl-(CR7 R$)õ-X or aryl-(CR'R$)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONRSR6, -OR5 and alkyl, n is 1-6, X is selected from the group consisting of -NR5R6, -OR5, -SO-R5, -SR5, S02R5, heteroaryl, heterocyclyl and aryl, wherein said heteroaryl or aryl can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -0-alkyl, alkyl, halo, or NR5R6;
R' and R 8 are each independently hydrogen, alkyl, heterocyclyl, aryl, heteroaryl or cycloalkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl, wherein each of said alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryI, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyi, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryi, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl,can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, amino, aminodialkyl, aminocycloalkyl, halo, trihaloalkyl, dihaloalkyl, and monohaloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, heterocyclenyl, halo, trihaloalkyl, dihaloalkyl, CN and monohaloalkyl.
The compounds of Formula I can be useful as protein kinase inhibitors. The compounds of Formula I can also be useful as Aurora kinase inhibitors. The compounds of Formula I can be useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis, neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
Detailed Description In an embodiment, the present invention provides imidazopyrazine compounds, especially imidazo[1,2-a]pyrazine compounds which are represented by structural Formula I, or pharmaceutically acceptable salts, solvates, esters or prodrug thereof, wherein the various moieties are as described above.
In another embodiment, the present invention provides compounds represented by Formula I:
R' R2 R~N
~1\
N Y`N
R3.IN.H
Formula I
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkenyl, heterocyclenyl, -C(O)NR5R6, -N(R5)C(O)R6, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5 and -NR5R6;
R' is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(O)NR5R6 and -OR5;
R2 is H, halo, or heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR'R8),-X, heterocyclenyl-(CR'R$)n-X, heteroaryl-(CR'R$)n-X or aryI-(CR'R$)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONR5R6, -OR5 and alkyl, n is 1, X is selected from the group consisting of, -NR5R6, -OR5, -SO-R5 and -SR5, R' and R 8 are each independently hydrogen or alkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalky;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl can be unsubstituted or substituted with one or 5 more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
10 further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of 15 hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In an embodiment, R, R' and R2 are not all H simultaneously.
In another embodiment, in Formula I, R2 is unsubstituted heteroaryl or heteroaryl substituted with alkyl.
In another embodiment, in Formula I, R2 is heteroaryl substituted with alkyl.
In another embodiment, in Formula I, R2 is pyrazolyl.
In another embodiment, in Formula I, R2 is pyrazolyl substituted with alkyl.
In another embodiment, in Formula I, R2 is 1-methyl-pyrazol-4-yl.
In another embodiment, in Formula I, R is H.
In another embodiment, in Formula I, R is CN.
In another embodiment, in Formula I, R is -C(O)NR5R6.
In another embodiment, in Formula I, R is -C(O)NH2.
In another embodiment, in Formula I, R is heterocyclenyl.
In another embodiment, in Formula I, R is tetrahydropyridinyl.
In another embodiment, in Formula I, R is 1,2,3,6-tetrahydropyridinyl.
In another embodiment, in Formula I, R is alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR' and -NR5R6.
In another embodiment, in Formula I, R is alkyl substituted with one or more -NR5R6.
In another embodiment, in Formula I, R is alkyl substituted with -NH2.
In another embodiment, in Formula I, R is alkyl substituted with -NH(methyl).
In another embodiment, R is unsubstituted alkyl.
In some embodiments, both R and R' are not H simultaneously.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X, wherein X is -OR5, -SOR5, -NR5R6, or -SR5; R5 is hydrogen, -alkylN(alkyl)2, heterocyclylalkyl or heterocyclenylalkyl; or R5 and R6 can optionally be joined together with the N
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONRR6, wherein X
In another embodiment, in Formula I, R is 1,2,3,6-tetrahydropyridinyl.
In another embodiment, in Formula I, R is alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR' and -NR5R6.
In another embodiment, in Formula I, R is alkyl substituted with one or more -NR5R6.
In another embodiment, in Formula I, R is alkyl substituted with -NH2.
In another embodiment, in Formula I, R is alkyl substituted with -NH(methyl).
In another embodiment, R is unsubstituted alkyl.
In some embodiments, both R and R' are not H simultaneously.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X, wherein X is -OR5, -SOR5, -NR5R6, or -SR5; R5 is hydrogen, -alkylN(alkyl)2, heterocyclylalkyl or heterocyclenylalkyl; or R5 and R6 can optionally be joined together with the N
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
In another embodiment, in Formula I, R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONRR6, wherein X
is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form a cyclic ring.
In another embodiment, in Formula I, R3 is aryl-CH2-X, wherein the aryl of said aryl-CH2-X is substituted with alkyl, wherein X is heterocyclyl.
s ~op, / SrX gs, t / x In another embodiment, in Formula I, R3 is s-N X, , N ~~.`
S' \
X ~ ~ X
x m or wherein X is selected from the rou consisting of, -NR5R6, -OR5 -SO-R5 and -SR5, R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalky;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, - heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In another embodiment, in Formula I, R3 is isothiazole, thiophene or pyrimidine substituted with:
~j ~
CH3 HgC y H3C~CH3, r~- ~- ~~- ~ i ~
N ~ N N
N
H3CO V \ Q 2O , , , OH, , HO
N /+
N N N
CH1 N ~ Or I / f f f f 1 0 1 ~~ ~, N r N NJ~
~ N~ N
~ I J CH3 N N c~ ~ ON
, H3C ~, OH
O s 0= S\-\ OH
N- N- N
OH, -~~
OH, N
OH
O\_ OH OH
_ -~ OH k($-o_ N
Or HO1",O
r N
Or HO,,,_",o In another embodiment, in Formula I, R3 is pyrimidinyl substituted with heterocyclylmethyl.
In another embodiment, in Formula I, R3 is pyrimidinyl substituted with morpholinylmethyll or pyrrolidinylmethyl.
In another embodiment, in Formula I, R3 is phenyl substituted with heterocyclylalkyl, wherein said heterocyclylalkyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of alkyl.
In another embodiment, in Formula I, R3 is phenyl-CHmethyl-X or phenyl-CH2-X , wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting alkyl.
In another embodiment, in Formula I, R3 is phenyl substituted with heterocyclylmethyl, wherein said phenyl group is further substituted with alkyl.
5 In another embodiment, in Formula I, R3 is phenyl substituted with piperidinylmethyl, morpholinylmethyl or thiomorpholinylmethyl, wherein said phenyl group is further substituted with methyl.
s N ls~cS
In another embodiment, in Formula I, R3 is x , N or ;is s x,wherein X is heterocyclyl wherein said heterocyclyl can be 10 unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of hydroxyl, alkyl, hydroxyalkyl, alkoxyl, -CO2alkyl, arylalkyl, aryl, alkoxyalkyl, and heterocyclyl.
N,, N
In another embodiment, in Formula I, R 3 is x wherein X is heterocyclyl 15 wherein said heterocyclyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of alkyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"l' N
~ 1\
NY`N
R3. IN,H
of said -NR5R6 to form a cyclic ring.
In another embodiment, in Formula I, R3 is aryl-CH2-X, wherein the aryl of said aryl-CH2-X is substituted with alkyl, wherein X is heterocyclyl.
s ~op, / SrX gs, t / x In another embodiment, in Formula I, R3 is s-N X, , N ~~.`
S' \
X ~ ~ X
x m or wherein X is selected from the rou consisting of, -NR5R6, -OR5 -SO-R5 and -SR5, R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalky;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, - heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In another embodiment, in Formula I, R3 is isothiazole, thiophene or pyrimidine substituted with:
~j ~
CH3 HgC y H3C~CH3, r~- ~- ~~- ~ i ~
N ~ N N
N
H3CO V \ Q 2O , , , OH, , HO
N /+
N N N
CH1 N ~ Or I / f f f f 1 0 1 ~~ ~, N r N NJ~
~ N~ N
~ I J CH3 N N c~ ~ ON
, H3C ~, OH
O s 0= S\-\ OH
N- N- N
OH, -~~
OH, N
OH
O\_ OH OH
_ -~ OH k($-o_ N
Or HO1",O
r N
Or HO,,,_",o In another embodiment, in Formula I, R3 is pyrimidinyl substituted with heterocyclylmethyl.
In another embodiment, in Formula I, R3 is pyrimidinyl substituted with morpholinylmethyll or pyrrolidinylmethyl.
In another embodiment, in Formula I, R3 is phenyl substituted with heterocyclylalkyl, wherein said heterocyclylalkyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of alkyl.
In another embodiment, in Formula I, R3 is phenyl-CHmethyl-X or phenyl-CH2-X , wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting alkyl.
In another embodiment, in Formula I, R3 is phenyl substituted with heterocyclylmethyl, wherein said phenyl group is further substituted with alkyl.
5 In another embodiment, in Formula I, R3 is phenyl substituted with piperidinylmethyl, morpholinylmethyl or thiomorpholinylmethyl, wherein said phenyl group is further substituted with methyl.
s N ls~cS
In another embodiment, in Formula I, R3 is x , N or ;is s x,wherein X is heterocyclyl wherein said heterocyclyl can be 10 unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of hydroxyl, alkyl, hydroxyalkyl, alkoxyl, -CO2alkyl, arylalkyl, aryl, alkoxyalkyl, and heterocyclyl.
N,, N
In another embodiment, in Formula I, R 3 is x wherein X is heterocyclyl 15 wherein said heterocyclyl can be unsubstituted or substituted with one or more moieties, which can be the same or different, each moiety being independently selected from the group consisting of alkyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"l' N
~ 1\
NY`N
R3. IN,H
20 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R`~N
/~ j\
NYN
R3~ N. H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(Rs)C(O)N(RsRs), -N(R syC(O)ORs, -(CH2)1_3-N(R s R s)and -NR s R s ; R, is H; R s is heteroaryl-CH2-X , wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R 6, wherein X is -NR5Rs or R 5 and R 6 are optionally joined together with the N of said -NR5R6 to form heterocyclyl; wherein R 5 and R 6 are as defined above.
In another embodiment, this invention discloses a. compound of the formula:
R' R2 R'rlk N
N N
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R 6 (where R 5 and R 6 form a cyclic amine together with the N of said -NR5R 6), -CN, arylalkyl, -CH2OR5, -S(O)R 5, -S(02)R5, -CN, -CHO, -SR 5, -C(O)ORs, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -ORs, heterocyclyl, -N(R5)C(O)N(R5R 6), -N(Rs)-C(O)ORs, -(CH2)1_3-N(R5R6 ) and -NR5Rs; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
r~=
N^~';` N N H3C N
CH3 C" v C ~ Y ~
3 3 V H C~CH3 f f f f f 3 t r5 N N N
N
YO
H3C V \ (0) N
OH, , HO
N /+
N
N / ~ c H3CNy 6'1, (s) \~ ~ Z O
f 7 ~~ ~, N r N NJ>
N~
hN I I CH3 N H3C ~, ~, OH
~~OH
~ O-\ - S 0= S
~ N
OH, -~~
OH, or HO~ ; wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R`
~ \
N~/j`N
R3. IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R`~N
/~ j\
NYN
R3~ N. H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(Rs)C(O)N(RsRs), -N(R syC(O)ORs, -(CH2)1_3-N(R s R s)and -NR s R s ; R, is H; R s is heteroaryl-CH2-X , wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R 6, wherein X is -NR5Rs or R 5 and R 6 are optionally joined together with the N of said -NR5R6 to form heterocyclyl; wherein R 5 and R 6 are as defined above.
In another embodiment, this invention discloses a. compound of the formula:
R' R2 R'rlk N
N N
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R 6 (where R 5 and R 6 form a cyclic amine together with the N of said -NR5R 6), -CN, arylalkyl, -CH2OR5, -S(O)R 5, -S(02)R5, -CN, -CHO, -SR 5, -C(O)ORs, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -ORs, heterocyclyl, -N(R5)C(O)N(R5R 6), -N(Rs)-C(O)ORs, -(CH2)1_3-N(R5R6 ) and -NR5Rs; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
r~=
N^~';` N N H3C N
CH3 C" v C ~ Y ~
3 3 V H C~CH3 f f f f f 3 t r5 N N N
N
YO
H3C V \ (0) N
OH, , HO
N /+
N
N / ~ c H3CNy 6'1, (s) \~ ~ Z O
f 7 ~~ ~, N r N NJ>
N~
hN I I CH3 N H3C ~, ~, OH
~~OH
~ O-\ - S 0= S
~ N
OH, -~~
OH, or HO~ ; wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R`
~ \
N~/j`N
R3. IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
NN
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is S gs s / ~~ ~
~\(X / X x`~i X i S-r, :N X or P~
0--,\Xwherein X is selected from the group consisting of, -NR5R6, -OR5 -SO-R5 and -SRS, R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl and heterocyclenyl can be unsubstituted or substituted with one or more alkyl, R 6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, 5 heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl and heterocycloalkylalkyl can be unsubstituted or substituted with one or more alkyl, further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged 10 cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, 15 heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j' N
~ \
N~/j`N
20 R3~ IN, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, 25 aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is, S ~ S'N V S-N N
N N~ ~ S-N N
Q O N~ IS NOH ~
, OH, S , , O
TNN NS'N N s~s' ~O O S S-N N S O-\N
10~.N.~ , - , ~, , _1,N ' N
S 0=S
N - ~ r N o / N S i N / N
C?, O_ HN
'NJ~ ~ ~5~~ ~N
, N , or wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
l\
N
Y`N
R3. N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)ORS, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R 6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl, wherein R5 and R6 are as defined above; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R\~N
T/ 1\
~ Y`N
N
RO, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R 6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)ORs, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X , wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N of said -NR5R6 to form heterocyclyl;
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~
N N
R3.TN.H
R' R2 R
NN
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is S gs s / ~~ ~
~\(X / X x`~i X i S-r, :N X or P~
0--,\Xwherein X is selected from the group consisting of, -NR5R6, -OR5 -SO-R5 and -SRS, R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylaikoxyl, -S-alkylheterocyclyl, heterocyclyl and heterocyclenyl can be unsubstituted or substituted with one or more alkyl, R 6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, 5 heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl and heterocycloalkylalkyl can be unsubstituted or substituted with one or more alkyl, further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged 10 cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -C02-alkyl, -C02-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, 15 heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j' N
~ \
N~/j`N
20 R3~ IN, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is heteroaryl, wherein said heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, 25 aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is, S ~ S'N V S-N N
N N~ ~ S-N N
Q O N~ IS NOH ~
, OH, S , , O
TNN NS'N N s~s' ~O O S S-N N S O-\N
10~.N.~ , - , ~, , _1,N ' N
S 0=S
N - ~ r N o / N S i N / N
C?, O_ HN
'NJ~ ~ ~5~~ ~N
, N , or wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
l\
N
Y`N
R3. N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)ORS, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R 6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N
of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl, wherein R5 and R6 are as defined above; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R\~N
T/ 1\
~ Y`N
N
RO, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R 6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)ORs, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X , wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N of said -NR5R6 to form heterocyclyl;
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~
N N
R3.TN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R 6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
r~.
QN^s,'r N
CH3 H C~CH3 3 r e e t 3 r ~- _2 ~~- ~ /~
N N r~ r~ N N
N
H3CO V \ Q
YO , OH, , HO
N /+
+
N r~- P
/ / - c HsC~
No CH3 ~Ns~ ~ I O
t t t t , t t t N [-~' r~_ N
N hN 15 t H3C CH3 OH
~ O_ ~ ~~OH
N~J~ ~ N- N- ~~N~-~ N
, OH, -~~
OH, N
or HO,/0 ; wherein RS and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
NN
R3~N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
1\~
NN
R3. IN,H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being 5 independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6; R' is H; R3 is, S ~
S N~~~ N N g s~, QOH, SN O ~ S, , O
S-N N S
N S-N N S
N O ~S N
~ 1SN ~ 1SN
N S s 0=S ~
n I N.J NJ S N O-~No ~N_ S/ N- N_ HN
N _N S / N
10 N N i , and ~N
wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' Rz R\T"J' N
\
1Y`N
N
R3.N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is 15 pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)ORs, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
1\~
NN
RT N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; and R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl.
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'I')' ' N
j_ \1 NN
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
N^~ ~
CH3 C ~ H c cH ~
3 r 3 r > > 3 3e ,-- ~ ~~' ~
r N N N
N I
N N \ I
YO co O HsC OH, HO
r ~ N /+
N
N + H3C~
(N) N
NO
3 , s ,o o N
N N-?
\ ~ J cH3 N N c~ ~ O~-N
H3C ~f OH
-\ OH
- / O-~ S 0=S
/N , /N \1 , OH, I , -~~
OH, N
or HO,/o ;wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j' N
l\
N
Y`N
R3.N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"l' N
~ \
NYL`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-~ ~, N
S-N N
S-N N S
N
N(R5R6) and -NR5R6; R' is H; R3 is, O, OH, 0 S N os' S- N S'N N
O
SN OH INJ , Cb, O
~e NJ
`
O S S N N S NON N O N
ilr `-".N
~ N , N N HN
S s S
S N ON_ N_ N_ N~ ~~
N
SON
and wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r)' N
~1\
N ~/`N
R3. IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~ 1\~
NN
R3" N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yi; R is unsubstituted alkyl; R' is H; R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONRR6, wherein X
is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R 6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'~" N
~
N\\/l~'N
R3.~N.H
5 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is 1-H-pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
r~- ~~- ~~-^P. N N H3C N
CY CH3 C" Q ~CH
3 3 HC 3f 3 f r~- /+ r~/ /-s N N N N
N ~
N
H3CO aOHYO ~
0 , , H3C~ , 0 , HO
N /+
N ~- N
1 N ~- H3C~
N/ O
CH3 ~N $~ ~/ ~ I c 0 10 , ~~ ~-N r CN) N
I
H3C ~~f OH
~ 0= S ~/OH
O~_N\J~ ~ N- N- \~~N~ N
, OH, I , -~~
OH, N
or HO_/o ; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
1\~
NN
R3. N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X
can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl;
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j" N
~ ~
N \/1'N
R3.~N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is '-e S-N N
S-N N~
pyrazol-4-yl; R is unsubstituted alkyl; R' is H; and R3 is, oH, ~ S N N N SN N
S
'/I~ 1 .4:; N
S'N OH, S , NJ
''~' S ` ^>- , iss' O N~ ~S/-N N S N O~ N ~ ~ ~`O ~.~N
~,S , ,, ~OCN.~ N~-N
N N HN
S OS N S N S
S N ON_ N_ ~Nj' N~' SON
and In another embodiment, this invention discloses a compound of the formula:
R' R2 R'rlk N
~ \
N~/1`N
R3 IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is methyl, R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'~" N
~
N~N
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is methyl, R' is H; R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
NY`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is methyl, R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
N/\~ r~= r~~ ~~~
r.
CY/~s,:' N H3C
v ~CH3~
CH3 C Hc ~
3 f 3 ) f f 3 f ~~ _ r~- ~- r / S Ir y N N N
N
H,c0 N I~ I I/
0 H3C1.10 OH c0) HO Y
) f ) ) , ) ) ) N /+
~ji ~7 I N H3C
C:) O
CH `~ ~ / ~ / ~ - `' 3 S f~ f f f f f o r7 N
c ) -1N N-/
~ N N -~~ -~ ' \ ~ -=
\ I J CH3 N
OH
- / O-~ S 0= S /OH
N~ ~ _ ~N_ ~~ ~~ NI
OH, -~~
OH, N
or HO"/ v .
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~ ~
N \/1'N
R3"TN, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is methyl, R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
~
N N
R3.~N".H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is ~ :~ I ,~
S-N N
S-N N~ S
N
pyrazol-4-yl; R is methyl, R' is H; R3 is, ~O , OH, 0 , S S- N S'N N
N N ~ ~'J
S, , N , - , O
N
s~ T1,~ S N N S N O ~~ ~O ~ I` N
O ~,S ~N ~ ~ N `N~.N D
> > \' , .
~N HN
~
s N O-\_ N- ~S=/ N- O N- ~(=S I~~~Gs N
N N
SN
and N
In another embodiment, this invention discloses a compound of the formula:
H
N- N
N
NY `N
HNI
5 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R5 is alkyl; R6 is selected from the group consisting of alkoxyalkyl, hydroxyalkyl, cycloalkyl, wherein said cycloalkyl is substituted by hydroxyalkyl; or R5 and R6 together with the N of said -NR5R6 to form a cyclic ring, wherein said cyclic ring is substituted by one or more moieties independently selected from the group consisting of alkoxyalkyl, 10 hydroxyalkyl, and alkyl.
In another embodiment, this invention discloses a compound of the formula:
H
N- N
N
NY _N
HNI ~
/
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R5 is methyl, ethyl, or propyl; R6 is selected from the group consisting of ethoxyethyl, 1,1-15 dimethylhydroxyethyl, cyclopentyl, cyclohexyl, wherein each of said cyclopentyl and cyclohexyl is substituted by hydroxymethyl; or R5 and R6 together with the N
of said -NR5R6 to form a cyclic ring, wherein said cyclic ring is substituted by one or more moieties independently selected from the group consisting of ethoxymethyl, methoxymethyl, hydroxymethyl, and methyl.
Non-limiting examples of compounds of Formula I include:
H
N_ N H
N_ N_N H I N'N
N `N ~N \ \ ~
~N \ ~N1 \ ~N \ N~N ~N1~ \
NN NYN N~N HN ~\~ NY`N
HTN HN~ ^ HN~ S-' N HN 7 ~)--\ TS~-N/--~N ~
S-N S-N / / \ g-N// N
0, - , \--/ , HN-N
HN-N
N- H N
N~N
N N`N NH `N ~N N N
~N ` N\ N HN 1 S N HN 1 N
N, Nl~)-_N N~
N
HN
T_\/ HN~ HN~ ~ S 0=S
S-N N _ ~-\ 1~ }-\
S N 0~_ S-N 0~_No N-, ~N-~, N ,, N_ ~
H3C ~ H H
H3C CH3 CH3 N'N N- N
H3CN \ \ ~ I
NYN Nj N ~N \ N
FfN S. ~ S. NN ~ -N
~ IN CH3 IN l I
N~ No HN\ /S~N ~ ~gNH
L N , N
H H
N-N N-N
\ I \ I
H
N-N
HN-N ~N \ N \ \ I
H N~N N~N ~N \
N N HN H N ^ N` ~N
/
T --\ ~
NY N S-N N S-N N HN_ õ
N S NH ~~ S/-N ~N
~N~ , \, OMe, ~OH
H H
N'N H H N-N
\'N N-N
I
N
N
NN N N \ I \
HN N~N N~N N~N
/ HN1/\ HN ~ HN
N ~
S-N ( t r~ ~
--~
/\ S-N iI-<, g H H H
N'N H N,N N-N
N'N I I
N
NY `N ~N` N~N ~ N~N
NI~/1N HN N HN N
HN ~
N HNNrN/~ S S
S-N N~ No N
<\~
> > > O
s H H N' N
N- N
H3C`Y^N SN N
N/~ H3C ~ N~ H3C~N NY 'N
N N\~N N~N HN ~
HN`Y ^ H~N"~ HN I~ COyEt S'NkOH
1/ /}-\
S N OH, S'N OH, ~ N e ~
H
H N-\ `N \ ,N N
H "fO"~'N '-rN N
N~I_N Nllz~-- N
N N
T
HN,, HN` HN
~~--N S'N N S-N N S-N N
\~ ~, OH, H
N'N
H H
N~N N,N
I \TN I
lN N'^~N N
N~ ~/ N HN N
N
~ OH
~
HN O S-N N HN
S-N N \- S-N> OH
\~/
~ ~ ~
N-N N-N H
N'N
N N ~
NN N7` ~N \ N
OH N
S-N S-N S_N
H
N'N
N,N
I
~l f N NY~
'N
NN ' HN
HN O
S N N S-N H N- N_ a \r \r ~N \ N \ ~N \
~N \ NN N~
N N~T N
N N
HN r HN~ HN ~/ HN1/\
\ I- S-N S-N S-N N
S-N OH F
CF3 F F, CF3, H N_ \'r \ -r H
\ r N-I N \ ~N \ ~N \ N
N~N N~N N~N
N1--l-- N
HN HN1/\ HN~ HN
Q-\ ~~ /-S-N aF S-N N~ F S-N N S N
/ F
F
F 0 , H H H
N, N_ \r \_r \r a ~N
N~ ~N NY'l N
N NY N N I
HN N HN~
i / N / HN~ S-N N
S-N N ~Fo\--F ~F S-N N S-N N , ~/ 'F, ~''F, F
a~r H H N`
N'N N-~N \ \ I \ r N
N N N \
HN N N` ~ N~N
N N T
HN,,r HN~
No HN ~ ~\O S_N S-N HN-\-F
S /
N FJ or H
N'N
H ( N_ N
~ N \
~N \ N ~ _\
N~N N NY _N
HN ~N HN S H%~N
S- N
N ~ ~ N
- ~ - ~ - ~
H H
H N-N N' H
N'N \ I \ ~ N'r N~ N\ N N- \T^
HN N
N N N~
HN ~/ HN rN OMe HN ~
S-N S N N/ N/ ~ S'N N/ \ OMe H H
H N'N H N,N
~~N \ ~ N-N I
~N
N N I` ~N \ I- N\
NN ~ N N~ NN
Y HN N
HN
s-N r\ s N N/ \ S N r\ sN
N _ OMe, Me0 ~ F, HN Br, H
N-N N-N N'f`1 N-N
N \ -N NY N Nll)zN NY N
HN ~
/ HN ~ HN ~ HN
F r S-N S_N / \ S N S N
N N N
ci, - , - 1 H
N'N
H
N' ' N N
~
I N NY N
NN
HN TS- HN~ ~ N +
S-N bN1X NMeZ O,N~ \
and -or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings, including 5 any possible substitutions of the stated groups or moieties:
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
Preferred 10 alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. "Alkyl" may be unsubstituted or 15 optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, oxime (e.g., =N-OH), -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyl 20 groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in 25 the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. "Alkenyl"
may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.
"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.
"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. "Alkynyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
The aryl group can be optionally substituted with one or more "ring system substituents"
which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
"Bridged cyclic ring" is a hydrocarbon ring such as cycloalkyl, cyclenyl, or aryl or heteroatom containing ring such as, heterocyclyl, heterocyclenyl, or heteroaryl as described herein, that contains a bridge, which is a valence bond or an atom or an unbranched chain of atoms connecting two different parts of the ring. The two tertiary carbon atoms connected through the bridge are termed "bridgeheads".
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A
nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
"Heteroaryl" may also include a heteroaryl as defined above fused to an aryl as defined above. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms.
Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbomyl, adamantyl and the like.
"Cycloalkylalkyl" means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.
"Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contain at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyis include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like.
Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyl.
"Cycloalkenylalkyl" means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.
"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylaikenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, amide, -CHO, -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), oxime (e.g., =N-OH), YjY2N-, YIY2N-alkyl-, YlY2NC(O)-, Y1Y2NSO2- and -SO2NYjY2, wherein Y, and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent"
may also mean a single moiety which simultaneously replaces two available hydrogen on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH3)2- and the like which form moieties such as, for example:
O0 co 0~0 and "Heteroarylalkyl" means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryis include 2-pyridinylmethyl, quinolinylmethyl and the like.
"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like;
such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
'"HeterocyclyP' may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogen on the same carbon atom on a ring system.
Example of such moiety is pyrrolidone:
H
N
O
"Heterocyclylalkyl" means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
5 "Heterocyclenyl" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond.
10 There are no adjacent oxygen and/or sulfur atoms present in the ring system.
Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system 15 substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-20 imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.
"Heterocyclenyl" may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogen on the same carbon atom on a ring system.
Example 25 of such moiety is pyrrolidinone:
H
N
I
O
"Heterocyclenylalkyl" means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, 0 or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:
N
H
there is no -OH attached directly to carbons marked 2 and 5.
It should also be noted that tautomeric forms such as, for example, the moieties:
N O
H and N OH
are considered equivalent in certain embodiments of this invention.
"Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group.
Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Spiro ring systems" have two or more rings linked by one common atom.
Preferred spiro ring systems include spiroheteroaryl, spiroheterocyclenyl, spiroheterocyclyl, spirocycloalkyl, spirocyclenyl, and spiroaryl. The spiro ring systems can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. Non-limiting examples of suitable spiro ring systems include 7 6 4 spiro[4.5]decane, 8-azaspiro[4.5]dec-2-ene, and spiro[4.4]nona-2,7-diene.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined.
Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.
"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Alkylsulfonyl" means an alkyl-S(02)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
"Arylsulfonyl" means an aryl-S(02)- group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g. from a reaction mixture), or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like) , in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V.
Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
5 For example, if a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Cl-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-10 methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl-1 -(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-15 crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Cl-C2)alkylamino(C2-C3)alkyl (such as P-dimethylaminoethyl), carbamoyl-(Cj-C2)alkyl, N,N-di (Cl-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, and the like.
Similarly, if a compound of Formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group 20 with a group such as, for example, (CI-C6)alkanoyloxymethyl, 1-((Cl-C6)alkanoyloxy)ethyl, 1-methyl-1-((CI-C6)alkanoyloxy)ethyl, (Cl-C6)alkoxycarbonyloxymethyl, N-(Cl-Cs)alkoxycarbonylaminomethyl, succinoyl, (Cl-C6)alkanoyl, a-amino(Cl-C4)alkanyl, arylacyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoacyl group is independently selected from the naturally 25 occurring L-amino acids, P(O)(OH)2, -P(O)(O(CI-Cs)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
If a compound of Formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a 30 group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R
and R' are each independently (Cl-Clo)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural a-aminoacyl or natural a-aminoacyl, -C(OH)C(O)OY' wherein Y' is H, (Cl-C6)alkyl or benzyl, -C(OY2)Y3 wherein Y2 is (CI-C4) alkyl and Y3 is P-Cs)alkyl, carboxy P-Cs)alkyl, amino(Cj-C4)alkyl or mono-N--or di-N,N-(Cj-C6)alkylaminoalkyl, -C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N- or di-N,N-(Cj-C6)alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.
One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compourid of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate"
encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H20.
One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M.
Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C.
van Tonder et al, AAPS PharmSciTech., 50), article 12 (2004); and A. L.
Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula I may be formed, for example, by reacting a compound of Formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use.
(2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(l) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217;
Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York;
and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website).
These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C1_4alkyl, or Cl-4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl);
(4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1_20 alcohol or reactive derivative thereof, or by a 2,3-di (Cr,24)acyl glycerol.
Compounds of Formula I, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC
column.
It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.
Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R
configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of 5 isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 31õI, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S,18F, and 36CI, respectively.
Certain isotopically-labelled compounds of Formula (I) (e.g., those labeled with 3H and14C) are useful in compound and/or substrate tissue distribution assays.
10 Tritiated (i.e., 3H) and carbon-14 (i.e.,14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically 15 labeled compounds of Formula (I) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
Polymorphic forms of the compounds of Formula I, and of the salts, solvates, 20 esters and prodrugs of the compounds of Formula I, are intended to be included in the present invention.
The compounds according to the invention have pharmacological properties; in particular, the compounds of Formula I can be inhibitors, regulators or modulators of protein kinases. Non-limiting examples of protein kinases that can be inhibited, 25 regulated or modulated include cyclin-dependent kinases (CDKs), such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8, mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), Pim-1 kinases, Chk kinases (such as Chkl and Chk2), tyrosine kinases, such as the HER subfamily (including, for example, EGFR (HER1), HER2, HER3 and HER4), the insulin 30 subfamily (including, for example, INS-R, IGF-IR, IR, and IR-R), the PDGF
subfamily (including, for example, PDGF-alpha and beta receptors, CSFIR, c-kit and FLK-II), the FLK family (including, for example, kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1)), non-receptor protein tyrosine kinases, for example LCK, Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK, growth factor receptor tyrosine kinases such as VEGF-R2, FGF-R, TEK, Akt kinases, Aurora kinases (Aurora A, Aurora B, Aurora C) and the like.
The compounds of Formula I can be inhibitors of protein kinases such as, for example, the inhibitors of the checkpoint kinases such as Chkl, Chk2 and the like.
Preferred compounds can exhibit IC50 values of less than about 5pm, preferably about 0.001 to about 1.0 pm, and more preferably about 0.001 to about 0.1 pm. The assay methods are described in the Examples set forth below.
The compounds of Formula I can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
Many of these diseases and disorders are listed in U.S. 6,413,974 cited earlier, incorporated by reference herein.
More specifically, the compounds of Formula I can be useful in the treatment of a variety of cancers, including (but not limited to) the following:
tumor of the bladder, breast (including BRCA-mutated breast cancer, colorectal, colon, kidney, liver, lung, small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, bladder, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma and Burkett's lymphoma;
chronic lymphocytic leukemia ("CLL"), acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;
fibrosarcoma, rhabdomyosarcoma;
head and neck, mantle cell lymphoma, myeloma;
astrocytoma, neuroblastoma, glioma, glioblastoma, malignant glial tumors, astrocytoma, hepatocellular carcinoma, gastrointestinal stromal tumors ("GIST") and schwannomas;
melanoma, multiple myeloma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
Due to the key role of kinases in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
Compounds of Formula I may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that CDK5 is involved in the phosphorylation of tau protein (J. Biochem, (1995) 117, 741-749).
Compounds of Formula I may induce or inhibit apoptosis. The apoptotic response is aberrant in a variety of human diseases. Compounds of Formula I, as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned hereinabove), viral infections (including but not limited to herpevirus, poxvirus, Epstein- Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
Compounds of Formula I, as inhibitors of kinases, can modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).
Compounds of Formula I may also be useful in the chemoprevention of cancer.
Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
Compounds of Formula I may also be useful in inhibiting tumor angiogenesis and metastasis.
Compounds of Formula I may also act as inhibitors of cyclin dependent kinases and other protein kinases, e.g., protein kinase C, her2, raf 1, MEK1, MAP
kinase, EGF
receptor, PDGF receptor, IGF receptor, P13 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.
Another aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition associated with kinases (e.g., CDKs, CHK
and Aurora kinases) by administering a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound to the mammal.
A preferred dosage is about 0.001 to 1000 mg/kg of body weight/day of the compound of Formula I. An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound.
The compounds of this invention may also be useful in combination (administered together or sequentially) with one or more of anti-cancer treatments such as radiation therapy, and/or one or more anti-cancer agents different from the compound of Formula I. The compounds of the present invention can be present in the same dosage unit as the anti-cancer agent or in separate dosage units.
Another aspect of the present invention is a method of treating one or more diseases associated with a kinase (such as CDK, CHK and Aurora), comprising administering to a mammal in need of such treatment: an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of Formula 1, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Non-limiting examples of suitable anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin (e.g., Caelyx , Myocet , Doxil ), taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777 , L778,123 , BMS 2146628 , Iressa , Tarceva , antibodies to EGFR, antibodies to IGFR (including, for example, those published in US 2005/0136063 published June 23, 2005), KSP inhibitors (such as, for example, those published in WO 2006/098962 and WO 2006/098961;
ispinesib, SB-743921 from Cytokinetics), centrosome associated protein E
("CENP-E") inhibitors (e.g., GSK-923295), Gleevec , intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATINTM, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine; Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, bortezomib ("Velcade"), Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225 , satriplatin, mylotarg, Avastin, Rituxan, panitubimab, Sutent, sorafinib, Sprycel (dastinib), nilotinib, Tykerb (lapatinib) and Campath.
If formulated as a fixed dose, such combination products employ the 5 compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range. For example, the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897. Compounds of Formula I
may also be administered sequentially with known anticancer or cytotoxic agents 10 when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula I may be administered either prior to or after administration of the known anticancer or cytotoxic agent. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 15 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
Accordingly, in an aspect, this invention includes combinations comprising an amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, and an amount of one or more anti-cancer 20 treatments and anti-cancer agents listed above wherein the amounts of the compounds/ treatments result in desired therapeutic effect.
Another aspect of the present invention is a method of inhibiting one or more Aurora kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a 25 pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Aurora kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or 30 prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with Aurora kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Aurora kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the Aurora kinase to be inhibited can be Aurora A, Aurora B and/or Aurora C.
Another aspect of the present invention is a method of inhibiting one or more Checkpoint kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Checkpoint kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with Checkpoint kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Checkpoint kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the checkpoint kinase to be inhibited can be Chkl and/or Chk2.
Another aspect of the present invention is a method of inhibiting one or more cyclin dependent kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more cyclin dependent kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with cyclin dependent kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more cyclin dependent kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the checkpoint kinase to be inhibited can be CDK1 and/or CDK2.
Another aspect of the present invention is a method of inhibiting one or more tyrosine kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more tyrosine kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating one or more diseases associated with tyrosine kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more tyrosine kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the tyrosine kinase can be VEGFR (VEGF-R2), EGFR, HER2, SRC, JAK and/or TEK.
Another aspect of the present invention is a method of inhibiting one or more Pim-1 kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Pim-1 kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating one or more diseases associated with Pim-1 kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Pim-1 kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which are described herein below have been carried out with compounds according to the invention and their salts, solvates, esters or prodrugs.
This invention is also directed to pharmaceutical compositions which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and at least one pharmaceutically acceptable carrier.
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid.
Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose.
Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal 5 administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
Also included are solid form preparations that are intended to be converted, 10 shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type 15 as are conventional in the art for this purpose.
The compounds of this invention may also be delivered subcutaneously.
Preferably the compound is administered orally or intravenously.
Also contemplated are delivery methods that are combinations of the above-noted delivery methods, Such methods are typically decided by those skilled in the art.
20 Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or 25 adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the 30 proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
Yet another aspect of this invention is a kit comprising an amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and an amount of at least one anticancer therapy and/or anti-cancer agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect.
The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure.
Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
Where NMR data are presented, 1 H spectra were obtained on either a Varian VXR-200 (200 MHz, 1 H), Varian Gemini-300 (300 MHz) or XL-400 (400 MHz) and are reported as ppm down field from Me4Si with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33mm x 7mm ID; gradient flow: 0 min - 10% CH3CN, 5 min - 95% CH3CN, 7 min -95% CH3CN, 7.5 min - 10% CH3CN, 9 min - stop. The retention time and observed parent ion are given.
The following solvents and reagents may be referred to by their abbreviations in parenthesis:
Thin layer chromatography: TLC
dichloromethane: CH2CI2 ethyl acetate: AcOEt or EtOAc methanol: MeOH
trifluoroacetate: TFA
triethylamine: Et3N or TEA
butoxycarbonyl: n-Boc or Boc nuclear magnetic resonance spectroscopy: NMR
liquid chromatography mass spectrometry: LCMS
high resolution mass spectrometry: HRMS
milliliters: mL
millimoles: mmol microliters: l grams: g milligrams: mg room temperature or rt (ambient): about 25 C.
dimethoxyethane: DME
The synthesis of the inventive compounds is illustrated below. Also, it should be noted that the disclosure of commonly-owned U.S. 6,919,341 and U.S. Appl. No.
is incorporated herein by reference.
NIS, DMF I
60 C, 95% NBr Part B N' IN
N^ Br 1.25 equiv NaSMe ~N~ _Br Sl~
N N
7 MeOH, rt, 95% N~
N cat. Pd(PPh3)4, K2C03 Br S~ Part A trimethylboroxine, DMF
100 C, 90% N
N~N
Part C
S~
N NIS, DMF N
(, ~1V N </ _ ~ `1 N 60 C, 95% NN
S~ Part D SNI
SEM
N,N SEM
cat. PdCI2(dppf) I / N,N
K3PO4, boronate 1I /
DME, water N ~CPBA, DCM
100 C, 60-75% N~N rt, 90% N~ N
Part E S~ Part F o S O
I
Part A: Prepared according to US20060106023 (Al).
Part B: To a solution of compound from Example 1, Part A (2.00 g, 8.19 mmol) in DMF
(50 mL) was added N-iodosuccinimide (1.84 g, 8.19 mmol). The reaction mixture was stirred at 60C for 16 hours. The mixture was cooled to 25C and concentrated.
The residue was dissolved in DCM with a small amount of methanol and then loaded on.
the column. Purification by column chromatography (Si02, 40% ethyl acetate/hexanes) afforded compound 4 as a white solid 2.30 g (76%). 'H-NMR
(400-MHz, DMSO-d6) 6 8.3 (s, 1 H), 7.8 (s, 1 H), 2.6 (s, 3H). HPLC-MS tR = 1.87 Min (UV
254nm). Mass calculated for formula C7H5BrIN3S 370.01, observed LC/MS m/z 370.9 (M+H).
Part C: A suspension of bromide from Part B (45.6 g), Pd(PPh3)4 (10.8 g), potassium carbonate (77.4 g), trimethylboroxine (46.9 g) and potassium carbonate (77.4 g) in DMF (410 mL) was heated overnight under nitrogen at 105C. After cooling, the mixture was diluted with ethyl acetate (1 L), washed with brine (2 x 500 mL), dried (magnesium sulfate), filtered, concentrated and purified by chromatography on silica gel. The title compound was obtained as a pale yellow solid (21.4 g, 64%).
Part D: To a DMF (400 mL) solution of compound from Example 1, Part C (21.8 g) was added N-iodosuccinimide (26.9 g) and the resulting mixture was heated overnight at 60C. The mixture was concentrated and water (400 mL) was added. After stirring 1 hr at rt, saturated sodium carbonate was added (250 mL) and subsequently stirred an additional 30 min at rt. The mixture was filtered, washed with water, methanol (100 mL) and the filter cake was dried overnight under vacuum. A brown solid was obtained (31.4 g, 87%).
Part E: A flask was charged with iodide from Part D (1.00 equiv), Bpin-compound 5a (1.3 equiv), PdCI2(dppf) (0.1 equiv) and potassium phosphate monohydrate (3.0 equiv). After purging the flask with argon, 1,4-dioxane (50 mL) and water (5) were added and the resulting mixture was heated at 80C ovemight (23 h). The reaction was cooled to room temperature. EtOAc was added to the reaction mixture and filtered through Celite. After concentration the residue was purified by column chromatography (silica gel, 25% EtOAc/hexane) to give the title compound.
Part F: To a solution of compound from Example 1, Part E (1.0 equiv) in DCM
(10 mL) was added m-CPBA (2.05 equiv) in one portion. The resulting mixture was stirred at room temperature for 30 min. The mixture was concentrated and then partitioned between EtOAc and water. The organic layer was washed with NaHCO3 (sat. aq., twice), brine and dried (Na2SO4). After concentration, the title compound was obtained and used in the next step directly without further purification.
~S N02 S N02 ~
N\ ~ N\
HO2C Me02C
To a solution of 1' (1.04 g, 5.98 mmol) in 20 mL of DMF, was added K2CO3 (2.48 g, 17.9 mmol) and Mel (1.27 g, 8.96 mmol). The reaction was stirred at room temperature overnight. It was diluted with 200 mL of 50% EtOAc/hexanes and washed with water (200 mL) and brine (100 mL). The organic was concentrated.
To the residue was added 20 mL of hexanes. The solid was collected by filtration to give 2. The filtrate was concentrated and purified by column eluting with 25%
EtOAc/hexanes to give additional amount of 2. The combined yield of 2 is 1.05 g. 'H
NMR (400 MHz, CDCI3) 6 8.37 (s, 1 H), 4.05 (s, 3H).
C02Me C02Me N
~
S
To a solution of 2 (260 mg, 1.38 mmol) in 6 mL of AcOH was added iron powder (774 5 mg, 13.8 mmol). The reaction mixture was heated at 70-75 C for 12 min. The mixture was cooled to room temperature and then added 20 mL of MeOH. The resulting mixture was filtered through celite (the celite was rinsed with additional amount MeOH). The filtrate was concentrated to remove most of AcOH. To the residue was added 15 mL of 20% MeOH/CH2CI2 followed by 20 mL of saturated 10 aqueous NaHCO3. The mixture was stirred until it stops bobbling. The mixture was extracted by EtOAc (60 mL x 2), dried over Na2SO4, and then concentrated. To the residue was added 5 mL of ether followed by 5 mL of hexanes. The solid was collected by filtration to give 160 mg of crude 3 which contains a little acylated amine but pure enough for the sulfone displacement reaction. The filtrate was purified by 15 column with 20% of AcOEt/ CH2CI2 to give additional 30 mg of 3. 'H NMR (400 MHz, CDCI3) 6 6.85 (s, 1 H), 4.61 (brs, 2H), 3.92 (s, 3H).
SEM
SEM N-N
C02Me N~N \ ~
Br /
~ N + Br , --~ NI`
H2N S~ N1~ NN
N\/'N
S02Me COZMe S-N
20 To a solution of compound 3 (89 mg, 0.56 mmol) and 6-bromo-8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine (258 mg, 0.55 mmol) in 2 mL of DMF, was added NaH (60% dispersion in oil, 44 mg, 1.1 mmol).
The reaction was stirred at room temperature for 15 min. It was quenched with 5 mL
of saturated aqueous NH4CI and diluted with 30 mL of water. The solid was collected by filtration, washed with water and MeOH. It was dried under vacuum to give 255 mg of compound 4. 'H NMR (400 MHz, DMSO-d6) b 8.85 (s, 1 H), 8.22 (s, 1 H), 8.15 (s, 1 H), 7.96 (s, 1 H), 7.62 (s, 1 H), 5.50 (s, 2H), 3.85 (s, 3H), 3.60 (t, 2H), 1.83 (t, 2H), 0.00 (s, 9H).
SEM
SEM SEM N-N
N \'N
/ I \
BrN N Stey Step A N N
N
N N N N
HN HN
S C02Me S C02Me S-N OH
N N
Step A: To a solution of 4 (76 mg, 0.14 mmol) in 6 mL of THF was added Pd(PPh3)4 (16 mg, 0.014 mmol) and 0.35 mL of MeZnCI (2 M solution in THF, 0.69 mmol).
The reaction was stirred at 80 C for 20 min. It was cooled to room temperature and quenched by adding 0.5 mL of MeOH. It was diluted with 30 mL of CH2CI2 and washed with 20 mL of 0.5 N aqueous HCI solution. The solvent was removed under vacuum. The residue was purified by flash chromatography eluting with 5%
MeOH/CH2CI2 to give 50 mg of 5-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-ylamino}-isothiazole-3-carboxylic acid methyl ester contaminated by a small amount of triphenylphosphine oxide.
Step B: The above crude material was dissolved in 5 mL of THF. To the solution was added 0.5 mL of LiBHEt3 (1 M solution in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding 5 mL of saturated aqueous solution. The mixture was extracted by 30 mL of CH2CI2. The organic was concentrated and purified by flash chromatography eluting with 5% MeOH/CH2CI2 to give 25 mg of compound 5. NMR (400 MHz, CDCI3) 6 7.90 (s, 1 H), 7.82 (s, 1 H), 7.60 (s, 1 H), 7.48 (s, 1 H), 6.90 (s, 1 H), 5.55 (s, 2H), 4.75 (brs, 2H), 3.65 (t, 2H), 2.50 (s, 3H), 1.00 (t, 2H), 0.00 (s, 9H).
SEM
N`N SEM
N'N
N \ -- N
N\\/'N
~HN
S-N OH /
S-N OMs To a solution of compound 5 (200 mg, 0.438 mmol) in 20 mL of THF, was added triethylamine (0.21 mL, 1.5 mmol) and methanesulfonylchloride (0.10 mL, 1.3 mmol).
5 The reaction was stirred at room temperature for 30 min. It was quenched by adding 1 mL of MeOH. The solution was diluted by 30 mL of CH2CI2, washed consecutively with 15 mL of 2 N aqueous HCI, water, and brine. The solvent was removed under vacuum to give 230 mg of crude compound 6 which was used in further transformations without further purification.
SEM SEM SEM
~ N'N N'N
N
N \ I \ I
N Step A N Step B _\
N YN1` N
~ ~ -i N~ N N
N I
HN HN HN
50~~
OMs 3 z Step A: Mixture of compound 6 (17 mg, 0.032 mmol) and sodium azide (15 mg, 0.23 mmol) in 1 mL of DMF was heated at 70 C for 3 h. It was cooled to room temperature and added 10 mL of water. The resulting solid was collected by filtration and purified by flash chromatography eluting with 5% MeOH/CH2CI2 to give 12 mg of (3-azidomethyl-isothiazol-5-yl)-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-amine.
Step B: The above material was dissolved in 3 mL of MeOH. To the solution was added 15 mg of 10% wt. Pd/C. The mixture was stirred under H2 (1 atm) for 1 h.
It was filtered through celite. The filtrate was concentrated under vacuum to give 12 mg of compound 7. NMR (400 MHz, CDCI3) 6 7.88 (s, 1H), 7.80 (s, 1H), 7.60 (s, 1H), 7.47 (s, 1 H), 6.86 (s, 1 H), 5.55 (s, 2H), 4.00 (brs, 2H), 3.65 (t, 2H), 2.50 (s, 3H), 1.00 (t, 2H), 0.00 (s, 9H).
SEM H
N'N
N I
N N
N N
HN
NHN
S-N NH
To a solution of compound 7 (12 mg, 0.026 mmol) in 2 mL of THF heated at 70 C, was added 0.5 mL of 4 N HCI in dioxane. To the resulting mixture was added MeOH
until it became homogeneous. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. The solid was collected by filtration and washed with ether to give 9 mg of compound 8 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.23 (s, 1 H), 8.20 (s, 2H), 8.03 (s, 1 H), 7.20 (s, 1 H), 4.22 (s, 2H), 2.59 (s, 3H). HPLC-MS tR = 1.82 min (UV 254nm). Mass calculated for formula C14H14N$S 326.1;
observed MH+ (LCMS) 327.2 (m/z).
SEM SEM H
N-N N, N'N
N
\
N Step N \ Step B' N
N
N_~ N N_ N N
~
~ HN
HN HN
S-N N-Step A: To a solution of compound 7 (9 mg, 0.02 mmol) in 1 mL of MeOH/CH2CI2 (1:1), was added formaldehyde (40% wt. in water, 6 mg, 0.2 mmol). It was stirred at room temperature for 15 min when NaBH4 (16 mg, 0.4 mmol) was added in two portions. The mixture was purified by flash chromatography eluting with NH4CI
(aq.)/MeOH/CH2CI2 (1:5:190) to give 5 mg of (3-dimethylaminomethyl-isothiazol-5-yl)-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-amine.
Step B: The above material was then dissolved in 2 mL of THF. The resulting solution was heated at 70 C when 0.5 mL of 4 N HCI in dioxane was added. To the resulting mixture was added 1 mL of MeOH. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. Most of the solvent was removed under vacuum. To the residue was added 5 mL of ether. The solid was collected by filtration and washed with ether to give 5 mg of compound 9 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.21 (s, 1 H), 8.18 (s, 2H), 8.08 (s, 1 H), 7.30 (s, 1 H), 4.42 (s, 2H), 2.95 (s, 6H), 2.59 (s, 3H). HPLC-MS tR = 2.04 min (UV 254nm). Mass calculated for formula 354.1; observed MH+ (LCMS) 355.2 (m/z).
SEM SEM
N-N N- N
\ I \ I
N N
N~N N~N
HN HN
CHO
S-N OH S-N
To a solution of compound 5 (2.50 g, 5.47 mmol) in 100 mL of THF, was added 0.3 5 mL of water followed by Dess-Martin periodinane (6.96 g, 16.4 mmol). The reaction was stirred at room temperature for 30 min. The solid was filtered off. The filtrate was diluted with 200 mL of CH2C12, and washed with 100 mL of saturated aqueous solution. The organic was dried over anhydrous Na2SO4 and then concentrated.
To the residue was added 30 mL of acetonitrile. The solid was collected by filtration to 10 give 2.05 g of compound 10. NMR (400 MHz, DMSO-d6) 6 12.38 (s, 1 H), 9.84 (s, 1 H), 8.60 (s, 1 H), 8.11 (s, 1 H), 7.96 (s, 1 H), 7.91 (s, 1 H), 7.55 (s, 1 H), 5.50 (s, 2H), 3.60 (t, 2H), 2.45 (s, 3H), 1.83 (t, 2H), 0.00 (s, 9H).
SEM SEM H
N- % N N-N N'N
\ I \ I \ ~
Step A Step B
N \ ~ I N - ~Nl~
N \~N N~N N~ 'N
HN CHO HN HN
/
S-N S-N N S-N N
Step A: A solution of compound 10 (100 mg, 0.220 mmol) and pyrrolidine (156 mg, 2.20 mmol) in 14 mL of CH2CI2 was stirred at room temperature for 20 min. To the solution was added two drops of acetic acid, followed by NaBH4 (67 mg, 1.8 mmol).
The resulting mixture was stirred at room temperature for 5 min when 3 mL of MeOH
was added. The stirring was continued for additional 20 min. The reaction was quenched by adding 15 mL of saturated aqueous NaHCO3 solution. After diluted with 20 mL of CH2CI2, the organic was isolated. The solvent was removed under vacuum.
The residue was purified by flash chromatography eluting with NH4CI
(aq.)/MeOH/CH2CI2 (1:10:190) to give 98 mg of {6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-(3-pyrrolidin-1-ylmethyl-isothiazol-5-yl)-amine. NMR (400 MHz, CDCI3) 6 7.88 (s, 1 H), 7.81 (s, 1 H), 7.60 (s, 1 H), 7.48 (s, 1 H), 6.96 (s, 1 H), 5.55 (s, 2H), 3.80 (s, 2H), 3.65 (t, 2H), 2.70 (brs, 4H), 2.50 (s, 3H), 1.85 (brs, 4H), 0.96 (t, 2H), 0.00 (s, 9H).
Step B: To a solution of {6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-(3-pyrrolidin-1-ylmethyl-isothiazol-5-yl)-amine (98 mg, 0.19 mmol) in 8 mL of THF heated at 70 C, was added 2 mL of 4 N HCI in dioxane.
To the resulting mixture was added MeOH until it became homogeneous. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. To the mixture was added 3 mL of ether. The solid was collected by filtration and washed with ether to give 79 mg of compound 11 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.18 (s, 2H), 8.13 (s, 1 H), 8.00 (s, 1 H), 7.22 (s, 1 H), 4.50 (s, 2H), 3.62-3.68 (m, 2H), 3.06-3.15 (m, 2H), 2.58 (s, 3H), 1.95-2.22 (m, 4H). HPLC-MS tR = 2.03 min (UV 254nm)= Mass calculated for formula C1$H2ON$S 380.2; observed MH+ (LCMS) 381.2 (m/z).
By essentially the same procedure set forth in Example 11, only replacing pyrrolidine with other respective aliphatic amines- in step A, compounds shown in column 2 of Table 1 were prepared.
SEM SEM H
N-N N-N N'N
Step A Step B
N \ --- I N \ -~ Nl~
N \~N N`\ ~N N~
HN
CHO HN HN
R~ R, TABLE I
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z H
N'N
\ I
N
12-1 NY-1--- N 382.5 383.2 2.15 HN~
~~ / --~
S-N N--\
H
N-N
I \
N
12-2 NY-1-N 408.5 409.2 2.31 HN~
S-N N
H
N'N
N
12-3 NY-,-- N 396.5 229.2 1.49 HN' r / --~
S-N N~
`-0 H
N' N
N
12-4 NY-,-- N 394.5 395.2 2.18 HN
S-N N
H
N'N
N
12-5 N 408.5 409.2 2.26 HN~^
~~ /--\
S-N N
H
N' I N
N
12-6 N~ N 424.5 425.2 1.95 HN\ ^
~/ /
S-N N
OH
H
N'N
N
12-7 N~N 408.5 409.2 2.35 HN~ ^
~~ /--\
S-N N
\__/
N, N
12-8 N~ N 409.5 410.2 1.76 HN~ ^
~~ /~--\
S-N N~
~N
H
N'N
N
12-9 N 424.5 425.2 2.18 HN
S-N N
OMe H
N' I N
~N \
12-10 N-)-- N 410.5 411.2 2.04 HN~
S-N aOH
H
N' I N
N
12-11 NY-,-- N 412.5 413.2 2.23 HN~
S-N N~
~S
H
N'N
N
12-12 N N 430.5 431.2 2.35 HN~
S-N
b /N
H
N-N
N
N`\/'N
12-13 HN~ 444.6 445.2 2.40 ih S-N N
b H
N' I N
N
12-14 NY-1--- N 422.5 423.2 2.50 HN~
S-N N
H
N'N
\ I
N
12-15 NY-,-- N 448.6 449.2 2.69 HN\ ^
~/ /
S-N N
H
N'N
12-16 N \
IN ; - N 428.5 429.2 2.34 HN~ ^
'(~ /
S-N N
H
N'N
NYl-- N 445.5 446.2 1.76 HN' r / --~
S-N N
~ \
-N
H
N' I N
'-e'N
12-18 N~N 442.5 443.2 2.39 HN\
~//
S-N N
b H
N' I N
N
12-19 NY-,-- N 408.5 409.2 2.15 HN\
S-N N
H
N'N
N
12-20 N~N 466.6 467.3 2.23 HN~
S'N N
O~
O
H
N, I N
N
12-21 NY-1- N 466.6 467.3 2.24 HN~
O
S-N a-o H
N'N
N'Ilf~ N
12-22 N~N 422.5 423.2 2.41 HN~
~~ /~----~
H
N'N
\ I
N
12-23 NY-1--- N 442.5 443.2 3.51 HN~ ^ -/~
S N N
H
N'N
N
12-24 NY-,-- N 408.5 409.2 2.32 HN
S-N N ' H
N'N
N
12-25 Nj,)'- N 448.5 449.2 2.65 HN~
/~--~
S-N N
N' I N
~N \
12-26 N) N 424.5 425.2 2.07 HN S-N aj OH
H
N'N
N~~
NY'N
12-27 HN 484.6 485.3 2.79 S-N N
H
N' I N
N
12-28 NY-,-- N 470.6 471.3 2.60 HN\
S-N N
H
N'N
N
12-29 NY-,-- N 428.5 429.2 3.27 HN
S-N to N- N
I
N
12-30 NY-,-- N 382.17 393.17 1.97 HN\ ^
~/ /
S-N -~
H
N'N
N \
12-31 N~N 396.18 397.18 2.01 HN~
S N --~
N'N
N \
12-32 N~N 410.20 411.20 2.04 HN~ ^
~~ /~
S-N N-~-\
H
N' I N
\
N
12-33 N N 422.20 423.20 2.52 HN\ ^ ~
~S/-N~N
H
N'N
N
12-34 NY~-- N 396.18 397.18 2.25 HN\
S-NN-~
H
N' I N
NI_ 12-35 NN 406.17 407.17 2.24 HN /^
S_NN
H
N-N
12-36 N~N 438.20 439.20 2.36 HN
O
S-N
H
N'N
N
12-37 HN N 442.19 443.19 2.30 Y\lr o S-N N~
O
H
N' N
N
12-38 N\~ N 398.16 399.16 2.12 O
HN
S_N~--\N--/' SEM
SEM N%
- N
% N
C02Me `N
N + / --~ ~ \
N
S02Me C02Me S-N
By essentially the same procedure set forth in Example 4, only replacing 6-bromo-8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine with 8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine, compound 13 was prepared. NMR (400 MHz, DMSO-d6) b 8.66 (s, 1 H), 8.22 (d, 1 H), 8.21 (s, 1 H), 8.03 (s, 1 H), 7.82 (d, 1 H), 5.58 (s, 2H), 3.96 (s, 3H), 3.69 (t, 2H), 3.40 (s, 1 H), 0.95 (t, 2H), 0.02 (s, 9H).
SEM SEM
N- N N~N
\ I \ I
N N
N N NJIL-- N
HTN HN
C02Me S-N S-N OH
To a solution of compound 13 (830 mg, 1.76 mmol) in 50 mL of CH2CI2 stirred at 0 C, was added 7.05 mL of LiBHEt3 (1 M solution in THF). The reaction was stirred at room temperature for 10 min. It was quenched by adding saturated aqueous NH4CI
solution. The organic was separated and washed with saturated aqueous NaHCO3 solution. The solvent was removed under vacuum. To the residue was added 10 mL
of MeOH. The solid was collected by filtration to give 530 mg of compound 14.
NMR
(400 MHz, CD3OD) 6 8.38 (s, 1H), 7.98 (s, 1H), 7.97 (d, 2H), 7.78 (s, 1H), 7.69 (d, 2H), 7.15 (s, 1 H), 5.55 (s, 2H), 4.62 (s, 2H), 3.66 (t, 2H), 0.92 (t, 2H), 0.00 (s, 9H).
SEM SEM
`N `N
N \ -~ N
N T\--- N NY-,-- N
HN HN
CHO
/
y /
S-N N OH S-N
To a solution of compound 14 (258 mg, 0.582 mmol) in 20 mL of THF, was added 0.05 mL of water followed by Dess-Martin periodinane (740 mg, 1.75 mmol). The reaction was stirred at room temperature for 1.5 h. The solid was filtered off. The filtrate was diluted with 100 mL of CH2CI2, and washed with water and brine.
The solvent was removed under vacuum, the residue was purified by flash chromatography eluting with 5% of MeOH/CH2CI2 to give 230 mg of compound 15.
SEM SEM H
N-N N-N N'N
Step A Step B ^
~ \N N r~_ N
NN N N~/1`\N
HN HN H'N
/
f / CHO
R~ R, By essentially the same procedure set forth in Example 11, compounds shown in column 2 of Table 2 were prepared by replacing compound 10 with compound 15, and 15 replacing pyrrolidine with other respective aliphatic amines in step A.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N'N
N
16-1 N~N 394.5 395.2 2.02 HN~
H
N'N
\
~N \
16-2 N~ N 394.5 395.2 2.13 HN~
S-N N
H
N'N
N
~
16-3 N~ N 434.6 435.2 2.50 HN~
S-N
H
N'N
N
~
16-4 Nl N 428.5 429.2 2.22 HN S-N
H
N' I N
N
16-5 Nj,'I'-N 408.5 409.2 2.18 HN S-N N
H
N' ( N
N
~
16-6 N~ N 408.5 409.2 2.21 HN S-N
N' I N
N
16-7 N'~'-N 381.2 382.2 2.55 HN\
S'N N
H
N'N
N
16-8 NY-I--N 366.14 367.14 2.43 HN~ ^
~~ /-~
S-N N
1) Walsh R.J.A.; Wooldridge, K. R. H. J. Chem. Soc. Perkin Trans. 1972, 1247.
SEM SEM SEM SEM
N'N N,N N-N N-N
I I I I
N Part A N Part B Part C N
N~ ~)~ \ Y~N \ -~ ~ \
N N1\_N N~N N~N
HN S~N S N S, N S
1~N SEM" I/N SEM" 1 ~N SEM"
CO2CH3 COZCH3 OH p S--O
~ 2 3 4 SEM H
\'N \'N
Pa-~ N Pa E
YN
NN N I N
"N S H`TN~g SEM
TL /N N
R r{
O O
Part A: A solution of ester (2.38 g, 4.91 mmol, 1 equivalent) in DMF (40 mL) was treated with NaH (60% dispersion in oil, 1.5 equivalents) for 20 min at rt, at which time, the reaction mixture was cooled to -10C and 2-(trimethylsilyl)ethoxymethyl chloride ( 0.87 mL, 1 equivalent) added to the reaction mixture. The resulting solution was allowed to slowly warm to rt and continued to stir at rt for a further 1 h. LC-MS
analysis indicated the reaction was complete. The reaction was quenched with methanol (15 mL), diluted with ethyl acetate (300 mL) and washed with sat.
sodium bicarbonate, water, brine, dried (sodium sulfate) and concentrated.
Purification by column chromatography (Si02 40% ethyl acetate / hexanes) afforded the desired product as a yellow solid 1.2 g (40%). HPLC-MS tR = 2.79 Min (UV 254,m). Mass calculated for formula C27H41 N7O4SSi2 615.25, observed LC/MS m/z 616.2 (M+H).
Part B: To a solution of compound from Part A (1.2 g, 1.90 mmol, 1 equivalent) in THF
(100 mL) was added superhydride solution (4 equivalents) at rt. The resulting solution was stirred at rt for 30 minutes at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. ammonium chloride and then extracted with dichloromethane (x2). The combined organic layers were dried (sodium sulfate) and concentrated. Purification by column chromatography (Si02 60 %
ethyl acetate / hexanes) afforded alcohol as a clear oil (47%). HPLC-MS tR = 2.49 Min (UV
254nm). Mass calculated for formula C26H41 N7O3SSi2 587.25, observed LC/MS m/z 588.3 (M+H).
Part C: A solution of alcohol from Part B (0.52 g, 0.88 mmol, 1 equivalent) in DCM (15 mL) was treated with triethylamine (1.5 equivalents) for 15 min at OC (ice-bath), at which time, methanesulfonyl chloride (1.2 equivalents) was added to the reaction at OC. The resulting solution was allowed to slowly warm to rt and continued to stir at rt for a further 3h. LC-MS analysis indicated the reaction was complete. The reaction mixture was diluted with ethyl acetate (100mL) and washed with water, brine, dried (anh. sodium sulfate) and concentrated to afford mesylate as a red/brown oil 0.59 g (100%) which was used without further purification. HPLC-MS tR = 2.66 Min (UV
254nm). Mass calculated for formula C27H43N7O5S2Si2 665.23, observed LC/MS m/z 666.1 (M+H).
Part D: A solution of the respective alcohol (3 equivalents) in THF (1.5 mL) was treated with NaH (60% dispersion in oil, 2 equivalents) for 15 min at rt, at which time, mesylate from Part C (40 mg, 0.06 mmol, 1 equivalent) was added to the reaction mixture. After stirring at rt for 1 h, LC-MS analysis indicated the reaction was complete.
The reaction was quenched with sat. aq. ammonium chloride and then extracted with ethyl acetate (twice). The combined organic layer was dried (sodium sulfate) and concentrated to afford crude ether, which was used without further purification.
Part E: A solution of compound from Part D in 1,4-dioxane (1 mL) was treated with 4N
HCI in 1,4-dioxane solution (1 mL) at 60C for 10 min at which time HPLC-MS
indicated that the reaction was complete. The solvent was removed and the residue was purified by Prep-LC. Conversion to a hydrochloric salt afforded compounds listed in Table 3.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N'N
N
17-1 NY-,-- N 398.2 399.2 2.55 HN\
S-NO-N\_ /
N
\
H
N-I N
~N \
N1-1-- N 438.2 439.3 2.79 HN` ^
~
~S-N~O-\_N~J
H
N-I N
\
17-3 N~N 426.2 427.3 2.68 HN\
~S-N~O-~-N
H
N' I N
N
Y`
17-4 N N I 440.2 441.2 2.75 HN
S_N
N-\
H
N'N
I
N
17-5 Nyl-- N 424.2 425.2 2.59 HN~
S N~- O
N
N'N
N
NY`N
17-6 HN S, 412.2 413.2 2.54 N
O
HN-N
I
N
NN
17-7 HN S/ N 424.2 425.2 2.61 O
DN
HN-N
N
17-8 N~N 410.1 411.1 1.113 H N 1 S%N 0 ~_O
~j HN-N
N
N~N 424.1 425.2 1.290 HN S, N
HN-N
N
17-10 NN 396.1 397.1 1.103 HN S, ~_N
~N \
17-11 N I 438.2 439.1 1.343 H N 1 S%N O
~_O
N
HN-N
~N \
17-12 Nyl N 377.1 378.2 1.94 H N
N /-' N
HN-N
N
17-13 N~N 377.1 378.2 2.65 HN S, N
NJ
HN-N
N
17-14 Ny'N 394.1 395.2 3.96 HN S, ~ /N 0 N
HN-N
. \~
N
17-15 Nyl-:::~ N 409.1 410.8 3.17 HN
/N O
NH
HN-N
N
N~ 'N
17-16 480.2 481.3 3.54 HN S, ~ /N
N
JN
HN
HN-N
N
17-17 "~" 423.2 424.3 3.15 HN
~NN-HN-N
N
17-18 H IN s, 438.2 439.1 3.32 /" 0~
N _~/
HN-N
~N \
N~_N
17-19 438.2 439.1 3.32 HN S, A N
HN-N
N
N~_N
17-20 HN S 452.2 453.3 3.55 N
/ `
HN-N
N
N~_N
17-21 HN s, 452.2 453.1 3.55 N
H
N-\ I, N
N~
17-22 N 405.1 406.2 2.57 HN SE N
N
N i~
0~~~!/
H
a 5~' N
NY
17-23 N I 482.0 483.3 2.98 HN S' i(Br No/
HN-N
~N \
N~N 410.1 411.1 2.77 H N 1S, /N O
N~
H
N- N
~N \
17-25 N11-1-- N 424.1 425.1 3.06 HN
S-N O
O
HN-N
N
N~N 487.1 488.4 3.82 HN 1 /N S~
N
~-~`,~-CH3 HN-N
N
N~ N 451.2 452.2 3.40 O
N \,JN- \
HN-N
N
17-28 N~ N 408.2 409.6 3.87 HN , N
H
N-N
N
N~
17_29 N 530.3 531.3 3.34 HN S.
, /N
N
H
N' I N
\
N
N\/ ' 17-30 N T 418.5 419.2 3.00 HN S
y ~N
N ~
O
H
N'N
N
17-31 N~N 473.1 / \
HN N _ S-N N
O~O
H
N- N
N
17-32 N Y-,-- N 473.1 HN
/
~
S-N ~
H
a N
17-33 N ~ N 473.1 HN
/
S-N ~
O O
H
N-N
N
17-34 NY-,-- N 465.2 NH
HN
O O
H
N-~N \
17-35 N~N 467.1 HN
S- N~
O2~NHAc O
H
N-N
17-36 N Y-,-- N 445.1 HN~
~' } N~
S-N N ~
H
N-A' N
17-37 Nyl-- N 445.1 HN
_ ~
S N ~
p\p N
H
N- N
N
17-38 NY-,-- N 445.1 HN ~
S-N ~ \
o 0 H
N-N
NI_ 17-39 N Y'' N 445.1 HN
S-N ~
N
O p H
N-~
\
N
N Y `N
17-40 HN ~ 472.1 S-NhN
O
,O
H
N-N
~ I
N
"N 457.1 HN
s "- N-0 O N
H
N-5:;~' N
"Yl-- N 409.1 HN~
S-N ON
H
N-N
"Y-,-- N 451.2 HN
S N
O N
I
SEM SEM SEM SEM
N'N N N- N N- N
i I I I
I/~N Part ' f/^N \ Part B N Pa rt~ I~ N
N'Y _N N)lj--N N - N N YN
HN S, N S N S, N S, 1 ~ N SEM I/N SEM 1 ~N SEM ~~NO /
CO2CH3 OH S~o SEM H
\'N \'N
PaRO' N Part E N NY N NY`N
SEM S HN S
~ /N ~ /N
R R
O O
By essentially the same procedures given in Preparative Example 17, compounds given in Table 4 can be prepared.
MS
Example Column 2 Exact m/z HPLC
mass (M+H) MS tR
H
N-N
N
NY-`N
18-1 HN S, N 412.2 413.2 2.36 O
N~
HN-N
N
N~N
18-2 HN S, 426.2 427.1 2.71 N
HN-N
~N
NN
18-3 HN 1 S, 400.1 401.1 2.47 N
S
/ N-HN-N
\ I
vl~ N
18-4 HN S, 416.1 417.1 2.23 0=S
/ N-I I
H3C\ N~ H3CN
NN N11 _N
IN
Example 19 was prepared in similar manner to Example 4. 'H NMR (300 MHz,.
DMSO-d6) 6 12.4 (bs, 1 H), 7.81 (s, 1 H), 7.75 (s, 1 H), 7.59 (s, 1 H), 3.85 (s, 3H), 2.49 (s, 3H).
I I
H3CN~ H3CN~
N `N --' N
~/ Y `N
HNI N SEM N I N
Example 20 was prepared in similar manner to Example 17, Part A. 'H NMR (300 MHz, CDCI3) 6 7.81 (s, 1 H), 7.73 (s, 1 H), 7.63 (s, 1 H), 6.61 (s, 2H), 3.98 (s, 3H), 3.74 (t, J = 8 Hz, 2H), 2.62 (s, 3H), 0.94 (t, J = 8 Hz, 2H), -0.83 (s, 9H).
I I
H3CN~ H3CN~
NY N Nj~N
S E M N N SEM' N I N
To a stirring solution of ester (2.40 g, 4.40 mmol) in tetrahydrofuran (96 mL) at -78 C
was added DIBAL-H (1M in dichloromethane, 11.0 mL, 11.0 mmol) dropwise. The mixture was stirred at -78 C for 3 hours at which time thin layer chromatography (30% ethyl acetate/hexanes) indicated the reaction was complete. The mixture was quickly poured into stirring saturated aqueous sodium potassium tartrate and stirred at room temperature for 14 hours. The mixture was extracted with ethyl acetate (2x250 mL), the organic layers were combined, washed with brine (100 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure affording compound 21 as a yellow solid 2.20 g (97%). 'H NMR (300 MHz, CDCI3) 8 9.99 (s, 1 H), 7.74 (s, 1 H), 7.73 (s, 1 H), 7.65 (s, 1 H), 6.60 (s, 2H), 3.74 (t, J =
8 Hz, 2H), 2.64 (s, 3H), 0.94 (t, J = 8 Hz, 2H), -0.07 (s, 9H).
I I
H3C\ N~ H3CN~
NI/`N NY _N
SEM' N I N SEM' N I S`N
CHO No To a stirring solution of aldehyde (1.30 g, 2.52 mmol), piperidine (257 mg, 3.02 mmol), and acetic acid (150 L, 2.52 mmol) in 1,2-dichloroethane (17 mL) at room temperature was added sodium triacetoxyborohydride (801 mg, 3.78 mmol) in one portion. The mixture was stirred at room temperature for 2 hours at which time thin layer chromatography (40% ethyl acetate/hexanes) indicated the reaction was complete. The reaction was quenched with 1 N sodium hydroxide (25 mL) and stirred for 20 minutes. The mixture was extracted with chloroform (3X20 mL), the organic layers were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Afforded compound 22 as a yellow solid 1.35 g (92%). 'H NMR
(300 MHz, CDCI3) S 7.70 (s, 1 H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2 H), 3.72 (t, J = 8 Hz, 2H), 3.62 (s, 2H), 2.58 (s, 3H), 2.47 (m, 4H), 1.58 (m, 6H), 0.93 (t, J =
8 Hz, 2H), -0.086 (s, 9H).
I I
H3C ^N~( H3CN~
N\~N NN
SEM N I N SEM N I S`N
CHO N
E
Example 23 was prepared in a similar manner to example 22 with the substitution of 3-methylpiperidine for piperidine. 'H NMR (300 MHz, CDCI3) S 7.70 (s, 1H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2H), 3.72 (t, J = 8 Hz, 2H), 3.62 (s, 2H), 2.85 (m, 2H), 2.59 (s, 3H), 1.98 (m, 1 H), 1.65 (m, 6H), 0.93 (t, J 8 Hz, 2H), 0.84 (d, J 6 Hz, 3H), -0.076 (s, 9H).
I I
H3CN~ H3C~N~
N~N NN
SEM N N SEM N I N
CHO No Example 24 was prepared in a similar manner to example 23 with the substitution of pyrrolidine for piperidine. 1 H NMR (300 MHz, CDCI3) 6 7.70 (s, 1 H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2H), 3.77 (s, 2H), 3.72 (t, J = 8 Hz, 2H), 2.61 (m, 4H), 2.59 (s, 3H), 1.81 (m, 4H), 0.92 (t, J = 8 Hz, 2H), -0.90 (s, 9H).
I I
H3C\ N~ H3CN
N N --~ N~ N/
T =2 HCl SEM- N S` HN
, IN , IN
No No A solution of iodide from Example 24 (20 mg, 0.035 mmol) in 1,4-dioxane (1 mL) was treated with 4N HCI in 1,4-dioxane (1 mL). The mixture was sonicated at room temperature for 2.5 hours, at which time HPLC indicated the reaction was complete.
The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded compound 25 as a white solid 15 mg (83%). 'H NMR (300 MHz, CD3OD) S 7.88 (s, 1H), 7.79 (s, 1 H), 7.17 (s, 1 H), 4.51 (s, 2H), 3.71 (m, 2H), 3,22 (m, 2H), 2.57 (s, 3H), 2.07 (m, 4H).
HPLC tR = 4.83 min (UV 254 nm). Mass calculated for formula C15H IN6S 440.03;
observed MH+ (MS) 441.5 (m/z).
I I
H3C\ ^N H3C` ^N~
N~N/ N`\'/N
~ =HCl SEMN f HN
/ N C fN H3 E
N N
Example 26 was prepared in a similar manner to example 25. 'H NMR (300 MHz, CD3OD) S 7.87 (s, 1 H), 7.79 (s, 1 H), 7.22 (s, 1 H), 4.39 (s, 2H), 3.52 (m, 2H), 2.96 (m, 1 H), 2.70 (m, 1 H), 2.57 (s, 3H), 1.90 (m, 4H), 1.21 (m, 1 H), 0.99 (d, J = 6 Hz, 3H).
HPLC tR = 5.06 min (UV 25A,m). Mass calculated for C H21IN6S 468.3; observed MH+
(MS) 469.7 (m/z).
The compounds shown in column 2 of Table 5 were prepared as follows:
R\ N~ RN3 N\~N N\) N
~ T = HCl SEM' N I S`N ~ I S`N
R1 R, A flask containing the prepared aryl iodide scaffolds (compound from Example 22, 23, or 24, 1 equivalent), commercially available or readily prepared in 1 to 3 steps aryl/heteroaryl/alkyl boronic acid/ester/boroxine or aryl/heteroaryl/alkyl magnesium bromide or aryl/heteroaryl/alkyl zinc chloride (1.5 - 3 equivalents), potassium phosphate or potassium carbonate (2- 3 equivalents) and Pd(PPh3)4 or PdCl2dppf (0.05 - 0.10 equivalents) was evacuated, backfilled with nitrogen and repeated. 1,4-Dioxane or N,N-dimethylformamide or 1,2-dimethoxyethane (1 - 3 mL) was added and the mixture was stirred at 50 - 130 C until reaction was complete as judged by thin layer chromatography (ethyl acetate/hexanes) or HPLC. The mixture was diluted with water (3 - 10 mL) and extracted with ethyl acetate (2-3 x 10-30 mL). The organic layers were combined, washed with brine (15 - 30 mL), dried over magnesium sulfate, filtered, concentrated, and purified by column chromatography (Si02, ethyl acetate/hexanes). The product obtained was dissolved in 1,4-dioxane (1 mL) and treated with 4 N HCI in 1,4-dioxane (1 mL) and sonicated at room temperature for 1-5 hours, at which time HPLC indicated the reaction was complete. The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded compounds 27-1 to 27-7.
MS
Example Column 2 MW MH+ HPLC
tR
m/z N~
H3C\-T/_ ,\
N~-`N
27-1 HN_, S I328.4 329.1 3.52 N
N' I
H3C ~J
N y~'-N
27-2 ~ S 370.5 371.1 4.34 IN
No H3C~N
~ 1 \
N\\ T/ '-N
27-3 HN S 356.4 357.4 3.98 , ~N
No H3C%
N' N
H3C-T~ N
27-4 N11)'-N 408.5 409.6 4.21 HN
, /N
No H3C\ N~
~/_ NY`N
27-5 HN' s, 356.4 357.4 3.91 ~ N CH3 N
H3C\
_IN
NYI\ `N
27-6 HN 342.4 343.2 3.71 C
~N
ND
N- NH
H3C ~
~
H3C\ N CH3 ~
27-7 N N 422.5 423.2 3.87 HN s I'N
No H3C\ ~N H3C\ N~
NY-' N/ N N =HCl SEM' N S, HN S, ~ N /N
ON N
A mixture of iodide (60 mg, 0.103 mmol), trimethyl(trifluoromethyl)silane (44 mg, 0.308 mmol), copper iodide (73 mg, 0.385 mmol), potassium fluoride (15 mg, 0.257 mmol), and anhydrous DMF (1.0 mL) was degassed with nitrogen then heated at 80 C in a sealed tube overnight. The mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/concentrated ammonium hydroxide). The resulting residue was dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added.
The resulting solution was sonicated at room temperature for 2 hours and concentrated under reduced pressure to dryness. Purification by preparative HPLC
and conversion to the hydrochloride salt afforded the title compound as an off-white solid 3.1 mg (6%). 'H NMR (300 MHz, CD3OD) 6 8.07 (s, 1 H), 7.85 (s, 1 H), 7.24 (s, 1 H), 4.40 (s, 2H), 3.61 (d, J = 12.3 Hz, 2H), 3.07 (t, J= 12.3 Hz, 2H), 2.55 (s, 3H), 1.75-2.03 (m, 5H), 1.56 (m, 1H). HPLC tR = 7.19 min. Mass calculated for formula C17H19F3N6S 396.13; observed MH+ 397.2 (m/z).
H3CIN N\ H3CN\ /
N 1 N NN =HCl SEM' N S~ HN S, ~ N N
A mixture of iodide (100 mg, 0.171 mmol) in anhydrous THF (2.0 mL) was cooled to -78 C and n-butyl lithium (2.5 M solution in hexanes, 89 pL, 0.222 mmol) was added dropwise. After stirring for 15 minutes a solution of hexachloroethane (45 mg, 0.188 mmol) in THF (1.0 mL) was added dropwise. After stirring the reaction at -78 C for 30 minutes the solution was quenched with a saturated aqueous solution of ammonium chloride (3.0 mL) and warmed to room temperature. The reaction was concentrated under reduced pressure, extracted with ethyl acetate (50 mL) and the organic layer dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/concentrated ammonium hydroxide). The resulting residue was dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added.
The resulting solution was sonicated at room temperature for 2 hours and concentrated under reduced pressure to dryness. Purification by preparative HPLC
and conversion to the hydrochloride salt afforded the title compound as an off-white solid 30 mg (40%). ' H NMR (300 MHz, CD3OD) 6 7.80 (s, 1 H), 7.73 (s, 1H), 7.22 (s, 1H), 4.39 (s, 2H), 3.59 (d, J = 12.3 Hz, 2H), 3.08 (t, J= 12.3 Hz, 2H), 2.55 (s, 3H), 1.75-2.03 (m, 5H), 1.56 (m, 1 H). HPLC tR = 4.79 min. Mass calculated for formula C16H19CIN6S 362.11; observed MH+ 363.7 (m/z).
H3C\ N~ H3C\ ~N~
N/ N1~ N =HCl SEM.N S, HN S~
~ N ~ N
N N
Example 30 was prepared in a similar manner as Example 29. 'H NMR (300 MHz, CD3OD) b 7.77 (s, 1H), 7.68 (s, 1H), 7.20 (s, 1H), 4.39 (s, 2H), 3.47-3.67 (m, 2H), 2.97 (m, 1 H), 2.71 (m, 1 H), 2.55 (s, 3H), 1.77-2.01 (m, 4H), 1.20 (m, 1 H), 1.00 (d, J=
6.4 Hz, 3H). HPLC tR = 4.98 min. Mass calculated for formula C17H21CIN6S
376.12;
observed MH+ 377.6 (m/z).
I Br H3CIN N\ / H3C~N\ /
N N NN =HCl SEM' N S, HN S~
N
~ 1 N 1, ON N
Example 31 was prepared in a similar manner to compound 29 with the substitution of tetrachlorodibromoethane for hexachloroethane. 'H NMR (300 MHz, CD3OD) 6 7.84 (s, 1 H), 7.83 (s, 1 H), 7.25 (s, 1 H), 4.41 (s, 2H), 3.61 (d, J = 12.3 Hz, 2H), 3.08 (t, J=
12.3 Hz, 2H), 2.57 (s 3H), 1.77-2.03 (m, 5H), 1.55 (m, 1 H). HPLC tR = 5.19 min.
Mass calculated for formula C16H19BrNsS 406.06; observed MH+ 407.4 (m/z).
F
/
N `T` /NHZ N `T\/N \ I
B I N , B ~N 0 O O
To a solution of aminopyrimidine (100 mg, 0.452 mmol) in anhydrous pyridine (2.0 mL) was added 3-fluorobenzoyl chloride (72 mg, 0.452 mmol). After stirring at room temperature overnight, the reaction was concentrated under reduced pressure, diluted with water (30 mL), and extracted with methylene chloride (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to afford the title compound as an off-white solid 124 mg (80%). 'H NMR (300 MHz, CDCI3) 6 8.95 (s, 2H), 8.72 (s, 1 H), 7.66-7.72 (m, 2H), 7.49 (m, 2H), 1.36 (s, 12H).
/ F
H
N NH2 N N \ I F
BY BY
O, ,N G N 0 i i O O
Prepared in a similar manner as compound 31 affording the title compound as an off-white solid 131 mg (80%). 'H NMR (300 MHz, CDCI3) 6 8.93 (s, 2H), 8.65 (s, 1H), 7.83 (m, 1 H), 7.69 (m, 1 H), 7.30 (m, 1 H), 1.34 (s, 12H).
-N
H3C\ N H3C` N H3C\ N
N~ N~ N=HCl + N~ =HCl SEM- N ~ S, ~, IN
~ ~N I ~N
a a a A mixture of iodide (60 mg, 0.103 mmol), tri-n-butyl(pyridyl)tin (57 mg, 0.154 mmol), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (8 mg, 0.0103 mmol), and potassium fluoride (18 mg, 0.309 mmol) in anhydrous 1,4-dioxane (1.0 mL) was degassed with nitrogen then heated at 85 C in a sealed tube overnight. The mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (2 x 100 mL). The organic layer was then separated, dried over sodium sulfate, filtered, concentrated under reduced pressure to residue, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/ concentrated ammonium hydroxide). The resulting residue was then dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added. The resulting solution was sonicated at room temperature for 2 hours and then concentrated under reduced pressure to dryness. Purification by preparative HPLC and conversion to the hydrochloride salt afforded de-halogenated product 3.2 mg (10%) as an off-white solid: 'H NMR (300 MHz, CD3OD) 6 8.23 (s, 1H), 8.13 (s, 2H), 7.29 (s, 1 H), 4.55 (s, 2H), 3.72 (br s, 2H), 3.29 (m, 2H), 2.61 (s, 3H), 2.05-2.18 (m, 4H). HPLC tR =3.49 min. Mass calculated for formula C15H16N6S 314.13;
observed MH+ 315.2 (m/z).
Also afforded coupling product 5.0 mg (10%) as an off-white solid: 'H NMR (300 MHz, CD3OD) 6 8.95 (s, 1 H), 8.86 (d, J = 5.1 Hz, 1 H), 8.50 (s, 1 H), 8.28 (t, J = 7.5 Hz, 1 H), 8.18 (d, J = 7.8 Hz, 1 H), 7.70 (t, J = 6.3 Hz, 1 H), 7.26 (s, 1 H), 4.54 (s, 2H), 3.74 (m, 2H), 3.29 (m, 2H), 1.99-2.30 (m, 4H). HPLC tR =4.80 min. Mass calculated for formula C20H21N7S 391.16; observed MH+ 392.5 (m/z).
H3C\ ^N \ N
N y ~
N~ ~N N =HCl HN
SSEM N I N f IN
Sodium borohydride (3 mg, 0.073 mmol) was added to a room temperature suspension of iodide (15 mg, 0.037) in methanol (1 mL). The reaction was allowed to stir for 30 minutes then quenched with water (20 mL). The mixture was diluted with diethyl ether (20 mL) and the phases were allowed to separate. The organic layer was dried (sodium sulfate), filtered and concentrated to afford a protected de-halogenated intermediate. The reduced product (7 mg, 0.017 mmol) was subjected to the acidic conditions outlined previously to afford the title compound as a yellow solid 2 mg (17%). 1 H NMR (300 MHz, CD3OD) 6 7.94 (s, 1 H), 7.90 (s, 1 H), 7.74 (s, 1 H), 7.55 (s, 1 H), 3.94 (s, 3H), 2.50 (s, 3H). HPLC tR = 4.67 min (UV 254nm)= Mass calculated for formula C12HI1N502S 289.06; observed MH- (ESI MS) 288.0 (m/z).
I I
H3CN g3C_ ^N~
NN N
7 --~ =HCl SEM N HN
, /N f IN
No No Example 36 was prepared in a similar manner to Example 31. 'H NMR (300 MHz, CD3OD) 6 7.72 (s, 1 H), 7.69 (s, 1 H), 7.15 (s, 1 H), 4.38 (s, 2H), 3.69-3.52 (m, 2H), 3.17-2.96 (m, 2H), 2.54 (s, 3H), 2.06-1.70 (m, 5H), 1.65-1.44 (m, 1 H). HPLC
tR = 5.00 min (UV 254nm). Mass calculated for formula C16H191N6S 454.04; observed MH+
(ESI
MS) 455.0 (m/z).
I CN
H3C\ N H3C\ ^N~( N~N/ --~ NN
=HCl SEMN ' HN
~ /N ~ IN
No N_ ) Pd2(dba)3 (5 mg, 0.005 mmol) was added to a room temperature solution of DPPF (6 mg, 0.103 mmol) in N,N'-dimethylformamide (1 mL) and stirred for 10 minutes. The mixture was then added to a solution of iodide (60 mg, 0.103 mmol), Zn(CN)2 (12 mg, 0.103 mmol) in N,N'dimethylformamide (4 mL). The reaction was heated to 150 C in the microwave for 30 minutes, cooled to room temperature then.
concentrated to dryness. Purification of the resultant residue by flash chromatography.
(Si02; 12 g; 10% methanol in methylene chloride) afforded impure nitrile as a yellow solid. The impure nitrile (22 mg, 0.045 mmol) was dissolved in 2 N HCI (4 mL) without further purification. The resultant solution was sonicated at 45 C for 2 hours. Upon completion, the reaction was concentrated to dryness. Purification of the resultant residue by prep-HPLC afforded the title compound as a white solid 8 mg (18%).
'H
NMR (300 MHz, CD3OD) b 8.22 (s, 1 H), 7.93 (s, 1 H), 7.22 (s, 1 H), 4.40 (s, 2H), 3.73-3.52 (m, 2H), 3.20-2.97 (m, 2H), 2.55 (s, 3H), 2.06-1.71 (m, 5H), 1.66-1.42 (m, 1 H).
HPLC tR = 4.50 min (UV 254nm). Mass calculated for formula C17H19N7S 353.14;
observed MH+ (ESI MS) 354.3 (m/z).
H3C\T5^N~ H3C ^ N \
N) Y`,~
N --- N~N
1 =HCl SEM'N S. HN S~
( N , IN
No N
o A mixture of iodide (70 mg, 0.12 mmol), Pd(dppf)C12 (9 mg, 0.012 mmol), sodium tert-butoxide (35 mg, 0.36 mmol) and sodium thiomethoxide (17 mg, 0.24 mmol) was flushed with nitrogen then dissolved into 1,4-dioxane (5 mL). The solution was heated to 95 C in the microwave for 90 minutes. The reaction was cooled to room temperature, diluted with ethyl acetate (100 mL), and filtered through celite. The organic layer was washed with water (50 mL) and brine (50 mL) then dried (sodium sulfate), filtered and concentrated to dryness. Purification of the resultant residue by prep-HPLC afforded the protected thiomethylether. The thiomethylether (35 mg, 0.07 mmol) was subjected to the reaction conditions outlined in example 110 to afford the title compound as a white solid 6 mg (11%). 'H NMR (300 MHz, CD3OD) 6 8.28 (s, 1 H), 8.25 (s, 1H), 7.34 (s, 1H), 4.43 (s, 2H), 3.68-3.52 (m, 2H), 3.18-2.98 (m, 2H), 2.67 (s, 3H), 2.49 (s, 3H), 2.05-1.71 (m, 5H), 1.65-1.44 (m, 1 H). HPLC tR =
4.74 min (UV 254nm). Mass calculated for formula C17H22N6S2 374.13; observed MH+ (ESI
MS) 375.3 (m/z).
SEt H3C\ N \\ H3C ^ N \
N/~
N
=HCl SEMN S. HN1S"~ ~N No N
~
A combined mixture of iodide (70 mg, 0.12 mmol), sodium thioethoxide (20 mg, 0.24 mmol), Pd(dppf)C12 (9 mg, 0.012 mmol) and sodium tert-butoxide (35 mg, 0.36 mmol) was flushed with nitrogen gas then dissolved into 1,4-dioxane (5 mL).
The reaction was heated to 95 C and stirred for 72 hours. The reaction was then cooled to room temperature, diluted with ethyl acetate (100 ml), and filtered through celite.
The filtrate was washed with water (50 mL) and brine (50 mL) then dried (sodium sulfate), filtered and concentrated to dryness. Purification of the resultant residue by flash chromatography (Si02; 12 g; 0% to 10% methanol in methylene chloride) afforded a thioethylether intermediate as a yellow solid. The thioethylether (10 mg, 0.019 mmol) was subjected to the reaction conditions outlined in example 110 to afford the title compound as a white solid 2 mg (4%). 'H NMR (300 MHz, CD3OD) 8.32 (s, 1 H), 8.28 (s, 1 H), 7.35 (s, 1 H), 4.43 (s, 2H), 3.68-3.55 (m, 2H), 3.17-3.01 (m, 2H), 2.90 (q, J = 7.3 Hz, 2H), 2.67 (s, 3H), 2.07-1.71 (m, 5H), 1.65-1.42 (m, 1 H), 1.28 (t, J = 7.3 Hz, 3H). HPLC tR = 5.27 min (UV 254nm). Mass calculated for formula C18H24N6S2 388.15; observed MH+ (ESI MS) 389.7 (m/z).
0 DPPA / Et3N O~y N S Part B N Na104 / OSOq HO ~ i S t-BuOH / 80 C OI -j ~B~ ~Sn t Bu ~ ~S Dioxane: H20 (3;1) Br `N O N~ 2,6rLutidine / rt N Part A 1,4dioxane/
Pd(0) Part C
H RR1-NH / NaBH(OAc)3 / R
O~N S H CH3COOH (cat.)DCM / O H RI ~ TMSI / DCM H N ~
\ O ~N O NaBH4 O N~SN R 20 min 2S~N-R
X\ ~ ~ i Part D N Part E N
H
N'N
NaH/DMSO I
H N
N'N N\ ~N ~~ I
\ T
N_ IN
Y ~N
1 O 0=S=0 Part A: To a stirred solution of 2-Bromo-thiazole-5-carboxylic acid (2.0 g, 9.615 mmol) in t-Butanol (30 mL) and triethyl amine (1.5 mL, 10.57 mmol) was added diphenylphosphoryl azide (2.9 g, 10.57 mmol) and reaction mixture was heated to 80 C and stirred for 12 hrs, LCMS showed the complete disappearance of the starting material. Reaction mixture was cooled to room temp., solvent removed under vacuum, water (100 mL) added and extracted with ethyl acetate (3 x 100 mL). Organic layer was washed with water, brine, dried over sodium sulfate and concentrated, crude material was passed through small pad of silica gel and resultant (2-Bromo-thiazol-5-yl)-carbamic acid tert-butyl ester (solid) was used as such in the next step, yield 2.5 g (90%). 'H NMR (400 MHz, DMSO-d6 6 7.10 (s, 1 H), 7.05 (s, 1 H), 1.51 (s, 9H).Mass calculated for formula C8H11 BrN2O2S 277.97; observed MH+ (LCMS) 279.0 (m/z).
Part B: To a stirred solution of (2-Bromo-thiazol-5-yl)-carbamic acid tert-butyl ester (2.5 g, 8.9928 mmol) in 1,4-dioxane (20.0 mL) were added tributy(vinyl)tin (2.9 mL, 9.892 mmol), 2,6-di-tert-butyl-4-methylphenol (cat. amt) and tetrakis(triphenyl phosphine) palladium(0) (506.0 mg, 0.4496 mmol). The reaction mixture was heated to 100 C and stirred for 12 hrs, LCMS showed the complete disappearance of the starting material. Reaction mixture was cooled to room temp, filtered and solid washed with ethyl acetate, combined filtrate (organic solvent) was removed under vacuum, crude material was purified using biotage HPLC using hexane / ethyl acetate gradient 0.0 to 100 % to yield (2-Vinyl-thiazol-5-yl)-carbamic acid tert-butyl ester (solid) 1.1 g (54%). 1 H NMR (400 MHz, CDCI3 b 7.27 (d, J = 12.7 Hz,2H), 7.19 (brs, 1 H), 6.84-6.77 (m, 1H), 6.87 (d, J = 17.0 Hz, 1H), 5.43 (d, J = 10.5 Hz,1 H), 1.52 (s, 9H).
Mass calculated for formula CjoH14N202S 226.08; observed MH+ (LCMS) 227.1 (m/z).
Part C: To a stirred solution of (2-Vinyl-thiazol-5-yl)-carbamic acid tert-butyl ester (0.76 g, 2.857 mmol) in 1,4-dioxane : water (30 : 9 mL), were added sodium periodate (2.5 g, 11.43 mmol) osmium tetroxide (2.5% solution in 2-propanol) (0.5 mL) and 2,6-lutidine (0.663 mL, 5.714 mmol) and reaction mixture was stirred for 4 hrs, LCMS
showed the almost disappearance of the starting material. Reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate, organic layer was washed with water, brine, dried over sodium sulfate and concentrated under high vacuum to yield aidehyde 710 mg (92%). Crude product was used as such in the next reaction. 1 H NMR (400 MHz, DMSO-d6 6 11.45 (s, 1 H), 9.76 (s, 1 H), 7.58 (s, 1 H), 1.40 (s, 9H). Mass calculated for formula C9H12N203S 228.06; observed MH+
(LCMS) 229.1 (m/z).
Part D: To a stirred solution of (2-Formyl-thiazol-5-yl)-carbamic acid tert-butyl ester (0.76 g, 2.857 mmol) in 1,2-dichloroethane(10 mL) were added Morpholine (250 mg, 1.1135 mmol) triacetoxysodium borohydride (472 mg, 2.227 mmol) and Cat amount acetic acid (three drops) and stirred for two hrs at room temp. To the reaction mixture was added sodium borohydride (126 mg, 3.3405 mmol) and stirred for one hrs.
LCMS
showed the disappearance of the starting material. Reaction mixture was diluted with water (100 mL) and extracted with dichloromethane, organic layer was washed with water, brine, dried over sodium sulfate and concentrated under high vacuum to yield (2-Morpholin-4-ylmethyl-thiazol-5-yl)-carbamic acid tert-butyl ester 298 mg (91 %).
Crude product was used as such in the next reaction. Mass calculated for formula C14H25N303S 315.43; observed MH+ (LCMS) 300.3 (m/z).
Part E: To a stirred solution of (2-Morpholin-4-ylmethyl-thiazol-5-yl)-carbamic acid tert-butyl ester (80.0 mg, 0.268 mmol) in dichloromethane(5 mL) was added iodotirmethylsilane ( 44 pL, 0.321 mmol) and stirred for 10 min. LCMS showed the disappearance of the starting material. Reaction mixture was diluted with water (10 mL), 1 N aqueous NaOH solution (5 mL) and extracted with 10% 2-propanol in DCM
(3 x 25 mL) and organic layer dried over sodium sulfate and concentrated under high vacuum to yield 2-Morpholin-4-ylmethyl-thiazol-5-ylamine 30.0 mg (56%). Crude product was used as such in the next reaction. Mass calculated for formula C8H13N3OS 199.27; observed MH+ (LCMS) 200.1 (m/z).
Part F: To a stirred solution of 2-Morpholin-4-ylmethyl-thiazol-5-ylamine (30.0 mg, 0.151 mmol) in DMSO (2.5 mL) was added 8-Methanesulfonyl-6-methyl-3-(1 H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine ( 25.0 mg, 0.09045 mmol) followed by NaH
60%
in mineral oil (48 mg, 1.206 mmol) and stirred for 30 min. LCMS showed the disappearance of the starting material. Reaction mixture was quenched 1:1 mixture of acetonitriie and saturated ammonium chloride (10 mL), and extracted with 10% 2-propanol in DCM (3 x 25 mL) and organic layer was concentrated under high vacuum to yield crude [6-Methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazin-8-yl]-(2-morpholin-4-ylmethyl-thiazol-5-yl)-amine which was subsequently purified by Agilent reverse phase HPLC using formic acid method to yield 10 mg (28%). HPLC-MS (10 min method) tR = 2.06 min (UV 254nm). Mass calculated for formula C18H2ON8OS
396.47;
observed MH+ (LCMS) 397.5 (m/z).
The compounds shown in Table 6 were prepared using procedures described in Example 40.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
\ N,N
I
N
N~N 396.47 397.5 2.06 40-1 ^ 'NH
S
H
N.N
40-2 NY'L'N 394.50 395.5 2.38 /^~,-NH
N\ ' S
CN
H
N-N
380.47 381.5 2.25 40-3 "~ N
HN
'*I Q-J
g H
N' I N
408.52 409.2 2.56 40-4 "y)--N ~
HN N
N
H
N' ~ N
" ~N 409.51 410.3 2.14 40-5 "N J
HN S N
c"
N
H
N-N
I
" 422.55 423.5 2.74 40-6 "N
~N~NH
H
N'N
Nl--'--N
422.55 423.3 2.75 40-7 N~N S v NH
~
HN-N
N N
"` ~N 449.58 450.3 1.85 40-8 ~( N s NH
4\ 1 N
H
N-~ N
`~" 382.49 383.2 2.28 40-9 NY `N
/-N\-/ S NH
\~ D, -N
H
N'N
HN
435.55 436.44 1.78 N g NH
\-~ J
N
H
N' N
^ I
LN>
~" 463.60 464.27 1.90 40-11 ~ "~N
N NH
N
H
N' N
I
-" 411.53 412.25 1.76 ~NL< g NH
~
N
H
N-N
40-13 ~N 422.55 423.28 2.74 "~ $ NH
\\ ~
N
HO -11/ ~ --, H3CO ~ ~
To a solution of 5-nitrothiophene-3-carboxylic acid (5.00 g, 28.88 mmol) in dimethylformamide (40 mL) was added potassium carbonate (11.98 g, 86.71 mmol) and iodomethane (2.70 mL, 43.37 mmol). The reaction mixture was stirred at RT
for 16 hr. After the starting material had been consumed, the reaction was diluted with 50% ethyl acetate/hexanes (350 mL) and extracted with H20 (350 mL). The organic layer was washed with brine (150 mL) and concentrated. Hexanes (50 mL) was added to the solid and concentrated again to yield 5.456 g (99%) of product.
'H NMR
(400 MHz) CDCI3 6 8.30 (s, 1 H), 8.25 (s, 1 H), 3.93 (s, 3H). Mass calculated for formula C6H5NO4S 187.17; observed M4H+ (MS) 191.15 (m/z) O O
H3CO ~ ~ H3CO ~ ~
g N02 g NHZ
To a solution of the nitro-ester (1.006 g, 5.375 mmol) in TFA (15 mL), Fe powder (1.5135 g, 27.10 mmol) was slowly added to the round bottom flask. The reaction was heated to 60 C for 45 min at which time TLC (1:1, ethyl acetate to hexanes) showed consumption of starting material. The reaction was diluted with ethyl acetate and the Fe was filtered off. The filtrate was neutralized with aqueous Na2CO3 and allowed to stir for 1 hr. The aqueous layer was extracted with EtOAc.
The organic layer was washed with brine, dried over Na2SO4, and concentrated to give 0.701 g (83%) of a yellow solid. 'H NMR (400 MHz) CD3OD 6 7.29 (s, 1 H), 6.44 (s, 1 H), 3.79 (s, 3H). Mass calculated for formula C6H7NO2S 157.19; observed MH+
(LCMS) 158.1 (m/z).
NE N NEM
O N
\ I
N + HgC\ ^N
N\" ~~N H2N S ~N/\
~
0=S=0 NH
Cys A solution of the sulfone (1.27 g, 3.11 mmol) and 2-aminothiophene-4-carboxylate methyl ester (0.701 g, 4.46 mmol) in DMF (35 mL) were treated with NaH
(60% dispersion in oil, 0.402 g, 10.05 mmol) at room temperature until mass spectrometry and thin layer chromatography (50% ethyl acetate/hexanes) indicated that the reaction was complete. Saturated ammonium chloride (15 mL) and water (50 mL) were added to the reaction. The reaction was stirred for 10 minutes. The precipitated solid was collected via filtration to yield the desired product.
'H NMR (400 MHz) CDCI3 b 8.78 (s, 1 H), 7.88 (s, 1 H), 7.82 (s, 3H), 7.68 (s, 1 H), 7.58 (s, 1 H), 7.44 (s, 1 H), 7.16 (s, 3H), 5.54 (s, 2H), 3.87 (s, 3H), 3.67 (t, 2H), 2.46 (s, 3H), 0.97 (t, 2H), 0.01 (s, 9H). Mass calculated for formula C22H28N6O3SSi 484.65; observed MH+
(MS) 485.1 (m/z).
SEM SEM
N- N N- N
\ I \ I
H3C N H3~ N
N\~N N\~N
NH TNH
H3CO2C H02C Cy S S
A solution of the ester prepared in Example 43 (0.565 g, 1.17 mmol) in THF (10 mL) and MeOH (3 mL) was treated with solid NaOH (9 pellets) followed by H20 (5 mL). The reaction was stirred vigorously at room temperature for 16 hr. The THF and MeOH were removed in vacuo and the residue was extracted with EtOAc (3 x 20 mL).
The aqueous phase was brought to a pH of 3-4 with aqueous HCI. The acidified aqueous phase was extracted with EtOAc (5 x 20 mL) and concentrated in vacuo to give 0.393 g(71 %) of the desired carboxylic acid.
SEM SEM
N,N N-N
\ I \ I
Hs~N HsC~ N
NYI-- N N),)'-N
~ NH HN O
HOZC--L S. S HN-O
A solution of the carboxylic acid (prepared in Example 4) (0.054 g, 0.115 mmol) in DMF (3 mL) was treated with amine (0.03 mL, 0.262 mmol), NMM (0.07 mL, 0.637 mmol) and then HATU (0.141 g, 0.372 mmol). The reaction was stirred at room temperature for 16 hr. Water (15 mL) was added and the reaction was stirred for 10 minutes. The precipitated solid was collected via filtration to yield 0.038 g (60%) of the desired amide. 'H NMR (400 MHz) CDCI3 6 9.13 (s, 1H), 7.86 (s, 1H), 7.80 (s, 3H), 7.54 (s, 1 H), 7.41 (s, 1 H), 7.31 (s, 1 H), 7.08 (s, 3H), 5.83 (d, 1 H), 5.53 (s, 2H), 3.93 (m, 1H), 3.67 (t, 2H), 2.44 (s, 3H), 1.70 (m, 10H), 0.96 (t, 2H), 0.00 (s, 9H). Mass calculated for formula C27H37N7O2SSi 551.78; observed MH+ (MS) 552.1 (m/z).
By essentially the same procedure set forth in Example 45, only substituting the amines shown in Column 2 of Table 7, the compounds in Column 3 were prepared:
MH+ LCMS
Example Column 2 Column 3 MW m/z MS tR
SEM
N-N
\I
N H3C~N \
45-1 N~)--N 523.7 524.1 S ~ N
SEM
N-N
N H3C~ N
45-2 CJ NN 539.7 540.2 HN O
S I/ No SEM
N-I N
N H3~ N
45-3 ( ) NYI-- N 552.8 553.3 N HN S
I TL ~
O ~~N
SEM
N
H3~N
45-4 H N~ 497.7 498.3 4.16 N
~N~
HN S
~ /
N
O
N.
I N
H2N Hs~N
I' 45-5 N 537.8 538.1 HN S
NH
O ~
SEM
N, N
H ~~OH H3~N ~
45-6 2N N~N 513.7 514.3 HN S
H
N~~OH
N.
~ I N
HgC N
_`~
45-7 ~~OMe N7 N 527.7 528.2 HzN HN S
O~
NH
~
OMe SEM
I
H3 C-~N
H N~N~ Ni-)- N
45-8 2 ~ S 540.8 541.2 I/
NH
O ~
/ N-SEM
N,N
H3C-~-N \
45-9 NH N."~N 497.7 498.1 2 ~
HN S
N,_,,-O
SEM
N- N
45-10 H2N N. ~N 511.7 512.1 HN ~V S
N, N H3 N
45-11 N~ N\~N 525.7 526.1 H HN ~V S
~
N~
SEM
N- I N
H3~N~
NN
45-12 HN 541.7 542.2 NH
O ---\
\
SEM
N-~ N
H3C~
i~ N
\
45-13 NN HS 554.8 555.3 Oi N
~
N-/
SEM
N-N
OH FbCT~~- N \
45-14 N~N 553.8 554.2 HN S
N
H N
SEM
I N
OH H3 ~N
45-15 HN N1-1- N 557.7 558.2 pH HN S
/
O N
\-~
OH
SEM
N.N
H H3 C-~N
45-16 i_,N N~N 568.8 569.2 I HN /
IN
N, N
OMe ~~N
45-17 HN Nll)zz:N 585.8 586.2 OMe HN ~-OMe ~ N
0 OMe ~
N~
N 584.8 585.2 HN S
N
~
OH N
O \--\
/ N-NEM
N
45-19 HN,~OMe N1-1-- N 555.8 556.3 4.37 l HN S
\ t Me N
. ; ' SEM H
N-N N-N
\ I \ I
H3 N HsN
N),),-N N 'I~")-- N 10 HN O HN
-O
S // HN--O S /HN
To a solution of the amide (0.038 g, 0.069 mmol) in dichloromethane (4 mL) was added lithium aluminum hydride (0.029 g, 0.775 mmol) and ethyl ether (0.8 mL).
The reaction mixture was stirred at RT for 10 min then refluxed at 40 C for 5 hr. The reaction was monitored by mass spectrometry. Upon consumption of the starting amide, the reaction was cooled to RT and quenched with H20 (2 mL). The reaction was diluted with DCM and filtered. The filtrate was washed with H20 (<_ 8 mL).
The organic layer was concentrated to give 0.019 g (52 %) of the amine. The above amine in THF was further treated with 4 N HCI/dioxane at 60 C for 1 hr. Upon cooling to RT, Et20 was added and the mixture was stirred for 10 min. The precipitated solid was collected giving 13.9 mg (96 % yield) of the desired amine.
By essentially the same procedure set forth in Example 46, the following compounds shown in Column 2 of Table 8 were prepared:
LCMS
Example Column 2 MW MH+ LCMS
m/z MS tR
H`N, N
H3C\ N \
46-1 N`Jzz': N 395.5 396.2 2.06 HN 'S ^O
C / Nr J
H.N`N
H3C~N
46-2 N\ 379.5 381.2 2.12 HN S
~ / N
H`N, N
H3CN ~
46-3 N~N 381.5 382.2 2.03 HN g ~
~/
.N`N
H3C~ N
\
T'Lz:N 367.5 368.2 1.95 HN S
N
,_r H
N' ~ N
/
46-5 H3N N 353.4 354.2 1.97 HN
N' N
\ I
H3~N
46-6 N1-1- N 408.5 409.2 1.77 HN
5=/ q H,N`N
H3~N \
46-7 N`~N 393.5 394.2 2.06 HN S
N
H.N`N
H3C , N 369.4 370.2 1.76 ~
HN S
I ~ H
N`~OH
H, N,N
46-9 ~ ~N 383.5 384.2 1.78 HN S
C~ H
N--"OMe H.N`N
H3C-Tl~ N
46-10 N~N 396.5 397.2 1.52 HN S
N
H, N,N
H3C\ N
46-11 N` ~N 353.4 354.2 1.79 HN S
N
H.N`N
\ 1 46-12 ~ ~N 397.5 398.2 1.93 HN S
N
H.N`N
H3C-rl~ N
46-13 N.~N 410.5 411.2 1.76 HNI S
N
H.N`N
46-14 H3CY`N 409.5 410.2 1.94 N'lljz'N
HN S
~N_ rOH
H.N`N
46-15 H3C -T~~ N 413.5 414.2 1.87 N~N
HN S H
OH
H`N`N
H3C-fo~ N
46-16 NN 424.6 425.2 1.80 HN S /
I'-"-"Ni H`N'N
H3C~N
46-17 N~N 441.6 442.2 2.23 HN S ~OMe OMe H,N`N
\ I
H3C_rl~ N
\
46-18 N~N OH 440.6 441.2 1.78 HN S
N
O O O __N
+ NOH O I
CI
Ethyl 4-chloro-3-oxobutanoate (14.15 g, 86 mmol), cyanoacetic acid (8.00 g, 86 mmol), NH4OAc (1.32 g, 17.2 mmol), AcOH (2.46 mL, 43 mmol), and benzene (40 mL) was stirred overnight at reflux with a Dean-Stark trap. The mixture was cooled to room temperature, diluted with EtOAc, washed with sat. NaHCO3, brine, dried with Na2SO4, and concentrated to afford crude product 1 (9.29g, 58%). HPLC-MS tR
=1.67 Min (UV 254nm). Mass calculated for M+ 187.0, observed LC/MS m/z 188.1(M+H).
UN
iN
O-/
CI I
Morpholine (580 uL, 6.65 mmol) was added dropwise to a mixture of ethyl 3-(chloromethyl)-4-cyanobut-3-enoate (622 mg, 3.33 mmol) and S-flakes (116 mg, 3.63mmol) in EtOH (5 mL). The reaction stirred at room temperature overnight.
The mixture was concentrated. The mixture was diluted with EtOAc, washed with brine, dried with Na2SO4, and concentrated to afford crude product. Purification by Prep-LC
afforded the title compound (182 mg, 20%). HPLC-MS tR = 0.80 Min (UV 2wm).
Mass calculated for M+ 270.1, observed LC/MS m/z 271.1(M+H).
SEM
N.N
SEM
N (0) N \ 1 N N~N O
N H2N ~ ~ HN NJ
NT\~N S O\1 To S02Me O
O \--A solution of ethyl 5-amino-3-(morpholinomethyl)thiophene-2-carboxylate (61.0 mg, 0.225 mmol) and sulfone (71.0 mg, 0.173 mmol) in DMF (2 mL) was treated with NaH
(60% dispersion in oil, 20.9 mg, 0.521 mmol) at room temperature. The mixture was stirred at room temperature until LCMS indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford title compound. HPLC-MS tR = 1.79 Min (UV 254nm).
Mass calculated for M+ 597.2, observed LC/MS m/z 598.3(M+H).
SEM
N, I N NE 1 N
N
N
N N O HN CD
N H~ -y ~
g To -~
3/O O ~
A solution of i-PrMgCi in THF (0.78 uL, 1.56 mmol) was added dropwise to a solution of crude compound from example 49 (104.2 mg, 0.173 mmol) and diethylamine (91 uL, 0.782 mmol) in THF (3 mL) at -20 C. The mixture was slowly warmed up to room temperature and stirred at this temperature until LCMS indicate the reaction was complete. The reaction mixture was cooled to 0 C and quenched with Sat. NH4C1.
The reaction mixture was extracted with EtOAc and the organic layer was dried with Na2SO4 and concentrated to afford crude product 4. HPLC-MS tR = 1.81 Min (UV
254nm). Mass calculated for M+ 624.3, observed LC/MS m/z 625.3(M+H).
`
SEM NH
N- N N
N\ O N~ N O
H~ N --~ HN
TN N ~ N
S
N
O
-- O \--4N HCI in dioxane (1 mL) was added to crude compound 4 (17mg, 0.027 mmol) at 0 C. The mixture was warmed to room temperature and stirred at this temperature until LCMS indicate the reaction was complete. Concentration and purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound.
HPLC-MS
tR = 1.14 Min (UV 254nm). Mass calculated for M+ 494.2, observed LC/MS m/z 495.2(M+H).
By essentially the same procedure, compounds given in Column 2 of Table 9 can be prepared.
LCMS
Example Column 2 MW MH+ LCMS
MS tR
m/z H
N.N
~ j 51-1 HN "~~ 524.1 525.1 1.09 N
S
0 k--/s N- I N
'-r-N
51-2 "ly)' N<- 478.2 479.2 1.32 HN N
s N
O ~
H
N-~ "
~N \
51-3 H~N ~ 490.2 491.2 1.35 N
i S
N
O
/ ~ / ~
HOzC S CO2H HOZC S NHBOC
A solution of thiophene-2,5-dicarboxylic acid (2.73 g, 15.84 mmol), diphenylphosphoryl azide (3.41 mL g, 15.84 mmol) and triethylamine (4.4 mL, 31.68 mmol) in tert-butanol (80 mL) was heated at refluxing 5h. The reaction mixture was cooled to room temperature and then concentrated to afford the crude title compound.
HPLC-MS tR =1.52 Min (UV 254nm). Mass calculated for M+ 243.0, observed LC/MS
m/z 244.1(M+H).
O
Et3N (1261.6 uL, 9.05 mmol) was added at 0 C to a mixture of 5-tert-Butoxycarbonylamino- thiophene-2-carboxylic acid (550 mg, 2.26mmol), EDCI
(1086 mg, 5.65 mmol) , and piperidine (447 uL, 4.52 mmol) in DMF (6ml). The reaction mixture was warmed up to room temperature and stirred at this temperature ovemight.
The mixture was diluted with EtOAc, washed with brine (2X), dried over Na2SO4 and concentrated to afford crude residue. Purification by Biotage afforded compound 2 (368 mg, 53%). HPLC-MS tR =1.89 Min (UV 254nm). Mass calculated for M+ 310.1, observed LC/MS m/z 311.2(M+H). HPLC-MS tR =2.4 Min (UV 254nm).
~ 1N C'-\ JJ.-NHBOC N N
HZ
S O O
Compound from Example 53 (90 mg, 0.29 mmol) was stirred in 20% TFA / CH2CI2 solution (5 mL) at room temperature for 1.5 hrs. The reaction mixture was concentrated to afford compound 3. The crude product was used without further purification. HPLC-MS tR =1.16 Min (UV 254nm). Mass calculated for M+210.0, observed LC/MS m/z 211.1(M+H).
SEM
SEM N,N
N-N I
Y~\N
+ ~N \ N\
\ NHZ ~N
ON S NN ~
HN
0 SO2Me s ~
O No A solution of crude material from Example 54 and sulfone (98.0 mg, 0.241 mmol) in DMF (2 mL) was treated with NaH (60% dispersion in oil, 29.0 mg, 0.725 mmol) at room temperature. The mixture was stirred until LCMS indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford crude product 4. Purification by Biotage afforded the title compound (82 mg, 63%). HPLC-MS tR = 2.30 Min (UV 254,1m).
Mass calculated for M+ 537.2, observed LC/MS m/z 538.2(M+H).
SEM SEM
; - ; , N "I -N
N Y-I-- N N-N
HN HN
S /
N No O
To a solution of the amide (47.6 mg, 0.089 mmol) in dichloromethane (5 mL) was added lithium aluminum hydride (39.9 mg, 1.0 mmol) and ethyl ether (1 mL). The reaction mixture was stirred at room temperature for 10 min then refluxed at until LCMS indicate the reaction was complete. The reaction was cooled to room temperature and quenched with H20 (0.5 mL). The reaction was diluted with dichloromethane, dried over Na2SO4 and concentrated to afford crude title compound.
HPLC-MS tR = 1.52 Min (UV 254nm). Mass calculated for M+ 523.2, observed LC/MS
m/z 524.2 (M+H).
SEM H
\r N
N_ N
HN _ HN
S / S
No No 4N HCI in dioxane (2mL) was added to crude compound from example 56 at 0 C.
The mixture was warmed to room temperature and stirred at this temperature until LCMS
indicate the reaction was complete. Concentration afforded crude title compound.
Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR = 0.91 Min (UV 2Wm). Mass calculated for M+ 393.1, observed LC/MS m/z 394.1 (M+H).
By essentially the same procedure, the compounds in Table 10 were prepared.
LCMS
Example Column 3 MW MH+ HPLC MS
m/z tR
N-N
57-1 ~" \ 411.1 412.1 1.05 YN
HN ~
S ~
N~~
~JS
N-N
57-2 ~N 381.1 382.0 0.88 ~N
HN
S I-/N /-H
N-N
57-3 ~" 461.1 462.1 1.08 Y'N
HN
S /~
N ) H
N'N
~~Nl \
NY`N
57-4 HN 491.1 492.1 1.41 OH
N-N
/ N
57-5 N~N 421.2 422.0 1.04 HN
S
N
H
N, 57-6 ~" 437.2 438.3 1.20 N
HN O-S
No H
N'N
\ I
~N \
57-7 N~N 409.1 410 1.00 HN
SIN
OH
s~ s~
N N
H3CN H3C` N
N~N Nl,'J'-N
To a solution of 8-methanesulfonyl-6-methyl-3-thiazol-2-yl-imidazo [1, 2-a]
pyrazine (0.070 g; 0.24 mmol) and 5-amino-3-carbomethoxy-isothiazole (0.039g;
0.25 mmol) in dimethyl formamide (DMF; 0.8 mL) was added sodium hydride (NaH; 60%
in oil; 0.024 g). The reaction mixture was stirred at room temperature for 0.5 hr and then quenched with saturated aqueous solution of ammonium chloride (NH4CI). Diluted with more water and filtered. The filter cake was washed with water and hexanes. The filter cake was dried in vacuo to obtain the title compound as yellow solid (0.078 g;
87%). ' H NMR (400 MHz, DMSO-d6): 8.85 (s, 1 H), 8.42 (s, 1 H), 8.1 (s, 1 H), 7.9 (s, 1 H), 7.65 (s, 1 H), 3.85 (s, 3H) 2.5 (s, 3H). HPLC-MS tR = 4.35 (UV254nm).
Mass Calc.
for C15H12N602S2 372.04; obsd MH+ (LCMS) 373.2 (m/z).
s~ s~
- N - N
N H3C5;"'_N\
H3C-Ir N~N N (Y1'N
~
HN~O H N
A solution of lithium triethylborohydride (Super Hydride; 1 M in THF; 0.32 mL) was added dropwise to a solution of the methyl ester (0.03 g; 0.08 mmol) in dry THF
(0.8 mL). After stirring at room temperature for 1.5 hr, the reaction mixture was quenched with saturated aqueous NH4CI solution (8 mL) and diluted with water.
Small amount of the precipitated yellow solid was filtered and washed with water and ether.
The solid was dried in vacuo to obtain -10 mg (36%) of the alcohol. 'H NMR
(400 MHz, DMSO-d6): 8.8 (s, 1 H), 8.4 (s, 1 H), 8.1 (s, 1 H), 7.9 (s, 1 H), 7.2 (s, 1 H), 5.4 (t, 1 H). 4.5 (d, 2H), 2.5 (s, 3H). HPLC-MS tR = 2.98 (UV254nm). Mass Calc. for C14H12N6OS2 344.05; obsd MH+ (LCMS) 345.2 (m/z).
s~ s~
H3C\ ^N H3C\ N
- N N
NY N NY N
HN O O
S-~OCH3 S-~OCH3 A solution of ester (0.113 g; 0.3 mmol) in DMF (1.5 mL) was treated with NaH
(60% in oil; 0.03 g; 0.76 mmol) followed by 2-(Trimethylsilyl) ethoxymethyl chloride (SEM-CI; 0.1 mL; 0.61 mmol). The reaction mixture was stirred at room temperature for 3 hr and quenched with saturated aqueous NH4CI and water. The precipitated yellow solid was collected by filtration, washed with water and dried. The title compound was obtained as yellow solid (0.142 g; 92%). 'H NMR (400 MHz, CDCI3):
9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.8 (s, 1 H), 7.4 (s, 1 H), 6.65 (s, 2H), 4.0 (s, 3H), 3.78 (t, 2H), 2.65 (s, 3H), 1.0 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 5.98 (UV254nm). Mass Calc. for C21 H26N6O3S2Si 502.13; obsd MH+ (LCMS) 503.3 (m/z).
s s~
H3C\ N H3C_ N
- N - N
NJ,)" N
O NY
Si-,O,-, N N I S-N OCH3 S-OH
A solution of lithium triethylborohydride (Super Hydride; 1 M in THF; 1 mL) was added dropwise to a solution of the methyl ester 2 in dry THF. After stirring at room temperature for 1 hr, the reaction mixture was quenched with saturated aqueous NH4CI solution (8 mL) and saturated aqueous solution of Rochelle salt. The organic product was extracted with dichloromethane (CH2CI2), washed with water and brine.
Concentration in vacuo gave -120 mg (100%) of the alcohol. HPLC-MS tR = 4.22 (UV254nm). Mass Calc. for C20H26N6O2S2Si 474.13; obsd MH+ (LCMS) 475.3 (m/z).
s~ s~
N N
N Nj>'- N
OvN iSi,-,,-,O,-, N ~ CHO
S N OH I S N
Dess-Martin periodinane (0.147 g; 0.35 mmol) was added to a solution of alcohol (0.11 g; 0.23 mmol) in dry THF and stirred at room temperature for 40 minutes. The reaction mixture was diluted with 30 mL of CH2CI2, washed with saturated sodium bicarbonate (NaHCO3) solution, water and dried. Concentration furnished a yellow solid which was re-dissolved in CH2CI2 and filtered. The filtrate was concentrated to obtain 120 mg of crude title compound as a yellow solid which was used as is in the next step. 'H NMR (400 MHz, CDCI3): 10 (s, 1 H), 9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.78 (s, 1 H), 7.4 (s, 1 H), 6.6 (s, 2H), 3.78 (t, 2H), 2.65 (s, 3H), 1.0 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 6.14 (UV254nm). Mass Calc. for C20H24N6O2S2Si 472.12; obsd MH+ (LCMS) 473.3 (m/z).
s~ sN
H3C\ ^N \ H3C~N
- N
(_ ~\ NY `N
NY 'N I
N
~Si~iO~ SN ~ CHO S_N N
I
A solution of aldehyde (0.05 g; 0.1 mmol) and piperidine (0.05 mL; 0.5 mmol) in CH2CI2 (1 mL) was treated with glacial acetic acid (AcOH; 1 drop) and stirred at room temperature (RT) for 3 hr. Solid sodium borohydride (NaBH4; 0.016 g; 0.42 mmol) was added and the reaction mixture was cooled in an ice/brine bath (-5 C) and methanol (0.2 mL) was added dropwise. After stirring at low temperature for 30 minutes, the reaction was quenched with saturated NH4CI and extracted into CH2CI2. The organic extract was washed with saturated NH4CI, water and brine. Removal of solvent gave the crude product which was purified by preparative thin layer chromatography (Prep TLC) using CH2CI2 with 4% CH3OH and 1% ammonium hydroxide. The title compound was isolated as yellow film (25 mg; 45%). 'H NMR (400 MHz, CDCI3):
9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.4 (s, 1 H),7.3 (s, 1 H), 6.6 (s, 2H), 3.8 (t, 2H), 3.6 (s, 2H), 2.65 (s, 3H), 2.5 (br-s, 4H),1.7 (br-s, 4H), 1.45 (br-s, 2H), 0.98 (t, 2H), 0.0 (s, 9H).
HPLC-MS tR = 3.82 (UV254nm). Mass Calc. for C25H35N7OS2Si 541.21; obsd MH+
(LCMS) 542.3 (m/z).
sN sN
~~ 1 NY N NYN
N HN
jSI
S-N S-N
A solution of compound from Example 63 (0.013 g; 0.02 mmol) in 0.5 mL of THF was treated with HCI in dioxane (4M; 0.5 mL) and placed in an oil bath at 70 C.
After heating for 30 min, a precipitate formed which dissolved upon adding 0.5 mL of methanol. The reaction mixture was heated at a bath temperature of 70 C for an additional 1 hr. The contents of the reaction were cooled to RT and all the volatiles were removed on a rotary evaporator. The residue was suspended in THF and triturated with ether. The precipitate was collected by filtration, washed with - 10 mL of ether and dried in air (0.5 hr) and in vacuo (16 hr) to furnish 10 mg (93%) of the title compound as a yellow solid. ' H NMR (400 MHz, CD3OD): 9.0 (s, 1 H), 8.3 (s, 1 H), 8.05 (s, 1 H), 7.7 (s, 1 H), 7.25 (s, 1 H), 4.4 (s, 2H), 3.6 (d, 2H), 3.1 (t, 2H), 2.6 (s, 3H), 2.0 (d, 2H), 1.85 (t, 4H), 1.6 (t, 1 H). HPLC-MS tR = 2.96 (UV254nm). Mass Calc. for 411.13; obsd MH+ (LCMS) 412.2 (m/z).
Compounds in the Table 11 were prepared as per above examples:
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
s^1 N
59-1 H3C 344.05 345.2 2.98 N
N
HN
QOH
S
59-2 H'C~~N 343.06 344.2 2.78 NY 'N
HN`
S-NOH
S
N
64-1 i~ ^ 411.13 412.2 2.96 Y'N < J
HNN
S-N
S
N
64-2 H3C " 397.11 398.2 3.11 N N Y'N
HNN
S-N
s-64-3 ~ i~ 413.11 414.2 2.86 Y'N
HNN
S-N
N
64-4 H3C~N 411.13 412.2 2.99 N 7\-J-- N 0 HNN
S-N
s ci \ I
64-5 H'c~N 444.09 445.2 3.29 N\~N 0 HNN
i S-N
$i~O N- N N-N
~ N- N H2N ~O
\ I I~ NJ H3CTl-'N Part B H3CN
H3C\ N NN N 'N
N\/~N Part A HN ~ /~ HIN r )4; NJO I ~ N~/
Part A: Lithium hexamethyldisilazide (1 M in THF; 0.18 mL) was added to an amber solution of 4-morpholin-4-ylmethyl phenylamine (0.013g; 0.068 mmol) and 8-methanesulfonyl-6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1, 2-a]pyrazine (0.025g; 0.061 mmol) in 2 mL of THF at RT resulting in a burgundy solution. After stirring at RT for 20 minutes, the reaction mixture was quenched with saturated aqueous NH4CI solution. The contents were diluted with ethyl acetate and washed with water and brine. The crude material from the organic extract was purified by prep TLC (5% methanol-CH2CI2) to obtain the title compound as pale yellow oil (0.025 g; 80%). 'H NMR (400 MHz, CDCI3): 8 (s, 1 H), 7.9 (d, 2H), 7.85 (s, 1 H), 7.8 (s, 1 H), 7.5 (s, 1 H), 7.4 (s, 1 H), 7.35 (d, 2H), 5.55 (s, 2H), 3.75 (br-s, 4H), 3.7 (t, 2H), 3.5 (br-s, 2H), 2.5 (br-s, 2H), 2.4 (s, 3H), 1.6 (br-s, 2H), 0.95 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 3.05 (UV254nm). Mass Calc. for C27H37N7O2Si 519.27;
obsd MH+ (LCMS) 520.3 (m/z).
Part B: The compound from Part A (0.025g; 0.048 mmol) was suspended in dry THF
and treated with HCI in dioxane (4M; 1 mL) and heated in an oil bath set to 70 C for 15 minutes when a white precipitate was formed. Methanol was added to dissolve some of the solid and the reaction mixture was continued to be heated for 45 minutes more. After cooling to RT, the volatiles were removed on the rotary evaporator. The residue was suspended in THF and the precipitated solid was collected by filtration, washed with ether and dried in vacuo overnight. The title compound was isolated as a beige solid (14 mg; 78%). All the analogues in Table 12 were similarly prepared.
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
N- N
65-1 H3C~N 389.19 390.2 1.7 NN
HTN
N
N- N
\ I
65-2 H3C -eN \ 389.19 390.2 1.76 NY 'N
HN
/ N
(DO
S
65-3 H3C -J-~"~1N 405.16 406.2 2.38 NY ~N
HN ~
I NJ
N- N
65-4 Br"ro~:.'N 451.11 452.2 2.51 NY 'N
HN
N
N-N
65-5 H3C~N 387.22 388.2 1.85 N'N
H'N N
Na 65-6 H3C~N \ 459.24 460.3 2.03 NY~N
HN I ) aC02Et NN- N
\I
65-7 B~N 437.1 438.2 2.38 NY'N
HN N
N- N
\I
65-8 H3C -1-:-"N 373.2 374.2 1.65 NY 'N
HN N
H
a 65-11 Br~N 452.11 453.3 1.93 NYN
HN I )zz~ rNH
N- N
\ 1 65-12 H3C -10~" N \ 388.21 389.2 1.59 NY'N
HN X~~ rNH
Na 65-13 H3C ~N \ 402.23 403.2 1.51 N`/'N
H~N /
N
N- N
65-14 H3C -rN \ 416.24 417.2 1.54 NII N
HN )~~ ^NJ
I N( f H ~/
N- N
65-15 Br~N \ 467.1 468.3 2.27 N T\/'N
HN I: O
r ^
N- N
65-16 H3C~N 403.21 404.2 1.9 NY N
HN ~ ^O
Nr.J
N-N
65-17 H3CN 390.19 391.2 1.36 NY 'N
HN N
Si'\'O~
I \- N H2N I \ \~N \~N
v `COZCH3 Br /
Br\ N
T1~ N\~N N -N
NY'N 1" I
Part A Part B
SOZCH3 HNI \ HN I \
~ CO CH
2 3 ~ COyCHg Part A: A solution of 4-Amino-2-methyl-benzoic acid methyl ester (0.33 g; 2 mmol;
prepared from commercially available 4-nitro-2-methyl-benzoic acid) and 8-methanesulfonyl-6-bromo-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1, 2-a]pyrazine (0.472 g; 1.0 mmol) was treated with LiHMDS (1M in THF; 2 mL) at RT. The resulting burgundy solution was stirred at RT for 20 minutes and then quenched with saturated aqueous NH4CI solution. Standard work up as described for Example 65 and flash silicagel chromatography (25% EtOAc in CH2CI2) provided the title compound as pale yellow foam (0.48 g; 86%).
NMR (400 MHz, CDCI3): 8.18 (s, 1 H), 8 (d, 1 H), 7.9 (s, 1 H), 7.85 (d, 1 H), 7.78 (s, 1 H), 7.7 (s, 1 H), 7.62 (s, 1 H), 7.58 (s, 1 H), 5.5 (s, 2H), 3.9 (s, 3H), 3.65 (t, 2H), 2.6 (s, 3H), 0.98 (t, 2H), 0.0 (s, 9H). Mass Calc. for C24H29BrN6O3Si 556.13; Obsd MH+ (CI-MS) 557 / 559 (m/z).
Part B: A solution of compound from Part A (0.48 g; 0.86 mmol) in 2 mL of dry THF
was treated with a solution of dimethyl zinc (2M; 4 mL) dropwise. After the effervescence ceased, solid Pd(PPh3)4 was added and the reaction was flushed with nitrogen, fitted with a reflux condenser and heated in an oil bath at 65-70 C.
After 0.5 hr, the reaction mixture had turned from yellow orange to deep red and after 4 more hours, it had become an opaque black. TLC (25% EtOAc- CH2CI2) indicated the formation of a slightly more polar spot. The reaction was cooled to RT, quenched with saturated aqueous NH4CI solution and extracted with EtOAc. Flash silicagel chromatography of the crude material gave the 6-methyl title compound as yellow solid (0.38 g; 90%). NMR (400 MHz, CDCI3): 8.1 (s, 1 H), 8 (d, 1 H), 7.9 (d, 1 H), 7.85 (s, 1 H), 7.8 (s, 1 H), 7.7 (s, 1 H), 7.58 (s, 1 H), 7.4 (s, 1 H), 5.5 (s, 2H), 3.9 (s, 3H), 3.65 (t, 2H), 2.65 (s, 3H), 2.4 (s, 3H), 0.98 (t, 2H), 0.0 (s, 9H). Mass Calc. for C25H32N6O3Si 492.23; Obsd MH+ (CI-MS) 493.11 (m/z).
~ i ~~'O~ ~iiO~ R
N- N N-N N-N
\ I \ I \ I
H3C\ ^N H3C\ ^N H3C\ ^N
N~N N~ 'N N
HN HN HN
[ / ( / N' 1 Part A: Ester was first reduced to the alcohol using LiBEt3H in THF at RT and subsequently oxidized using Dess-Marin periodinane to the aidehyde as described previously. The reductive amination of aldehyde with various secondary amines was carried out provided SEM-protected title compound. Removal of the SEM
protecting group was carried out under conditions described previously. In a similar manner, other tertiary amines listed in Table 13 were also prepared by the similar reaction scheme with the corresponding secondary amines followed by removal of the SEM
protecting group.
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
N- N
67-1 H3C~N 401.23 402.2 1.87 NY 'N
HN I N
N- N
67-2 H3C~N 403.21 404.2 1.71 NY 'N
HN
I,:,::~
N
N- N
67-3 H3C~N 419.19 420.2 1.95 N T\/'N
HN
I X,,z S
N- N
67-4 H3C -f--"' N 415.25 416.2 2.0 NY
_HNOCQ
NH2 NHCbz r\
N~NN iN
Et0 OEt EtO~OEt The substrate (1 g, 5.07 mmol) was dissolved in THF:H20 (12 mL, 1:1, v/v) and treated with K2C03 (1.4 g, 10.15 mmol) at room temperature. Then benzyl chloroformate (0.79 ml, 5.58 mmol) in THF (2 mL) was slowly added. The mixture was stirred for 16 h. It was diluted with ethyl acetate (25 mL). The two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 25 mL).
The combined organic layer was washed with brine (1 x 30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (SiO2) eluting ethyl acetate-hexane.
NHCbz NHCbz r\
N~N~N
EtO OEt O
The substrate acetal (1.2 g, 3.64 g) was dissolved in acetone (20 mL), and treated with 1 N aqueous HCI (2 mL) at room temperature, and the mixture was stirred for 7 h.
Then acetone was evaporated off, and the residue was diluted with saturated aqueous NaHCO3 (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL).
The combined organic layer was washed with brine (1 x 30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product as solid which was used in the next step without any further purification.
NHCbz NHCbz NH2 r~ r~ I \
ON~ N N~N N~NI~
~ V
The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H (2 eq.) in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
The crude product was hydrogenated in ethyl acetate using 10% Pd/C at 1 atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
NHCbz NHCbz NH2 Part A r~ Part B r~
N\/ N NT N N~N
O N N
Part A: The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
Part B: The crude product was hydrogenated in ethyl acetate using 10% Pd/C at atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
NHCbz NHCbz NH2 /~ Part A 6-~ Part B 6~
N\/ N N~N N~N
N~ N
OJ ~
~O ~O
Part A: The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
Part B: The crude product was hydrogenated in ethyl acetate using 10% Pd/C at atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
N'NSEM N'NSEM N-NH
NHZ
R_ N Part A R_ ~N \ Part B RN
+
N\)-- N N\~N NYl- N
SOZMe RR1 HN CN R' HN I~R' z N, i N-N R2 N RZ
Part A: The substrate (1 eq.) and amine (1.5-2 eq.) was dissolved in DMSO
under argon, and treated with NaH (5 eq., 60% dispersion in oil). After 30 min, LC-MS
analysis indicated complete consumption of starting material. The reaction was quenched by addition of saturated aqueous NH4CI-acetonitrile (1:1, v/v). The two layers were separated, and the aqueous layer was extracted with ethyl acetate.
The combined organic layer was washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the crude product.
Part B: The substrate was dissolved in 4N HCI in dioxane, and stirred at room temperature for 30 min. The solvent was then evaporated, and the residue was purified by Prep-LC. Conversion to hydrochloride salt afforded the product as solid.
LCMS HPLC MS
Example Column MW MH+ m/z tR
'NH
73-1 N\~N
H 375.4 376.1 0.83 1N ~
N' N
NH
73-2 NN 389.4 390.2 1.05 HN C N fD
N
'NH
73-3 NN 391.4 392.1 0.78 HN
NH
rN
73-4 N~N 361.4 362.2 0.74 HN
~N
'NH
rN
73-5 N\~N
H 375.4 376.2 0.85 iN N
NND
'NH
rN
73-6 N~N 377.4 378.3 0.87 HN C
~N' Part A (~~N~~ Part B Part C N
~ 'N ~ N~N N~N
NYN - NY
HN S HN S
HN S HN I S N I iN \
OH CHO
Part A: By essentially the same procedure as described for Example 1 and 13.
Part B: To a solution of compound from Example 74, Part A (0.16 g, 0.57 mmol) in THF (20 mL) and water (0.025 mL) was added Dess-Martin periodinane (3 equivalents). The resulting solution was stirred at rt for 1.5h at which time LC-MS
analysis indicated the reaction was complete. The reaction mixture was diluted: with dichloromethane (75 mL), washed with water, dried (sodium sulfate) and concentrated. Purification by column chromatography (Si02 10% methanol / DCM) afforded the title compound as a yellow solid 0.08 g (49%). HPLC-MS tR = 1.59 Min (UV 254nm). Mass calculated for formula C13H11 N5OS 285.07, observed LC/MS m/z 286.1 (M+H).
Part C: To a solution of compound from Part B (30 mg, 0.105 mmol, 1 equivalent), 3-methylpiperidine (10 equivalents) in dichloromethane:methanol (5:1) (3 ml) was added acetic acid (1 drop). The resulting solution was stirred at rt for 30 minutes, and then sodium borohydride (8 equivalents) added to the reaction. The reaction mixture was stirred at rt for 1 hour at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. sodium bicarbonate and then extracted with dichloromethane (x2). The combined organic layer was dried (sodium sulfate) and concentrated. Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR = 3.73 Min (UV 254nm). Mass calculated for formula C19H24N6S 368.18, observed LC/MS m/z 369.2 (M+H).
7~N N
Part A
N ` N 0- Ny N
HN g HN S
/N
CHO No Part A: To a solution of compound 1 (30 mg, 0.105 mmol, 1 equivalent), piperidine (10 equivalents) in dichloromethane:methanol (5:1) (3 ml) was added acetic acid (1 drop).
The resulting solution was stirred at rt for 30 minutes, and then sodium borohydride (8 equivalents) added to the reaction. The reaction mixture was stirred at rt for 1 h at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. sodium bicarbonate and then extracted with dichloromethane (x2). The combined organic layer was dried (sodium sulfate) and concentrated.
Purification by Prep-LC and conversion to a hydrochloric salt afforded compound 2.
HPLC-MS tR = 3.47 Min (UV 254nm). Mass calculated for formula C18H22N6S
354.16, observed LC/MS m/z 355.1 (M+H).
SEM
SEM N-N
N-N I
N NaH / DMF/ RT - N
~
NN O 93% HN S`
O
0=S=0 Step A /N
O
O
SEM H
N-N N-N
\ I ~ >~OH
N
H
1) LAH, THF (66%) 3) K2CO3 / 80 C (65%) N7\Ij--N NY)'-N
2) MsCI / Et3N (85%) HN I S N 4) 4M HCI, dioxane (95%) HN ~ SN
Step B ~
Step C ~OH
OMs N
Step A: Sodium hydride (60% dispersion in mineral oil, 6.68 g, 3.40 equiv) was slowly added in one portion to a stirring mixture of compound sulfone (20.0 g, 1.00 equiv) and aminoisothiazole (11.5 g, 1.20 equiv, as HCI salt) in DMF (490 mL) at room temperature (with aid of a room temperature water bath). Reaction was allowed to stir for 1 hour at which time HPLC analysis indicated the reaction was complete.
The reaction was carefully quenched with saturated aqueous sodium bicarbonate (200 mL) and then diluted with water (1 L). This mixture was stirred for 20 minutes at room temperature, and then the resulting precipitate was collected by filtration, washed with water (200 mL), and dried under high vacuum for 16 hours. The resulting waxy solid was dissolved in 1.8 L of 1:1 chloroform : methanol, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (22.3 g, 93%) as a dark yellow solid. 1 H NMR (300 MHz, DMSO-d6) b 12.3 (bs, 1 H), 8.60 (s, 1 H), 8.10 (s, 1 H), 7.88 (s, 2H), 7.59 (s, 1 H), 5.51 (s, 2H), 3.85 (s, 3H), 3.63 (d, J
= 8 Hz, 2H), 2.48 (s, 3H), 0.88 (d, J = 8 Hz, 2H), -0.026 (s, 9H). Mass calculated for formula C21H27N7O3SSi 485.63; observed MH+ (MS) 486.6 (m/z).
Step B: A mixture of compound from Step A (4.27g, 3.73 mmol) was dissolved in mL of THF. The resulting solution was cooled to 0 C and LiAIH4 powder (2.6 g, 68.5 mmol) was carefully added. The cooling bath was removed and the reaction was stirred at RT under a N2 atmosphere for 1.5 hr. The reaction was cooled to 0 C
and carefully quenched by the sequential addition of 2.6 mL of H20; 2.6 mL of 15 %
NaOH
(aq); 7.8 mL H20. After stirring for 10 min, the reaction was filtered through a very thin pad of Celite (rinsing with THF, EtOAc and DCM). Concentration of the filtrate yielded a light yellow solid. Pure alcohol (2.66 g, 66 % yield) was obtained via triturating with MeOH and used directly in Step C.
Step B (Alternative procedure; e.g. Example 76-39): A solution of 4,4-difluoropiperidine hydrochloride (25.1 mg, 0.16 mmol) in THF (2.0 mL) was added NaH (60% dispersion in mineral oil, 12 mg, 0.30 mmol). The mixture was stirred under a N2 atmosphere at room temperature for 10 min, then mesylate (31.4 mg, 0.06 mmol) and Nal (4 mg, 0.03 mmol) were added to the reaction flask. The reaction was heated at 80 C under a N2 atmosphere for 8 hr. The reaction was cooled to room temperature and 15 mL of saturated NH4CI (aq) solution was added. The reaction was diluted with dichloromethane (20 mL) and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL). The organic phase was washed with 15 mL of saturated NaHCO3 (aq), then brine (15 mL). The organic phase was dried over NaSO4 and concentrated in vacuo. Purification via preparative TLC (10% MeOH/CH2CI2) gave 19.7 mg (60% yield) of the title compound.
Step C: A mixture of compound from Step B (2.40 g, 4.49 mmol), amine (1.57 g, 13.46 mmol), and Nal (63.0 mg, 0.449 mmol) in 45 mL of THF was heated at 80 C for 12 h.
It was diluted with 200 mL of CH2CI2, and washed with 100 mL of saturated aqueous NaHCO3 solution, then with brine (100 mL). The solvent was removed under vacuum.
The residue was purified by flash chromatography eluting with 5% to 10%
MeOH/CH2CI2 to give 1.68 g of the title compound. 'H NMR (400 MHz, CDCI3) b 9.49 (brs, 1 H), 7.89 (s, 1 H), 7.82 (s, 1 H), 7.60 (s, 1 H), 7.49 (s, 1 H), 6.86 (s, 1 H), 5.54 (s, 2H), 3.79 (brs, 3H), 3.67 (t, J = 8.3 Hz, 2H), 3.36 (s, 2H), 2.65-2.80 (m, 2H), 2.50 (s, 3H), 1.11 (s, 6H), 1.02(t, J = 7.1 Hz, 2H), 0.96 (t, J = 8.2 Hz, 2H), 0.01 (s, 9H). To a solution of Sem-protected compound (2.0 g, 3.6 mmol) in 36 mL of MeOH/CH2CI2 (1:1) stirred at 80 C, was added 36 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 30 min. After it was cooled to the room temperature, 120 mL of ether was added. The solid was collected by filtration, washed with ether and dried under vacuum to give 2.0 g of the title compound as its HCI salt form. Mass calculated for formula C20H26N$OS 426.2; observed MH+ (LCMS) 427.2 (m/z).
Using essentially the same procedures as described for Example 76, the following compounds were prepared.
LCMS
Example Column 2 EM MH+ HPLC
m/z MS tR
H
N-N
N1\
NY`
76-1 N I 426.2 427.2 2.28 HN~
S N N--\-O\.-NV
N
76-2 N~N 426.2 427.2 2.21 HN~
S-N N
OH
NV
~N \
76-3 NY-1- N 452.2 453.2 2.26 HN S-N N
\ OH
N' I N
\
N
76-4 N)-)- N 466.3 467.3 2.48 HN--r / --~
S-N N
\ OH
N,N
\ I
N
NY-,-- N 452.2 453.2 2.35 HN^
iS~_ N~--~N
N' I N
N
NN 440.2 441.2 2.39 HN
OH
S-N N~
N' I N
~N \
76-7 NN 438.1 439.1 1.81 HN`
S_N~N OH
H
N'N
N
76-8 N~N 438.1 439.1 1.03 HN` /OH
'(i S-N N
N'N
\ I
N
76-9 N~N 452.2 453.3 1.48 HN O
S_N N =
N' ~ N
N
76-10 NY-1-- N 452.2 453.1 1.48 HN
N' I N
N
NN 452.2 453.3 1.35 HN~^
~S~-N~N
H
NV
N
76-12 N~N 452.2 453.2 1.36 HN~^
~S~-N~-\N
''.
H
4N-~
\
N
76-13 NY'L-- N 452.2 453.2 1.041 HN~
, ~ /--~
S'N N
OH
H
N-N
76-14 N~N 424.2 425.2 1.091 HN,r /~--~
S'N N
/
OH
H
N-~N \
76-15 \ I, N)-,-- N 410.2 411.2 1.048 HN,r /~--~
S-N /N
OH
H
N'N
~N \
76-16 N~N 426.2 427.1 1.16 HN
S-N N~
~
HO O
H
N-N
NY-`~ N
.76-17 HN 476.2 477.3 2.69 S-N
N N
~
H
N-76-18 \ I , ~N \
NY~- N 424.2 425.2 2.15 HN
S-N N--\_O, H
ci ~N \
76-19 NY-,-- N 426.2 427.2 2.21 HN
S-N N-~~
OH
H
N-76-20 ~ N \
NN 412.2 413.1 1.086 HN
S'N N
/ OH
H
N-~
\
N
76-21 N~N 438.2 439.1 1.090 HN,r /~---\
S'N N
/
H
N-N
76-22 NY-,-- N 424.2 425.2 1.162 HN~
~~ /~--~
S-N /N
H
N-~
N
452.2 453.3 1.286 76-23 NY-,-- N
HN
S'N N
/
I
H
N-\I, N
76-24 NYl-- N 424.2 425.2 1.12 HN,, S-N /N.
OEt H
N -N
NY _N
76-25 HN~ 462.2 463.2 2.62 S'N N
O
,N
N-{\
H
N-N
NY-,-- N 452.2 453.2 2.58 HN~
S-NN
b H
N-N
NY)-- N 466.2 467.3 2.74 HN~
S-N
N-~N \
76-28 N)--l- N 438.2 439.2 2.39 HN~
S~- N~--\N -\_ 6 O, H
N-N
Nyl-- N 466.2 467.2 1.553 HN~
/~--~
S'N N
O
H
N-N
NY-,-- N 436.2 437.2 1.16 HN~
S'N N
-O H
H
N-N
76-31 NY-1--- N 438.2 439.1 1.48 HN
S-N N.,,,7 OEt H
4N-~
"e'N
76-32 NYl- N 466.2 467.3 2.62 HN~
/~--~
S'N N
~ OH
H
N-\I' N
76-33 NY-1- N 454.2 455.0 0.910 HN~
~~ /~--~
S'N N
OH
H
N-N
N~
76-34 N 468.2 469.1 1.031 HN~
S'N N
/
O
H
N-76-35 ~N \
N~N 468.2 469.1 1.232 HN~
1' /
S'N N
` OH
H
N-N
76-36 N 354.1 355.2 2.03 N
HN~
1' /
S-N HN-\
H
a N
76-37 N~N 398.2 399.2 1.95 HN~
S-N HN
HO
H
N-~
\
N
76-38 NY)- N 480.2 481.3 2.46 HN
S-N
H
N-^I
\ I' N
N~ N 430.1 431.2 2.64 HN
S-N~-~
qF
F
H
N-N
76-40 N Y _ N 412.2 413.2 2.53 HN~
1S'-NN
F
H
N-N
76-41 NY-,-- N 462.2 463.3 2.99 HN
S-NaCF3 H N-\I, N
76-42 N~N 448.1 449.2 3.33 S-N
H
N-~ N \
76-43 N~N 398.1 399.2 2.41 HN~
S-N N
F
H
N-e N
76-44 Ny),- N 378.1 379.2 2.43 HN~
S-N
H
N-N
76-45 N~N 430.1 431.2 2.45 HN~
S-N~a F
F
H
N-\I, N
N)-)-- N 462.2 463.3 2.62 HN~
S-N~- N
- \
H
N-~
\
N
76-47 N)--1- N 416.1 417.2 2.37 HN
S-N N F
a F
H
N-N
76-48 NY)--- N 424.2 425.2 1.105 HN,~^
, S-N
O
H
N-~
\
N
76-49 N 412.2 413.2 2.48 ~ N
HN~
S~-N~-QF
H
a N 422.1 391.2 2.27 T N
HN
TS-N~HN-\-C F3 H
\i-NT~N
76-51 N)-,-- N 390.1 391.2 2.27 HN
S-NHN-\
r F
F
H
a N
Y _ 76-52 N N 518.1 519.3 3.32 HN
S-N~-\~N-\_CF3 N-N
76-53 NY-,-- N 402.1 403.2 2.39 HN
5-N~- N
~F
F
H
N-~
\
N
76-54 N Y~-- N 398.1 399.2 2.37 HN
S-N
N
H
N-A' \I, N
76-55 NY-1--- N 398.1 399.2 2.37 HN
S-N~- N
F
H
N-N
76-56 Ni-)-- N 444.2 445.2 2.61 HN~ F
'S'-N~HN--&F
H
N-^I
"e'N
76-57 NY-,-- N 448.1 449.2 3.27 HN ~
;CF3 S-N N
"-r \
~N \
N~N
76-58 467.2 468.4 3.90 HN~
S-N N~\
(\_N
H
N-N
N~N
76-59 HN~\ 466.2 467.4 3.59 S-N
S N O
~
/
N
H
N-~N
NY
76-60 N 473.1 474.2 3.67 HN
S-N ~I~\
(\-N). S .O
c~
H
N-\I7~N \
N~
76-61 N 535.2 536.3 4.42 HN~
S-N ON, .O
0 Ph H
N-\
~N \
76-62 N~N 409.1 410.4 3.31 HN~
~S~-N~--~
NH
H
N-\I, ~N
N~
76-63 N 423.2 424.1 3.24 HN
NO
>
N
"-r \
~N \
NN
76-64 HN489.2 490.4 4.64 S-N C) N
F
H
N`
~N \
76-65 N 437.2 438.2 3.45 HN
S-N CN
11--o H
N-N
NY N
76-66 HNy 462.2 463.3 3.17 iI~
S-N N~
~
F O-F
H
N-'-T~N
N)-)-- N
76-67 HN466.2 467.2 3.56 S-N C N HN, H
N-~N \
NY _N
76-68 HN467.2 468.1 3.44 S-N ~1~
-N~
O
~O
H
4N-~
\
~N \
NY _N
76-69 HN473.2 474.3 3.92 ~
S-N ~-~
N
H
\ I.
~N \
76-70 N-)-- N 423.2 424.2 3.38 HN~
S-N C--o N
N-~N \
NY N
76-71 HN477.2 478.2 3.56 S-N N-\-N) ~D
H
"`
~N \
NY
7g_72 N 499.2 500.5 3.91 HN
S-N CN
Ph H
"`
~N \
"Y N
76-73 439.2 440.6 3.14 HN~
S-N CN
OH
H
N-76-74 ~N \
N 384.1 385.1 0.981 HN~
S-NHN-\
`-\OH
H
"`I
\
~N \
76-75 "N 412.2 413.2 0.932 HN~
S-NHN
\ OH
H
"`
370.1 371.2 0.788 76-76 N` N
HN~
1S'-NI HN--\-OH
H
N-~N \
76-77 "~N 422.2 423.3 1.224 HN~
~S-N~-H
N-N
\ I
~N \
"Y)-- N 419.2 420.3 3.69 HN~
S-N~-~
CN
H
N-~N \
"Yl-- N 451.2 452.3 3.46 HN~
S-N
N HAc H
N-~
\
"T~N
"~" 444.1 445.5 3.65 HN~
S-N
(\-~ O
H
N-N
"r)-- " 495.2 496.8 4.63 HN~
~~ /~--~
S-N
qPh NC
H
N-N
NYl-- N
76-82 HN~ 451.2 452.4 3.48 S-N
O
H
H
N-~N \
NY
76-83 N 450.2 451.2 2.81 HN
S-N
H
N-",T~N
N~
76-84 N 437.2 438.2 1.76 HN~
S-N
N-/
H
N-N
\ I
~N \
76-85 N -)'N 452.1 453.2 2.97 HN, S-N I-OH
H
N,N
~N
76-86 N~N 411.5 411.2 2.38 HN~
S-N N
H
N'N
N
76-87 NY-1- N 424.1 425.2 1.09 HN\ ^
~S/-N~HN
HO
H
N'N
I
Nl\
NY`N
76-88 HN 453.2 454.3 0.86 S_N a OH
H
N'N
N
NY`N
76_89 432.1 433.1 1.05 HN
Y~S-- \N
N-N
/
H
N'N
N
76-90 N 429.1 430.2 0.99 HN~ ^
~S~-N~- \N
N
N-N
I
N
76-91 N~N 438.1 439.1 0.97 HN\ ^
S/-~N~
/ N
OH
H
N-N
76-92 NYl-- N 448.1 HN
S- N~N
~/ -CF3 N-N
H3C~
76-93 Nlrt'N 480.2 481.3 3.33 HN
S-N j --\__ \ OEt N-N
NI_ 76-94 N ~ N 462.2 HN
~--~ F3 S-nj H
\ ~r H3C~I N
N'Y N
76-95 HN 444.2 S-N N
\~ F
F
H
a H3C~I N
N'Y
76-96 N 426.2 HN
S-N~aF
H
a N
H3C e INY N
~ 476.2 S-N aCF3 H
N-N
76-98 N yl-- N 436.1 HN
S-N~- N-\
( CF3 H
N-~
\
N
76_99 N N 404.1 Y
HN
S-NHN
F F
H
N-~
\
N
NY N
76-100 HN~ 448.2 S-N
F
HO
H
N-~
\
76-101 N I 490.1 HN
S-N N-\
(\ CF3 H
N-~
\
~N \
76-102 N~ N 478.2 HN\^ OH
~S/-N~N CF3 H
N-~
\
N
NY N
76-103 HN477.2 478.3 1.85 S-N Q
N
H
N
N \
76-104 N N 546.3 Y
HN~
S- N~N
Ph Ph H
N-~
\
N
NY N
76-105 HN ~ 463.2 S-N N
~ N
H
N-~
N
N~N 468.2 HN
S-N~- N
OH
Ph N-~
N
"Y N
76-107 HN -r 476.2 S-N N
N
H
N-N
"yl-- N 423.2 HN
S-N~Q,--NH
H
N-~
~N \
N Y _N
76-109 ""~ 554.2 S-N
OH
H
a N
76-110 N~ N 378.1 379.2 2.43 HN
S-N ~
/
N-N
N
76-111 N~ 408.1 409.2 2.59 T N
HN
S-NHN-\
H
N-N
I N
Nl,'I--N 506.2 507.3 2.59 HN~
S-N N
N-N
H3C"
"yl-- " 484.2 485.3 2.54 HN~
S-N N
COZEt F
H
N-N
\I
H3C\ ^N
76-114 7N::;~- N 382.1 HN\ ^
'S~/-N~N
OH
H
N-N
H3C\ ^N
76-115 ~NYl- N 391.1 392.2 2.01 HN`
S- NN
q CN
H
N- N
H3C\ N
76-116 NYl- N
HN\ ^
~S/-N~N
~q F
N-N
H3C\ ^N
TNY N
HN
S-N N~
L_ I\OMe N-N
\ I
H3C~N
NY'N
76-118 ~ ~~
HN`
S-N N
~q OiPr H
N-H3C\~N
76-119 N 1"\--- N 366.1 HN\^
S-N N
D
N-H3C\^
N 'N
TY N
76-120 h0''467.2 S-N N
CN
H
N
N
Y
76-121 N N 442.2 HN~
~S~- N~- ~N
POH
F
H
N-76-122 NN 380.2 HN~^ =
S- N~- N
~
H
N-~
~
N \
76-123 NN 394.2 HN
S- N~-\N
Et H
N-H3C~N
76-124 "'IY)- N 400.1 HN
S- N~ N
CI
H
N-H3C~N
76-125 "N 444.1 HN
S-N~N
Br H
N-H3C-r,7~N
" N
76-126 HNr-,~~ 467.2 S-N N
F
H
N-H3C~N ~
I"'~N 450.1 HN
S-N~N
OH
H
N-H3C Yl~N
NY N
76-128 HN451.2 S-N N
q QO
Example 76-1: 'H NMR (400 MHz, CD3OD) b 8.24 (s, 1 H), 8.23 (s, 2H), 8.07 (s, 1 H), 7.35 (s, 1 H), 4.57 (d, J = 12.8 Hz, 2H), 3.81 (t, J = 4.8, 2H), 3.57 (q, J =
14.0, 6.8 Hz, 2H), 3.52 (m, 2H), 3.41 (m, 2H), 2.60 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 6.8 Hz, 3H). HPLC-MS tR = 2.28 min (UV 254nm). Mass calculated for formula 426.2; observed MH+ (LCMS) 427.2 (m/z).
Example 76-2: 'H NMR (400 MHz, CD3OD) 6 8.31 (s, 1 H), 8.29 (s, 2H), 7.32 (s, 1 H), 4.88 (d, 1 H), 4.46 (d, J= 16.1 Hz, 1 H), 3.82 (d, J= 12.3 Hz, 1 H), 3.71 (d, J= 12.3 Hz, 1 H), 3.64 (m, 1 H), 2.65 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.31 (t, J =
7.1 Hz, 3H).
HPLC-MS tR = 2.26 min (UV 254nm).
Example 76-3: 'H NMR (400 MHz, CD3OD) 6 8.16 (s, 2H), 8.13 (s, 1H), 7.99 (s, 1H), 7.25 (s, 1 H), 4.72 (d, J = 15.6 Hz, 1 H), 4.53 (t, J = 15.6, 1 H), 3.66 (s, 2H), 3.61 (m, 1 H), 3.40 (m, 1 H), 2.57 (s, 3H), 1.33-0.95 (8H), 1.17 (t, J= 6.8 Hz, 3H).
HPLC-MS tR =
2.26 min (UV 254nm). Mass calculated for formula C20H26N80S 452.2; observed MH+
(LCMS) 453.2 (m/z).
Example 76-4: 'H NMR (400 MHz, CD3OD) 6 8.16 (s, 2H), 8.15 (s, 1H), 8.00 (s, 1H), 7.21 (s, 1 H), 4.95 (d, J= 16.0 Hz, 1 H), 4.35 (d, J= 16.8 Hz, 1 H), 4.07 (d, J= 12.4 Hz 1 H), 3.82 (d, J = 12.8 Hz 1 H), 3.52 (m, 2H), 2.57 (s, 3H), 1.96-1.58 (10H), 1.26 (t, J =
6.8 Hz, 3H). HPLC-MS tR = 2.48 min (UV 254nm). Mass calculated for formula C20H26N80S 466.3; observed MH+ (LCMS) 467.3 (m/z).
Example 76-5: 'H NMR (400 MHz, CD3OD) b 8.28 (s, 1 H), 8.25 (s, 2H), 8.10 (s, 1 H), 7.39 (s, 1 H), 4.65 (d, J = 14.0 Hz, 1 H), 4.52 (d, J = 10.8 Hz, 1 H), 4.24 (d, J = 14.0 Hz 1 H), 3.85 (d, J = 18.0 Hz 1 H), 3.65-3.44 (4H), 2.65 (s, 3H), 1.97-1.58 (6H), 1.29 (t, J =
7.2 Hz, 3H). HPLC-MS tR = 2.35 min (UV 254nm). Mass calculated for formula C20H26N80S 452.2; observed MH+ (LCMS) 453.2 (m/z).
Example 76-6 'H NMR (400 MHz, CD3OD) 6 8.21 (s, 3H), 8.03 (s, 1 H), 7.23 (s, 1 H), 4.38 (d, J = 5.6 Hz, 1 H), 3.79 (d, J = 5.4 Hz, 1 H), 3.63 (d, J = 12.4 Hz 1 H), 3.53 (m, 1H), 3.10 (m, 1H), 2.58 (s, 3H), 1.34 (s, 6H), 0.87 (t, J = 6.2 Hz, 3H). HPLC-MS tR =
2.39 min (UV 254nm). Mass calculated for formula C20H26N80S 440.2; observed MH+
(LCMS) 441.2 (m/z).
Example 76-7: 'H-NMR (400 MHz, CD3OD ) 6 8.33 m (3H), 8.15 s (1H), 7.41 s (1H), 4.80 (d, 2H), 4.15 (d, 2H), 4.06 (d, 2H), 3.62 (d, 2H), 3.58 (m, 1 H), 2.68 (d, 3H), 2.21 (m, 1 H), 1.81 (m , 6H) and 1.45 (s, 3H). HPLC-MS tR =1.80Min (UV 254nm). Mass calculated for formula C21 H26N80S 438.55, observed LC/MS m/z 439.1 (M+H).
Example 76-8: 'H-NMR (400 MHz, DMSO-d6) 6 12.73 bs (1H), 9.2 bs (1H), 8.28 s (2H), 8.09 s (1 H), 8.08 s (1 H), 7.36 s (1 H), 4.71 m (1 H), 4.05 m (1 H), 3.82 m (1 H), 3.63 m (1 H), 3.25 m (2H), 1.97 m (1 H), 1.65 m (6H) and 1.30 s (3H).
Example 76-9: 'H-NMR (400 MHz, DMSO-d6) S 8.28 (1H), 8.25 (2H), 8.08 (1 H), 7.32 (1 H), 4.71 (1 H), 4.08 (1 H), 3.84 (1 H), 3.52 (3 H), 3.46 (1 H), 2.63 (3 H), 2.17 (2 H), 1.87-1.73 (6 H), 1.45 (3 H).
Example 76-10: 'H-NMR (400 MHz, DMSO-d6 ) S 8.28 (1H), 8.25 (2H), 8.08 (1 H), 7.32 (1 H), 4.71 (1 H),4.08(1 H),3.84(1 H), 3.52 (3 H), 3.46 (1 H), 2.63 (3 H), 2.17 (2 H), 1.87-1.73 (6 H), 1.45 (3 H).
Example 76-11: 'HNMR (400 MHz, CD3OD) S 8.20 (s, 2H), 8.14 (s, 1 H), 8.03 (s, 1 H), 7.25 (s, 1 H), 4.48 (d, 1 H), 4.37 (d, 1 H), 3.46 (s, 3H), 2.91-3.60 (m, 6H), 2.62 (s, 3H), 1.40 - 1.89 (m, 4H), 0.92 (s, 3H).
Example 76-12: 'HNMR (400 MHz, CD3OD) S 8.20 (s, 2H), 8.14 (s, 1 H), 8.03 (s, 1 H), 7.25 (s, 1 H), 4.48 (d, 1 H), 4.37 (d, 1 H), 3.46 (s, 3H), 2.91-3.60 (m, 6H), 2.62 (s, 3H), 1.40 - 1.89 (m, 4H), 0.92 (s, 3H).
Example 76-40:1 H NMR (400 MHz, CD3OD) S 8.28 (s, 1 H), 8.25 (s, 2H), 8.10 (s, 1 H), 7.38 (s, 1 H), 4.59 (s, 2H), 3.3-3.9 (m, 4H), 2.64 (s, 3H), 2.3-2.5 (m, 4H).
Example 76-42: 'H NMR (400 MHz, CD3OD) b 8.13 (broad s, 2H), 7.85 (s, 1 H), 7.78 (s, 1 H), 7.15 (s, 1 H), 4.10 (d, J - 14 Hz, 1 H), 3.96 (d, J -14 Hz, 1 H), 3.54-3.66 (m, 1 H), 3.07-3.17 (m, 1 H), 2.62-2.72 (m, 1 H), 2.53 (s, 3H), 1.82-2.21 (m, 4H).
~OH OH
A mixture of iodoethane (52.5 g, 336.5 mmol) and 2-amino-2-methyl-l-propanol (30.0 g, 336.5 mmol) was stirred at 60 C for 15 min. It was diluted with 500 mL of ether, and basified by adding 5 N aqueous NaOH until it reaches pH =10. The organic layer was separated. The aqueous layer was extracted with ether (500 mL X 3). The combined organic was washed sequentially with 100 mL of water, and 100 mL of brine, then dried over anhydrous Na2SO4. The solvent was removed to provide 20 g of the crude product, which was purified by recrystallization in 150 mL of hexanes to give 13 g of a white solid. The solid was further purified by sublimation under reduced pressure to give 12 g of the title compound. 'H NMR (400 MHz, CDCI3) b 3.28 (s, 2H), 2.54 (qt, J = 7.1 Hz, 2H), 1.09 (t, J = 7.0 Hz, 3H), 1.07 (s, 6H).
1. LiAIHa +
HCI. H 2. CbzCI, K2CO3 Cbz Cbz 3. Chiral Separation Peak 1 Peak 2 Step A
Pd(OH)2, H2 C>--O
OH
O
Cbz Step B Cbz Step C H
Peak 1 or Peak 2 Step A: The substrate (10 g) was suspended in THF (200 mL). Then lithium aluminum hydride solution (110 mL, 2M in THF) was slowly added. The mixture was stirred at room temperature for 12 h. The solution was cooled to 0 C, and saturated aqueous Na2SO4 (200 mL) was slowly added. The mixture was filtered through Celite, and filtercake was washed with ethyl acetate (400 mL). The organic layer was washed with water (200 mL) and brine (200 mL). The organic layer was dried (anhydrous Na2SO4), filtered and evaporated to give the amino alcohol (6.9g). The amino alcohol (6.9 g) was dissolved in THF (80 mL) and water (80 mL) at room temperature. The potassium carbonate (14.76 g) was added. Then benzyl chloroformate (8.28 mL) in THF (40 mL) was added dropwise. The mixture was stirred at room temperature for 30 min.
Solvent was evaporated off under reduced pressure, and ethyl acetate (100 mL) was added.
Two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with brine (200 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography. The racemic aminoalcohol was chirally separated by SFC HPCL method. Then enatiomers corresponding to peak 1 and peak 2 were separately taken forward to prepare the corresponding building blocks.
Step B: The alcohol from Step A (1.936 g) was dissolved in dichloromethane (80 mL), and treated with proton sponge (8.32 g) at room temperature. Then trimethyloxonium tetrafluoroborate (5.69 g) was added. The mixture was stirred for 1 h. The reaction was quenched with saturated aqueous ammonium chloride solution (100 mL). The two layers were separated, and the aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layer was washed sequentially with hydrochloric acid (200 mL, 1 N), saturated sodium bicarbonate solution (200 mL), brine (200 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography.
Step C: The enantiomerically pure methyl ether from Step B in EtOH was treated with Pd(OH)2 on carbon (20% wt) and stirred in hydrogen atmosphere at atmospheric pressure at room temperature for 2 h. The mixture was filtered off, and the filtrate was evaporated under reduced pressure to give the amine.
1. LDA, THF; Mel 1. NaH, Mel, DMF
JOEt OH O
N 2. LiBHEt3 N 2. 20% TFA/DCM N
i i Boc Step A Boc Step B
1. CBZCI, K2CO3 20% Pd(OH)2 2. Chiral Separation N,, O N O- N O-~ Step D H
Step C Cbz Cbz Step A: At -78 C, ester (6359 mg, 24.7 mmol) in THF (50m1) was added dropwise to LDA (1.8 M in THF, 27.5 ml, 49.4 mmol) in THF (200m1). The reaction mixture was slowly warmed up to room temperature and stirred at that temperature overnight. The reaction was cooled to 0 C and quenched with saturated NH4CI solution. The mixture was diluted with H20 and extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (6221 mg, 93%). LCMS tR =2.27 Min.
Mass calculated for, M+ 271.1, observed LC/MS m/z 216.1 (M+H-C4H8). To a solution of ester (4659 mg, 17.2 mmol) in THF (300 ml) was added LiBHEt3 (69 ml, 1 M in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding saturated NH4CI. The mixture was extracted with CH2CI2. The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (3032mg, 77%). LCMS tR =1.82 Min. Mass calculated for, M+ 229.1, observed LC/MS m/z 174.1 (M+H-C4H8).
Step B: NaH (1324 mg, 60% dispersion in mineral oil, 33.1 mmol) was added portion wise to a mixture of compound from Step A and Mel (3.3 ml, 52.9 mmol) in DMF
(66 mL) at 0 C. The reaction mixture was slowly warmed up to room temperature and stirred at that temperature ovemight. The reaction was cooled to 0 C and quenched with saturated NH4CI solution. The mixture was diluted with H20 and extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (2633 mg, 82%). LCMS tR =2.32 Min. Mass calculated for, M+ 243.1, observed LC/MS m/z 188.1 (M+H-C4H8). A solution of compound 4 (901 mg, 3.71 mmol) was stirred in 20 % TFA in CH2CI2 (20 mL) at 0 C for 30 min and then room temperature for 15 min. The reaction mixture was concentrated. The crude residue was used for example without further purification. LCMS tR =0.26 Min. Mass calculated for, M+
143.1, observed LC/MS m/z 144.1 (M+H).
Step C: CbzCl (604 ul, 4.08 mmol) in THF (1 ml) was added to a mixture of compound from Step B and K2CO3 (1125 mg, 8.15 mmol) in THF (20 ml) and H20 (20 ml) at 0 C.
After stirring at room temperature for 30 min, the reaction mixture was extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the titlte compound (965mg, 94%). LCMS tR =2.28 Min (UV 254nm). Mass calculated for, M+ 277.1, observed LC/MS m/z 278.1 (M+H). The title amines were chirally separated utilizing a Gilson GX-281 liquid handling system with HPLC capabilities. Separation was accomplished with the following conditions: Chiral Technologies Chiral PAK AD
column (5 x 50 cm; 20 p); flow = 50 mUmin; 7.5% isopropanol in hexanes (isocratic);
observed at 210 nm.
Step D: The enatiomerically pure isomers from Step C were dissolved in (1 mmol, 277 mg) in EtOH (6 ml) was mixed with 20% Pd(OH)2 (51 mg) and stirred under H2 balloon at room temperature for 2h. Filtration through celite and concentration afforded the title compound, which was used for next step without further purification.
LCMS tR
=0.26 Min. Mass calculated for, M+ 143.1, observed LC/MS m/z 144.1 (M+H).
SEM SEM H
- N,N
-" \N \~
N N 2N HCI, dioxane N
N N\~N N~N
StepA
T Step B HN SHN SHN SI/ O`R
~OH ~ ~OR ~
N\-- N~
\--Step A: The parent compounds were prepared from Example 76-2 using acid chlorides, acids, ureas and isocyanates using standard reaction conditions.
Step B: Sem-protected material from Step A was dissolved in 1,4-dioxane (1 mL) and treated with 4 N HCI in 1,4-dioxane (1 mL). then heated at 60C for 1 hr.. The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded the title compound as a colorless solid.
Using essentially the same procedures as described for Example 80, the following compounds were prepared.
LCMS
HPLC
Example Column 2 MW MH MS tR
m/z H
N-N
80-1 N N 468.2 469.3 2.62 HN , I /
N ~
~O 0 H
N-N
80_2 N N 510.3 511.3 3.12 HN g~
N
-rO O
H
N-AI
\ I , N
Y
80-3 N N f 496.2 497.3 2.98 HN S, /
N
~O O
H
\ `I
N
N Y N
80-4 496.2 497.3 2.98 HN S, y L /
N
-rO O
H
N-AI
~N \
80-5 N N 482.2 483.3 2.82 Y
HN S.
/
N ~
rO O
H
N-AI
\ , N
NY N
80-6 ' 494.2 495.3 2.83 HN S~
I
N
~O O
H
N -\ , N
Y
80-7 N N f 530.2 531.3 3.34 HN S~
i N
~O O
H
N-AI
N
N Y N
80-8 I 508.2 509.3 3.03 HN gI
N
-rO O
H
N-\I, N
N~
N 510.3 511.3 3.08 HN gI
N
C o H
N-\I' N
N~
N
80-10 525.3 526.3 2.21 HN S~
N
~O O
H
a N
~
80-11 N N 508.2 509.3 2.87 HN g~
I
N
-rO 0 H
N-~
\
N
80-12 N N 509.2 510.3 1.85 HN gI
-rO O
H
a ~N \
80-13 N N 525.3 526.3 2.37 HN g~
,,,NH2 I /
N
-rO 0 H
N-~
\
N
80-14 N N 539.3 540.3 2.86 Y
HN SI
,,,NH2 N
~O O
H
N
\
N
N~N 550.3 551.3 3.56 HN gI /
N
-rO O
H
N-^I
\ I , N
80-16 N N 497.2 498.3 2.65 Y
HN gI
\N~
N
~O O
H
a N
Nll)'-N 536.3 537.3 3.27 HN gI /
N
--rO 0 H
N-N
~
80-18 N N 522.3 523.3 2.98 HN SI
N
-rO O
H
N-N
80-19 N N 483.2 484.2 2.25 Y
HN SI
~NH2 N
,rO
H
N'N
~N \
N N
80-20 HN ~_\ 539.3 540.3 2.65 S-N
ol-~~
H
N-I N
~N \
NY N
80-21 HN` 557.2 558.2 2.53 S-N
O
SMe H
N'N
N
N Y _N
yf- -~ 573.3 574.2 2.74 i S-N
Ph H
N
N \
N N
80-23 HN 523.2 524.2 2.38 S-N
N
H
N-N
~N \
NY N
80-24 HN 497.2 498.3 2.29 S-Nl~
H
'N
N
NN
80-25 HN ~ 511.2 512.3 2.28 ~N~
S~-O
H
N
~N \
NY N
80-26 HN 484.2 485.3 2.77 S-N
~
Olp I
H
N-N
~N \
NY N
80-27 HN 512.2 513.3 3.03 S-Nh H
N-N
~N \
NY N
498.2 499.3 2.65 'S-NI~ ~
Ol H
N-N
N
NY N
HN 551.3 554.3 1.98 80-29 ~ /
S-N
N
c ) O
H
N-\f.
N
N Y _N
HN S 540.3 541.3 3.21 S-N \ O~
H
N-N
~N \
NY N
\ 511.2 512.2 3.32 80-31 HN Yl S-N
pINH
~
H
~N \
NY _N
HN
80-32 S_ N 563.2 564.2 3.36 pINH
F
H
N-N
~N \
N Y _N
80-33 HN S 583.3 584.2 3.52 o HN o O
O
H
N'N
N
NY N
80-34 HN531.2 532.2 2.99 S-N
p I ~N
H
N-~N \
N Y N
80-35 HN s, 569.2 570.2 3.16 iN `
N/\ O
~OH
~N
O ' O ~
H
N'N
N
NY
80-36 HN N 664.4 665.3 6.22 S-Nl~
p )14 H
N-N
N
NY N
80-37 HN 497.2 498.2 3.09 S-Nh pINH
H
~N \
NY N
80-38 HN r ~/ 511.2 512.2 3.32 S-N
pINH
H
N \
N Y N
HN
80-39 S N 525.3 526.2 3.56 pINH
H
N-~N \
NY N
80-40 HN 525.3 526.2 3.53 S-Nl~
pl NH
H
'N
\ I
N
NY N
80-41 HN 576.2 577.3 3.29 S-N
CF
SEM
SEM N' N
H2N N NaH / DMF/ RT ~N \
N
~
NY'~-N O O Step A HN S,0==0 \ ~ ~N
I O
O\
SEM H
N- -1) LAH, THF N 1) amine, K2CO3 / 80 C 5:P'N
NN NN
2) MsCI / Et3N
HN S2) 2N HCI, dioxane HN S.
Step ' p Step C
C0Ms NRZ
Step A: The starting sulfone was prepared by essentially the same procedure described in Example 6 except that ethylboronic acid or cyclopropylboronic acid was used. Final products listed in Table 17 were obtained by using the procedures described for Example 76.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N-\I' N
81-1 N N 440.2 441.2 1.21 Y
HN
I
N
/r0H
H
N-\ I, N
N ~ _N
81 _2 HN 440.2 441.2 1.29 I/
N
O --\
H
N-\ I , N
81-3 N Y~- N 422.2 423.1 1.26 HN g~
/
N
H
N-\ I, N
NY
81-4 N I 424.2 425.2 1.29 HN g~
~ k N
H
\ `I
N \
81-5 NY-,-- N 436.2 437.2 1.34 HN g~
~ N
N
H
\~r N
81-6 N~N 492.2 493.3 3.34 HN
, /N
N OH
H
\~r N \
81-7 N~N 478.2 479.3 3.17 H N
, /N
N OH
H
N`
N \
81-8 NYl-- N 494.2 495.3 2.93 HN IgO
/N
N OH
H
N`
N
81-9 NY-1--- N 434.2 435.3 3.08 H N g~
, /N
N
H
\ `I
N
81-10 N~N 408.2 409.3 2.86 HN g~ N
N
~
H
N-N
81-11 N N 422.2 423.3 2.97 HN g~
N
N
H
N-~ f.
N
81-12 N N 434.2 435.3 3.07 Y `
HN g, N
N
H
N-N
81-13 N N 436.2 437.3 3.12 ~
HN
/N
N
-A~
H
N'N
~ N \
~
81-14 N N 432.2 433.3 2.98 HN S~
, /
N
H
\~r N
81-15 N N 452.2 453.3 2.97 HN S~
E / N
N
HO\~
H " \
N-\ f' N
N Y _ 81-16 N 452.2 453.3 3.15 HN g~
T N - /O
N
H
N-N
81-17 NY-1- N 434.2 435.3 3.07 HN S~ / N
N
H
\~r N \
81-18 N Y ' N 448.2 449.3 3.29 HN gI N
N
~
H
N`
N
NY_ 81-19 N 478.2 479.3 3.35 HN g~
t N
N
<N. ,SEM N, ,SEM <JNH
N N Step A ~N \ Step B ~N \
NY-1--- N NN --~ N` N
HN N~T SNHNY S~
~ ~N ~ ~N y ~N
R
OMs NH
Step A: The title compound was prepared using as described for Example 7 except that t-butylamine was used.
Step B: To a solution of the product of Step A (1 equivalent) in THF (3 mL) was added DIEA (3 equivalents), and the respective trifilate (1.2 equivalents) at room temperature. The reaction was heated at reflux until consumption of starting material was observed by LC-MS analysis. The solution was cooled to room temperature and concentrated under reduced pressure. Purification by column chromatography (Si02, 30% ethyl acetate/dichloromethane) afforded the desired coupled intermediate.
This material was dissolved in 1,4-dioxane, HCI (4N in dioxane) was added and the mixture was sonicated until such time that HPLC indicated no starting material remained. The mixture was concentrated under reduced pressure, purified by prep-HPLC, and conversion to the hydrochloride salt afforded the title compounds as off-white solids in Table 18.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
tNH
H3C\ ^N
101-1 N 464.2 465.1 5.22 HN S
f IN
N
k N'NH
H3C\
N
101-2 S 446.2 447.2 4.09 HNT IN
N, , SEM N, , SEM N-~ N N NH
N Step A 5:;'N \ Step B N
NY-- N NY-`N NY N
HN ' H N ' HN SI IN I IN N
OMs SCH3 S02CH3 Step A: Sodium thiomethoxide (39 mg, 3.00 equiv) was added to a stirring mixture of mesylate prepared in example 7(100 mg, 1.00 equiv) and sodium iodide (14 mg, 0.50 equiv) in DMF (6 mL) at room temperature. The resulting mixture was allowed to stir for 2.5 hours at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with saturated aqueous sodium bicarbonate (30 mL) and then extracted with dichloromethane (2 x 70 mL). The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford the title compound as a yellow solid, 100 mg (>99%).
Step B: m-Chloroperbenzoic acid (66 mg, 2.05 equiv) was added to a stirring solution of compound from Step A (91 mg, 1.00 equiv) in dichloromethane (3 mL) at room temperature. The mixture was allowed to stir for 2 hours at which time thin layer chromatography indicated the reaction was complete. The mixture was diluted with ethyl acetate (40 mL) and then washed with saturated aqueous sodium bicarbonate (15 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. This material was dissolved in 1,4-dioxane, HCI (4N in dioxane) was added and the mixture was sonicated until such time that HPLC indicated no starting material remained. The mixture was concentrated under reduced pressure, purified by prep-HPLC, and conversion to the hydrochloride salt afforded the title compound as an off-white solid, 18 mg (27%). 'H NMR (300 MHz, DMSO-d6) S 12.19 (s, 1 H), 8.24 (s, 2H), 7.96 (s, 1 H), 7.83 (s, 1 H), 7.28 (s, 1 H), 4.61 (s, 2H), 3.01 (s, 3H), 2.53 (s, 3H). HPLC tr = 4.04 min (UV 254nm). Mass calculated for C15H15N702S2 389.1; observed MH+ (MS) 390.7 (m/z).
/ F Step A c(0,N11IIII) F Step BO / I F S~p C F
--' ~ S N -~ H2N S I N
SEM SEM H
SEM \ -\~r 1 Step D~N \ Step E N Step F~N
N_ 1\N N
+ ~N \ -- N~N NN N
Y ` HN ~ HN
S02Me S/ F S/ F HN ~/ F
NNo S No Step A: EtN(iPr)2 (10.55 mL, 60.69 mmol) was added at 0 C to acid (2953 mg, 20.23 mmol, prepared according to Bioorganic & Medicinal Chemistry, 11(20), 4333-4340;
2003), EDCI (5817 mg, 30.34 mmol), HOBT (4100 mg, 30.34 mmol) and piperidine (2398 uL, 24.28 mmol) in DMF (100 mL). After stirring at room temperature overnight, the crude reaction material was diluted with EtOAc and washed with brine (2X).
The organic layer was dried over Na2SO4, filtered, and concentrated to give the crude product which was chromatographed to give the product amide. HPLC-MS tR =1.57 Min (UV 254nm)=Mass calculated for formula, M+ 213.0, observed LC/MS m/z 214.1 (M+H).
Step B: Powdered KNO3 (1100.8 mg, 10.89 mmol) was added portionwise to a stirred solution of amide (927.6 mg, 4.356 mmol) in conc. H2SO4 (20 mL) at 0 C. After stirring at 0 C for 30 min, the reaction mixture was poured onto ice. Extraction with and the combined organic lawyer was washed with H20, dried over Na2SO4 and concentrated. Purification by column chromatography afforded first the undesired nitration product 545.5 mg (48.5%), HPLC-MS tR = 1.79 Min (UV 254nm)= Mass calculated for M+ 258.0, observed LC/MS m/z 259.1(M+H),'HNMR (400 MHz, CDCI3) 6 7.58 (d, 1 H, J = 0.4 Hz), 3.67 (m, 4H), 1.73 (m, 6H), then the desired nitration product 435.6 mg (38.8%), HPLC-MS tR = 1.68 Min (UV 254nm). Mass calculated for M+
258.0, observed LC/MS m/z 259.1(M+H).1 H NMR (400 MHz, CDC13) 6 8.37 (d, 1H, J
= 3.2 Hz), 3.67 (m, 4H), 1.71 (m, 6H).
Step C: To a solution of nitroamide (435.6 mg, 1.69 mmol) in HOAc (20 mL) was added iron powder (471.5 mg, 8.44 mmol). The reaction mixture was heated at 70 C
for 30 min. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added 30mL of 20% MeOH/CH2CI2 followed by 20 mL of saturated aqueous NaHCO3. The mixture was stirred until it stoped bobbling.
The mixture was extracted by EtOAc (x 2), dried over Na2SO4, and then concentrated. The crude amine was used for displacement reaction without further purification.
HPLC-MS tR = 1.32 Min (UV 254nm). Mass calculated for M+ 228.0, observed LC/MS m/z 229.1(M+H).
Step D: A solution of crude amine from Step C (491.5 mg, 2.156 mmol) and sulfone (292 mg, 0.719 mmol) in DMSO (10 mL) was treated with NaH (60% dispersion in oil, 172.5 mg, 4.312 mmol) at room temperature. The mixture was stirred until LCMS
indicated the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford crude product 4. Purification afforded compound 4. HPLC-MS tR = 2.503 Min (UV 254nm). Mass calculated for M+ 555.2, observed LC/MS m/z 556.3(M+H).
Step E: To a solution of the amide from Step D (120 mg, 0.216 mmol) in dichloromethane (12 mL) was added lithium aluminum hydride (86.4 mg, 2.162 mmol) and ethyl ether (3 mL) at 0 C. The reaction mixture was stirred at room temperature until LCMS indicate the reaction was complete. The reaction was quenched with (86 uL), 3N NaOH (86 uL) and H20 (264 uL). The reaction was filtered and concentrated to afford crude compound 5. HPLC-MS tR = 1.738 Min (UV 254nm).
Mass calculated for M+ 541.2, observed LC/MS m/z 542.2 (M+H).
Step F: 4N HCI in dioxane (3mL) was added to crude product from Step E at 0 C.
The mixture was stirred at room temperature until LCMS indicated the reaction was complete. Concentration afforded crude product. Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR =
0.923 Min (UV 254nm). Mass calculated for M+ 411.1, observed LC/MS m/z 412.2 (M+H).
H
N-\
N
N~/ N
HN -~/
S
N
By essentially the same procedure given in Example 84, the title compound can be prepared. HPLC-MS tR = 1.005 Min (UV 254nm). Mass calculated for M+ 425.1, observed LC/MS m/z 426.2 (M+H).
SEM
N-NEM
~ IJV /N
A / ~ I+ B c OZN I IO HZN _O N ~ -- N\~N
II S~ T
SO2Me O
O
SEM SEM NEM
N-D I` F
N N
~ ---- N~N E - NY-,--N - N
H N ~ H N HN _ N~N
S/ S HN ~
OH O Na F S / ^
}-F
Step A: To a solution of nitroester (2285 mg, 12.22 mmol) in HOAc (55 mL) was added iron powder (6825 mg, 122.20 mmol). The reaction mixture was heated at 75 C for 10 min. The mixture was cooled to room temperature and then added 200 mL of MeOH. The resulting mixture was filtered through celite (the celite was rinsed with additional amount MeOH). The filtrate was concentrated to remove most of AcOH. To the residue was added 50 mL of 20% MeOH/CH2CI2 followed by saturated aqueous NaHCO3 until it stoped bubbling. The mixture was extracted by EtOAc (x 2), dried over Na2SO4, and then concentrated. The crude amine was used without further purification. HPLC-MS tR = 1.07 Min (UV 254,m). Mass calculated for M+
157Ø0, observed LC/MS m/z 158.1(M+H).
Step B: To a solution of the aminoester (850 mg, 5.414 mmol)) and sulfone from Example 1 (1 equivalent, 1469 mg, 3.609 mmol) in DMSO (36 mL) was treated with NaH (60% dispersion in oil, 14.43 mmol, 577 mg) at room temperature portionwise.
After 10 min, LC-MS analysis of the reaction indicated the reaction was complete.
While cooling by water bath, the reaction was quenched with sat. NH4C1 dropwise (5 ml) and then added H20 (160 ml) extracted with ethyl acetate (2x). The combined organic layers were washed with brine and dried (sodium sulfate). Evaporation and purification by column chromatography (0 to 100% EtOAc/Hexane) afforded title compound (1492 mg, 85%). HPLC-MS tR = 2.41 Min (UV 254nm). Mass calculated for M+ 484.1, observed LC/MS m/z 485.2 (M+H).
Step C: To a solution of the product of Step B (206 mg, 0.4271 mmol) in THF (8 mL) was treated with DIBAL (1.0 M in CH2C12, 2.56 mL) at -78 C dropwise. After stirring at -78 C for 4.5h, LCMS indicated the existence of small amount of starting material..
Two more equivalents DIBAL (0.85 mL) were added. After stirring at -78 C for another 0.5 h, brine (6 mL) was added portionwise at -78 C to quench the excess reagents.
The reaction mixture was extracted with CH2CI2 (3X). Evaporation of solvent and purification by column chromatography (0 -> 100% 2% MeOH in EtOAc/Hexane) afforded alcohol (153 mg, 79%). HPLC-MS tR = 2.01 Min (UV 254nm). Mass calculated for M+ 456.1, observed LC/MS m/z 457.1 (M+H).
Step D: To a solution of alcohol from Step C (537 mg, 1.17 mmol) in THF (26 mL), was added H20 (0.078 mL) followed by Dess-Martin periodinane (599 mg, 1.41 mmol) at 0 C. The reaction was stirred at room temperature until LCMS
indicated the reaction was complete. The reaction mixture was diluted with CH2CI2, and washed with saturated aqueous NH4CI solution. The organic was dried over anhydrous Na2SO4 and then concentrated. Purification by column chromatography afforded aldehyde (237.1 mg, 44%). HPLC-MS tR = 2.15 Min (UV 254nm). Mass calculated for M+ 454.1, observed LC/MS m/z 455.1 (M+H).
Step E: To a mixture of aldehyde (94 mg, 0.21 mmol) and 4-fluoropiperidine hydrochloride (58 mg, 0.41 mmol) in DCE (10 mL) was added DIEA (144 uL, 0.828 mmol), followed by NaBH(OAc)3 (139 mg, 0.62 mmol). The reaction mixture was stirred at room temperature ovemight and then diluted with CH2CI2, and washed with saturated NaHCO3 solution. The organic was dried over anhydrous Na2SO4 and then concentrated. The crude product was used without purification for next step.
HPLC-MS tR = 1.57 Min (UV 254,1m). Mass calculated for M+ 541.2, observed LC/MS m/z 542.2 (M+H).
Step F: 4N HCI in dioxane (5mL) was added to crude amine at 0 C. The mixture was stirred at room temperature until LCMS indicated the reaction was complete.
Concentration and purification by Prep-LC the title compound. HPLC-MS tR =
0.89 Min (UV 254nm). Mass calculated for M+ 411.1, observed LC/MS m/z 412.1 (M+H).
H
N -\ I , N
NY _N
HN ~
S ~
Na F
F
By essentially the same procedure as Example 86, the title compound can be prepared. HPLC-MS tR = 0.97 Min (UV 254nm). Mass calculated for M+ 429.1, observed LC/MS m/z 430.1 (M+H).
H
N- N
N
NY N
HNI l S F N F
By essentially the same procedure as Example 86, the title compound can be prepared. HPLC-MS tR = 0.99 Min (UV 254nm). Mass calculated for M+ 443.1, observed LC/MS m/z 444.1 (M+H).
SEM SEM SEM SEM
-~' Br B
~/~N N c F / N
T~` l- N N -)- N N N N Y-,-- N
N Y
SMe SMe SMe SOZMe SEM SEM
N-~ F
a N F
+ H2N ~ D N` ~ E - F NN ---S~COZMe ~ N HN
N HN
-COZMe ~
S-N S_N OH
SEM H
F a F F N \ G N
N\/ N N~N
HiN HN
S-N OMs S N N
Part A: A mixture of 6-bromo compound (4562 mg, 10.39 mmol), PdCl2dppf (424.3 mg, 0.519 mmoL), Cul (296.9 mg, 1.56 mmol) and tributyl(1-ethoxyvinyl)tin (5617 uL, 16.627 mmol) in CH3CN (100 mL) was refluxing until LCMS indicate the reaction was complete. 1 N HCI (15 mL) was added and the mixture was stirred until LCMS
indicate the conversion to ketone. The reaction mixture was diluted with EtOAc, washed with sat NH4C1, dried with Na2SO4, and concentrated. Purification afforded ketone (3200 mg, 76%). HPLC-MS tR = 2.32 Min (UV 254nm)= Mass calculated for M+ 403.1, observed LC/MS m/z 404.2 (M+H).
Part B: Bis(2-methoxyethyl)aminosulfur trifluoride (2745 uL, 14.89 mmoL) was added dropwise to ketone from Part A (600 mg, 1.489 mmoL) in CH2CI2 (1 mL) at 0 C.
The mixture was stirred at room temperature for 1 week and then carefully added dropeise to Sat NaHCO3 solution. The mixture was extracted with CH2CI2 and the organic layer was dried over Na2SO4, and concentrated. Purification afforded di-fluoro compound.
HPLC-MS tR = 2.52 Min (UV 254nm). Mass calculated for M+ 425.1, observed LC/MS
m/z 426.2 (M+H).
Part C: m-CPBA (1515.7 mg, 6.76 mmoL) was added to a solution the product of Part B (1307 mg, 3.07 mmoL) in CH2CI2 (31 mL). After stirring at room temperature for 2h, the reaction mixture was diluted with EtOAc, washed with sat NaHCO3, dried with Na2SO4, and concentrated. The sulfone (5-A) was used directly without further purification. HPLC-MS tR = 2.17 Min (UV 254nm). Mass calculated for M+ 457.1, observed LC/MS m/z 458.0 (M+H).
Part D: To a solution of the aminoisothiazole (400 mg, 2.53 mmol) and sulfone from Part C (964 mg, 2.11 mmol) in DMF (13 mL) was treated with NaH (60% dispersion in oil, 4.64 mmol, 186 mg) at room temperature. The mixture was stirred until LCMS
indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated. Purification afforded the displacement product (438.5 mg, 39%). HPLC-MS tR = 2.22 Min (UV 254nm).
Mass calculated for M+ 535.1, observed LC/MS m/z 536.1 (M+H).
Part E: To the solution of ester (406.5 mg, 0.759 mmol) in THF (39 mL) was added LiBHEt3 (3.79 mL, 1 M solution in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding saturated aqueous NH4CI (15 mL). The mixture was extracted by 30 mL of CH2CI2. The organic was concentrated and the crude alcohol was used for next step without further purification. HPLC-MS tR
= 1.99 Min (UV 254nm). Mass calculated for M+ 507.1, observed LC/MS m/z 508.1 (M+H).
Part F: To a solution of crude alcohol from Part E in THF (40 mL), was added triethylamine (365 uL, 2.62 mmol) and methanesulfonylchloride (173 uL, 2.23 mmol).
The reaction was stirred at room temperature for 30 min. It was quenched by adding MeOH. The solution was diluted by 30 mL of CH2CI2, washed consecutively with mL of 2 N aqueous HCI, water, and brine. The solvent was removed under vacuum to give crude mesylate which was used in next transformations without further purification. HPLC-MS tR = 2.35 Min (UV 254nm)= Mass calculated for M+ 585.1, observed LC/MS m/z 586.1 (M+H).
Part G: A mixture of crude compound (30mg, 0.051 mmol), 3-methyl piperidine (24 uL, 0.205 mmol), EtN(iPr)2 (54 uL, 0.307 mmol) and Nal (1 mg) in THF (2ml) was heated at 80 C for 1 h and 10 min. The mixture was cooled dot room temperature and then concentrated. 4N HCI in dioxane (3mL) was added to crude displacement product at 0 C. The mixture was stirred at room temperature until LCMS indicated the reaction was complete. Concentration and purification afforded compound 5-1. HPLC-MS tR
=
1.27 Min (UV 254nm). Mass calculated for M+ 458.1, observed LC/MS m/z 459.1 (M+H).
By essentially the same procedure given in Example 89, the compounds listed in Table 19 can be prepared.
Table 19 LCMS MH+ HPLC
Example Column 2 MW m/z MS tR
H
N'N
F F
N_ \
89-2 N~IN 444.1 445.1 1.20 HN~ ^ ~
'(S~-N~- 0 H
N'N
F F
i I N_ 89-3 N~IN 458.1 459.1 1.26 HN S-N
N- I N
F F
~N
89-4 NY-,-- N 502.2 503.2 1.18 HN` ^
S-NN
OH
H
N' I N
F
N
89_5 Nl,)'-N 516.2 517.2 1.23 HN` ^
NQ OH
H
N' I N
F F
~N
89_6 NY-,-- N 502.2 503.2 1.36 HN S-N ~~J -O-l H
N'N
F F
NI_ 89-7 N~N 432.1 433.1 1.19 HN~ ^
S(~ N~- \N--\
H
N'N
F F
N
89-8 NY-1- N 518.1 519.1 1.20 HN O
i S-N N
\ HO
H
N' I N
F F
i I N
89-9 N~ N 446.1 447.1 1.22 HN~
S`N N-~
H
N' ~ N
F F
~ I N
NY-1--- N 472.1 43.2 1.34 HN
S-N~--\N
N-N
F F
, N
NN 476.1 477.1 1.19 HN~
S N N-~
p \,-H
N' I N
F F
N
89-12 NY-1--- N 456.1 457.1 1.13 HN~ ^
~S~-Nk-\N
H
N' I N
F F
~N
89-13 N~N 476.1 477.1 1.06 HN~ pH
S NN-Y
H
N' I N
F F
j~N
89-14 N~N 460.1 461.2 1.13 HN~ ^
S(~~N~N4L
H
N'N
F F
N
89-15 NN 458.1 459.2 1.26 HN\ ^
~S/-N~N
SEM SEM SEM SEM
- N-r `~' \ -N
~
N Step A ~N \ Step B ~N \ Step C- N
I _ -- - 1/
NN NY'L-- N N~N NN
SEM"N 1/ SEMN SEM"N i SEM"N
~S-NOMs S-N CN S_NH2 S-OH
Step A: To a solution of mesylate (1.1 g, 1.65 mmol) in DMSO (20 mL) at room temperature was added Nal (280 mg, 1.88 mmol) and NaCN (300 mg, 6.12 mmol).
The mixture was stirred at 60 C for 1 h. It was diluted with 200 mL of EtOAc and washed with water (200 mL X 2). The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 60% EtOAc/hexanes) to afford 980 mg of the title compound. 'H NMR (400 MHz, CDCI3) b 7.90 (s, 1 H), 7.82 (s, 1 H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.20 (s, 1 H), 6.61 (brs, 2H), 5.56 (s, 2H), 3.88 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 2.53 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.07 (s, 9H).
Step B: A solution of compound from Step A (530 mg, 0.889 mmol) in 30 mL of CH2CI2 was cooled to 0 C. To this was slowly added DIBAL-H solution (1 M in CH2CI2, 3.56 mL, 3.56 mmol). The reaction was stirred at 0 C for 20 min. It was quenched with 1 mL of MeOH, and the resulting solution was stirred at room temperature with 50 mL of saturated Rochelle salt solution for 2 h. The organic layer was isolated and the solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 10% 7N NH3 in MeOH/ CH2CI2) to give 450 mg of the title compound. 'H NMR (400 MHz, CDCI3) 6 7.90 (s, 1H), 7:83 (s, 1H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.05 (s, 1 H), 6.65 (brs, 2H), 5.55 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 3.16 (t, 2H), 2.95 (t, 2H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step C: A solution of compound from Step B (400 mg, 0.667 mmol) and NaOAc (400 mg, 4.88 mmol) in 20 mL of AcOH was stirred at 60 C. To this was slowly added t-butyl nitrite (1.40 mL, 11.8 mmol). The reaction was stirred at 60 C for 20 min. It was cooled to room temperature and added 20 mL of CH2CI2. The solid was filtered off, and the solvent in the filtrate was removed under vacuum. The residue was diluted with 100 mL of CH2CI2 and washed with 50 mL of saturated NaHCO3 aqueous solution. The organic portion was concentrated. The residuw was dissolved in 10 mL
of MeOH. To this solution was added a solution of NaOH (200 mg) in 1 mL of water.
After stirred at room temperature for 30 min, it was diluted with 100 mL of CH2CI2 and washed with 100 mL of brine. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 75% EtOAc/hexanes) to give 240 mg of the title compound. ' H NMR (400 MHz, CDCI3) b 7.90 (s, 1 H), 7.81 (s, 1 H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.05 (s, 1 H), 6.65 (brs, 2H), 5.57 (s, 2H), 4.03 (t, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 3.01(t, 2H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
SEM SEM SEM H
, \ , N, \ -N- r N St--~~N Step Step N \ ~N NN
N N N~ ~ N
HN
SEM"N SEM i/ SEM"N
S'N OH S-N OMs 1-N N S SN
S
Step A: To a solution of Example 90 (200 mg, 0.333 mol) in 10 mL of THF, was added NEt3 (84 mg, 0.830 mmol) followed by methanesulfonyl chloride (76.4 mg, 0.667 mmol). The reaction was stirred at room temperature for 20 min. It was quenched by adding 10 mL of water and diluted with 50 mL of CH2CI2. The mixture was washed with 20 mL of 0.5 N aqueous HCI solution. The organic was dried over anhydrous Na2SO4. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 70% EtOAc/hexanes) to give 180 mg of the title compound.
Step B: A mixture of mesylate from Step A (42 mg, 0.062 mmol), thiomorpholine (16 mg, 0.16 mmol), K2CO3 (8.5 mg, 0.062 mmol) and a trace amount of Nal in 1.5 mL
of THF was stirred at 80 C for 24 h. It was cooled to room temperature. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 5% 7 N NH3 in MeOH/CH2CI2) to give 37 mg of the title compound. 'H NMR
(400 MHz, CDCI3) b 7.88 (s, 1 H), 7.81 (s, 1 H), 7.64 (s, 1 H), 7.57 (s, 1 H), 7.05 (s, 1 H), 6.64 (brs, 2H), 5.55 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 2.64-3.08(m, 8H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
Step C: To a solution of product from Step B (37 mg, 0.054 mmol) in 2 mL of THF/MeOH (1:1) stirred at 80 C, was added 0.5 mL of 4 N HCI in dioxane solution.
The reaction was stirred at 80 C for 30 min. It was cooled to room temperature and diluted with 2 mL of THF and 1 mL of ether. The solid was collected by filtration and washed with ether to give 26 mg of the title compound as its HCI salt form.
HPLC-MS
tR = 2.21 min (UV 254nm). Mass calculated for formula C19H2ON$OS 426.1;
observed MH+ (LCMS) 427.2 (m/z).
By essentially the same procedure set forth in Example 91 only replacing thiomorpholine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 20 were prepared.
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z H
N' I N
\
91-1 NN 410.5 411.2 1.95 N
HN ~
S N
N \-j N-N
91-2 N\ N 396.5 397.2 2.38 ~N
HN ~
S-N N
H
N' I N
91-3 N N 408.5 409.2 2.51 N
HN
N No N- I N
\
N
91-4 NY-,-- N 426.5 427.2 2.29 HN
NNo N' I N
~N \
91-5 Yl- N OEt 440.6 441.2 2.52 HN
S- N ~NJ
/
H
NV
~N \
91-6 NY-,-- N 424.6 425.2 2.60 HN
S-NJJJ
N, I N
N
91-7 NY-1-- N 422.5 423.2 2.46 HN ~
S- N
H
N' ~ N
~N \
91-8 N~N 476.5 477.3 2.62 HN ~~_ /~ \_N~CF
SN
SEM SEM H
SEM
% N, Y Y
'r \ N Step AN Step B N N
"
N St ~
N _~
- N ~ " " N
NyL- N
" SEM~N SEM-" HN Y
SEM" Z CHO S_ N Br SN O S-N O
S-" Br ON N
Step A: To a solution of carbon tetrabromide (170 mg, 0.512 mmol) in 4 mL of stirred at 0 C, was added PPh3 (267 mg, 1.02 mmol). The reaction was stirred at 0 C for 15 min when the aidehyde (200 mg, 0.341 mmol) was added. The resulting solution was further stirred at 0 C for 15 min. It was quenched with 10 mL of saturated NaHCO3 aqueous solution. The mixture was extracted by 20 mL of CH2CI2.
The aqueous phase was further extracted by CH2CI2 (10 mL X 2). The combined organics were concentrated and further purified by column chromatography (Si02, 50% EtOAc/hexanes) to give 150 mg of the title compound.
Step B: A stirred solution of compound from Step A (40 mg, 0.054 mmol) and pyrrolidine (30 mg, 0.43 mmol) in 0.6 mL of DMSO and 0.15 mL of water was stirred at 100 C for 3 h. It was cooled to room temperature and diluted with 15 mL of CH2CI2. The content was washed with water, saturated aqueous NaHCO3 and brine sequentially. The organic was concentrated and purified by column chromatography (Si02, 3.5% 7 N NH3 in MeOH/ CH2CI2) to give 20 mg of the title compound. 'H
NMR
(400 MHz, CDCI3) b 7.88 (s, 1 H), 7.81 (s, 1 H), 7.64 (s, 1 H), 7.57 (s, 1 H), 7.18 (s, 1 H), 6.62 (brs, 2H), 5.55 (s, 2H), 3.90 (s, 2H), 3.75 (t, 2H), 3.67 (t, 2H), 3.45-3.62 (m, 4H), 2.52 (s, 3H), 1.35-1.63 (m, 6H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step C: A solution of compound from Part B (20 mg, 0.029 mmol) in 1 mL of THF
and 2 mL of TFA was stirred at 60 C for 2 h. The solvent was removed under vacuum.
The residue was dissolved in 2 mL of THF. To the stirred solution was added 1 mL of 1 M HCI in ether.The solid was collected by filtration and washed with ether to give 10 mg of the title compound as its HCI salt form. HPLC-MS tR = 2.55 min (UV
254nm).
Mass calculated for formula C19H2ON80S 408.2; observed MH+ (LCMS) 409.2 (m/z).
By essentially the same procedure set forth in Example 92, only replacing pyrrolidine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 21 were prepared.
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z N- I N
N
92-1 N`~N 422.5 423.2 2.83 H~N' n S N No H
N-I N
N
92-2 Nyj'-N 436.5 437.2 3.15 HN
S N N~
O
N-I N
N
92-3 NN 410.5 411.2 2.82 HN
S-N N
O
H
N-I N
~N \
92-4 N\ ~N 440.5 441.2 2.92 H~N' ~
_ S
S N N
O
H
N
92-5 N \ ~ \ 424.1 N
HN 5:
SN
SE
H
SEM
%
SE N, \ '~1 `
N'~v ~ ~N N
N Step A I N Step B' N, Step C N\~N
N~ ~ -- N Y_ N `r ~N I I
SEM"N i HN ~
SEM"N1/\ SEMN1/\ /
S_N
S'N N
/
S'N Br bo S'N OMs .
Step A: To a solution of mesylate (560 mg, 0.841 mmol) in 16 mL of acetone was added LiBr (730 mg, 8.41 mmol). The mixture was stirred at room temperature for 1.5 h. It was diluted with 100 mL of CH2CI2 and washed with brine (100 mL). The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 506 mg of the title compound. 6 7.88 (s, 1 H), 7.81 (s, 1 H), 7.65 (s, 1 H), 7.58 (s, 1 H), 7.30 (s, 1 H), 6.70 (brs, 2H), 5.57 (s, 2H), 4.55 (s, 2H), 3.78 (t, 2H), 3.68 (t, 2H), 2.56 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step B: To a solution of compound from Step A (40 mg, 0.061 mmol) in 1.5 mL of THF, was added 2-tri-n-butylstannylpyridine (45 mg, 0.12 mmol), and Pd(PPh3)4 (17 mg, 0.015 mmol). The reaction was stirred at 80 C in a sealed vial for 16 h.
The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 3% 7 N NH3 in MeOH/ CH2CI2) to give 32 mg of crude title compound contaminated by triphenylphosphine oxide. This material was used in Step C without further purification.
Step C: The product of Step B was dissolved in 2 mL of MeOH/THF (1:1) at 80 C. To this solution was added 0.5 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 30 min. It was cooled to room temperature and diluted with 1 mL of THF.
The solid was collected by filtration and washed with THF and ether to give 15 mg of the title compound as its HCI salt form. 6 8.8(d, 1 H), 8.86 (t, 1 H), 8.10 (s, 3H), 7.92-8.08 (m, 3H), 7.22 (s, 1 H), 4.60 (s, 2H), 2.58 (s, 3H). HPLC-MS tR = 2.00 min (UV
254nm).
Mass calculated for formula C19H16N8S 388.1; observed MH+ (LCMS) 389.2 (m/z).
By essentially the same procedure set forth in Example 93, only replacing 2-tri-n-butylstannylpyridine with other respective stannyl reagents in Step B, compounds shown in column 2 of Table 22 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N' I N
N
93-1 NY-,-- N 402.1 HN TN, N
H
N' ~ N
N
93-2 NY-,-- N 402.1 HN ~
/
S-N
N
H
N' I N
N
93-3 NY-,-- N 402.1 HN
S-N
N
H
N' ~ N
N
93-4 N N 402.1 HN
S-N
N
H
N-N
93-5 Nl,),-N 418.1 HN ~
/ OMe S-N N/ ~
H
N' I N
\
N
93-6 N N 418.1 HN ~
/
S-N N/
OMe H
N-N
~N \
93-7 N~N 418.1 HN
/
S-N
OMe H
N' I N
N
93-8 N N 418.1 HN
S-N
N
MeO
H
N-N
93-9 N~N 406.1 HN
/
S-N N/ \
F
H
N'N
\ I
N
93-10 N~N 466.1 HN
/
S-N
Br H
N'N
~N \
93-11 N~N 422.1 HN
/
S-N
CI
H
N' N
N
93-12 Nyl-- N 406.1 HN ~N/ F
S- / ~
N
H
N'N
N
93-13 NN 466.1 HNS-~
/ r N
N
H
N'N
N
93-14 N 422.1 / CI
HNS-~
N
N
H
N'N
N
93-15 N ~ N 431.2 HN ~
/
S-N N/ ~
NMe H
N-I N
N
93-16 NY-1-- N 404.1 HN ~
S-N O +~ \
~-N
SEM SEM SEM
\~r N-r N-r N Step A ~N Step B N
~
N
NY-L--N N)--1-N N
SEM"N SEM"N SEM"N ~ OH
CHO S- ~ S- /
N N N
MeS
SEM SEM H
N-N ~
o I
N Step C ~N \ Step D N
I' NN
NN NN
T 7 HN SMe SEMN OH SEM"N i SMe r /
S- / S_ S'N N
N N N
MeS
Step A: To a mixture of 10 mL of THF/DMF (1:1)was added NaH (39.3 mg, 1.64 mmol). It was cooled to -10 C and a solution of trimethylsulfonium iodide (334 mg, 1.64 mmol) in 5 mL of DMSO was then slowly added. To the resulting mixture was added aldehyde. The reaction was stirred at room temperature for 40 min. It was quenched with ice water, and diluted with 50 mL of CH2CI2. The mixture was washed with water and brine. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 390 mg of the title compound. 6 7.90 (s, 1 H), 7.82 (s, 1 H), 7.67 (s, 1 H), 7.59 (s, 1 H), 7.10 (s, 1 H), 6.80 (brd, 1 H), 6.56 (brd, 1 H), 5.57 (s, 2H), 4.02-4.10 (m, 1 H), 3.78 (t, 2H), 3.69 (t, 2H), 3.07-3.25 (m, 2H), 2.58 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step B: A solution of compound from Step A (270 mg, 0.450 mmol) in 4 mL of DMF
was treated with sodium methanethiolate (100 mg, 1.43 mmol). The reaction was stirred at room temperature for 30 min. It was diluted with 15 mL of water.
The mixture was extracted with EtOAc (20 mL x 3). The combined organics were washed with brine (20 mL) and then concentrated. The residue was purified by column chromatography (Si02, 70% EtOAc/hexanes) to give 220 mg of the title compound.
7.90 (s, 1 H), 7.82 (s, 1 H), 7.65 (s, 1 H), 7.58 (s, 1 H), 7.21 (s, 1 H), 6.76 (brd, 1 H), 6.56 (brd, 1 H), 5.57 (s, 2H), 4.94 (m, 1 H), 3.40-3.80 (m, 5H), 2.80-3.15 (m, 2H), 2.58 (s, 3H), 2.12 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
Step C: To a solution of compound from Step B (30 mg, 0.046 mol) in 1 mL of THF, was added NEt3 (14 mg, 0.14 mmol) followed by methanesulfonyl chloride (16 mg, 0.14 mmol). The reaction was stirred at room temperature for 15 min. It was quenched by adding 2 mL of water and diluted with 15 mL of CH2CI2. The mixture was washed with 10 mL of 0.2 N aqueous HCI solution. The organic was dried over anhydrous Na2SO4 and then concentrated. The residue was treated with Nal (10 mg, 0.071 mmol) and piperidine (13 mg, 0.15 mmol) in 1 mL of THF. The resulting mixture was stirred at 80 C for 12 h. It was diluted with 15 mL of CH2CI2 and washed with 15 mL of saturated aqueous NaHCO3 solution. The solvent was removed under vacuum, and the residue was purified by column chromatography (Si02, 3% 7 N NH3 in MeOH/
CH2CI2) to give 12 mg of the title compound.
Step D: To a solution of compound from Step C (12 mg, 0.017 mmol) in 1 mL of THF/MeOH (1:1), was added 0.5 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 1 h. It was cooled to room temperature and diluted with 10 mL of ether.
The solid was collected by filtration and washed with ether to give 8 mg of the title compound as its HCI salt form. HPLC-MS tR = 2.88 min (UV 254nm). Mass calculated for formula C21H26N$S2 454.2; observed MH+ (LCMS) 455.3 (m/z).
By essentially the same procedure set forth in Example 94, only replacing piperidine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 23 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
N- N
94-1 N 440.6 441.2 2.57 N T\l-- N
HN ~
S_\' N ~--SMe N- N
94-2 N 468.6 469.3 2.83 N\~N
HTN N
S N SMe By essentially the same procedure set forth in Example 94, only replacing sodium methanethiolate with sodium benzenethiolate in Step A, and employing the respective aliphatic amines to replace piperidine in Step B, compounds shown in column 2 of Table 24 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MStR
H
N' N
95-1 N ^ 516.7 517.3 3.23 NN ~ 1 HTN ` J
S_ N SPh H
N' I N
95-2 N 502.6 503.3 3.09 N T\'t-- N ~
HN ~
S_\~ N ~SPh H
N' ~ N
95-3 N 530.7 531.3 3.23 YN
HN N
S N SPh SEM SEM
N \`r `
N
N \ ~ ~ \
NyL-- N NY~'-N
SEM-N SEM-N OH
~CHO
S'N S'N SO2Me A stirred solution of dimethylsulfone (281 mg, 2.99 mmol) in 5 mL of DMF was treated with sodium t-butoxide (287 mg, 2.99 mmol) at room temperature for 5 min.
Aldehyde was then added. The reaction was stirred at room temperature for 15 min.
It was quenched with saturated aqueous NH4CI solution (5 mL). The mixture was diluted with 50 mL of water and extracted with 50 mL of EtOAc/hexanes (1:1), followed by 25 mL of EtOAc. The combined organic phase was washed with brine and then concentrated. The residue was purified by column chromatography (Si02, 50% EtOAc/hexanes) to give 270 mg of the title compound. b 7.90 (s, 1 H), 7.82 (s, 1 H), 7.68 (s, 1 H), 7.60 (s, 1 H), 7.20 (s, 1 H), 6.67 (brs, 2H), 5.55 (s, 2H), 5.34-5.47 (brs, 1 H), 3.90-3.98 (brs, 1 H), 3.78 (t, 2H), 3.68 (t, 2H), 3.10 (s, 3H), 2.58 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
By essentially the same procedure set forth in Step B and Step C in Example 96, compounds shown in column 2 of Table 25 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N' N
N
96-1 N~N 472.6 473.3 2.23 HN N
Me S N SO
O
N'N
N
96-2 N` ~N 0 486.6 487.3 2.62 HN N
Me S_N S O
O
N' N
N
"N ~ 500.6 501.3 2.75 96-3 N\' N
HN
Me S_N SO
SEM SEM SEM H
`~' -~' ` ~~ `N
ci ci N Step A N Step B N Step N
N N N N NN N~N
HN
SEMN SEM"N~, I CHO SEM'N i/ _ / /r S
S-N OH S-N S-N RN-R2 N R`~-R2 , ~
The compounds shown in column 2 of Table 24 were prepared according to the above reaction scheme and employing the following general procedures.
Step A: To a stirred solution of compound alcohol (1.00 g, 1.70 mmol) in 20 mL
of THF, was added Dess-Martin periodinane (1.84 g, 4.26 mmol) and a trace amount of water. The reaction was stirred at room temperature for 40 min. It was diluted with 200 mL of-CH2CI2, and washed with water and brine. The organic was dried over anhydrous Na2SO4. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 250 mg of the title compound.
Step B: To a solution of compound from Step A (0.05 mmol) in 1 mL of CH2CI2/MeOH
(1:1) was added the respective amine (5 equivalent) and a trace amount of trifluoroacetic acid. The mixture was stirred at room temperature for 30 min when NaBH4 (10 equivalent) was added. The stirring was continued for additional 10 min.
The reaction was quenched with saturated aqueous NH4CI solution. The mixture was extracted with CH2CI2. The organic was concentrated and the residue was purified by column chromatography (Si02, 5% 7 N NH3 in MeOH/ CH2CI2) to give title compound.
Step C: To a solution of compound from Step B(0.05 mmol) in 1 mL of THF/MeOH
(1:1), was added 1 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C
for 30 min. It was cooled to room temperature and diluted with 10 mL of ether. The solid was collected by filtration to afford compound 97-1 and 97-2, respectively.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N'N
CI \ I
N
97-1 N~N 428.9 429.2 2.63 HN~
S-N~-~N
H
N'N
CI \ I
N
97-2 NY-1- N 446.9 447.2 2.68 HN\
~S/-NN
F
SEM SEM
N CH3MgBr N Et3N / MsCI
~ THF/RT N THF
SEMN H Part A SEMN ~/
Part B
R
SEM Part C N`
\~r \
1)R1R2N/THF/A N
N
2) 4N-HCI- Dioxane NY N
RN
SEMN~~^ Part D 10-3 (R = SEM) ~
S,N N.R
S-N OMs YX (R = H) R2 Part A: To a solution of the isothiazole-aldehyde (534 mg; 0.9 mmol) in anhydrous THF (9 mL) was added methyl magnesium bromide (3M; 1.8 mL) at room temperature. After stirring for 20 min, the reaction mixture was quenched with 5 mL of saturated aqueous NH4CI solution and diluted with CH2CI2. The organic layer was washed with water and brine. The aqueous layer was back extracted with CH2CI2.
The combined organic layers were dried over sodium sulfate and concentrated to obtain the crude product. Flash silica gel chromatography (EtOAc: CH2CI2 = 2:1) gave the desired carbinol as a white solid (460 mg; 84%) along with unreacted aidehyde (50 mg). 'H-NMR (CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H); 7.55 (s, 1 H);
7.1 (s, 1 H);
6.75-6.65 (br-dd, 2H); 5.55 (s, 2H); 4.95 (t, J = 3 Hz, 1 H); 3.8 (t, J = 6 Hz, 2H); 3.7 (t, J
= 6 Hz, 2H); 2.55 (s, 3H); 1.6 (d, J = 3 Hz, 3H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part B: Triethylamine (136mg; 1.35mmol) and methanesulfonyl chloride (88 mg;
0.77 mmol) were added to a solution of the carbinol from Part A (232 mg; 0.39 mmol) in 12 mL of THF at room temperature. After 10 min, the reaction was quenched with water and diluted with CH2CI2. The organic layer was washed with water and brine, dried over Na2SO4_and concentrated to obtain crude product. Rapid elution with CH2CI2:
EtOAc (2:1) from a flash silica gel column gave the desired mesylate as white solid (268 mg; 100%). 'H-NMR (CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H);
7.55 (s, 1 H);
7.3 (s, 1 H); 6.7 (br-s, 2H); 5.85 (q, J = 4 Hz, 1 H); 5.55 (s, 2H); 3.8 (t, J
= 6 Hz, 2H); 3.7 (t, J = 6 Hz, 2H); 2.95 (s, 3H); 2.6 (s, 3H); 1.85 (d, J = 4 Hz, 3H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part C: A solution of the mesylate (40 mg; 0.06 mmol) in 2 mL of anhydrous THF
was treated with hexamethyleneimine (15 mg; 0.15 mmol) plus a catalytic amount of Nal and the mixture was heated at reflux in an oil bath (80 C; 20 h). The reaction mixture was cooled to room temperature and diluted with water and CH2CI2. The organic layer was washed with water, brine and dried over Na2SO4. Concentration in vacuo gave the crude product. Purification was carried out on flash silica gel column, eluting the product with CH2CI2 containing 2-4% of 7N-Ammonia in methanol. The desired di-SEM protected amine product was obtained as a colorless film (31 mg; 75%).1H-NMR
(CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H); 7.55 (s, 1 H); 7.3 (s, 1 H); 6.6 (br-s, 2H);
5.55 (s, 2H); 4.0 (br-s, 1 H); 3.8 (t, J = 6 Hz, 2H); 3.7 (t, J = 6 Hz, 2H);
2.8 (br-s, 4H);
2.6 (s, 3H); 1.75-1.5 (m, 11 H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part D: To a solution of the above di-SEM protected amine from Part C (31 mg;
0.045 mmol) in 0.2 mL of THF and 0.2 mL of CH3OH was added 4N-HCI in dioxane (0.2 mL). The resulting mixture was heated at 80 C in an oil bath for 30 min and then allowed to cool to room temperature. THF (2 mL) was added to the reaction mixture and the precipitated product was collected by filtration. The filer cake was washed with THF and ether and dried under vacuum to obtain the title product as white solid (23 mg)-By using appropriate Grignard reagents in the first step and appropriate amine in the third step in the procedures described above, all the target compounds listed in Table 1 were prepared and characterized.
LCMS
HPLC
Example Structure EM MH+
MS tR
m/z H
\ `I
N
98-1 N-?- N 422.2 423.2 2.46 HN~ ,~
~~ /~--~
S'N N
H
I
N
98-2 NY-1- N 398.2 399.2 2.06 HN~
S-N HN
HO
H
\ `I
N
N~N 426.2 427.2 2.13 S'N N
~ HO
H
N-~ N \
98-4 N~N 396.2 397.2 2.57 HN~
S-N N--\
H
\ `I
98-5 '-T~N 422.2 423.2 2.74 N~N
HN
S'N N
H
\ `I
N
98-6 N,N 436.2 437.2 2.86 HN ~
S'N N
H
\ `I
N
98-7 N- -N 470.3 471.3 3.01 HN
H
ci N \
98-8 NYl- N 440.2 441.2 2.39 HN~
/
S-N N
EtO
H
\ `I
~N \
98-9 N N 426.5 427.2 2.25 HN~ ~+
~~ /--~
S'N N
F
H
\ `I
N \
~
98-9 Ny N 440.2 441.2 2.35 HN~
S'N N
F
HO DPPA, Et3N, t-BuOH ~ ~
S BocHN
O O O
The substrate (500 mg) was suspended in t-BuOH (30 mL), and Et3N (0.45 mL) and DPPA (0.73 mL) was added sequentially at room temperature. Then the mixture was heated at 85 C overnight. The reaction mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The residue was taken up in ethyl acetate (50 mL) and water (50 mL) was added. The biphasic mixture was stirred for 15 min. Then two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with brine (50 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (SiO2). HPLC-MS tR =
1.70. Mass calculated for CjjH15N03S 241.08; observed MH+ (LCMS) 242.2 (m/z) (UV254nm).
HO ~~ OH ~TU' Et3N HO ~ NQ DPPA, Et3N
S Me(Me0)NH.HCI 'BuOH BOcHN S 11 O O O O O
Part A Part B
MgBr ~ ~ 30% TFA in CH2CI~
BocHN S TFA.HZN
THF-Et20 O
Part D s 0 Part C
N-NSEM N-NSEM N'NH
, DMF 1). Ti(OiPr)4, NaBH4, pip N
NaH
+ \~N \ N Part F
~ ~ N N
_`~
NY N Part E N Y N
I 2). HCI (PartG) HN
SOZMe HN
Part A: Diacid (3 g) was suspended in CH2CI2 (50 mL), and N,O-dimethylhydroxylamine hydrochloride (1.69 g), HATU (6.6 g) and diisopropylethylamine (12.12 mL) was added sequentially at room temperature.
The reaction mixture was stirred overnight, and quenched by addition of water (100 mL).
The two layers were separated. The aqueous layer was acidified to pH 4.0, and extracted with CHCI3 (5 x 100 mL). The organic layers were combined, and dried (Na2SO4), filtered and evaporated under reduced pressure to give the product.
HPLC-MS tR = 1.14. Mass calculated for C$H9NO4S 215.03; observed MH+ (LCMS) 216.1 (m/Z) (UV254nm).
Part B: The substrate from Part A (3.2 g) was suspended in t-BuOH (100 mL), and Et3N (2.27 mL) and DPPA (3.64 mL) was added sequentially at room temperature.
Then the mixture was heated at 85 C overnight. The reaction mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The residue was taken up in ethyl acetate (100 mL) and water (100 mL) was added.
The biphasic mixture was stirred for 15 min. Then two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with brine (150 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02). HPLC-MS tR = 1.55. Mass calculated for C12H18N204S
286.1;
observed MH+ (LCMS) 287.2 (m/z) (UV254nm).
Part C: The substrate from Part B (191 mg) was dissolved in THF/Et20 (3mU6mL) and cooled to 0 C. Then methylmagnesium bromide (0.83 mL, 2.0 M solution) was added dropwise. The reaction mixture was warmed to room temperature, and stirred for 12 h and quenched by addition of saturated ammonium chloride (10 mL). The two layers were separated and the aqueous layer was extracted with ethyl acetate (10 mL). The combined organic layer was washed with brine (30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02).
Part D: The substrate from Part C (10 mg) was dissolved in 30% TFA in CH2CI2 (2 mL), and the mixture was stirred for 30 min. Then the solvent was evaporated under reduced pressure and the residue was dried in vacuum. The crude product was used in the next step without further purification.
Part E: The sulfone (574.19 mg) and amine trifluoroacetic acid salt (514 mg) was dissolved in DMF (15 mL) under argon and treated with NaH (432 mg, 60%
dispersion in oil). After LCMS indicated complete conversion of starting material to product, the reaction mixture was quenched with saturated ammonium chloride solution (15 mL).
Then ethyl acetate (25 mL) was added. The two layers were separated, and the aqueous layer was extracted with ethyl acetate (25 mL). The combined organic layer was washed with brine (30 ml), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02). HPLC-MS tR = 2.31. Mass calculated for C22H28N6O2SSi 468.2; observed MH+
(LCMS) 469.1 (m/z) (UV254nm).
Part F: Ketone (25 mg) was suspended in Ti(O-i-Pr)4 (1 mL) and treated with piperidine (0.2 mL) under argon. The mixture was stirred at room temperature overnight. Then methanol (2 mL) was added followed by NaBH4 (10 mg). The reaction mixture was stirred for additional 30 min. and quenched by addition of 2M
aqueous NaOH (5 mL). It was filtered, and ethyl acetate (5 ml) was added to the filtrate. The two layers were separated, and the aqueous layer was extracted with ethyl acetate (5 ml). The combined organic layer was dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was taken to the next step without further purification.
Part G: The substrate was dissolved in 4N HCI in dioxane and stirred for 30 min.
LCMS indicated complete conversion of starting material to the product. Then solvent was evaporated under reduced pressure, and the crude material was purified by reverse phase HPLC. HPLC-MS tR = 1.28. Mass calculated for C21H25N7S 407.2;
observed (M-84)+ (LCMS) 323 (m/z) (UV254nm)=
The compounds in Table 28 were prepared following similar procedure.
LCMS
Example Column 2 MW (M- HPLC
84)+ MS tR
m/z N-NH
N
NY lN
100-1 HN 407.2 323 1.28 ~
N-NH
N
NY N
100-2 H INs 421.2 337.1 1.34 ~
TFAA / Et2O; H
H2N,_,-\OEt K2C03 (36%) F3CyN ~~OEt LAH / EtZO (36%) F3Cv N
Step A O Step B ,,~ OEt Step A: To a solution of 2-ethoxyethylamine (2.0 g, 22.4 mmol) in diethyl ether (40 mL) at 0 C was added trifluoroacetic anhydride (4.7 g, 22.4 mmol) dropwise.
The reaction was stirred at room temperature for 1 hr. Potassium carbonate (10 g) was added to the reaction solution. The reaction was stirred at room temperature for 1 hr.
The mixture was filtered through Celite and the organic filtrate was concentrated to give 1.5 g (36% yield) of the title compound.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (1.5 g, 8.1 mmol) in Et20 (20 mL) was added to a flask charged with lithium aluminum hydride (0.92 g, 24.3 mmol) in Et20 (20 mL). The reaction was stirred at room temperature for 30 min, then at reflux for 12 hr. The reaction was cooled to room temperature and quenched with MeOH until the bubbling ceased. The reaction was diluted with Et20 (30 mL) and filtered through a pad of Celite. The filtrate was concentrated by distillation to give 0.5 g (36% yield) of title compound as a colorless liquid. The amine was used without further purification.
F F F
F
F O F+ F~N~\OEt pYr/CHppy(55%) F~N'-'-\OEt LAH/Et20(83%) _ O 0 StepA O Step B F OEt Step A: To a solution of 2-ethoxyethylamine (1.0 g, 11.2 mmol) in dichloromethane (50 mL) at 0 C was added pyridine (2.2 g, 28.1 mmol). Difluoroacetic anhydride (2.3 g, 13.5 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 2.5 hr. The reaction was diluted with dichloromethane (50 mL) and H20 (20 mL). The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 1.03 g (55%
yield) of the (difluoromethyl)acetamide as a colorless liquid.
Step B: A solution of the (difluoromethyl)acetamide from Step A (1.04 g, 6.20 mmol) in Et20 (21 mL) was added to a flask charged with lithium aluminum hydride (0.47 g, 12.39 mmol) in Et20 (25 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at room temperature for 2 hr. The reaction was quenched by the sequential addition of 0.47 mL of H20; 0.47 mL of 15 % NaOH
(aq) solution; 1.4 mL H20. The reaction was stirred at room temperature for 15 min then filtered through a pad of Celite. The filtrate was concentrated by distillation to give 0.79 g (83% yield) of the title compound as a colorless liquid. The amine was used without further purification.
H2N OH TFAA / pyr / CH2q2 (60%) F3Cy N
H OH LAH / Et20 (65%0) F3 ~N OH
A 0~ Step B 5 Step A: To a solution of 1-amino-l-cyclopentane methanol (1.0 g, 8.68 mmol) in dichloromethane (35 mL) at 0 C was added pyridine (2.4 g, 30.4 mmol).
Trifluoroacetic anhydride (4.6 g, 21.7 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 16 hr. The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 1.07 g (60% yield) of the title compound as a light brown liquid. The title compound was used directly in the next reaction (Step B) without further purification.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (0.64 g, 3.06 mmol) in Et20 (10 mL) was added to a flask charged with lithium aluminum hydride (0.35 g, 9.1 mmol) in Et20 (30 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at 0 C for 30 min, then at room temperature for 19 hr.
The reaction was cooled to room temperature and stirred for 3 days. The reaction was then cooled to 0 C and quenched by the sequential addition of 0.35 mL of H20;
0.35 mL of 15 % NaOH (aq) solution; 1.05 mL H20. The reaction was stirred at room temperature for 20 min then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 0.39 g (65% yield) of the title compound as a white solid. The amine was used without further purification.
~OH TFAA / pyr / CHpCIp (38%) ~ u OH LAH / Et20 (92%) F C^N "OH
H2N Step A F3C H' ~/ Step B 3 H
Step A: To a solution of 2-amino-2-methyl-l-propanol (1.0 g, 11.2 mmol) in dichloromethane (100 mL) at 0 C was added pyridine (3.1 g, 39.6 mmol).
Trifluoroacetic anhydride (5.9 g, 28.1 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 16 hr. The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 0.79 g (38% yield) of the title compound as a white solid.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (0.79 g, 4.29 mmol) in Et20 (43 mL) was added to a flask charged with lithium aluminum hydride (0.49 g, 12.91 mmol) in Et20 (13 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at 0 C for 30 min, then at reflux for 4 hr. The reaction was cooled to room temperature and stirred for 3 days. The reaction was then cooled to 0 C and quenched by the sequential addition of 0.49 mL of H20; 0.49 mL of 15 %
NaOH (aq) solution; 1.47 mL H20. The reaction was stirred at room temperature for 20 min, then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 0.67 g (92% yield) of the title compound as a white solid. The amine was used without further purification.
O F ~
F~ ~F ~OH pyr/CHZCIp(74%) F` ~O~ LAH/Et20(97%) F~N OH
0 0 +HN Step A 7F H O Step B F H
Step A: To a solution of 2-amino-2-methyl-l-propanol (1.0 g, 11.2 mmol) in dichloromethane (50 mL) at 0 C was added pyridine (2.7 g, 33.7 mmol).
Difluoroacetic anhydride (3.9 g, 22.4 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 2 hr. The reaction was diluted with dichloromethane (50 mL) and H20 (20 mL).
The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq);
brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 2.04 g (74% yield) of the title compound as a colorless liquid.
Step B: A solution of the (difluoromethyl)acetamide from Step A (2.04 g, 8.31 mmol) in Et20 (17 mL) was added to a flask charged with lithium aluminum hydride (0.95 g, 24.92 mmol) in Et20 (50 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at room temperature for 2 hr. The reaction was quenched by the sequential addition of 0.95 mL of H20; 0.95 mL of 15 % NaOH
(aq) solution; 2.85 mL H20. The reaction was stirred at room temperature for 15 min then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 1.23 g (97% yield) of the title compound as white needles.
The amine was used without further purification.
N SteP A N Step 6 N
N~ N Me3SI / NaH N
~ N Dess-Martin 1 SEMN Oxidation SEMN DMSO / RT SEMN
~ ~-CHO
/
S-N OH S-N S-N
Step C N N
NaOMe / CH3OH N~N 4) MsCI / Et3N (Step D) N - \
N
SEMN, OCH3 5) 4-F-Piperidine (Step E) SEMN OCH3 N
/l \
S-N OH 6) 4N-HCI-Dioxane (Step F) S-N
F
Step A: Dess-Martin periodinane reagent (1.3 g; 3.1 mmol) was added to a solution of the isothiazole-alcohol (450 mg; 1 mmol) in 30 mL of THF containing 0.06 mL of water and the reaction mixture was stirred at room temperature for 45 min. The reaction was diluted with ether and filtered and washed with more ether. The filtrate was washed with saturated NaHCO3 solution, brine and dried. Concentration in vacuo gave the isothiazole aldehyde (418 mg; 93%). 1H-NMR (CDCI3): 10 (s, 1H); 7.68 (s, 1H);
7.65 (s, 1 H); 7.4 (s, 1 H); 7.3 (s, 1 H); 6.65 (s, 2H); 3.7 (t, J = 6 Hz, 2H); 2.6 (s, 3H); 1.95 (m,1 H); 1.1 (q, J = 2, 6 Hz, 2H); 1.0 (t, J = 6 Hz, 2H); 0.8 (q, J = 2, 6 Hz, 2H); -0.05 (s, 9H).
Step B: To a solution of sodium hydride (60% in mineral oil; 169 mg; 4.2 mmol) in a mixture of 3.6 mL of DMSO and 3.6 mL of THF cooled to -10 C, was added a solution of trimethyl sulfonium iodide (863 mg; 4.2 mmol) in 3.6 mL of DMSO drop wise.
This was followed by the addition of a solution of the aldyhyde (363 mg; 0.84 mmol) in 5.6 mL of anhydrous THF, added in one portion. After stirring at room temperature for one hour, the reaction mixture was quenched with ice water. The organic products were extracted with EtOAc. The combined aqueous layers were back extracted with ethyl acetate. All the organic extracts were pooled and washed with water, brine and dried over Na2SO4 and concentrated to obtain the crude product. Elution of the major spot from Flash silica gel using 25% EtOAc in hexanes gave the desired isothiazole epoxide (316 mg; 85%). 1 H-NMR (CDCI3): 7.7 (s, 1 H); 7.35 (s, 1 H); 7.05 (s, 1 H); 6.8 (d,J=4Hz, 1 H); 6.5 (d, J = 4 Hz, 1 H); 4.05 (t, J = 2 Hz, 1 H); 3.7 (t, J = 6 Hz, 2 H); 3.2 (t, J 4 Hz, 1 H); 3.05 (t, J = 2 Hz, 1 H); 2.6 (s, 3H); 1.95 (m,1 H); 1.1 (q, J = 2, 6 Hz, 2H); 0.95 (t, J = 6 Hz, 2H); 0.8 (q, J = 2, 6 Hz, 2H); -0.05 (s, 9H).
Step C: A solution of sodium methoxide in methanol (25% by wt; 4.5 mmol; 1 mL) was added to a solution of the epoxide (201 mg; 0.45 mmol) in a 1:1 mixture of DMF-methanol (4 mL). The resulting solution was heated at 60 C for 3.5 hr, then cooled to room temperature and quenched with water. Extracted the organic product with EtOAc, washed the organic extract with water and brine and dried over Na2SO4.
Concentration gave the crude product. Purification by flash silica gel chromatography using 1:1 mixture of CH2CI2 and EtOAc provided the desired methoxymethyl carbinol (180 mg; 84%) as colorless oil. 'H-NMR (CDCI3): 7.7 (s, 1 H); 7.35 (s, 1 H);
7.2 (s, 1 H);
6.7 (d, J = 4 Hz, 1 H); 6.58 (d, J = 4 Hz, 1 H); 5.0 (d, J = 2 Hz, 1 H); 3.7 (m, 3H); 3.5 (s, 3H); 2.95 (d, J = 14 Hz, 1 H); 2.6 (s, 3H); 1.95 (m,1 H); 1.05 (d, J = 4 Hz, 2H); 0.95 (t, J
= 6 Hz, 2H); 0.8 (d, J = 4 Hz, 2H), -0.05 (s, 9H).
Step D-F: This sequence of steps was carried out as described for Example 76 in 64%
overall yield for the 3 step sequence. HPLC. HPLC-MS tR = 2.85. Mass calculated for C21H27FN60S = 430.2; observed (M-H)+ (LCMS) 431.2 (m/z) (UV25anm)=
ASSAYS:
Aurora Enzyme Assay An in vitro assay was developed that utilizes recombinant Aurora A or Aurora B
as an enzyme source and a peptide based on PKA as the substrate.
Aurora A Assay:
Aurora A kinase assays were performed in low protein binding 384-well plates (Coming Inc). All reagents were thawed on ice. Compounds were diluted in 100%
DMSO to desirable concentrations. Each reaction consisted of 8 nM enzyme (Aurora A, Upstate cat#14-511), 100 nM Tamra-PKAtide (Molecular Devices, 5TAMRA-GRTGRRNSICOOH ), 25 M ATP (Roche), 1 mM DTT (Pierce), and kinase buffer (10 mM Tris, 10 mM MgCI2, 0.01 % Tween 20). For each reaction, 14 l containing TAMRA-PKAtide, ATP, DTT and kinase buffer were combined with 1 pl diluted compound. The kinase reaction was started by the addition of 5 l diluted enzyme.
The reaction was allowed to run for 2 hours at room temperature. The reaction was stopped by adding 60 l IMAP beads (1:400 beads in progressive (94.7% buffer A:
5.3% buffer B) 1X buffer, 24 mM NaCI). After an additional 2 hours, fluorescent polarization was measured using an Analyst AD (Molecular devices).
Aurora B Assay:
Aurora B kinase assays were performed in low protein binding 384-well plates (Corning Inc). All reagents were thawed on ice. Compounds were diluted in 100%
DMSO to desirable concentrations. Each reaction consisted of 26 nM enzyme (Aurora B, Invitrogen cat#pv3970), 100 nM Tamra-PKAtide (Molecular Devices, 5TAMRA-GRTGRRNSICOOH ), 50 M ATP (Roche), 1 mM DTT (Pierce), and kinase buffer (10 mM Tris, 10 mM MgC12, 0.01 % Tween 20). For each reaction, 14 i containing TAMRA-PKAtide, ATP, DTT and kinase buffer were combined with 1 l diluted compound. The kinase reaction was started by the addition of 5 l diluted enzyme. The reaction was allowed to run for 2 hours at room temperature. The reaction was stopped by adding 60 l IMAP beads (1:400 beads in progressive (94.7% buffer A: 5.3% buffer B) 1 X buffer, 24 mM NaCI). After an additional 2 hours, fluorescent polarization was measured using an Analyst AD (Molecular devices).
IC50 Determinations:
Dose-response curves were plotted from inhibition data generated each in duplicate, from 8 point serial dilutions of inhibitory compounds.
Concentration of compound was plotted against kinase activity, calculated by degree of fluorescent polarization. To generate IC50 values, the dose-response curves were then fitted to a standard sigmoidal curve and IC50 values were derived by nonlinear regression analysis.
Compounds of the present invention exhibit Aurora A IC50 values of about 4 nm to about 3000 nM, Aurora B IC50 values of about 13 nM to about 3000 nM, and p-IC50 values of about 1 nM to about 10,000 nM.
While the present invention has been described in conjunction with the specific embodiments set forth above, many altematives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.
r~.
QN^s,'r N
CH3 H C~CH3 3 r e e t 3 r ~- _2 ~~- ~ /~
N N r~ r~ N N
N
H3CO V \ Q
YO , OH, , HO
N /+
+
N r~- P
/ / - c HsC~
No CH3 ~Ns~ ~ I O
t t t t , t t t N [-~' r~_ N
N hN 15 t H3C CH3 OH
~ O_ ~ ~~OH
N~J~ ~ N- N- ~~N~-~ N
, OH, -~~
OH, N
or HO,/0 ; wherein RS and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
NN
R3~N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
1\~
NN
R3. IN,H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazolyl, wherein said pyrazolyl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (where R5 and R6 form a cyclic amine together with the N of said -NR5R6), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(02)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being 5 independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6; R' is H; R3 is, S ~
S N~~~ N N g s~, QOH, SN O ~ S, , O
S-N N S
N S-N N S
N O ~S N
~ 1SN ~ 1SN
N S s 0=S ~
n I N.J NJ S N O-~No ~N_ S/ N- N_ HN
N _N S / N
10 N N i , and ~N
wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' Rz R\T"J' N
\
1Y`N
N
R3.N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is 15 pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)ORs, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
1\~
NN
RT N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; and R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl.
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'I')' ' N
j_ \1 NN
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1_3-N(R5R6) and -NR5R6; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
N^~ ~
CH3 C ~ H c cH ~
3 r 3 r > > 3 3e ,-- ~ ~~' ~
r N N N
N I
N N \ I
YO co O HsC OH, HO
r ~ N /+
N
N + H3C~
(N) N
NO
3 , s ,o o N
N N-?
\ ~ J cH3 N N c~ ~ O~-N
H3C ~f OH
-\ OH
- / O-~ S 0=S
/N , /N \1 , OH, I , -~~
OH, N
or HO,/o ;wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j' N
l\
N
Y`N
R3.N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"l' N
~ \
NYL`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-~ ~, N
S-N N
S-N N S
N
N(R5R6) and -NR5R6; R' is H; R3 is, O, OH, 0 S N os' S- N S'N N
O
SN OH INJ , Cb, O
~e NJ
`
O S S N N S NON N O N
ilr `-".N
~ N , N N HN
S s S
S N ON_ N_ N_ N~ ~~
N
SON
and wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r)' N
~1\
N ~/`N
R3. IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R 6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~ 1\~
NN
R3" N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yi; R is unsubstituted alkyl; R' is H; R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONRR6, wherein X
is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R 6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'~" N
~
N\\/l~'N
R3.~N.H
5 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is 1-H-pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
r~- ~~- ~~-^P. N N H3C N
CY CH3 C" Q ~CH
3 3 HC 3f 3 f r~- /+ r~/ /-s N N N N
N ~
N
H3CO aOHYO ~
0 , , H3C~ , 0 , HO
N /+
N ~- N
1 N ~- H3C~
N/ O
CH3 ~N $~ ~/ ~ I c 0 10 , ~~ ~-N r CN) N
I
H3C ~~f OH
~ 0= S ~/OH
O~_N\J~ ~ N- N- \~~N~ N
, OH, I , -~~
OH, N
or HO_/o ; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
1\~
NN
R3. N, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is unsubstituted alkyl; R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X
can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl;
wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'r"j" N
~ ~
N \/1'N
R3.~N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is '-e S-N N
S-N N~
pyrazol-4-yl; R is unsubstituted alkyl; R' is H; and R3 is, oH, ~ S N N N SN N
S
'/I~ 1 .4:; N
S'N OH, S , NJ
''~' S ` ^>- , iss' O N~ ~S/-N N S N O~ N ~ ~ ~`O ~.~N
~,S , ,, ~OCN.~ N~-N
N N HN
S OS N S N S
S N ON_ N_ ~Nj' N~' SON
and In another embodiment, this invention discloses a compound of the formula:
R' R2 R'rlk N
~ \
N~/1`N
R3 IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is methyl, R' is H; R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R'~" N
~
N~N
R3.N.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is pyrazol-4-yl; R is methyl, R' is H; R3 is heteroaryl-CH2-X, wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form heterocyclyl; wherein R5 and R6 are as defined above.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
NY`N
R3.IN.H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is methyl, R' is H; R3 is isothiazole, thiophene or pyrimidine substituted with:
N/\~ r~= r~~ ~~~
r.
CY/~s,:' N H3C
v ~CH3~
CH3 C Hc ~
3 f 3 ) f f 3 f ~~ _ r~- ~- r / S Ir y N N N
N
H,c0 N I~ I I/
0 H3C1.10 OH c0) HO Y
) f ) ) , ) ) ) N /+
~ji ~7 I N H3C
C:) O
CH `~ ~ / ~ / ~ - `' 3 S f~ f f f f f o r7 N
c ) -1N N-/
~ N N -~~ -~ ' \ ~ -=
\ I J CH3 N
OH
- / O-~ S 0= S /OH
N~ ~ _ ~N_ ~~ ~~ NI
OH, -~~
OH, N
or HO"/ v .
In another embodiment, this invention discloses a compound of the formula:
R' R2 R~N
~ ~
N \/1'N
R3"TN, H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is H-pyrazol-4-yl; R is methyl, R' is H; R3 is phenyl-CHmethyl-X or phenyl-CH2-X, wherein said phenyl of each of said phenyl-CHmethyl-X or phenyl-CH2-X can be unsubstituted or substituted with alkyl, further wherein X is piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl wherein each of said piperazinyl, piperadinyl, pyrrolidinyl, morpholinyl or thiomorpholinyl can be unsubstituted or substituted with alkyl.
In another embodiment, this invention discloses a compound of the formula:
R' R2 R
~
N N
R3.~N".H
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R2 is ~ :~ I ,~
S-N N
S-N N~ S
N
pyrazol-4-yl; R is methyl, R' is H; R3 is, ~O , OH, 0 , S S- N S'N N
N N ~ ~'J
S, , N , - , O
N
s~ T1,~ S N N S N O ~~ ~O ~ I` N
O ~,S ~N ~ ~ N `N~.N D
> > \' , .
~N HN
~
s N O-\_ N- ~S=/ N- O N- ~(=S I~~~Gs N
N N
SN
and N
In another embodiment, this invention discloses a compound of the formula:
H
N- N
N
NY `N
HNI
5 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R5 is alkyl; R6 is selected from the group consisting of alkoxyalkyl, hydroxyalkyl, cycloalkyl, wherein said cycloalkyl is substituted by hydroxyalkyl; or R5 and R6 together with the N of said -NR5R6 to form a cyclic ring, wherein said cyclic ring is substituted by one or more moieties independently selected from the group consisting of alkoxyalkyl, 10 hydroxyalkyl, and alkyl.
In another embodiment, this invention discloses a compound of the formula:
H
N- N
N
NY _N
HNI ~
/
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R5 is methyl, ethyl, or propyl; R6 is selected from the group consisting of ethoxyethyl, 1,1-15 dimethylhydroxyethyl, cyclopentyl, cyclohexyl, wherein each of said cyclopentyl and cyclohexyl is substituted by hydroxymethyl; or R5 and R6 together with the N
of said -NR5R6 to form a cyclic ring, wherein said cyclic ring is substituted by one or more moieties independently selected from the group consisting of ethoxymethyl, methoxymethyl, hydroxymethyl, and methyl.
Non-limiting examples of compounds of Formula I include:
H
N_ N H
N_ N_N H I N'N
N `N ~N \ \ ~
~N \ ~N1 \ ~N \ N~N ~N1~ \
NN NYN N~N HN ~\~ NY`N
HTN HN~ ^ HN~ S-' N HN 7 ~)--\ TS~-N/--~N ~
S-N S-N / / \ g-N// N
0, - , \--/ , HN-N
HN-N
N- H N
N~N
N N`N NH `N ~N N N
~N ` N\ N HN 1 S N HN 1 N
N, Nl~)-_N N~
N
HN
T_\/ HN~ HN~ ~ S 0=S
S-N N _ ~-\ 1~ }-\
S N 0~_ S-N 0~_No N-, ~N-~, N ,, N_ ~
H3C ~ H H
H3C CH3 CH3 N'N N- N
H3CN \ \ ~ I
NYN Nj N ~N \ N
FfN S. ~ S. NN ~ -N
~ IN CH3 IN l I
N~ No HN\ /S~N ~ ~gNH
L N , N
H H
N-N N-N
\ I \ I
H
N-N
HN-N ~N \ N \ \ I
H N~N N~N ~N \
N N HN H N ^ N` ~N
/
T --\ ~
NY N S-N N S-N N HN_ õ
N S NH ~~ S/-N ~N
~N~ , \, OMe, ~OH
H H
N'N H H N-N
\'N N-N
I
N
N
NN N N \ I \
HN N~N N~N N~N
/ HN1/\ HN ~ HN
N ~
S-N ( t r~ ~
--~
/\ S-N iI-<, g H H H
N'N H N,N N-N
N'N I I
N
NY `N ~N` N~N ~ N~N
NI~/1N HN N HN N
HN ~
N HNNrN/~ S S
S-N N~ No N
<\~
> > > O
s H H N' N
N- N
H3C`Y^N SN N
N/~ H3C ~ N~ H3C~N NY 'N
N N\~N N~N HN ~
HN`Y ^ H~N"~ HN I~ COyEt S'NkOH
1/ /}-\
S N OH, S'N OH, ~ N e ~
H
H N-\ `N \ ,N N
H "fO"~'N '-rN N
N~I_N Nllz~-- N
N N
T
HN,, HN` HN
~~--N S'N N S-N N S-N N
\~ ~, OH, H
N'N
H H
N~N N,N
I \TN I
lN N'^~N N
N~ ~/ N HN N
N
~ OH
~
HN O S-N N HN
S-N N \- S-N> OH
\~/
~ ~ ~
N-N N-N H
N'N
N N ~
NN N7` ~N \ N
OH N
S-N S-N S_N
H
N'N
N,N
I
~l f N NY~
'N
NN ' HN
HN O
S N N S-N H N- N_ a \r \r ~N \ N \ ~N \
~N \ NN N~
N N~T N
N N
HN r HN~ HN ~/ HN1/\
\ I- S-N S-N S-N N
S-N OH F
CF3 F F, CF3, H N_ \'r \ -r H
\ r N-I N \ ~N \ ~N \ N
N~N N~N N~N
N1--l-- N
HN HN1/\ HN~ HN
Q-\ ~~ /-S-N aF S-N N~ F S-N N S N
/ F
F
F 0 , H H H
N, N_ \r \_r \r a ~N
N~ ~N NY'l N
N NY N N I
HN N HN~
i / N / HN~ S-N N
S-N N ~Fo\--F ~F S-N N S-N N , ~/ 'F, ~''F, F
a~r H H N`
N'N N-~N \ \ I \ r N
N N N \
HN N N` ~ N~N
N N T
HN,,r HN~
No HN ~ ~\O S_N S-N HN-\-F
S /
N FJ or H
N'N
H ( N_ N
~ N \
~N \ N ~ _\
N~N N NY _N
HN ~N HN S H%~N
S- N
N ~ ~ N
- ~ - ~ - ~
H H
H N-N N' H
N'N \ I \ ~ N'r N~ N\ N N- \T^
HN N
N N N~
HN ~/ HN rN OMe HN ~
S-N S N N/ N/ ~ S'N N/ \ OMe H H
H N'N H N,N
~~N \ ~ N-N I
~N
N N I` ~N \ I- N\
NN ~ N N~ NN
Y HN N
HN
s-N r\ s N N/ \ S N r\ sN
N _ OMe, Me0 ~ F, HN Br, H
N-N N-N N'f`1 N-N
N \ -N NY N Nll)zN NY N
HN ~
/ HN ~ HN ~ HN
F r S-N S_N / \ S N S N
N N N
ci, - , - 1 H
N'N
H
N' ' N N
~
I N NY N
NN
HN TS- HN~ ~ N +
S-N bN1X NMeZ O,N~ \
and -or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings, including 5 any possible substitutions of the stated groups or moieties:
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain.
Preferred 10 alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. "Alkyl" may be unsubstituted or 15 optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, oxime (e.g., =N-OH), -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyl 20 groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in 25 the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. "Alkenyl"
may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.
"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.
"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more, lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. "Alkynyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
The aryl group can be optionally substituted with one or more "ring system substituents"
which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
"Bridged cyclic ring" is a hydrocarbon ring such as cycloalkyl, cyclenyl, or aryl or heteroatom containing ring such as, heterocyclyl, heterocyclenyl, or heteroaryl as described herein, that contains a bridge, which is a valence bond or an atom or an unbranched chain of atoms connecting two different parts of the ring. The two tertiary carbon atoms connected through the bridge are termed "bridgeheads".
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A
nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
"Heteroaryl" may also include a heteroaryl as defined above fused to an aryl as defined above. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms.
Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbomyl, adamantyl and the like.
"Cycloalkylalkyl" means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.
"Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contain at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyis include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like.
Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyl.
"Cycloalkenylalkyl" means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.
"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylaikenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, amide, -CHO, -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), oxime (e.g., =N-OH), YjY2N-, YIY2N-alkyl-, YlY2NC(O)-, Y1Y2NSO2- and -SO2NYjY2, wherein Y, and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent"
may also mean a single moiety which simultaneously replaces two available hydrogen on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CH3)2- and the like which form moieties such as, for example:
O0 co 0~0 and "Heteroarylalkyl" means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryis include 2-pyridinylmethyl, quinolinylmethyl and the like.
"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like;
such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
'"HeterocyclyP' may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogen on the same carbon atom on a ring system.
Example of such moiety is pyrrolidone:
H
N
O
"Heterocyclylalkyl" means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
5 "Heterocyclenyl" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond.
10 There are no adjacent oxygen and/or sulfur atoms present in the ring system.
Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system 15 substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-20 imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.
"Heterocyclenyl" may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogen on the same carbon atom on a ring system.
Example 25 of such moiety is pyrrolidinone:
H
N
I
O
"Heterocyclenylalkyl" means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, 0 or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:
N
H
there is no -OH attached directly to carbons marked 2 and 5.
It should also be noted that tautomeric forms such as, for example, the moieties:
N O
H and N OH
are considered equivalent in certain embodiments of this invention.
"Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group.
Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Spiro ring systems" have two or more rings linked by one common atom.
Preferred spiro ring systems include spiroheteroaryl, spiroheterocyclenyl, spiroheterocyclyl, spirocycloalkyl, spirocyclenyl, and spiroaryl. The spiro ring systems can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. Non-limiting examples of suitable spiro ring systems include 7 6 4 spiro[4.5]decane, 8-azaspiro[4.5]dec-2-ene, and spiro[4.4]nona-2,7-diene.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined.
Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl.
"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Alkylsulfonyl" means an alkyl-S(02)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
"Arylsulfonyl" means an aryl-S(02)- group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g. from a reaction mixture), or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like) , in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V.
Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
5 For example, if a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Cl-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-10 methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl-1 -(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-15 crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Cl-C2)alkylamino(C2-C3)alkyl (such as P-dimethylaminoethyl), carbamoyl-(Cj-C2)alkyl, N,N-di (Cl-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, and the like.
Similarly, if a compound of Formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group 20 with a group such as, for example, (CI-C6)alkanoyloxymethyl, 1-((Cl-C6)alkanoyloxy)ethyl, 1-methyl-1-((CI-C6)alkanoyloxy)ethyl, (Cl-C6)alkoxycarbonyloxymethyl, N-(Cl-Cs)alkoxycarbonylaminomethyl, succinoyl, (Cl-C6)alkanoyl, a-amino(Cl-C4)alkanyl, arylacyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoacyl group is independently selected from the naturally 25 occurring L-amino acids, P(O)(OH)2, -P(O)(O(CI-Cs)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
If a compound of Formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a 30 group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R
and R' are each independently (Cl-Clo)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural a-aminoacyl or natural a-aminoacyl, -C(OH)C(O)OY' wherein Y' is H, (Cl-C6)alkyl or benzyl, -C(OY2)Y3 wherein Y2 is (CI-C4) alkyl and Y3 is P-Cs)alkyl, carboxy P-Cs)alkyl, amino(Cj-C4)alkyl or mono-N--or di-N,N-(Cj-C6)alkylaminoalkyl, -C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N- or di-N,N-(Cj-C6)alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.
One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compourid of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate"
encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H20.
One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M.
Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describes the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C.
van Tonder et al, AAPS PharmSciTech., 50), article 12 (2004); and A. L.
Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula I contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula I may be formed, for example, by reacting a compound of Formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use.
(2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(l) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217;
Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York;
and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website).
These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C1_4alkyl, or Cl-4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl);
(4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1_20 alcohol or reactive derivative thereof, or by a 2,3-di (Cr,24)acyl glycerol.
Compounds of Formula I, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC
column.
It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.
Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R
configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of 5 isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 31õI, 13C, 14C, 15N, 180, 170, 31P, 32P, 35S,18F, and 36CI, respectively.
Certain isotopically-labelled compounds of Formula (I) (e.g., those labeled with 3H and14C) are useful in compound and/or substrate tissue distribution assays.
10 Tritiated (i.e., 3H) and carbon-14 (i.e.,14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically 15 labeled compounds of Formula (I) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
Polymorphic forms of the compounds of Formula I, and of the salts, solvates, 20 esters and prodrugs of the compounds of Formula I, are intended to be included in the present invention.
The compounds according to the invention have pharmacological properties; in particular, the compounds of Formula I can be inhibitors, regulators or modulators of protein kinases. Non-limiting examples of protein kinases that can be inhibited, 25 regulated or modulated include cyclin-dependent kinases (CDKs), such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8, mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), Pim-1 kinases, Chk kinases (such as Chkl and Chk2), tyrosine kinases, such as the HER subfamily (including, for example, EGFR (HER1), HER2, HER3 and HER4), the insulin 30 subfamily (including, for example, INS-R, IGF-IR, IR, and IR-R), the PDGF
subfamily (including, for example, PDGF-alpha and beta receptors, CSFIR, c-kit and FLK-II), the FLK family (including, for example, kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1)), non-receptor protein tyrosine kinases, for example LCK, Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK, growth factor receptor tyrosine kinases such as VEGF-R2, FGF-R, TEK, Akt kinases, Aurora kinases (Aurora A, Aurora B, Aurora C) and the like.
The compounds of Formula I can be inhibitors of protein kinases such as, for example, the inhibitors of the checkpoint kinases such as Chkl, Chk2 and the like.
Preferred compounds can exhibit IC50 values of less than about 5pm, preferably about 0.001 to about 1.0 pm, and more preferably about 0.001 to about 0.1 pm. The assay methods are described in the Examples set forth below.
The compounds of Formula I can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
Many of these diseases and disorders are listed in U.S. 6,413,974 cited earlier, incorporated by reference herein.
More specifically, the compounds of Formula I can be useful in the treatment of a variety of cancers, including (but not limited to) the following:
tumor of the bladder, breast (including BRCA-mutated breast cancer, colorectal, colon, kidney, liver, lung, small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, bladder, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma and Burkett's lymphoma;
chronic lymphocytic leukemia ("CLL"), acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;
fibrosarcoma, rhabdomyosarcoma;
head and neck, mantle cell lymphoma, myeloma;
astrocytoma, neuroblastoma, glioma, glioblastoma, malignant glial tumors, astrocytoma, hepatocellular carcinoma, gastrointestinal stromal tumors ("GIST") and schwannomas;
melanoma, multiple myeloma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
Due to the key role of kinases in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
Compounds of Formula I may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that CDK5 is involved in the phosphorylation of tau protein (J. Biochem, (1995) 117, 741-749).
Compounds of Formula I may induce or inhibit apoptosis. The apoptotic response is aberrant in a variety of human diseases. Compounds of Formula I, as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned hereinabove), viral infections (including but not limited to herpevirus, poxvirus, Epstein- Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
Compounds of Formula I, as inhibitors of kinases, can modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).
Compounds of Formula I may also be useful in the chemoprevention of cancer.
Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
Compounds of Formula I may also be useful in inhibiting tumor angiogenesis and metastasis.
Compounds of Formula I may also act as inhibitors of cyclin dependent kinases and other protein kinases, e.g., protein kinase C, her2, raf 1, MEK1, MAP
kinase, EGF
receptor, PDGF receptor, IGF receptor, P13 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.
Another aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition associated with kinases (e.g., CDKs, CHK
and Aurora kinases) by administering a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound to the mammal.
A preferred dosage is about 0.001 to 1000 mg/kg of body weight/day of the compound of Formula I. An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound.
The compounds of this invention may also be useful in combination (administered together or sequentially) with one or more of anti-cancer treatments such as radiation therapy, and/or one or more anti-cancer agents different from the compound of Formula I. The compounds of the present invention can be present in the same dosage unit as the anti-cancer agent or in separate dosage units.
Another aspect of the present invention is a method of treating one or more diseases associated with a kinase (such as CDK, CHK and Aurora), comprising administering to a mammal in need of such treatment: an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of Formula 1, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Non-limiting examples of suitable anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin (e.g., Caelyx , Myocet , Doxil ), taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777 , L778,123 , BMS 2146628 , Iressa , Tarceva , antibodies to EGFR, antibodies to IGFR (including, for example, those published in US 2005/0136063 published June 23, 2005), KSP inhibitors (such as, for example, those published in WO 2006/098962 and WO 2006/098961;
ispinesib, SB-743921 from Cytokinetics), centrosome associated protein E
("CENP-E") inhibitors (e.g., GSK-923295), Gleevec , intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATINTM, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine; Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, bortezomib ("Velcade"), Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225 , satriplatin, mylotarg, Avastin, Rituxan, panitubimab, Sutent, sorafinib, Sprycel (dastinib), nilotinib, Tykerb (lapatinib) and Campath.
If formulated as a fixed dose, such combination products employ the 5 compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range. For example, the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897. Compounds of Formula I
may also be administered sequentially with known anticancer or cytotoxic agents 10 when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula I may be administered either prior to or after administration of the known anticancer or cytotoxic agent. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 15 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
Accordingly, in an aspect, this invention includes combinations comprising an amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, and an amount of one or more anti-cancer 20 treatments and anti-cancer agents listed above wherein the amounts of the compounds/ treatments result in desired therapeutic effect.
Another aspect of the present invention is a method of inhibiting one or more Aurora kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a 25 pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Aurora kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or 30 prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with Aurora kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Aurora kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the Aurora kinase to be inhibited can be Aurora A, Aurora B and/or Aurora C.
Another aspect of the present invention is a method of inhibiting one or more Checkpoint kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Checkpoint kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with Checkpoint kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Checkpoint kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the checkpoint kinase to be inhibited can be Chkl and/or Chk2.
Another aspect of the present invention is a method of inhibiting one or more cyclin dependent kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more cyclin dependent kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating one or more diseases associated with cyclin dependent kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof; and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more cyclin dependent kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the checkpoint kinase to be inhibited can be CDK1 and/or CDK2.
Another aspect of the present invention is a method of inhibiting one or more tyrosine kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more tyrosine kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating one or more diseases associated with tyrosine kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more tyrosine kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
In the above methods, the tyrosine kinase can be VEGFR (VEGF-R2), EGFR, HER2, SRC, JAK and/or TEK.
Another aspect of the present invention is a method of inhibiting one or more Pim-1 kinases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Yet another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Pim-1 kinases in a patient in need thereof, comprising administering a therapeutically effective amount of at least one compound of Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
Another aspect of the present invention is a method of treating one or more diseases associated with Pim-1 kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent, wherein the amounts of the first compound and the second compound result in a therapeutic effect.
Another aspect of the present invention is a method of treating, or slowing the progression of, a disease associated with one or more Pim-1 kinases in a patient in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising in combination at least one pharmaceutically acceptable carrier and at least one compound according to Formula 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which are described herein below have been carried out with compounds according to the invention and their salts, solvates, esters or prodrugs.
This invention is also directed to pharmaceutical compositions which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and at least one pharmaceutically acceptable carrier.
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid.
Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose.
Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal 5 administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
Also included are solid form preparations that are intended to be converted, 10 shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type 15 as are conventional in the art for this purpose.
The compounds of this invention may also be delivered subcutaneously.
Preferably the compound is administered orally or intravenously.
Also contemplated are delivery methods that are combinations of the above-noted delivery methods, Such methods are typically decided by those skilled in the art.
20 Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or 25 adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the 30 proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
Yet another aspect of this invention is a kit comprising an amount of at least one compound of Formula I, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and an amount of at least one anticancer therapy and/or anti-cancer agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect.
The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure.
Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.
Where NMR data are presented, 1 H spectra were obtained on either a Varian VXR-200 (200 MHz, 1 H), Varian Gemini-300 (300 MHz) or XL-400 (400 MHz) and are reported as ppm down field from Me4Si with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33mm x 7mm ID; gradient flow: 0 min - 10% CH3CN, 5 min - 95% CH3CN, 7 min -95% CH3CN, 7.5 min - 10% CH3CN, 9 min - stop. The retention time and observed parent ion are given.
The following solvents and reagents may be referred to by their abbreviations in parenthesis:
Thin layer chromatography: TLC
dichloromethane: CH2CI2 ethyl acetate: AcOEt or EtOAc methanol: MeOH
trifluoroacetate: TFA
triethylamine: Et3N or TEA
butoxycarbonyl: n-Boc or Boc nuclear magnetic resonance spectroscopy: NMR
liquid chromatography mass spectrometry: LCMS
high resolution mass spectrometry: HRMS
milliliters: mL
millimoles: mmol microliters: l grams: g milligrams: mg room temperature or rt (ambient): about 25 C.
dimethoxyethane: DME
The synthesis of the inventive compounds is illustrated below. Also, it should be noted that the disclosure of commonly-owned U.S. 6,919,341 and U.S. Appl. No.
is incorporated herein by reference.
NIS, DMF I
60 C, 95% NBr Part B N' IN
N^ Br 1.25 equiv NaSMe ~N~ _Br Sl~
N N
7 MeOH, rt, 95% N~
N cat. Pd(PPh3)4, K2C03 Br S~ Part A trimethylboroxine, DMF
100 C, 90% N
N~N
Part C
S~
N NIS, DMF N
(, ~1V N </ _ ~ `1 N 60 C, 95% NN
S~ Part D SNI
SEM
N,N SEM
cat. PdCI2(dppf) I / N,N
K3PO4, boronate 1I /
DME, water N ~CPBA, DCM
100 C, 60-75% N~N rt, 90% N~ N
Part E S~ Part F o S O
I
Part A: Prepared according to US20060106023 (Al).
Part B: To a solution of compound from Example 1, Part A (2.00 g, 8.19 mmol) in DMF
(50 mL) was added N-iodosuccinimide (1.84 g, 8.19 mmol). The reaction mixture was stirred at 60C for 16 hours. The mixture was cooled to 25C and concentrated.
The residue was dissolved in DCM with a small amount of methanol and then loaded on.
the column. Purification by column chromatography (Si02, 40% ethyl acetate/hexanes) afforded compound 4 as a white solid 2.30 g (76%). 'H-NMR
(400-MHz, DMSO-d6) 6 8.3 (s, 1 H), 7.8 (s, 1 H), 2.6 (s, 3H). HPLC-MS tR = 1.87 Min (UV
254nm). Mass calculated for formula C7H5BrIN3S 370.01, observed LC/MS m/z 370.9 (M+H).
Part C: A suspension of bromide from Part B (45.6 g), Pd(PPh3)4 (10.8 g), potassium carbonate (77.4 g), trimethylboroxine (46.9 g) and potassium carbonate (77.4 g) in DMF (410 mL) was heated overnight under nitrogen at 105C. After cooling, the mixture was diluted with ethyl acetate (1 L), washed with brine (2 x 500 mL), dried (magnesium sulfate), filtered, concentrated and purified by chromatography on silica gel. The title compound was obtained as a pale yellow solid (21.4 g, 64%).
Part D: To a DMF (400 mL) solution of compound from Example 1, Part C (21.8 g) was added N-iodosuccinimide (26.9 g) and the resulting mixture was heated overnight at 60C. The mixture was concentrated and water (400 mL) was added. After stirring 1 hr at rt, saturated sodium carbonate was added (250 mL) and subsequently stirred an additional 30 min at rt. The mixture was filtered, washed with water, methanol (100 mL) and the filter cake was dried overnight under vacuum. A brown solid was obtained (31.4 g, 87%).
Part E: A flask was charged with iodide from Part D (1.00 equiv), Bpin-compound 5a (1.3 equiv), PdCI2(dppf) (0.1 equiv) and potassium phosphate monohydrate (3.0 equiv). After purging the flask with argon, 1,4-dioxane (50 mL) and water (5) were added and the resulting mixture was heated at 80C ovemight (23 h). The reaction was cooled to room temperature. EtOAc was added to the reaction mixture and filtered through Celite. After concentration the residue was purified by column chromatography (silica gel, 25% EtOAc/hexane) to give the title compound.
Part F: To a solution of compound from Example 1, Part E (1.0 equiv) in DCM
(10 mL) was added m-CPBA (2.05 equiv) in one portion. The resulting mixture was stirred at room temperature for 30 min. The mixture was concentrated and then partitioned between EtOAc and water. The organic layer was washed with NaHCO3 (sat. aq., twice), brine and dried (Na2SO4). After concentration, the title compound was obtained and used in the next step directly without further purification.
~S N02 S N02 ~
N\ ~ N\
HO2C Me02C
To a solution of 1' (1.04 g, 5.98 mmol) in 20 mL of DMF, was added K2CO3 (2.48 g, 17.9 mmol) and Mel (1.27 g, 8.96 mmol). The reaction was stirred at room temperature overnight. It was diluted with 200 mL of 50% EtOAc/hexanes and washed with water (200 mL) and brine (100 mL). The organic was concentrated.
To the residue was added 20 mL of hexanes. The solid was collected by filtration to give 2. The filtrate was concentrated and purified by column eluting with 25%
EtOAc/hexanes to give additional amount of 2. The combined yield of 2 is 1.05 g. 'H
NMR (400 MHz, CDCI3) 6 8.37 (s, 1 H), 4.05 (s, 3H).
C02Me C02Me N
~
S
To a solution of 2 (260 mg, 1.38 mmol) in 6 mL of AcOH was added iron powder (774 5 mg, 13.8 mmol). The reaction mixture was heated at 70-75 C for 12 min. The mixture was cooled to room temperature and then added 20 mL of MeOH. The resulting mixture was filtered through celite (the celite was rinsed with additional amount MeOH). The filtrate was concentrated to remove most of AcOH. To the residue was added 15 mL of 20% MeOH/CH2CI2 followed by 20 mL of saturated 10 aqueous NaHCO3. The mixture was stirred until it stops bobbling. The mixture was extracted by EtOAc (60 mL x 2), dried over Na2SO4, and then concentrated. To the residue was added 5 mL of ether followed by 5 mL of hexanes. The solid was collected by filtration to give 160 mg of crude 3 which contains a little acylated amine but pure enough for the sulfone displacement reaction. The filtrate was purified by 15 column with 20% of AcOEt/ CH2CI2 to give additional 30 mg of 3. 'H NMR (400 MHz, CDCI3) 6 6.85 (s, 1 H), 4.61 (brs, 2H), 3.92 (s, 3H).
SEM
SEM N-N
C02Me N~N \ ~
Br /
~ N + Br , --~ NI`
H2N S~ N1~ NN
N\/'N
S02Me COZMe S-N
20 To a solution of compound 3 (89 mg, 0.56 mmol) and 6-bromo-8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine (258 mg, 0.55 mmol) in 2 mL of DMF, was added NaH (60% dispersion in oil, 44 mg, 1.1 mmol).
The reaction was stirred at room temperature for 15 min. It was quenched with 5 mL
of saturated aqueous NH4CI and diluted with 30 mL of water. The solid was collected by filtration, washed with water and MeOH. It was dried under vacuum to give 255 mg of compound 4. 'H NMR (400 MHz, DMSO-d6) b 8.85 (s, 1 H), 8.22 (s, 1 H), 8.15 (s, 1 H), 7.96 (s, 1 H), 7.62 (s, 1 H), 5.50 (s, 2H), 3.85 (s, 3H), 3.60 (t, 2H), 1.83 (t, 2H), 0.00 (s, 9H).
SEM
SEM SEM N-N
N \'N
/ I \
BrN N Stey Step A N N
N
N N N N
HN HN
S C02Me S C02Me S-N OH
N N
Step A: To a solution of 4 (76 mg, 0.14 mmol) in 6 mL of THF was added Pd(PPh3)4 (16 mg, 0.014 mmol) and 0.35 mL of MeZnCI (2 M solution in THF, 0.69 mmol).
The reaction was stirred at 80 C for 20 min. It was cooled to room temperature and quenched by adding 0.5 mL of MeOH. It was diluted with 30 mL of CH2CI2 and washed with 20 mL of 0.5 N aqueous HCI solution. The solvent was removed under vacuum. The residue was purified by flash chromatography eluting with 5%
MeOH/CH2CI2 to give 50 mg of 5-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-ylamino}-isothiazole-3-carboxylic acid methyl ester contaminated by a small amount of triphenylphosphine oxide.
Step B: The above crude material was dissolved in 5 mL of THF. To the solution was added 0.5 mL of LiBHEt3 (1 M solution in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding 5 mL of saturated aqueous solution. The mixture was extracted by 30 mL of CH2CI2. The organic was concentrated and purified by flash chromatography eluting with 5% MeOH/CH2CI2 to give 25 mg of compound 5. NMR (400 MHz, CDCI3) 6 7.90 (s, 1 H), 7.82 (s, 1 H), 7.60 (s, 1 H), 7.48 (s, 1 H), 6.90 (s, 1 H), 5.55 (s, 2H), 4.75 (brs, 2H), 3.65 (t, 2H), 2.50 (s, 3H), 1.00 (t, 2H), 0.00 (s, 9H).
SEM
N`N SEM
N'N
N \ -- N
N\\/'N
~HN
S-N OH /
S-N OMs To a solution of compound 5 (200 mg, 0.438 mmol) in 20 mL of THF, was added triethylamine (0.21 mL, 1.5 mmol) and methanesulfonylchloride (0.10 mL, 1.3 mmol).
5 The reaction was stirred at room temperature for 30 min. It was quenched by adding 1 mL of MeOH. The solution was diluted by 30 mL of CH2CI2, washed consecutively with 15 mL of 2 N aqueous HCI, water, and brine. The solvent was removed under vacuum to give 230 mg of crude compound 6 which was used in further transformations without further purification.
SEM SEM SEM
~ N'N N'N
N
N \ I \ I
N Step A N Step B _\
N YN1` N
~ ~ -i N~ N N
N I
HN HN HN
50~~
OMs 3 z Step A: Mixture of compound 6 (17 mg, 0.032 mmol) and sodium azide (15 mg, 0.23 mmol) in 1 mL of DMF was heated at 70 C for 3 h. It was cooled to room temperature and added 10 mL of water. The resulting solid was collected by filtration and purified by flash chromatography eluting with 5% MeOH/CH2CI2 to give 12 mg of (3-azidomethyl-isothiazol-5-yl)-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-amine.
Step B: The above material was dissolved in 3 mL of MeOH. To the solution was added 15 mg of 10% wt. Pd/C. The mixture was stirred under H2 (1 atm) for 1 h.
It was filtered through celite. The filtrate was concentrated under vacuum to give 12 mg of compound 7. NMR (400 MHz, CDCI3) 6 7.88 (s, 1H), 7.80 (s, 1H), 7.60 (s, 1H), 7.47 (s, 1 H), 6.86 (s, 1 H), 5.55 (s, 2H), 4.00 (brs, 2H), 3.65 (t, 2H), 2.50 (s, 3H), 1.00 (t, 2H), 0.00 (s, 9H).
SEM H
N'N
N I
N N
N N
HN
NHN
S-N NH
To a solution of compound 7 (12 mg, 0.026 mmol) in 2 mL of THF heated at 70 C, was added 0.5 mL of 4 N HCI in dioxane. To the resulting mixture was added MeOH
until it became homogeneous. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. The solid was collected by filtration and washed with ether to give 9 mg of compound 8 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.23 (s, 1 H), 8.20 (s, 2H), 8.03 (s, 1 H), 7.20 (s, 1 H), 4.22 (s, 2H), 2.59 (s, 3H). HPLC-MS tR = 1.82 min (UV 254nm). Mass calculated for formula C14H14N$S 326.1;
observed MH+ (LCMS) 327.2 (m/z).
SEM SEM H
N-N N, N'N
N
\
N Step N \ Step B' N
N
N_~ N N_ N N
~
~ HN
HN HN
S-N N-Step A: To a solution of compound 7 (9 mg, 0.02 mmol) in 1 mL of MeOH/CH2CI2 (1:1), was added formaldehyde (40% wt. in water, 6 mg, 0.2 mmol). It was stirred at room temperature for 15 min when NaBH4 (16 mg, 0.4 mmol) was added in two portions. The mixture was purified by flash chromatography eluting with NH4CI
(aq.)/MeOH/CH2CI2 (1:5:190) to give 5 mg of (3-dimethylaminomethyl-isothiazol-5-yl)-{6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-amine.
Step B: The above material was then dissolved in 2 mL of THF. The resulting solution was heated at 70 C when 0.5 mL of 4 N HCI in dioxane was added. To the resulting mixture was added 1 mL of MeOH. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. Most of the solvent was removed under vacuum. To the residue was added 5 mL of ether. The solid was collected by filtration and washed with ether to give 5 mg of compound 9 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.21 (s, 1 H), 8.18 (s, 2H), 8.08 (s, 1 H), 7.30 (s, 1 H), 4.42 (s, 2H), 2.95 (s, 6H), 2.59 (s, 3H). HPLC-MS tR = 2.04 min (UV 254nm). Mass calculated for formula 354.1; observed MH+ (LCMS) 355.2 (m/z).
SEM SEM
N-N N- N
\ I \ I
N N
N~N N~N
HN HN
CHO
S-N OH S-N
To a solution of compound 5 (2.50 g, 5.47 mmol) in 100 mL of THF, was added 0.3 5 mL of water followed by Dess-Martin periodinane (6.96 g, 16.4 mmol). The reaction was stirred at room temperature for 30 min. The solid was filtered off. The filtrate was diluted with 200 mL of CH2C12, and washed with 100 mL of saturated aqueous solution. The organic was dried over anhydrous Na2SO4 and then concentrated.
To the residue was added 30 mL of acetonitrile. The solid was collected by filtration to 10 give 2.05 g of compound 10. NMR (400 MHz, DMSO-d6) 6 12.38 (s, 1 H), 9.84 (s, 1 H), 8.60 (s, 1 H), 8.11 (s, 1 H), 7.96 (s, 1 H), 7.91 (s, 1 H), 7.55 (s, 1 H), 5.50 (s, 2H), 3.60 (t, 2H), 2.45 (s, 3H), 1.83 (t, 2H), 0.00 (s, 9H).
SEM SEM H
N- % N N-N N'N
\ I \ I \ ~
Step A Step B
N \ ~ I N - ~Nl~
N \~N N~N N~ 'N
HN CHO HN HN
/
S-N S-N N S-N N
Step A: A solution of compound 10 (100 mg, 0.220 mmol) and pyrrolidine (156 mg, 2.20 mmol) in 14 mL of CH2CI2 was stirred at room temperature for 20 min. To the solution was added two drops of acetic acid, followed by NaBH4 (67 mg, 1.8 mmol).
The resulting mixture was stirred at room temperature for 5 min when 3 mL of MeOH
was added. The stirring was continued for additional 20 min. The reaction was quenched by adding 15 mL of saturated aqueous NaHCO3 solution. After diluted with 20 mL of CH2CI2, the organic was isolated. The solvent was removed under vacuum.
The residue was purified by flash chromatography eluting with NH4CI
(aq.)/MeOH/CH2CI2 (1:10:190) to give 98 mg of {6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-(3-pyrrolidin-1-ylmethyl-isothiazol-5-yl)-amine. NMR (400 MHz, CDCI3) 6 7.88 (s, 1 H), 7.81 (s, 1 H), 7.60 (s, 1 H), 7.48 (s, 1 H), 6.96 (s, 1 H), 5.55 (s, 2H), 3.80 (s, 2H), 3.65 (t, 2H), 2.70 (brs, 4H), 2.50 (s, 3H), 1.85 (brs, 4H), 0.96 (t, 2H), 0.00 (s, 9H).
Step B: To a solution of {6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyrazin-8-yl}-(3-pyrrolidin-1-ylmethyl-isothiazol-5-yl)-amine (98 mg, 0.19 mmol) in 8 mL of THF heated at 70 C, was added 2 mL of 4 N HCI in dioxane.
To the resulting mixture was added MeOH until it became homogeneous. The reaction was stirred at 70 C for 1 h and then cooled to room temperature. To the mixture was added 3 mL of ether. The solid was collected by filtration and washed with ether to give 79 mg of compound 11 as its HCI salt form. NMR (400 MHz, CD3OD) 6 8.18 (s, 2H), 8.13 (s, 1 H), 8.00 (s, 1 H), 7.22 (s, 1 H), 4.50 (s, 2H), 3.62-3.68 (m, 2H), 3.06-3.15 (m, 2H), 2.58 (s, 3H), 1.95-2.22 (m, 4H). HPLC-MS tR = 2.03 min (UV 254nm)= Mass calculated for formula C1$H2ON$S 380.2; observed MH+ (LCMS) 381.2 (m/z).
By essentially the same procedure set forth in Example 11, only replacing pyrrolidine with other respective aliphatic amines- in step A, compounds shown in column 2 of Table 1 were prepared.
SEM SEM H
N-N N-N N'N
Step A Step B
N \ --- I N \ -~ Nl~
N \~N N`\ ~N N~
HN
CHO HN HN
R~ R, TABLE I
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z H
N'N
\ I
N
12-1 NY-1--- N 382.5 383.2 2.15 HN~
~~ / --~
S-N N--\
H
N-N
I \
N
12-2 NY-1-N 408.5 409.2 2.31 HN~
S-N N
H
N'N
N
12-3 NY-,-- N 396.5 229.2 1.49 HN' r / --~
S-N N~
`-0 H
N' N
N
12-4 NY-,-- N 394.5 395.2 2.18 HN
S-N N
H
N'N
N
12-5 N 408.5 409.2 2.26 HN~^
~~ /--\
S-N N
H
N' I N
N
12-6 N~ N 424.5 425.2 1.95 HN\ ^
~/ /
S-N N
OH
H
N'N
N
12-7 N~N 408.5 409.2 2.35 HN~ ^
~~ /--\
S-N N
\__/
N, N
12-8 N~ N 409.5 410.2 1.76 HN~ ^
~~ /~--\
S-N N~
~N
H
N'N
N
12-9 N 424.5 425.2 2.18 HN
S-N N
OMe H
N' I N
~N \
12-10 N-)-- N 410.5 411.2 2.04 HN~
S-N aOH
H
N' I N
N
12-11 NY-,-- N 412.5 413.2 2.23 HN~
S-N N~
~S
H
N'N
N
12-12 N N 430.5 431.2 2.35 HN~
S-N
b /N
H
N-N
N
N`\/'N
12-13 HN~ 444.6 445.2 2.40 ih S-N N
b H
N' I N
N
12-14 NY-1--- N 422.5 423.2 2.50 HN~
S-N N
H
N'N
\ I
N
12-15 NY-,-- N 448.6 449.2 2.69 HN\ ^
~/ /
S-N N
H
N'N
12-16 N \
IN ; - N 428.5 429.2 2.34 HN~ ^
'(~ /
S-N N
H
N'N
NYl-- N 445.5 446.2 1.76 HN' r / --~
S-N N
~ \
-N
H
N' I N
'-e'N
12-18 N~N 442.5 443.2 2.39 HN\
~//
S-N N
b H
N' I N
N
12-19 NY-,-- N 408.5 409.2 2.15 HN\
S-N N
H
N'N
N
12-20 N~N 466.6 467.3 2.23 HN~
S'N N
O~
O
H
N, I N
N
12-21 NY-1- N 466.6 467.3 2.24 HN~
O
S-N a-o H
N'N
N'Ilf~ N
12-22 N~N 422.5 423.2 2.41 HN~
~~ /~----~
H
N'N
\ I
N
12-23 NY-1--- N 442.5 443.2 3.51 HN~ ^ -/~
S N N
H
N'N
N
12-24 NY-,-- N 408.5 409.2 2.32 HN
S-N N ' H
N'N
N
12-25 Nj,)'- N 448.5 449.2 2.65 HN~
/~--~
S-N N
N' I N
~N \
12-26 N) N 424.5 425.2 2.07 HN S-N aj OH
H
N'N
N~~
NY'N
12-27 HN 484.6 485.3 2.79 S-N N
H
N' I N
N
12-28 NY-,-- N 470.6 471.3 2.60 HN\
S-N N
H
N'N
N
12-29 NY-,-- N 428.5 429.2 3.27 HN
S-N to N- N
I
N
12-30 NY-,-- N 382.17 393.17 1.97 HN\ ^
~/ /
S-N -~
H
N'N
N \
12-31 N~N 396.18 397.18 2.01 HN~
S N --~
N'N
N \
12-32 N~N 410.20 411.20 2.04 HN~ ^
~~ /~
S-N N-~-\
H
N' I N
\
N
12-33 N N 422.20 423.20 2.52 HN\ ^ ~
~S/-N~N
H
N'N
N
12-34 NY~-- N 396.18 397.18 2.25 HN\
S-NN-~
H
N' I N
NI_ 12-35 NN 406.17 407.17 2.24 HN /^
S_NN
H
N-N
12-36 N~N 438.20 439.20 2.36 HN
O
S-N
H
N'N
N
12-37 HN N 442.19 443.19 2.30 Y\lr o S-N N~
O
H
N' N
N
12-38 N\~ N 398.16 399.16 2.12 O
HN
S_N~--\N--/' SEM
SEM N%
- N
% N
C02Me `N
N + / --~ ~ \
N
S02Me C02Me S-N
By essentially the same procedure set forth in Example 4, only replacing 6-bromo-8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine with 8-methanesulfonyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1,2-a]pyrazine, compound 13 was prepared. NMR (400 MHz, DMSO-d6) b 8.66 (s, 1 H), 8.22 (d, 1 H), 8.21 (s, 1 H), 8.03 (s, 1 H), 7.82 (d, 1 H), 5.58 (s, 2H), 3.96 (s, 3H), 3.69 (t, 2H), 3.40 (s, 1 H), 0.95 (t, 2H), 0.02 (s, 9H).
SEM SEM
N- N N~N
\ I \ I
N N
N N NJIL-- N
HTN HN
C02Me S-N S-N OH
To a solution of compound 13 (830 mg, 1.76 mmol) in 50 mL of CH2CI2 stirred at 0 C, was added 7.05 mL of LiBHEt3 (1 M solution in THF). The reaction was stirred at room temperature for 10 min. It was quenched by adding saturated aqueous NH4CI
solution. The organic was separated and washed with saturated aqueous NaHCO3 solution. The solvent was removed under vacuum. To the residue was added 10 mL
of MeOH. The solid was collected by filtration to give 530 mg of compound 14.
NMR
(400 MHz, CD3OD) 6 8.38 (s, 1H), 7.98 (s, 1H), 7.97 (d, 2H), 7.78 (s, 1H), 7.69 (d, 2H), 7.15 (s, 1 H), 5.55 (s, 2H), 4.62 (s, 2H), 3.66 (t, 2H), 0.92 (t, 2H), 0.00 (s, 9H).
SEM SEM
`N `N
N \ -~ N
N T\--- N NY-,-- N
HN HN
CHO
/
y /
S-N N OH S-N
To a solution of compound 14 (258 mg, 0.582 mmol) in 20 mL of THF, was added 0.05 mL of water followed by Dess-Martin periodinane (740 mg, 1.75 mmol). The reaction was stirred at room temperature for 1.5 h. The solid was filtered off. The filtrate was diluted with 100 mL of CH2CI2, and washed with water and brine.
The solvent was removed under vacuum, the residue was purified by flash chromatography eluting with 5% of MeOH/CH2CI2 to give 230 mg of compound 15.
SEM SEM H
N-N N-N N'N
Step A Step B ^
~ \N N r~_ N
NN N N~/1`\N
HN HN H'N
/
f / CHO
R~ R, By essentially the same procedure set forth in Example 11, compounds shown in column 2 of Table 2 were prepared by replacing compound 10 with compound 15, and 15 replacing pyrrolidine with other respective aliphatic amines in step A.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N'N
N
16-1 N~N 394.5 395.2 2.02 HN~
H
N'N
\
~N \
16-2 N~ N 394.5 395.2 2.13 HN~
S-N N
H
N'N
N
~
16-3 N~ N 434.6 435.2 2.50 HN~
S-N
H
N'N
N
~
16-4 Nl N 428.5 429.2 2.22 HN S-N
H
N' I N
N
16-5 Nj,'I'-N 408.5 409.2 2.18 HN S-N N
H
N' ( N
N
~
16-6 N~ N 408.5 409.2 2.21 HN S-N
N' I N
N
16-7 N'~'-N 381.2 382.2 2.55 HN\
S'N N
H
N'N
N
16-8 NY-I--N 366.14 367.14 2.43 HN~ ^
~~ /-~
S-N N
1) Walsh R.J.A.; Wooldridge, K. R. H. J. Chem. Soc. Perkin Trans. 1972, 1247.
SEM SEM SEM SEM
N'N N,N N-N N-N
I I I I
N Part A N Part B Part C N
N~ ~)~ \ Y~N \ -~ ~ \
N N1\_N N~N N~N
HN S~N S N S, N S
1~N SEM" I/N SEM" 1 ~N SEM"
CO2CH3 COZCH3 OH p S--O
~ 2 3 4 SEM H
\'N \'N
Pa-~ N Pa E
YN
NN N I N
"N S H`TN~g SEM
TL /N N
R r{
O O
Part A: A solution of ester (2.38 g, 4.91 mmol, 1 equivalent) in DMF (40 mL) was treated with NaH (60% dispersion in oil, 1.5 equivalents) for 20 min at rt, at which time, the reaction mixture was cooled to -10C and 2-(trimethylsilyl)ethoxymethyl chloride ( 0.87 mL, 1 equivalent) added to the reaction mixture. The resulting solution was allowed to slowly warm to rt and continued to stir at rt for a further 1 h. LC-MS
analysis indicated the reaction was complete. The reaction was quenched with methanol (15 mL), diluted with ethyl acetate (300 mL) and washed with sat.
sodium bicarbonate, water, brine, dried (sodium sulfate) and concentrated.
Purification by column chromatography (Si02 40% ethyl acetate / hexanes) afforded the desired product as a yellow solid 1.2 g (40%). HPLC-MS tR = 2.79 Min (UV 254,m). Mass calculated for formula C27H41 N7O4SSi2 615.25, observed LC/MS m/z 616.2 (M+H).
Part B: To a solution of compound from Part A (1.2 g, 1.90 mmol, 1 equivalent) in THF
(100 mL) was added superhydride solution (4 equivalents) at rt. The resulting solution was stirred at rt for 30 minutes at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. ammonium chloride and then extracted with dichloromethane (x2). The combined organic layers were dried (sodium sulfate) and concentrated. Purification by column chromatography (Si02 60 %
ethyl acetate / hexanes) afforded alcohol as a clear oil (47%). HPLC-MS tR = 2.49 Min (UV
254nm). Mass calculated for formula C26H41 N7O3SSi2 587.25, observed LC/MS m/z 588.3 (M+H).
Part C: A solution of alcohol from Part B (0.52 g, 0.88 mmol, 1 equivalent) in DCM (15 mL) was treated with triethylamine (1.5 equivalents) for 15 min at OC (ice-bath), at which time, methanesulfonyl chloride (1.2 equivalents) was added to the reaction at OC. The resulting solution was allowed to slowly warm to rt and continued to stir at rt for a further 3h. LC-MS analysis indicated the reaction was complete. The reaction mixture was diluted with ethyl acetate (100mL) and washed with water, brine, dried (anh. sodium sulfate) and concentrated to afford mesylate as a red/brown oil 0.59 g (100%) which was used without further purification. HPLC-MS tR = 2.66 Min (UV
254nm). Mass calculated for formula C27H43N7O5S2Si2 665.23, observed LC/MS m/z 666.1 (M+H).
Part D: A solution of the respective alcohol (3 equivalents) in THF (1.5 mL) was treated with NaH (60% dispersion in oil, 2 equivalents) for 15 min at rt, at which time, mesylate from Part C (40 mg, 0.06 mmol, 1 equivalent) was added to the reaction mixture. After stirring at rt for 1 h, LC-MS analysis indicated the reaction was complete.
The reaction was quenched with sat. aq. ammonium chloride and then extracted with ethyl acetate (twice). The combined organic layer was dried (sodium sulfate) and concentrated to afford crude ether, which was used without further purification.
Part E: A solution of compound from Part D in 1,4-dioxane (1 mL) was treated with 4N
HCI in 1,4-dioxane solution (1 mL) at 60C for 10 min at which time HPLC-MS
indicated that the reaction was complete. The solvent was removed and the residue was purified by Prep-LC. Conversion to a hydrochloric salt afforded compounds listed in Table 3.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N'N
N
17-1 NY-,-- N 398.2 399.2 2.55 HN\
S-NO-N\_ /
N
\
H
N-I N
~N \
N1-1-- N 438.2 439.3 2.79 HN` ^
~
~S-N~O-\_N~J
H
N-I N
\
17-3 N~N 426.2 427.3 2.68 HN\
~S-N~O-~-N
H
N' I N
N
Y`
17-4 N N I 440.2 441.2 2.75 HN
S_N
N-\
H
N'N
I
N
17-5 Nyl-- N 424.2 425.2 2.59 HN~
S N~- O
N
N'N
N
NY`N
17-6 HN S, 412.2 413.2 2.54 N
O
HN-N
I
N
NN
17-7 HN S/ N 424.2 425.2 2.61 O
DN
HN-N
N
17-8 N~N 410.1 411.1 1.113 H N 1 S%N 0 ~_O
~j HN-N
N
N~N 424.1 425.2 1.290 HN S, N
HN-N
N
17-10 NN 396.1 397.1 1.103 HN S, ~_N
~N \
17-11 N I 438.2 439.1 1.343 H N 1 S%N O
~_O
N
HN-N
~N \
17-12 Nyl N 377.1 378.2 1.94 H N
N /-' N
HN-N
N
17-13 N~N 377.1 378.2 2.65 HN S, N
NJ
HN-N
N
17-14 Ny'N 394.1 395.2 3.96 HN S, ~ /N 0 N
HN-N
. \~
N
17-15 Nyl-:::~ N 409.1 410.8 3.17 HN
/N O
NH
HN-N
N
N~ 'N
17-16 480.2 481.3 3.54 HN S, ~ /N
N
JN
HN
HN-N
N
17-17 "~" 423.2 424.3 3.15 HN
~NN-HN-N
N
17-18 H IN s, 438.2 439.1 3.32 /" 0~
N _~/
HN-N
~N \
N~_N
17-19 438.2 439.1 3.32 HN S, A N
HN-N
N
N~_N
17-20 HN S 452.2 453.3 3.55 N
/ `
HN-N
N
N~_N
17-21 HN s, 452.2 453.1 3.55 N
H
N-\ I, N
N~
17-22 N 405.1 406.2 2.57 HN SE N
N
N i~
0~~~!/
H
a 5~' N
NY
17-23 N I 482.0 483.3 2.98 HN S' i(Br No/
HN-N
~N \
N~N 410.1 411.1 2.77 H N 1S, /N O
N~
H
N- N
~N \
17-25 N11-1-- N 424.1 425.1 3.06 HN
S-N O
O
HN-N
N
N~N 487.1 488.4 3.82 HN 1 /N S~
N
~-~`,~-CH3 HN-N
N
N~ N 451.2 452.2 3.40 O
N \,JN- \
HN-N
N
17-28 N~ N 408.2 409.6 3.87 HN , N
H
N-N
N
N~
17_29 N 530.3 531.3 3.34 HN S.
, /N
N
H
N' I N
\
N
N\/ ' 17-30 N T 418.5 419.2 3.00 HN S
y ~N
N ~
O
H
N'N
N
17-31 N~N 473.1 / \
HN N _ S-N N
O~O
H
N- N
N
17-32 N Y-,-- N 473.1 HN
/
~
S-N ~
H
a N
17-33 N ~ N 473.1 HN
/
S-N ~
O O
H
N-N
N
17-34 NY-,-- N 465.2 NH
HN
O O
H
N-~N \
17-35 N~N 467.1 HN
S- N~
O2~NHAc O
H
N-N
17-36 N Y-,-- N 445.1 HN~
~' } N~
S-N N ~
H
N-A' N
17-37 Nyl-- N 445.1 HN
_ ~
S N ~
p\p N
H
N- N
N
17-38 NY-,-- N 445.1 HN ~
S-N ~ \
o 0 H
N-N
NI_ 17-39 N Y'' N 445.1 HN
S-N ~
N
O p H
N-~
\
N
N Y `N
17-40 HN ~ 472.1 S-NhN
O
,O
H
N-N
~ I
N
"N 457.1 HN
s "- N-0 O N
H
N-5:;~' N
"Yl-- N 409.1 HN~
S-N ON
H
N-N
"Y-,-- N 451.2 HN
S N
O N
I
SEM SEM SEM SEM
N'N N N- N N- N
i I I I
I/~N Part ' f/^N \ Part B N Pa rt~ I~ N
N'Y _N N)lj--N N - N N YN
HN S, N S N S, N S, 1 ~ N SEM I/N SEM 1 ~N SEM ~~NO /
CO2CH3 OH S~o SEM H
\'N \'N
PaRO' N Part E N NY N NY`N
SEM S HN S
~ /N ~ /N
R R
O O
By essentially the same procedures given in Preparative Example 17, compounds given in Table 4 can be prepared.
MS
Example Column 2 Exact m/z HPLC
mass (M+H) MS tR
H
N-N
N
NY-`N
18-1 HN S, N 412.2 413.2 2.36 O
N~
HN-N
N
N~N
18-2 HN S, 426.2 427.1 2.71 N
HN-N
~N
NN
18-3 HN 1 S, 400.1 401.1 2.47 N
S
/ N-HN-N
\ I
vl~ N
18-4 HN S, 416.1 417.1 2.23 0=S
/ N-I I
H3C\ N~ H3CN
NN N11 _N
IN
Example 19 was prepared in similar manner to Example 4. 'H NMR (300 MHz,.
DMSO-d6) 6 12.4 (bs, 1 H), 7.81 (s, 1 H), 7.75 (s, 1 H), 7.59 (s, 1 H), 3.85 (s, 3H), 2.49 (s, 3H).
I I
H3CN~ H3CN~
N `N --' N
~/ Y `N
HNI N SEM N I N
Example 20 was prepared in similar manner to Example 17, Part A. 'H NMR (300 MHz, CDCI3) 6 7.81 (s, 1 H), 7.73 (s, 1 H), 7.63 (s, 1 H), 6.61 (s, 2H), 3.98 (s, 3H), 3.74 (t, J = 8 Hz, 2H), 2.62 (s, 3H), 0.94 (t, J = 8 Hz, 2H), -0.83 (s, 9H).
I I
H3CN~ H3CN~
NY N Nj~N
S E M N N SEM' N I N
To a stirring solution of ester (2.40 g, 4.40 mmol) in tetrahydrofuran (96 mL) at -78 C
was added DIBAL-H (1M in dichloromethane, 11.0 mL, 11.0 mmol) dropwise. The mixture was stirred at -78 C for 3 hours at which time thin layer chromatography (30% ethyl acetate/hexanes) indicated the reaction was complete. The mixture was quickly poured into stirring saturated aqueous sodium potassium tartrate and stirred at room temperature for 14 hours. The mixture was extracted with ethyl acetate (2x250 mL), the organic layers were combined, washed with brine (100 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure affording compound 21 as a yellow solid 2.20 g (97%). 'H NMR (300 MHz, CDCI3) 8 9.99 (s, 1 H), 7.74 (s, 1 H), 7.73 (s, 1 H), 7.65 (s, 1 H), 6.60 (s, 2H), 3.74 (t, J =
8 Hz, 2H), 2.64 (s, 3H), 0.94 (t, J = 8 Hz, 2H), -0.07 (s, 9H).
I I
H3C\ N~ H3CN~
NI/`N NY _N
SEM' N I N SEM' N I S`N
CHO No To a stirring solution of aldehyde (1.30 g, 2.52 mmol), piperidine (257 mg, 3.02 mmol), and acetic acid (150 L, 2.52 mmol) in 1,2-dichloroethane (17 mL) at room temperature was added sodium triacetoxyborohydride (801 mg, 3.78 mmol) in one portion. The mixture was stirred at room temperature for 2 hours at which time thin layer chromatography (40% ethyl acetate/hexanes) indicated the reaction was complete. The reaction was quenched with 1 N sodium hydroxide (25 mL) and stirred for 20 minutes. The mixture was extracted with chloroform (3X20 mL), the organic layers were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Afforded compound 22 as a yellow solid 1.35 g (92%). 'H NMR
(300 MHz, CDCI3) S 7.70 (s, 1 H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2 H), 3.72 (t, J = 8 Hz, 2H), 3.62 (s, 2H), 2.58 (s, 3H), 2.47 (m, 4H), 1.58 (m, 6H), 0.93 (t, J =
8 Hz, 2H), -0.086 (s, 9H).
I I
H3C ^N~( H3CN~
N\~N NN
SEM N I N SEM N I S`N
CHO N
E
Example 23 was prepared in a similar manner to example 22 with the substitution of 3-methylpiperidine for piperidine. 'H NMR (300 MHz, CDCI3) S 7.70 (s, 1H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2H), 3.72 (t, J = 8 Hz, 2H), 3.62 (s, 2H), 2.85 (m, 2H), 2.59 (s, 3H), 1.98 (m, 1 H), 1.65 (m, 6H), 0.93 (t, J 8 Hz, 2H), 0.84 (d, J 6 Hz, 3H), -0.076 (s, 9H).
I I
H3CN~ H3C~N~
N~N NN
SEM N N SEM N I N
CHO No Example 24 was prepared in a similar manner to example 23 with the substitution of pyrrolidine for piperidine. 1 H NMR (300 MHz, CDCI3) 6 7.70 (s, 1 H), 7.59 (s, 1 H), 7.23 (s, 1 H), 6.58 (s, 2H), 3.77 (s, 2H), 3.72 (t, J = 8 Hz, 2H), 2.61 (m, 4H), 2.59 (s, 3H), 1.81 (m, 4H), 0.92 (t, J = 8 Hz, 2H), -0.90 (s, 9H).
I I
H3C\ N~ H3CN
N N --~ N~ N/
T =2 HCl SEM- N S` HN
, IN , IN
No No A solution of iodide from Example 24 (20 mg, 0.035 mmol) in 1,4-dioxane (1 mL) was treated with 4N HCI in 1,4-dioxane (1 mL). The mixture was sonicated at room temperature for 2.5 hours, at which time HPLC indicated the reaction was complete.
The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded compound 25 as a white solid 15 mg (83%). 'H NMR (300 MHz, CD3OD) S 7.88 (s, 1H), 7.79 (s, 1 H), 7.17 (s, 1 H), 4.51 (s, 2H), 3.71 (m, 2H), 3,22 (m, 2H), 2.57 (s, 3H), 2.07 (m, 4H).
HPLC tR = 4.83 min (UV 254 nm). Mass calculated for formula C15H IN6S 440.03;
observed MH+ (MS) 441.5 (m/z).
I I
H3C\ ^N H3C` ^N~
N~N/ N`\'/N
~ =HCl SEMN f HN
/ N C fN H3 E
N N
Example 26 was prepared in a similar manner to example 25. 'H NMR (300 MHz, CD3OD) S 7.87 (s, 1 H), 7.79 (s, 1 H), 7.22 (s, 1 H), 4.39 (s, 2H), 3.52 (m, 2H), 2.96 (m, 1 H), 2.70 (m, 1 H), 2.57 (s, 3H), 1.90 (m, 4H), 1.21 (m, 1 H), 0.99 (d, J = 6 Hz, 3H).
HPLC tR = 5.06 min (UV 25A,m). Mass calculated for C H21IN6S 468.3; observed MH+
(MS) 469.7 (m/z).
The compounds shown in column 2 of Table 5 were prepared as follows:
R\ N~ RN3 N\~N N\) N
~ T = HCl SEM' N I S`N ~ I S`N
R1 R, A flask containing the prepared aryl iodide scaffolds (compound from Example 22, 23, or 24, 1 equivalent), commercially available or readily prepared in 1 to 3 steps aryl/heteroaryl/alkyl boronic acid/ester/boroxine or aryl/heteroaryl/alkyl magnesium bromide or aryl/heteroaryl/alkyl zinc chloride (1.5 - 3 equivalents), potassium phosphate or potassium carbonate (2- 3 equivalents) and Pd(PPh3)4 or PdCl2dppf (0.05 - 0.10 equivalents) was evacuated, backfilled with nitrogen and repeated. 1,4-Dioxane or N,N-dimethylformamide or 1,2-dimethoxyethane (1 - 3 mL) was added and the mixture was stirred at 50 - 130 C until reaction was complete as judged by thin layer chromatography (ethyl acetate/hexanes) or HPLC. The mixture was diluted with water (3 - 10 mL) and extracted with ethyl acetate (2-3 x 10-30 mL). The organic layers were combined, washed with brine (15 - 30 mL), dried over magnesium sulfate, filtered, concentrated, and purified by column chromatography (Si02, ethyl acetate/hexanes). The product obtained was dissolved in 1,4-dioxane (1 mL) and treated with 4 N HCI in 1,4-dioxane (1 mL) and sonicated at room temperature for 1-5 hours, at which time HPLC indicated the reaction was complete. The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded compounds 27-1 to 27-7.
MS
Example Column 2 MW MH+ HPLC
tR
m/z N~
H3C\-T/_ ,\
N~-`N
27-1 HN_, S I328.4 329.1 3.52 N
N' I
H3C ~J
N y~'-N
27-2 ~ S 370.5 371.1 4.34 IN
No H3C~N
~ 1 \
N\\ T/ '-N
27-3 HN S 356.4 357.4 3.98 , ~N
No H3C%
N' N
H3C-T~ N
27-4 N11)'-N 408.5 409.6 4.21 HN
, /N
No H3C\ N~
~/_ NY`N
27-5 HN' s, 356.4 357.4 3.91 ~ N CH3 N
H3C\
_IN
NYI\ `N
27-6 HN 342.4 343.2 3.71 C
~N
ND
N- NH
H3C ~
~
H3C\ N CH3 ~
27-7 N N 422.5 423.2 3.87 HN s I'N
No H3C\ ~N H3C\ N~
NY-' N/ N N =HCl SEM' N S, HN S, ~ N /N
ON N
A mixture of iodide (60 mg, 0.103 mmol), trimethyl(trifluoromethyl)silane (44 mg, 0.308 mmol), copper iodide (73 mg, 0.385 mmol), potassium fluoride (15 mg, 0.257 mmol), and anhydrous DMF (1.0 mL) was degassed with nitrogen then heated at 80 C in a sealed tube overnight. The mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/concentrated ammonium hydroxide). The resulting residue was dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added.
The resulting solution was sonicated at room temperature for 2 hours and concentrated under reduced pressure to dryness. Purification by preparative HPLC
and conversion to the hydrochloride salt afforded the title compound as an off-white solid 3.1 mg (6%). 'H NMR (300 MHz, CD3OD) 6 8.07 (s, 1 H), 7.85 (s, 1 H), 7.24 (s, 1 H), 4.40 (s, 2H), 3.61 (d, J = 12.3 Hz, 2H), 3.07 (t, J= 12.3 Hz, 2H), 2.55 (s, 3H), 1.75-2.03 (m, 5H), 1.56 (m, 1H). HPLC tR = 7.19 min. Mass calculated for formula C17H19F3N6S 396.13; observed MH+ 397.2 (m/z).
H3CIN N\ H3CN\ /
N 1 N NN =HCl SEM' N S~ HN S, ~ N N
A mixture of iodide (100 mg, 0.171 mmol) in anhydrous THF (2.0 mL) was cooled to -78 C and n-butyl lithium (2.5 M solution in hexanes, 89 pL, 0.222 mmol) was added dropwise. After stirring for 15 minutes a solution of hexachloroethane (45 mg, 0.188 mmol) in THF (1.0 mL) was added dropwise. After stirring the reaction at -78 C for 30 minutes the solution was quenched with a saturated aqueous solution of ammonium chloride (3.0 mL) and warmed to room temperature. The reaction was concentrated under reduced pressure, extracted with ethyl acetate (50 mL) and the organic layer dried over sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/concentrated ammonium hydroxide). The resulting residue was dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added.
The resulting solution was sonicated at room temperature for 2 hours and concentrated under reduced pressure to dryness. Purification by preparative HPLC
and conversion to the hydrochloride salt afforded the title compound as an off-white solid 30 mg (40%). ' H NMR (300 MHz, CD3OD) 6 7.80 (s, 1 H), 7.73 (s, 1H), 7.22 (s, 1H), 4.39 (s, 2H), 3.59 (d, J = 12.3 Hz, 2H), 3.08 (t, J= 12.3 Hz, 2H), 2.55 (s, 3H), 1.75-2.03 (m, 5H), 1.56 (m, 1 H). HPLC tR = 4.79 min. Mass calculated for formula C16H19CIN6S 362.11; observed MH+ 363.7 (m/z).
H3C\ N~ H3C\ ~N~
N/ N1~ N =HCl SEM.N S, HN S~
~ N ~ N
N N
Example 30 was prepared in a similar manner as Example 29. 'H NMR (300 MHz, CD3OD) b 7.77 (s, 1H), 7.68 (s, 1H), 7.20 (s, 1H), 4.39 (s, 2H), 3.47-3.67 (m, 2H), 2.97 (m, 1 H), 2.71 (m, 1 H), 2.55 (s, 3H), 1.77-2.01 (m, 4H), 1.20 (m, 1 H), 1.00 (d, J=
6.4 Hz, 3H). HPLC tR = 4.98 min. Mass calculated for formula C17H21CIN6S
376.12;
observed MH+ 377.6 (m/z).
I Br H3CIN N\ / H3C~N\ /
N N NN =HCl SEM' N S, HN S~
N
~ 1 N 1, ON N
Example 31 was prepared in a similar manner to compound 29 with the substitution of tetrachlorodibromoethane for hexachloroethane. 'H NMR (300 MHz, CD3OD) 6 7.84 (s, 1 H), 7.83 (s, 1 H), 7.25 (s, 1 H), 4.41 (s, 2H), 3.61 (d, J = 12.3 Hz, 2H), 3.08 (t, J=
12.3 Hz, 2H), 2.57 (s 3H), 1.77-2.03 (m, 5H), 1.55 (m, 1 H). HPLC tR = 5.19 min.
Mass calculated for formula C16H19BrNsS 406.06; observed MH+ 407.4 (m/z).
F
/
N `T` /NHZ N `T\/N \ I
B I N , B ~N 0 O O
To a solution of aminopyrimidine (100 mg, 0.452 mmol) in anhydrous pyridine (2.0 mL) was added 3-fluorobenzoyl chloride (72 mg, 0.452 mmol). After stirring at room temperature overnight, the reaction was concentrated under reduced pressure, diluted with water (30 mL), and extracted with methylene chloride (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to afford the title compound as an off-white solid 124 mg (80%). 'H NMR (300 MHz, CDCI3) 6 8.95 (s, 2H), 8.72 (s, 1 H), 7.66-7.72 (m, 2H), 7.49 (m, 2H), 1.36 (s, 12H).
/ F
H
N NH2 N N \ I F
BY BY
O, ,N G N 0 i i O O
Prepared in a similar manner as compound 31 affording the title compound as an off-white solid 131 mg (80%). 'H NMR (300 MHz, CDCI3) 6 8.93 (s, 2H), 8.65 (s, 1H), 7.83 (m, 1 H), 7.69 (m, 1 H), 7.30 (m, 1 H), 1.34 (s, 12H).
-N
H3C\ N H3C` N H3C\ N
N~ N~ N=HCl + N~ =HCl SEM- N ~ S, ~, IN
~ ~N I ~N
a a a A mixture of iodide (60 mg, 0.103 mmol), tri-n-butyl(pyridyl)tin (57 mg, 0.154 mmol), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (8 mg, 0.0103 mmol), and potassium fluoride (18 mg, 0.309 mmol) in anhydrous 1,4-dioxane (1.0 mL) was degassed with nitrogen then heated at 85 C in a sealed tube overnight. The mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (2 x 100 mL). The organic layer was then separated, dried over sodium sulfate, filtered, concentrated under reduced pressure to residue, and purified by column chromatography (Si02, 90:10:0.25 methylene chloride/methanol/ concentrated ammonium hydroxide). The resulting residue was then dissolved in anhydrous 1,4-dioxane (1mL) and 4 M HCI in dioxane (1 mL) was added. The resulting solution was sonicated at room temperature for 2 hours and then concentrated under reduced pressure to dryness. Purification by preparative HPLC and conversion to the hydrochloride salt afforded de-halogenated product 3.2 mg (10%) as an off-white solid: 'H NMR (300 MHz, CD3OD) 6 8.23 (s, 1H), 8.13 (s, 2H), 7.29 (s, 1 H), 4.55 (s, 2H), 3.72 (br s, 2H), 3.29 (m, 2H), 2.61 (s, 3H), 2.05-2.18 (m, 4H). HPLC tR =3.49 min. Mass calculated for formula C15H16N6S 314.13;
observed MH+ 315.2 (m/z).
Also afforded coupling product 5.0 mg (10%) as an off-white solid: 'H NMR (300 MHz, CD3OD) 6 8.95 (s, 1 H), 8.86 (d, J = 5.1 Hz, 1 H), 8.50 (s, 1 H), 8.28 (t, J = 7.5 Hz, 1 H), 8.18 (d, J = 7.8 Hz, 1 H), 7.70 (t, J = 6.3 Hz, 1 H), 7.26 (s, 1 H), 4.54 (s, 2H), 3.74 (m, 2H), 3.29 (m, 2H), 1.99-2.30 (m, 4H). HPLC tR =4.80 min. Mass calculated for formula C20H21N7S 391.16; observed MH+ 392.5 (m/z).
H3C\ ^N \ N
N y ~
N~ ~N N =HCl HN
SSEM N I N f IN
Sodium borohydride (3 mg, 0.073 mmol) was added to a room temperature suspension of iodide (15 mg, 0.037) in methanol (1 mL). The reaction was allowed to stir for 30 minutes then quenched with water (20 mL). The mixture was diluted with diethyl ether (20 mL) and the phases were allowed to separate. The organic layer was dried (sodium sulfate), filtered and concentrated to afford a protected de-halogenated intermediate. The reduced product (7 mg, 0.017 mmol) was subjected to the acidic conditions outlined previously to afford the title compound as a yellow solid 2 mg (17%). 1 H NMR (300 MHz, CD3OD) 6 7.94 (s, 1 H), 7.90 (s, 1 H), 7.74 (s, 1 H), 7.55 (s, 1 H), 3.94 (s, 3H), 2.50 (s, 3H). HPLC tR = 4.67 min (UV 254nm)= Mass calculated for formula C12HI1N502S 289.06; observed MH- (ESI MS) 288.0 (m/z).
I I
H3CN g3C_ ^N~
NN N
7 --~ =HCl SEM N HN
, /N f IN
No No Example 36 was prepared in a similar manner to Example 31. 'H NMR (300 MHz, CD3OD) 6 7.72 (s, 1 H), 7.69 (s, 1 H), 7.15 (s, 1 H), 4.38 (s, 2H), 3.69-3.52 (m, 2H), 3.17-2.96 (m, 2H), 2.54 (s, 3H), 2.06-1.70 (m, 5H), 1.65-1.44 (m, 1 H). HPLC
tR = 5.00 min (UV 254nm). Mass calculated for formula C16H191N6S 454.04; observed MH+
(ESI
MS) 455.0 (m/z).
I CN
H3C\ N H3C\ ^N~( N~N/ --~ NN
=HCl SEMN ' HN
~ /N ~ IN
No N_ ) Pd2(dba)3 (5 mg, 0.005 mmol) was added to a room temperature solution of DPPF (6 mg, 0.103 mmol) in N,N'-dimethylformamide (1 mL) and stirred for 10 minutes. The mixture was then added to a solution of iodide (60 mg, 0.103 mmol), Zn(CN)2 (12 mg, 0.103 mmol) in N,N'dimethylformamide (4 mL). The reaction was heated to 150 C in the microwave for 30 minutes, cooled to room temperature then.
concentrated to dryness. Purification of the resultant residue by flash chromatography.
(Si02; 12 g; 10% methanol in methylene chloride) afforded impure nitrile as a yellow solid. The impure nitrile (22 mg, 0.045 mmol) was dissolved in 2 N HCI (4 mL) without further purification. The resultant solution was sonicated at 45 C for 2 hours. Upon completion, the reaction was concentrated to dryness. Purification of the resultant residue by prep-HPLC afforded the title compound as a white solid 8 mg (18%).
'H
NMR (300 MHz, CD3OD) b 8.22 (s, 1 H), 7.93 (s, 1 H), 7.22 (s, 1 H), 4.40 (s, 2H), 3.73-3.52 (m, 2H), 3.20-2.97 (m, 2H), 2.55 (s, 3H), 2.06-1.71 (m, 5H), 1.66-1.42 (m, 1 H).
HPLC tR = 4.50 min (UV 254nm). Mass calculated for formula C17H19N7S 353.14;
observed MH+ (ESI MS) 354.3 (m/z).
H3C\T5^N~ H3C ^ N \
N) Y`,~
N --- N~N
1 =HCl SEM'N S. HN S~
( N , IN
No N
o A mixture of iodide (70 mg, 0.12 mmol), Pd(dppf)C12 (9 mg, 0.012 mmol), sodium tert-butoxide (35 mg, 0.36 mmol) and sodium thiomethoxide (17 mg, 0.24 mmol) was flushed with nitrogen then dissolved into 1,4-dioxane (5 mL). The solution was heated to 95 C in the microwave for 90 minutes. The reaction was cooled to room temperature, diluted with ethyl acetate (100 mL), and filtered through celite. The organic layer was washed with water (50 mL) and brine (50 mL) then dried (sodium sulfate), filtered and concentrated to dryness. Purification of the resultant residue by prep-HPLC afforded the protected thiomethylether. The thiomethylether (35 mg, 0.07 mmol) was subjected to the reaction conditions outlined in example 110 to afford the title compound as a white solid 6 mg (11%). 'H NMR (300 MHz, CD3OD) 6 8.28 (s, 1 H), 8.25 (s, 1H), 7.34 (s, 1H), 4.43 (s, 2H), 3.68-3.52 (m, 2H), 3.18-2.98 (m, 2H), 2.67 (s, 3H), 2.49 (s, 3H), 2.05-1.71 (m, 5H), 1.65-1.44 (m, 1 H). HPLC tR =
4.74 min (UV 254nm). Mass calculated for formula C17H22N6S2 374.13; observed MH+ (ESI
MS) 375.3 (m/z).
SEt H3C\ N \\ H3C ^ N \
N/~
N
=HCl SEMN S. HN1S"~ ~N No N
~
A combined mixture of iodide (70 mg, 0.12 mmol), sodium thioethoxide (20 mg, 0.24 mmol), Pd(dppf)C12 (9 mg, 0.012 mmol) and sodium tert-butoxide (35 mg, 0.36 mmol) was flushed with nitrogen gas then dissolved into 1,4-dioxane (5 mL).
The reaction was heated to 95 C and stirred for 72 hours. The reaction was then cooled to room temperature, diluted with ethyl acetate (100 ml), and filtered through celite.
The filtrate was washed with water (50 mL) and brine (50 mL) then dried (sodium sulfate), filtered and concentrated to dryness. Purification of the resultant residue by flash chromatography (Si02; 12 g; 0% to 10% methanol in methylene chloride) afforded a thioethylether intermediate as a yellow solid. The thioethylether (10 mg, 0.019 mmol) was subjected to the reaction conditions outlined in example 110 to afford the title compound as a white solid 2 mg (4%). 'H NMR (300 MHz, CD3OD) 8.32 (s, 1 H), 8.28 (s, 1 H), 7.35 (s, 1 H), 4.43 (s, 2H), 3.68-3.55 (m, 2H), 3.17-3.01 (m, 2H), 2.90 (q, J = 7.3 Hz, 2H), 2.67 (s, 3H), 2.07-1.71 (m, 5H), 1.65-1.42 (m, 1 H), 1.28 (t, J = 7.3 Hz, 3H). HPLC tR = 5.27 min (UV 254nm). Mass calculated for formula C18H24N6S2 388.15; observed MH+ (ESI MS) 389.7 (m/z).
0 DPPA / Et3N O~y N S Part B N Na104 / OSOq HO ~ i S t-BuOH / 80 C OI -j ~B~ ~Sn t Bu ~ ~S Dioxane: H20 (3;1) Br `N O N~ 2,6rLutidine / rt N Part A 1,4dioxane/
Pd(0) Part C
H RR1-NH / NaBH(OAc)3 / R
O~N S H CH3COOH (cat.)DCM / O H RI ~ TMSI / DCM H N ~
\ O ~N O NaBH4 O N~SN R 20 min 2S~N-R
X\ ~ ~ i Part D N Part E N
H
N'N
NaH/DMSO I
H N
N'N N\ ~N ~~ I
\ T
N_ IN
Y ~N
1 O 0=S=0 Part A: To a stirred solution of 2-Bromo-thiazole-5-carboxylic acid (2.0 g, 9.615 mmol) in t-Butanol (30 mL) and triethyl amine (1.5 mL, 10.57 mmol) was added diphenylphosphoryl azide (2.9 g, 10.57 mmol) and reaction mixture was heated to 80 C and stirred for 12 hrs, LCMS showed the complete disappearance of the starting material. Reaction mixture was cooled to room temp., solvent removed under vacuum, water (100 mL) added and extracted with ethyl acetate (3 x 100 mL). Organic layer was washed with water, brine, dried over sodium sulfate and concentrated, crude material was passed through small pad of silica gel and resultant (2-Bromo-thiazol-5-yl)-carbamic acid tert-butyl ester (solid) was used as such in the next step, yield 2.5 g (90%). 'H NMR (400 MHz, DMSO-d6 6 7.10 (s, 1 H), 7.05 (s, 1 H), 1.51 (s, 9H).Mass calculated for formula C8H11 BrN2O2S 277.97; observed MH+ (LCMS) 279.0 (m/z).
Part B: To a stirred solution of (2-Bromo-thiazol-5-yl)-carbamic acid tert-butyl ester (2.5 g, 8.9928 mmol) in 1,4-dioxane (20.0 mL) were added tributy(vinyl)tin (2.9 mL, 9.892 mmol), 2,6-di-tert-butyl-4-methylphenol (cat. amt) and tetrakis(triphenyl phosphine) palladium(0) (506.0 mg, 0.4496 mmol). The reaction mixture was heated to 100 C and stirred for 12 hrs, LCMS showed the complete disappearance of the starting material. Reaction mixture was cooled to room temp, filtered and solid washed with ethyl acetate, combined filtrate (organic solvent) was removed under vacuum, crude material was purified using biotage HPLC using hexane / ethyl acetate gradient 0.0 to 100 % to yield (2-Vinyl-thiazol-5-yl)-carbamic acid tert-butyl ester (solid) 1.1 g (54%). 1 H NMR (400 MHz, CDCI3 b 7.27 (d, J = 12.7 Hz,2H), 7.19 (brs, 1 H), 6.84-6.77 (m, 1H), 6.87 (d, J = 17.0 Hz, 1H), 5.43 (d, J = 10.5 Hz,1 H), 1.52 (s, 9H).
Mass calculated for formula CjoH14N202S 226.08; observed MH+ (LCMS) 227.1 (m/z).
Part C: To a stirred solution of (2-Vinyl-thiazol-5-yl)-carbamic acid tert-butyl ester (0.76 g, 2.857 mmol) in 1,4-dioxane : water (30 : 9 mL), were added sodium periodate (2.5 g, 11.43 mmol) osmium tetroxide (2.5% solution in 2-propanol) (0.5 mL) and 2,6-lutidine (0.663 mL, 5.714 mmol) and reaction mixture was stirred for 4 hrs, LCMS
showed the almost disappearance of the starting material. Reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate, organic layer was washed with water, brine, dried over sodium sulfate and concentrated under high vacuum to yield aidehyde 710 mg (92%). Crude product was used as such in the next reaction. 1 H NMR (400 MHz, DMSO-d6 6 11.45 (s, 1 H), 9.76 (s, 1 H), 7.58 (s, 1 H), 1.40 (s, 9H). Mass calculated for formula C9H12N203S 228.06; observed MH+
(LCMS) 229.1 (m/z).
Part D: To a stirred solution of (2-Formyl-thiazol-5-yl)-carbamic acid tert-butyl ester (0.76 g, 2.857 mmol) in 1,2-dichloroethane(10 mL) were added Morpholine (250 mg, 1.1135 mmol) triacetoxysodium borohydride (472 mg, 2.227 mmol) and Cat amount acetic acid (three drops) and stirred for two hrs at room temp. To the reaction mixture was added sodium borohydride (126 mg, 3.3405 mmol) and stirred for one hrs.
LCMS
showed the disappearance of the starting material. Reaction mixture was diluted with water (100 mL) and extracted with dichloromethane, organic layer was washed with water, brine, dried over sodium sulfate and concentrated under high vacuum to yield (2-Morpholin-4-ylmethyl-thiazol-5-yl)-carbamic acid tert-butyl ester 298 mg (91 %).
Crude product was used as such in the next reaction. Mass calculated for formula C14H25N303S 315.43; observed MH+ (LCMS) 300.3 (m/z).
Part E: To a stirred solution of (2-Morpholin-4-ylmethyl-thiazol-5-yl)-carbamic acid tert-butyl ester (80.0 mg, 0.268 mmol) in dichloromethane(5 mL) was added iodotirmethylsilane ( 44 pL, 0.321 mmol) and stirred for 10 min. LCMS showed the disappearance of the starting material. Reaction mixture was diluted with water (10 mL), 1 N aqueous NaOH solution (5 mL) and extracted with 10% 2-propanol in DCM
(3 x 25 mL) and organic layer dried over sodium sulfate and concentrated under high vacuum to yield 2-Morpholin-4-ylmethyl-thiazol-5-ylamine 30.0 mg (56%). Crude product was used as such in the next reaction. Mass calculated for formula C8H13N3OS 199.27; observed MH+ (LCMS) 200.1 (m/z).
Part F: To a stirred solution of 2-Morpholin-4-ylmethyl-thiazol-5-ylamine (30.0 mg, 0.151 mmol) in DMSO (2.5 mL) was added 8-Methanesulfonyl-6-methyl-3-(1 H-pyrazol-4-yl)-imidazo[1,2-a]pyrazine ( 25.0 mg, 0.09045 mmol) followed by NaH
60%
in mineral oil (48 mg, 1.206 mmol) and stirred for 30 min. LCMS showed the disappearance of the starting material. Reaction mixture was quenched 1:1 mixture of acetonitriie and saturated ammonium chloride (10 mL), and extracted with 10% 2-propanol in DCM (3 x 25 mL) and organic layer was concentrated under high vacuum to yield crude [6-Methyl-3-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazin-8-yl]-(2-morpholin-4-ylmethyl-thiazol-5-yl)-amine which was subsequently purified by Agilent reverse phase HPLC using formic acid method to yield 10 mg (28%). HPLC-MS (10 min method) tR = 2.06 min (UV 254nm). Mass calculated for formula C18H2ON8OS
396.47;
observed MH+ (LCMS) 397.5 (m/z).
The compounds shown in Table 6 were prepared using procedures described in Example 40.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
\ N,N
I
N
N~N 396.47 397.5 2.06 40-1 ^ 'NH
S
H
N.N
40-2 NY'L'N 394.50 395.5 2.38 /^~,-NH
N\ ' S
CN
H
N-N
380.47 381.5 2.25 40-3 "~ N
HN
'*I Q-J
g H
N' I N
408.52 409.2 2.56 40-4 "y)--N ~
HN N
N
H
N' ~ N
" ~N 409.51 410.3 2.14 40-5 "N J
HN S N
c"
N
H
N-N
I
" 422.55 423.5 2.74 40-6 "N
~N~NH
H
N'N
Nl--'--N
422.55 423.3 2.75 40-7 N~N S v NH
~
HN-N
N N
"` ~N 449.58 450.3 1.85 40-8 ~( N s NH
4\ 1 N
H
N-~ N
`~" 382.49 383.2 2.28 40-9 NY `N
/-N\-/ S NH
\~ D, -N
H
N'N
HN
435.55 436.44 1.78 N g NH
\-~ J
N
H
N' N
^ I
LN>
~" 463.60 464.27 1.90 40-11 ~ "~N
N NH
N
H
N' N
I
-" 411.53 412.25 1.76 ~NL< g NH
~
N
H
N-N
40-13 ~N 422.55 423.28 2.74 "~ $ NH
\\ ~
N
HO -11/ ~ --, H3CO ~ ~
To a solution of 5-nitrothiophene-3-carboxylic acid (5.00 g, 28.88 mmol) in dimethylformamide (40 mL) was added potassium carbonate (11.98 g, 86.71 mmol) and iodomethane (2.70 mL, 43.37 mmol). The reaction mixture was stirred at RT
for 16 hr. After the starting material had been consumed, the reaction was diluted with 50% ethyl acetate/hexanes (350 mL) and extracted with H20 (350 mL). The organic layer was washed with brine (150 mL) and concentrated. Hexanes (50 mL) was added to the solid and concentrated again to yield 5.456 g (99%) of product.
'H NMR
(400 MHz) CDCI3 6 8.30 (s, 1 H), 8.25 (s, 1 H), 3.93 (s, 3H). Mass calculated for formula C6H5NO4S 187.17; observed M4H+ (MS) 191.15 (m/z) O O
H3CO ~ ~ H3CO ~ ~
g N02 g NHZ
To a solution of the nitro-ester (1.006 g, 5.375 mmol) in TFA (15 mL), Fe powder (1.5135 g, 27.10 mmol) was slowly added to the round bottom flask. The reaction was heated to 60 C for 45 min at which time TLC (1:1, ethyl acetate to hexanes) showed consumption of starting material. The reaction was diluted with ethyl acetate and the Fe was filtered off. The filtrate was neutralized with aqueous Na2CO3 and allowed to stir for 1 hr. The aqueous layer was extracted with EtOAc.
The organic layer was washed with brine, dried over Na2SO4, and concentrated to give 0.701 g (83%) of a yellow solid. 'H NMR (400 MHz) CD3OD 6 7.29 (s, 1 H), 6.44 (s, 1 H), 3.79 (s, 3H). Mass calculated for formula C6H7NO2S 157.19; observed MH+
(LCMS) 158.1 (m/z).
NE N NEM
O N
\ I
N + HgC\ ^N
N\" ~~N H2N S ~N/\
~
0=S=0 NH
Cys A solution of the sulfone (1.27 g, 3.11 mmol) and 2-aminothiophene-4-carboxylate methyl ester (0.701 g, 4.46 mmol) in DMF (35 mL) were treated with NaH
(60% dispersion in oil, 0.402 g, 10.05 mmol) at room temperature until mass spectrometry and thin layer chromatography (50% ethyl acetate/hexanes) indicated that the reaction was complete. Saturated ammonium chloride (15 mL) and water (50 mL) were added to the reaction. The reaction was stirred for 10 minutes. The precipitated solid was collected via filtration to yield the desired product.
'H NMR (400 MHz) CDCI3 b 8.78 (s, 1 H), 7.88 (s, 1 H), 7.82 (s, 3H), 7.68 (s, 1 H), 7.58 (s, 1 H), 7.44 (s, 1 H), 7.16 (s, 3H), 5.54 (s, 2H), 3.87 (s, 3H), 3.67 (t, 2H), 2.46 (s, 3H), 0.97 (t, 2H), 0.01 (s, 9H). Mass calculated for formula C22H28N6O3SSi 484.65; observed MH+
(MS) 485.1 (m/z).
SEM SEM
N- N N- N
\ I \ I
H3C N H3~ N
N\~N N\~N
NH TNH
H3CO2C H02C Cy S S
A solution of the ester prepared in Example 43 (0.565 g, 1.17 mmol) in THF (10 mL) and MeOH (3 mL) was treated with solid NaOH (9 pellets) followed by H20 (5 mL). The reaction was stirred vigorously at room temperature for 16 hr. The THF and MeOH were removed in vacuo and the residue was extracted with EtOAc (3 x 20 mL).
The aqueous phase was brought to a pH of 3-4 with aqueous HCI. The acidified aqueous phase was extracted with EtOAc (5 x 20 mL) and concentrated in vacuo to give 0.393 g(71 %) of the desired carboxylic acid.
SEM SEM
N,N N-N
\ I \ I
Hs~N HsC~ N
NYI-- N N),)'-N
~ NH HN O
HOZC--L S. S HN-O
A solution of the carboxylic acid (prepared in Example 4) (0.054 g, 0.115 mmol) in DMF (3 mL) was treated with amine (0.03 mL, 0.262 mmol), NMM (0.07 mL, 0.637 mmol) and then HATU (0.141 g, 0.372 mmol). The reaction was stirred at room temperature for 16 hr. Water (15 mL) was added and the reaction was stirred for 10 minutes. The precipitated solid was collected via filtration to yield 0.038 g (60%) of the desired amide. 'H NMR (400 MHz) CDCI3 6 9.13 (s, 1H), 7.86 (s, 1H), 7.80 (s, 3H), 7.54 (s, 1 H), 7.41 (s, 1 H), 7.31 (s, 1 H), 7.08 (s, 3H), 5.83 (d, 1 H), 5.53 (s, 2H), 3.93 (m, 1H), 3.67 (t, 2H), 2.44 (s, 3H), 1.70 (m, 10H), 0.96 (t, 2H), 0.00 (s, 9H). Mass calculated for formula C27H37N7O2SSi 551.78; observed MH+ (MS) 552.1 (m/z).
By essentially the same procedure set forth in Example 45, only substituting the amines shown in Column 2 of Table 7, the compounds in Column 3 were prepared:
MH+ LCMS
Example Column 2 Column 3 MW m/z MS tR
SEM
N-N
\I
N H3C~N \
45-1 N~)--N 523.7 524.1 S ~ N
SEM
N-N
N H3C~ N
45-2 CJ NN 539.7 540.2 HN O
S I/ No SEM
N-I N
N H3~ N
45-3 ( ) NYI-- N 552.8 553.3 N HN S
I TL ~
O ~~N
SEM
N
H3~N
45-4 H N~ 497.7 498.3 4.16 N
~N~
HN S
~ /
N
O
N.
I N
H2N Hs~N
I' 45-5 N 537.8 538.1 HN S
NH
O ~
SEM
N, N
H ~~OH H3~N ~
45-6 2N N~N 513.7 514.3 HN S
H
N~~OH
N.
~ I N
HgC N
_`~
45-7 ~~OMe N7 N 527.7 528.2 HzN HN S
O~
NH
~
OMe SEM
I
H3 C-~N
H N~N~ Ni-)- N
45-8 2 ~ S 540.8 541.2 I/
NH
O ~
/ N-SEM
N,N
H3C-~-N \
45-9 NH N."~N 497.7 498.1 2 ~
HN S
N,_,,-O
SEM
N- N
45-10 H2N N. ~N 511.7 512.1 HN ~V S
N, N H3 N
45-11 N~ N\~N 525.7 526.1 H HN ~V S
~
N~
SEM
N- I N
H3~N~
NN
45-12 HN 541.7 542.2 NH
O ---\
\
SEM
N-~ N
H3C~
i~ N
\
45-13 NN HS 554.8 555.3 Oi N
~
N-/
SEM
N-N
OH FbCT~~- N \
45-14 N~N 553.8 554.2 HN S
N
H N
SEM
I N
OH H3 ~N
45-15 HN N1-1- N 557.7 558.2 pH HN S
/
O N
\-~
OH
SEM
N.N
H H3 C-~N
45-16 i_,N N~N 568.8 569.2 I HN /
IN
N, N
OMe ~~N
45-17 HN Nll)zz:N 585.8 586.2 OMe HN ~-OMe ~ N
0 OMe ~
N~
N 584.8 585.2 HN S
N
~
OH N
O \--\
/ N-NEM
N
45-19 HN,~OMe N1-1-- N 555.8 556.3 4.37 l HN S
\ t Me N
. ; ' SEM H
N-N N-N
\ I \ I
H3 N HsN
N),),-N N 'I~")-- N 10 HN O HN
-O
S // HN--O S /HN
To a solution of the amide (0.038 g, 0.069 mmol) in dichloromethane (4 mL) was added lithium aluminum hydride (0.029 g, 0.775 mmol) and ethyl ether (0.8 mL).
The reaction mixture was stirred at RT for 10 min then refluxed at 40 C for 5 hr. The reaction was monitored by mass spectrometry. Upon consumption of the starting amide, the reaction was cooled to RT and quenched with H20 (2 mL). The reaction was diluted with DCM and filtered. The filtrate was washed with H20 (<_ 8 mL).
The organic layer was concentrated to give 0.019 g (52 %) of the amine. The above amine in THF was further treated with 4 N HCI/dioxane at 60 C for 1 hr. Upon cooling to RT, Et20 was added and the mixture was stirred for 10 min. The precipitated solid was collected giving 13.9 mg (96 % yield) of the desired amine.
By essentially the same procedure set forth in Example 46, the following compounds shown in Column 2 of Table 8 were prepared:
LCMS
Example Column 2 MW MH+ LCMS
m/z MS tR
H`N, N
H3C\ N \
46-1 N`Jzz': N 395.5 396.2 2.06 HN 'S ^O
C / Nr J
H.N`N
H3C~N
46-2 N\ 379.5 381.2 2.12 HN S
~ / N
H`N, N
H3CN ~
46-3 N~N 381.5 382.2 2.03 HN g ~
~/
.N`N
H3C~ N
\
T'Lz:N 367.5 368.2 1.95 HN S
N
,_r H
N' ~ N
/
46-5 H3N N 353.4 354.2 1.97 HN
N' N
\ I
H3~N
46-6 N1-1- N 408.5 409.2 1.77 HN
5=/ q H,N`N
H3~N \
46-7 N`~N 393.5 394.2 2.06 HN S
N
H.N`N
H3C , N 369.4 370.2 1.76 ~
HN S
I ~ H
N`~OH
H, N,N
46-9 ~ ~N 383.5 384.2 1.78 HN S
C~ H
N--"OMe H.N`N
H3C-Tl~ N
46-10 N~N 396.5 397.2 1.52 HN S
N
H, N,N
H3C\ N
46-11 N` ~N 353.4 354.2 1.79 HN S
N
H.N`N
\ 1 46-12 ~ ~N 397.5 398.2 1.93 HN S
N
H.N`N
H3C-rl~ N
46-13 N.~N 410.5 411.2 1.76 HNI S
N
H.N`N
46-14 H3CY`N 409.5 410.2 1.94 N'lljz'N
HN S
~N_ rOH
H.N`N
46-15 H3C -T~~ N 413.5 414.2 1.87 N~N
HN S H
OH
H`N`N
H3C-fo~ N
46-16 NN 424.6 425.2 1.80 HN S /
I'-"-"Ni H`N'N
H3C~N
46-17 N~N 441.6 442.2 2.23 HN S ~OMe OMe H,N`N
\ I
H3C_rl~ N
\
46-18 N~N OH 440.6 441.2 1.78 HN S
N
O O O __N
+ NOH O I
CI
Ethyl 4-chloro-3-oxobutanoate (14.15 g, 86 mmol), cyanoacetic acid (8.00 g, 86 mmol), NH4OAc (1.32 g, 17.2 mmol), AcOH (2.46 mL, 43 mmol), and benzene (40 mL) was stirred overnight at reflux with a Dean-Stark trap. The mixture was cooled to room temperature, diluted with EtOAc, washed with sat. NaHCO3, brine, dried with Na2SO4, and concentrated to afford crude product 1 (9.29g, 58%). HPLC-MS tR
=1.67 Min (UV 254nm). Mass calculated for M+ 187.0, observed LC/MS m/z 188.1(M+H).
UN
iN
O-/
CI I
Morpholine (580 uL, 6.65 mmol) was added dropwise to a mixture of ethyl 3-(chloromethyl)-4-cyanobut-3-enoate (622 mg, 3.33 mmol) and S-flakes (116 mg, 3.63mmol) in EtOH (5 mL). The reaction stirred at room temperature overnight.
The mixture was concentrated. The mixture was diluted with EtOAc, washed with brine, dried with Na2SO4, and concentrated to afford crude product. Purification by Prep-LC
afforded the title compound (182 mg, 20%). HPLC-MS tR = 0.80 Min (UV 2wm).
Mass calculated for M+ 270.1, observed LC/MS m/z 271.1(M+H).
SEM
N.N
SEM
N (0) N \ 1 N N~N O
N H2N ~ ~ HN NJ
NT\~N S O\1 To S02Me O
O \--A solution of ethyl 5-amino-3-(morpholinomethyl)thiophene-2-carboxylate (61.0 mg, 0.225 mmol) and sulfone (71.0 mg, 0.173 mmol) in DMF (2 mL) was treated with NaH
(60% dispersion in oil, 20.9 mg, 0.521 mmol) at room temperature. The mixture was stirred at room temperature until LCMS indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford title compound. HPLC-MS tR = 1.79 Min (UV 254nm).
Mass calculated for M+ 597.2, observed LC/MS m/z 598.3(M+H).
SEM
N, I N NE 1 N
N
N
N N O HN CD
N H~ -y ~
g To -~
3/O O ~
A solution of i-PrMgCi in THF (0.78 uL, 1.56 mmol) was added dropwise to a solution of crude compound from example 49 (104.2 mg, 0.173 mmol) and diethylamine (91 uL, 0.782 mmol) in THF (3 mL) at -20 C. The mixture was slowly warmed up to room temperature and stirred at this temperature until LCMS indicate the reaction was complete. The reaction mixture was cooled to 0 C and quenched with Sat. NH4C1.
The reaction mixture was extracted with EtOAc and the organic layer was dried with Na2SO4 and concentrated to afford crude product 4. HPLC-MS tR = 1.81 Min (UV
254nm). Mass calculated for M+ 624.3, observed LC/MS m/z 625.3(M+H).
`
SEM NH
N- N N
N\ O N~ N O
H~ N --~ HN
TN N ~ N
S
N
O
-- O \--4N HCI in dioxane (1 mL) was added to crude compound 4 (17mg, 0.027 mmol) at 0 C. The mixture was warmed to room temperature and stirred at this temperature until LCMS indicate the reaction was complete. Concentration and purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound.
HPLC-MS
tR = 1.14 Min (UV 254nm). Mass calculated for M+ 494.2, observed LC/MS m/z 495.2(M+H).
By essentially the same procedure, compounds given in Column 2 of Table 9 can be prepared.
LCMS
Example Column 2 MW MH+ LCMS
MS tR
m/z H
N.N
~ j 51-1 HN "~~ 524.1 525.1 1.09 N
S
0 k--/s N- I N
'-r-N
51-2 "ly)' N<- 478.2 479.2 1.32 HN N
s N
O ~
H
N-~ "
~N \
51-3 H~N ~ 490.2 491.2 1.35 N
i S
N
O
/ ~ / ~
HOzC S CO2H HOZC S NHBOC
A solution of thiophene-2,5-dicarboxylic acid (2.73 g, 15.84 mmol), diphenylphosphoryl azide (3.41 mL g, 15.84 mmol) and triethylamine (4.4 mL, 31.68 mmol) in tert-butanol (80 mL) was heated at refluxing 5h. The reaction mixture was cooled to room temperature and then concentrated to afford the crude title compound.
HPLC-MS tR =1.52 Min (UV 254nm). Mass calculated for M+ 243.0, observed LC/MS
m/z 244.1(M+H).
O
Et3N (1261.6 uL, 9.05 mmol) was added at 0 C to a mixture of 5-tert-Butoxycarbonylamino- thiophene-2-carboxylic acid (550 mg, 2.26mmol), EDCI
(1086 mg, 5.65 mmol) , and piperidine (447 uL, 4.52 mmol) in DMF (6ml). The reaction mixture was warmed up to room temperature and stirred at this temperature ovemight.
The mixture was diluted with EtOAc, washed with brine (2X), dried over Na2SO4 and concentrated to afford crude residue. Purification by Biotage afforded compound 2 (368 mg, 53%). HPLC-MS tR =1.89 Min (UV 254nm). Mass calculated for M+ 310.1, observed LC/MS m/z 311.2(M+H). HPLC-MS tR =2.4 Min (UV 254nm).
~ 1N C'-\ JJ.-NHBOC N N
HZ
S O O
Compound from Example 53 (90 mg, 0.29 mmol) was stirred in 20% TFA / CH2CI2 solution (5 mL) at room temperature for 1.5 hrs. The reaction mixture was concentrated to afford compound 3. The crude product was used without further purification. HPLC-MS tR =1.16 Min (UV 254nm). Mass calculated for M+210.0, observed LC/MS m/z 211.1(M+H).
SEM
SEM N,N
N-N I
Y~\N
+ ~N \ N\
\ NHZ ~N
ON S NN ~
HN
0 SO2Me s ~
O No A solution of crude material from Example 54 and sulfone (98.0 mg, 0.241 mmol) in DMF (2 mL) was treated with NaH (60% dispersion in oil, 29.0 mg, 0.725 mmol) at room temperature. The mixture was stirred until LCMS indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford crude product 4. Purification by Biotage afforded the title compound (82 mg, 63%). HPLC-MS tR = 2.30 Min (UV 254,1m).
Mass calculated for M+ 537.2, observed LC/MS m/z 538.2(M+H).
SEM SEM
; - ; , N "I -N
N Y-I-- N N-N
HN HN
S /
N No O
To a solution of the amide (47.6 mg, 0.089 mmol) in dichloromethane (5 mL) was added lithium aluminum hydride (39.9 mg, 1.0 mmol) and ethyl ether (1 mL). The reaction mixture was stirred at room temperature for 10 min then refluxed at until LCMS indicate the reaction was complete. The reaction was cooled to room temperature and quenched with H20 (0.5 mL). The reaction was diluted with dichloromethane, dried over Na2SO4 and concentrated to afford crude title compound.
HPLC-MS tR = 1.52 Min (UV 254nm). Mass calculated for M+ 523.2, observed LC/MS
m/z 524.2 (M+H).
SEM H
\r N
N_ N
HN _ HN
S / S
No No 4N HCI in dioxane (2mL) was added to crude compound from example 56 at 0 C.
The mixture was warmed to room temperature and stirred at this temperature until LCMS
indicate the reaction was complete. Concentration afforded crude title compound.
Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR = 0.91 Min (UV 2Wm). Mass calculated for M+ 393.1, observed LC/MS m/z 394.1 (M+H).
By essentially the same procedure, the compounds in Table 10 were prepared.
LCMS
Example Column 3 MW MH+ HPLC MS
m/z tR
N-N
57-1 ~" \ 411.1 412.1 1.05 YN
HN ~
S ~
N~~
~JS
N-N
57-2 ~N 381.1 382.0 0.88 ~N
HN
S I-/N /-H
N-N
57-3 ~" 461.1 462.1 1.08 Y'N
HN
S /~
N ) H
N'N
~~Nl \
NY`N
57-4 HN 491.1 492.1 1.41 OH
N-N
/ N
57-5 N~N 421.2 422.0 1.04 HN
S
N
H
N, 57-6 ~" 437.2 438.3 1.20 N
HN O-S
No H
N'N
\ I
~N \
57-7 N~N 409.1 410 1.00 HN
SIN
OH
s~ s~
N N
H3CN H3C` N
N~N Nl,'J'-N
To a solution of 8-methanesulfonyl-6-methyl-3-thiazol-2-yl-imidazo [1, 2-a]
pyrazine (0.070 g; 0.24 mmol) and 5-amino-3-carbomethoxy-isothiazole (0.039g;
0.25 mmol) in dimethyl formamide (DMF; 0.8 mL) was added sodium hydride (NaH; 60%
in oil; 0.024 g). The reaction mixture was stirred at room temperature for 0.5 hr and then quenched with saturated aqueous solution of ammonium chloride (NH4CI). Diluted with more water and filtered. The filter cake was washed with water and hexanes. The filter cake was dried in vacuo to obtain the title compound as yellow solid (0.078 g;
87%). ' H NMR (400 MHz, DMSO-d6): 8.85 (s, 1 H), 8.42 (s, 1 H), 8.1 (s, 1 H), 7.9 (s, 1 H), 7.65 (s, 1 H), 3.85 (s, 3H) 2.5 (s, 3H). HPLC-MS tR = 4.35 (UV254nm).
Mass Calc.
for C15H12N602S2 372.04; obsd MH+ (LCMS) 373.2 (m/z).
s~ s~
- N - N
N H3C5;"'_N\
H3C-Ir N~N N (Y1'N
~
HN~O H N
A solution of lithium triethylborohydride (Super Hydride; 1 M in THF; 0.32 mL) was added dropwise to a solution of the methyl ester (0.03 g; 0.08 mmol) in dry THF
(0.8 mL). After stirring at room temperature for 1.5 hr, the reaction mixture was quenched with saturated aqueous NH4CI solution (8 mL) and diluted with water.
Small amount of the precipitated yellow solid was filtered and washed with water and ether.
The solid was dried in vacuo to obtain -10 mg (36%) of the alcohol. 'H NMR
(400 MHz, DMSO-d6): 8.8 (s, 1 H), 8.4 (s, 1 H), 8.1 (s, 1 H), 7.9 (s, 1 H), 7.2 (s, 1 H), 5.4 (t, 1 H). 4.5 (d, 2H), 2.5 (s, 3H). HPLC-MS tR = 2.98 (UV254nm). Mass Calc. for C14H12N6OS2 344.05; obsd MH+ (LCMS) 345.2 (m/z).
s~ s~
H3C\ ^N H3C\ N
- N N
NY N NY N
HN O O
S-~OCH3 S-~OCH3 A solution of ester (0.113 g; 0.3 mmol) in DMF (1.5 mL) was treated with NaH
(60% in oil; 0.03 g; 0.76 mmol) followed by 2-(Trimethylsilyl) ethoxymethyl chloride (SEM-CI; 0.1 mL; 0.61 mmol). The reaction mixture was stirred at room temperature for 3 hr and quenched with saturated aqueous NH4CI and water. The precipitated yellow solid was collected by filtration, washed with water and dried. The title compound was obtained as yellow solid (0.142 g; 92%). 'H NMR (400 MHz, CDCI3):
9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.8 (s, 1 H), 7.4 (s, 1 H), 6.65 (s, 2H), 4.0 (s, 3H), 3.78 (t, 2H), 2.65 (s, 3H), 1.0 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 5.98 (UV254nm). Mass Calc. for C21 H26N6O3S2Si 502.13; obsd MH+ (LCMS) 503.3 (m/z).
s s~
H3C\ N H3C_ N
- N - N
NJ,)" N
O NY
Si-,O,-, N N I S-N OCH3 S-OH
A solution of lithium triethylborohydride (Super Hydride; 1 M in THF; 1 mL) was added dropwise to a solution of the methyl ester 2 in dry THF. After stirring at room temperature for 1 hr, the reaction mixture was quenched with saturated aqueous NH4CI solution (8 mL) and saturated aqueous solution of Rochelle salt. The organic product was extracted with dichloromethane (CH2CI2), washed with water and brine.
Concentration in vacuo gave -120 mg (100%) of the alcohol. HPLC-MS tR = 4.22 (UV254nm). Mass Calc. for C20H26N6O2S2Si 474.13; obsd MH+ (LCMS) 475.3 (m/z).
s~ s~
N N
N Nj>'- N
OvN iSi,-,,-,O,-, N ~ CHO
S N OH I S N
Dess-Martin periodinane (0.147 g; 0.35 mmol) was added to a solution of alcohol (0.11 g; 0.23 mmol) in dry THF and stirred at room temperature for 40 minutes. The reaction mixture was diluted with 30 mL of CH2CI2, washed with saturated sodium bicarbonate (NaHCO3) solution, water and dried. Concentration furnished a yellow solid which was re-dissolved in CH2CI2 and filtered. The filtrate was concentrated to obtain 120 mg of crude title compound as a yellow solid which was used as is in the next step. 'H NMR (400 MHz, CDCI3): 10 (s, 1 H), 9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.78 (s, 1 H), 7.4 (s, 1 H), 6.6 (s, 2H), 3.78 (t, 2H), 2.65 (s, 3H), 1.0 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 6.14 (UV254nm). Mass Calc. for C20H24N6O2S2Si 472.12; obsd MH+ (LCMS) 473.3 (m/z).
s~ sN
H3C\ ^N \ H3C~N
- N
(_ ~\ NY `N
NY 'N I
N
~Si~iO~ SN ~ CHO S_N N
I
A solution of aldehyde (0.05 g; 0.1 mmol) and piperidine (0.05 mL; 0.5 mmol) in CH2CI2 (1 mL) was treated with glacial acetic acid (AcOH; 1 drop) and stirred at room temperature (RT) for 3 hr. Solid sodium borohydride (NaBH4; 0.016 g; 0.42 mmol) was added and the reaction mixture was cooled in an ice/brine bath (-5 C) and methanol (0.2 mL) was added dropwise. After stirring at low temperature for 30 minutes, the reaction was quenched with saturated NH4CI and extracted into CH2CI2. The organic extract was washed with saturated NH4CI, water and brine. Removal of solvent gave the crude product which was purified by preparative thin layer chromatography (Prep TLC) using CH2CI2 with 4% CH3OH and 1% ammonium hydroxide. The title compound was isolated as yellow film (25 mg; 45%). 'H NMR (400 MHz, CDCI3):
9.1 (s, 1 H), 8.1 (s, 1 H), 7.98 (s, 1 H), 7.4 (s, 1 H),7.3 (s, 1 H), 6.6 (s, 2H), 3.8 (t, 2H), 3.6 (s, 2H), 2.65 (s, 3H), 2.5 (br-s, 4H),1.7 (br-s, 4H), 1.45 (br-s, 2H), 0.98 (t, 2H), 0.0 (s, 9H).
HPLC-MS tR = 3.82 (UV254nm). Mass Calc. for C25H35N7OS2Si 541.21; obsd MH+
(LCMS) 542.3 (m/z).
sN sN
~~ 1 NY N NYN
N HN
jSI
S-N S-N
A solution of compound from Example 63 (0.013 g; 0.02 mmol) in 0.5 mL of THF was treated with HCI in dioxane (4M; 0.5 mL) and placed in an oil bath at 70 C.
After heating for 30 min, a precipitate formed which dissolved upon adding 0.5 mL of methanol. The reaction mixture was heated at a bath temperature of 70 C for an additional 1 hr. The contents of the reaction were cooled to RT and all the volatiles were removed on a rotary evaporator. The residue was suspended in THF and triturated with ether. The precipitate was collected by filtration, washed with - 10 mL of ether and dried in air (0.5 hr) and in vacuo (16 hr) to furnish 10 mg (93%) of the title compound as a yellow solid. ' H NMR (400 MHz, CD3OD): 9.0 (s, 1 H), 8.3 (s, 1 H), 8.05 (s, 1 H), 7.7 (s, 1 H), 7.25 (s, 1 H), 4.4 (s, 2H), 3.6 (d, 2H), 3.1 (t, 2H), 2.6 (s, 3H), 2.0 (d, 2H), 1.85 (t, 4H), 1.6 (t, 1 H). HPLC-MS tR = 2.96 (UV254nm). Mass Calc. for 411.13; obsd MH+ (LCMS) 412.2 (m/z).
Compounds in the Table 11 were prepared as per above examples:
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
s^1 N
59-1 H3C 344.05 345.2 2.98 N
N
HN
QOH
S
59-2 H'C~~N 343.06 344.2 2.78 NY 'N
HN`
S-NOH
S
N
64-1 i~ ^ 411.13 412.2 2.96 Y'N < J
HNN
S-N
S
N
64-2 H3C " 397.11 398.2 3.11 N N Y'N
HNN
S-N
s-64-3 ~ i~ 413.11 414.2 2.86 Y'N
HNN
S-N
N
64-4 H3C~N 411.13 412.2 2.99 N 7\-J-- N 0 HNN
S-N
s ci \ I
64-5 H'c~N 444.09 445.2 3.29 N\~N 0 HNN
i S-N
$i~O N- N N-N
~ N- N H2N ~O
\ I I~ NJ H3CTl-'N Part B H3CN
H3C\ N NN N 'N
N\/~N Part A HN ~ /~ HIN r )4; NJO I ~ N~/
Part A: Lithium hexamethyldisilazide (1 M in THF; 0.18 mL) was added to an amber solution of 4-morpholin-4-ylmethyl phenylamine (0.013g; 0.068 mmol) and 8-methanesulfonyl-6-methyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1, 2-a]pyrazine (0.025g; 0.061 mmol) in 2 mL of THF at RT resulting in a burgundy solution. After stirring at RT for 20 minutes, the reaction mixture was quenched with saturated aqueous NH4CI solution. The contents were diluted with ethyl acetate and washed with water and brine. The crude material from the organic extract was purified by prep TLC (5% methanol-CH2CI2) to obtain the title compound as pale yellow oil (0.025 g; 80%). 'H NMR (400 MHz, CDCI3): 8 (s, 1 H), 7.9 (d, 2H), 7.85 (s, 1 H), 7.8 (s, 1 H), 7.5 (s, 1 H), 7.4 (s, 1 H), 7.35 (d, 2H), 5.55 (s, 2H), 3.75 (br-s, 4H), 3.7 (t, 2H), 3.5 (br-s, 2H), 2.5 (br-s, 2H), 2.4 (s, 3H), 1.6 (br-s, 2H), 0.95 (t, 2H), 0.0 (s, 9H). HPLC-MS tR = 3.05 (UV254nm). Mass Calc. for C27H37N7O2Si 519.27;
obsd MH+ (LCMS) 520.3 (m/z).
Part B: The compound from Part A (0.025g; 0.048 mmol) was suspended in dry THF
and treated with HCI in dioxane (4M; 1 mL) and heated in an oil bath set to 70 C for 15 minutes when a white precipitate was formed. Methanol was added to dissolve some of the solid and the reaction mixture was continued to be heated for 45 minutes more. After cooling to RT, the volatiles were removed on the rotary evaporator. The residue was suspended in THF and the precipitated solid was collected by filtration, washed with ether and dried in vacuo overnight. The title compound was isolated as a beige solid (14 mg; 78%). All the analogues in Table 12 were similarly prepared.
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
N- N
65-1 H3C~N 389.19 390.2 1.7 NN
HTN
N
N- N
\ I
65-2 H3C -eN \ 389.19 390.2 1.76 NY 'N
HN
/ N
(DO
S
65-3 H3C -J-~"~1N 405.16 406.2 2.38 NY ~N
HN ~
I NJ
N- N
65-4 Br"ro~:.'N 451.11 452.2 2.51 NY 'N
HN
N
N-N
65-5 H3C~N 387.22 388.2 1.85 N'N
H'N N
Na 65-6 H3C~N \ 459.24 460.3 2.03 NY~N
HN I ) aC02Et NN- N
\I
65-7 B~N 437.1 438.2 2.38 NY'N
HN N
N- N
\I
65-8 H3C -1-:-"N 373.2 374.2 1.65 NY 'N
HN N
H
a 65-11 Br~N 452.11 453.3 1.93 NYN
HN I )zz~ rNH
N- N
\ 1 65-12 H3C -10~" N \ 388.21 389.2 1.59 NY'N
HN X~~ rNH
Na 65-13 H3C ~N \ 402.23 403.2 1.51 N`/'N
H~N /
N
N- N
65-14 H3C -rN \ 416.24 417.2 1.54 NII N
HN )~~ ^NJ
I N( f H ~/
N- N
65-15 Br~N \ 467.1 468.3 2.27 N T\/'N
HN I: O
r ^
N- N
65-16 H3C~N 403.21 404.2 1.9 NY N
HN ~ ^O
Nr.J
N-N
65-17 H3CN 390.19 391.2 1.36 NY 'N
HN N
Si'\'O~
I \- N H2N I \ \~N \~N
v `COZCH3 Br /
Br\ N
T1~ N\~N N -N
NY'N 1" I
Part A Part B
SOZCH3 HNI \ HN I \
~ CO CH
2 3 ~ COyCHg Part A: A solution of 4-Amino-2-methyl-benzoic acid methyl ester (0.33 g; 2 mmol;
prepared from commercially available 4-nitro-2-methyl-benzoic acid) and 8-methanesulfonyl-6-bromo-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1 H-pyrazol-4-yl]-imidazo[1, 2-a]pyrazine (0.472 g; 1.0 mmol) was treated with LiHMDS (1M in THF; 2 mL) at RT. The resulting burgundy solution was stirred at RT for 20 minutes and then quenched with saturated aqueous NH4CI solution. Standard work up as described for Example 65 and flash silicagel chromatography (25% EtOAc in CH2CI2) provided the title compound as pale yellow foam (0.48 g; 86%).
NMR (400 MHz, CDCI3): 8.18 (s, 1 H), 8 (d, 1 H), 7.9 (s, 1 H), 7.85 (d, 1 H), 7.78 (s, 1 H), 7.7 (s, 1 H), 7.62 (s, 1 H), 7.58 (s, 1 H), 5.5 (s, 2H), 3.9 (s, 3H), 3.65 (t, 2H), 2.6 (s, 3H), 0.98 (t, 2H), 0.0 (s, 9H). Mass Calc. for C24H29BrN6O3Si 556.13; Obsd MH+ (CI-MS) 557 / 559 (m/z).
Part B: A solution of compound from Part A (0.48 g; 0.86 mmol) in 2 mL of dry THF
was treated with a solution of dimethyl zinc (2M; 4 mL) dropwise. After the effervescence ceased, solid Pd(PPh3)4 was added and the reaction was flushed with nitrogen, fitted with a reflux condenser and heated in an oil bath at 65-70 C.
After 0.5 hr, the reaction mixture had turned from yellow orange to deep red and after 4 more hours, it had become an opaque black. TLC (25% EtOAc- CH2CI2) indicated the formation of a slightly more polar spot. The reaction was cooled to RT, quenched with saturated aqueous NH4CI solution and extracted with EtOAc. Flash silicagel chromatography of the crude material gave the 6-methyl title compound as yellow solid (0.38 g; 90%). NMR (400 MHz, CDCI3): 8.1 (s, 1 H), 8 (d, 1 H), 7.9 (d, 1 H), 7.85 (s, 1 H), 7.8 (s, 1 H), 7.7 (s, 1 H), 7.58 (s, 1 H), 7.4 (s, 1 H), 5.5 (s, 2H), 3.9 (s, 3H), 3.65 (t, 2H), 2.65 (s, 3H), 2.4 (s, 3H), 0.98 (t, 2H), 0.0 (s, 9H). Mass Calc. for C25H32N6O3Si 492.23; Obsd MH+ (CI-MS) 493.11 (m/z).
~ i ~~'O~ ~iiO~ R
N- N N-N N-N
\ I \ I \ I
H3C\ ^N H3C\ ^N H3C\ ^N
N~N N~ 'N N
HN HN HN
[ / ( / N' 1 Part A: Ester was first reduced to the alcohol using LiBEt3H in THF at RT and subsequently oxidized using Dess-Marin periodinane to the aidehyde as described previously. The reductive amination of aldehyde with various secondary amines was carried out provided SEM-protected title compound. Removal of the SEM
protecting group was carried out under conditions described previously. In a similar manner, other tertiary amines listed in Table 13 were also prepared by the similar reaction scheme with the corresponding secondary amines followed by removal of the SEM
protecting group.
Example Structure MW LCMS HPLC
MH+ (m/z) MS tR
N- N
67-1 H3C~N 401.23 402.2 1.87 NY 'N
HN I N
N- N
67-2 H3C~N 403.21 404.2 1.71 NY 'N
HN
I,:,::~
N
N- N
67-3 H3C~N 419.19 420.2 1.95 N T\/'N
HN
I X,,z S
N- N
67-4 H3C -f--"' N 415.25 416.2 2.0 NY
_HNOCQ
NH2 NHCbz r\
N~NN iN
Et0 OEt EtO~OEt The substrate (1 g, 5.07 mmol) was dissolved in THF:H20 (12 mL, 1:1, v/v) and treated with K2C03 (1.4 g, 10.15 mmol) at room temperature. Then benzyl chloroformate (0.79 ml, 5.58 mmol) in THF (2 mL) was slowly added. The mixture was stirred for 16 h. It was diluted with ethyl acetate (25 mL). The two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 25 mL).
The combined organic layer was washed with brine (1 x 30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (SiO2) eluting ethyl acetate-hexane.
NHCbz NHCbz r\
N~N~N
EtO OEt O
The substrate acetal (1.2 g, 3.64 g) was dissolved in acetone (20 mL), and treated with 1 N aqueous HCI (2 mL) at room temperature, and the mixture was stirred for 7 h.
Then acetone was evaporated off, and the residue was diluted with saturated aqueous NaHCO3 (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL).
The combined organic layer was washed with brine (1 x 30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product as solid which was used in the next step without any further purification.
NHCbz NHCbz NH2 r~ r~ I \
ON~ N N~N N~NI~
~ V
The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H (2 eq.) in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
The crude product was hydrogenated in ethyl acetate using 10% Pd/C at 1 atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
NHCbz NHCbz NH2 Part A r~ Part B r~
N\/ N NT N N~N
O N N
Part A: The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
Part B: The crude product was hydrogenated in ethyl acetate using 10% Pd/C at atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
NHCbz NHCbz NH2 /~ Part A 6-~ Part B 6~
N\/ N N~N N~N
N~ N
OJ ~
~O ~O
Part A: The substrate (1 eq.), amine (4 eq.), catalytic AcOH, NaB(OAc)3H in 1,2-dichloroethane was stirred at room temperature for 2 h. Then sodium borohydride (3 eq.) was added and the mixture was stirred for 30 min at which point LC-MS
analysis indicate complete consumption of starting material to product. Then the reaction was quenched with 2N aqueous NaOH, and the mixture was stirred vigorously until two clear layer separated. The organic layer was washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the product.
Part B: The crude product was hydrogenated in ethyl acetate using 10% Pd/C at atmosphere hydrogen pressure. The catalyst was filtered off, and solvent was evaporated under reduce pressure to give the crude product.
N'NSEM N'NSEM N-NH
NHZ
R_ N Part A R_ ~N \ Part B RN
+
N\)-- N N\~N NYl- N
SOZMe RR1 HN CN R' HN I~R' z N, i N-N R2 N RZ
Part A: The substrate (1 eq.) and amine (1.5-2 eq.) was dissolved in DMSO
under argon, and treated with NaH (5 eq., 60% dispersion in oil). After 30 min, LC-MS
analysis indicated complete consumption of starting material. The reaction was quenched by addition of saturated aqueous NH4CI-acetonitrile (1:1, v/v). The two layers were separated, and the aqueous layer was extracted with ethyl acetate.
The combined organic layer was washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give the crude product.
Part B: The substrate was dissolved in 4N HCI in dioxane, and stirred at room temperature for 30 min. The solvent was then evaporated, and the residue was purified by Prep-LC. Conversion to hydrochloride salt afforded the product as solid.
LCMS HPLC MS
Example Column MW MH+ m/z tR
'NH
73-1 N\~N
H 375.4 376.1 0.83 1N ~
N' N
NH
73-2 NN 389.4 390.2 1.05 HN C N fD
N
'NH
73-3 NN 391.4 392.1 0.78 HN
NH
rN
73-4 N~N 361.4 362.2 0.74 HN
~N
'NH
rN
73-5 N\~N
H 375.4 376.2 0.85 iN N
NND
'NH
rN
73-6 N~N 377.4 378.3 0.87 HN C
~N' Part A (~~N~~ Part B Part C N
~ 'N ~ N~N N~N
NYN - NY
HN S HN S
HN S HN I S N I iN \
OH CHO
Part A: By essentially the same procedure as described for Example 1 and 13.
Part B: To a solution of compound from Example 74, Part A (0.16 g, 0.57 mmol) in THF (20 mL) and water (0.025 mL) was added Dess-Martin periodinane (3 equivalents). The resulting solution was stirred at rt for 1.5h at which time LC-MS
analysis indicated the reaction was complete. The reaction mixture was diluted: with dichloromethane (75 mL), washed with water, dried (sodium sulfate) and concentrated. Purification by column chromatography (Si02 10% methanol / DCM) afforded the title compound as a yellow solid 0.08 g (49%). HPLC-MS tR = 1.59 Min (UV 254nm). Mass calculated for formula C13H11 N5OS 285.07, observed LC/MS m/z 286.1 (M+H).
Part C: To a solution of compound from Part B (30 mg, 0.105 mmol, 1 equivalent), 3-methylpiperidine (10 equivalents) in dichloromethane:methanol (5:1) (3 ml) was added acetic acid (1 drop). The resulting solution was stirred at rt for 30 minutes, and then sodium borohydride (8 equivalents) added to the reaction. The reaction mixture was stirred at rt for 1 hour at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. sodium bicarbonate and then extracted with dichloromethane (x2). The combined organic layer was dried (sodium sulfate) and concentrated. Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR = 3.73 Min (UV 254nm). Mass calculated for formula C19H24N6S 368.18, observed LC/MS m/z 369.2 (M+H).
7~N N
Part A
N ` N 0- Ny N
HN g HN S
/N
CHO No Part A: To a solution of compound 1 (30 mg, 0.105 mmol, 1 equivalent), piperidine (10 equivalents) in dichloromethane:methanol (5:1) (3 ml) was added acetic acid (1 drop).
The resulting solution was stirred at rt for 30 minutes, and then sodium borohydride (8 equivalents) added to the reaction. The reaction mixture was stirred at rt for 1 h at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with sat. aq. sodium bicarbonate and then extracted with dichloromethane (x2). The combined organic layer was dried (sodium sulfate) and concentrated.
Purification by Prep-LC and conversion to a hydrochloric salt afforded compound 2.
HPLC-MS tR = 3.47 Min (UV 254nm). Mass calculated for formula C18H22N6S
354.16, observed LC/MS m/z 355.1 (M+H).
SEM
SEM N-N
N-N I
N NaH / DMF/ RT - N
~
NN O 93% HN S`
O
0=S=0 Step A /N
O
O
SEM H
N-N N-N
\ I ~ >~OH
N
H
1) LAH, THF (66%) 3) K2CO3 / 80 C (65%) N7\Ij--N NY)'-N
2) MsCI / Et3N (85%) HN I S N 4) 4M HCI, dioxane (95%) HN ~ SN
Step B ~
Step C ~OH
OMs N
Step A: Sodium hydride (60% dispersion in mineral oil, 6.68 g, 3.40 equiv) was slowly added in one portion to a stirring mixture of compound sulfone (20.0 g, 1.00 equiv) and aminoisothiazole (11.5 g, 1.20 equiv, as HCI salt) in DMF (490 mL) at room temperature (with aid of a room temperature water bath). Reaction was allowed to stir for 1 hour at which time HPLC analysis indicated the reaction was complete.
The reaction was carefully quenched with saturated aqueous sodium bicarbonate (200 mL) and then diluted with water (1 L). This mixture was stirred for 20 minutes at room temperature, and then the resulting precipitate was collected by filtration, washed with water (200 mL), and dried under high vacuum for 16 hours. The resulting waxy solid was dissolved in 1.8 L of 1:1 chloroform : methanol, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (22.3 g, 93%) as a dark yellow solid. 1 H NMR (300 MHz, DMSO-d6) b 12.3 (bs, 1 H), 8.60 (s, 1 H), 8.10 (s, 1 H), 7.88 (s, 2H), 7.59 (s, 1 H), 5.51 (s, 2H), 3.85 (s, 3H), 3.63 (d, J
= 8 Hz, 2H), 2.48 (s, 3H), 0.88 (d, J = 8 Hz, 2H), -0.026 (s, 9H). Mass calculated for formula C21H27N7O3SSi 485.63; observed MH+ (MS) 486.6 (m/z).
Step B: A mixture of compound from Step A (4.27g, 3.73 mmol) was dissolved in mL of THF. The resulting solution was cooled to 0 C and LiAIH4 powder (2.6 g, 68.5 mmol) was carefully added. The cooling bath was removed and the reaction was stirred at RT under a N2 atmosphere for 1.5 hr. The reaction was cooled to 0 C
and carefully quenched by the sequential addition of 2.6 mL of H20; 2.6 mL of 15 %
NaOH
(aq); 7.8 mL H20. After stirring for 10 min, the reaction was filtered through a very thin pad of Celite (rinsing with THF, EtOAc and DCM). Concentration of the filtrate yielded a light yellow solid. Pure alcohol (2.66 g, 66 % yield) was obtained via triturating with MeOH and used directly in Step C.
Step B (Alternative procedure; e.g. Example 76-39): A solution of 4,4-difluoropiperidine hydrochloride (25.1 mg, 0.16 mmol) in THF (2.0 mL) was added NaH (60% dispersion in mineral oil, 12 mg, 0.30 mmol). The mixture was stirred under a N2 atmosphere at room temperature for 10 min, then mesylate (31.4 mg, 0.06 mmol) and Nal (4 mg, 0.03 mmol) were added to the reaction flask. The reaction was heated at 80 C under a N2 atmosphere for 8 hr. The reaction was cooled to room temperature and 15 mL of saturated NH4CI (aq) solution was added. The reaction was diluted with dichloromethane (20 mL) and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 20 mL). The organic phase was washed with 15 mL of saturated NaHCO3 (aq), then brine (15 mL). The organic phase was dried over NaSO4 and concentrated in vacuo. Purification via preparative TLC (10% MeOH/CH2CI2) gave 19.7 mg (60% yield) of the title compound.
Step C: A mixture of compound from Step B (2.40 g, 4.49 mmol), amine (1.57 g, 13.46 mmol), and Nal (63.0 mg, 0.449 mmol) in 45 mL of THF was heated at 80 C for 12 h.
It was diluted with 200 mL of CH2CI2, and washed with 100 mL of saturated aqueous NaHCO3 solution, then with brine (100 mL). The solvent was removed under vacuum.
The residue was purified by flash chromatography eluting with 5% to 10%
MeOH/CH2CI2 to give 1.68 g of the title compound. 'H NMR (400 MHz, CDCI3) b 9.49 (brs, 1 H), 7.89 (s, 1 H), 7.82 (s, 1 H), 7.60 (s, 1 H), 7.49 (s, 1 H), 6.86 (s, 1 H), 5.54 (s, 2H), 3.79 (brs, 3H), 3.67 (t, J = 8.3 Hz, 2H), 3.36 (s, 2H), 2.65-2.80 (m, 2H), 2.50 (s, 3H), 1.11 (s, 6H), 1.02(t, J = 7.1 Hz, 2H), 0.96 (t, J = 8.2 Hz, 2H), 0.01 (s, 9H). To a solution of Sem-protected compound (2.0 g, 3.6 mmol) in 36 mL of MeOH/CH2CI2 (1:1) stirred at 80 C, was added 36 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 30 min. After it was cooled to the room temperature, 120 mL of ether was added. The solid was collected by filtration, washed with ether and dried under vacuum to give 2.0 g of the title compound as its HCI salt form. Mass calculated for formula C20H26N$OS 426.2; observed MH+ (LCMS) 427.2 (m/z).
Using essentially the same procedures as described for Example 76, the following compounds were prepared.
LCMS
Example Column 2 EM MH+ HPLC
m/z MS tR
H
N-N
N1\
NY`
76-1 N I 426.2 427.2 2.28 HN~
S N N--\-O\.-NV
N
76-2 N~N 426.2 427.2 2.21 HN~
S-N N
OH
NV
~N \
76-3 NY-1- N 452.2 453.2 2.26 HN S-N N
\ OH
N' I N
\
N
76-4 N)-)- N 466.3 467.3 2.48 HN--r / --~
S-N N
\ OH
N,N
\ I
N
NY-,-- N 452.2 453.2 2.35 HN^
iS~_ N~--~N
N' I N
N
NN 440.2 441.2 2.39 HN
OH
S-N N~
N' I N
~N \
76-7 NN 438.1 439.1 1.81 HN`
S_N~N OH
H
N'N
N
76-8 N~N 438.1 439.1 1.03 HN` /OH
'(i S-N N
N'N
\ I
N
76-9 N~N 452.2 453.3 1.48 HN O
S_N N =
N' ~ N
N
76-10 NY-1-- N 452.2 453.1 1.48 HN
N' I N
N
NN 452.2 453.3 1.35 HN~^
~S~-N~N
H
NV
N
76-12 N~N 452.2 453.2 1.36 HN~^
~S~-N~-\N
''.
H
4N-~
\
N
76-13 NY'L-- N 452.2 453.2 1.041 HN~
, ~ /--~
S'N N
OH
H
N-N
76-14 N~N 424.2 425.2 1.091 HN,r /~--~
S'N N
/
OH
H
N-~N \
76-15 \ I, N)-,-- N 410.2 411.2 1.048 HN,r /~--~
S-N /N
OH
H
N'N
~N \
76-16 N~N 426.2 427.1 1.16 HN
S-N N~
~
HO O
H
N-N
NY-`~ N
.76-17 HN 476.2 477.3 2.69 S-N
N N
~
H
N-76-18 \ I , ~N \
NY~- N 424.2 425.2 2.15 HN
S-N N--\_O, H
ci ~N \
76-19 NY-,-- N 426.2 427.2 2.21 HN
S-N N-~~
OH
H
N-76-20 ~ N \
NN 412.2 413.1 1.086 HN
S'N N
/ OH
H
N-~
\
N
76-21 N~N 438.2 439.1 1.090 HN,r /~---\
S'N N
/
H
N-N
76-22 NY-,-- N 424.2 425.2 1.162 HN~
~~ /~--~
S-N /N
H
N-~
N
452.2 453.3 1.286 76-23 NY-,-- N
HN
S'N N
/
I
H
N-\I, N
76-24 NYl-- N 424.2 425.2 1.12 HN,, S-N /N.
OEt H
N -N
NY _N
76-25 HN~ 462.2 463.2 2.62 S'N N
O
,N
N-{\
H
N-N
NY-,-- N 452.2 453.2 2.58 HN~
S-NN
b H
N-N
NY)-- N 466.2 467.3 2.74 HN~
S-N
N-~N \
76-28 N)--l- N 438.2 439.2 2.39 HN~
S~- N~--\N -\_ 6 O, H
N-N
Nyl-- N 466.2 467.2 1.553 HN~
/~--~
S'N N
O
H
N-N
NY-,-- N 436.2 437.2 1.16 HN~
S'N N
-O H
H
N-N
76-31 NY-1--- N 438.2 439.1 1.48 HN
S-N N.,,,7 OEt H
4N-~
"e'N
76-32 NYl- N 466.2 467.3 2.62 HN~
/~--~
S'N N
~ OH
H
N-\I' N
76-33 NY-1- N 454.2 455.0 0.910 HN~
~~ /~--~
S'N N
OH
H
N-N
N~
76-34 N 468.2 469.1 1.031 HN~
S'N N
/
O
H
N-76-35 ~N \
N~N 468.2 469.1 1.232 HN~
1' /
S'N N
` OH
H
N-N
76-36 N 354.1 355.2 2.03 N
HN~
1' /
S-N HN-\
H
a N
76-37 N~N 398.2 399.2 1.95 HN~
S-N HN
HO
H
N-~
\
N
76-38 NY)- N 480.2 481.3 2.46 HN
S-N
H
N-^I
\ I' N
N~ N 430.1 431.2 2.64 HN
S-N~-~
qF
F
H
N-N
76-40 N Y _ N 412.2 413.2 2.53 HN~
1S'-NN
F
H
N-N
76-41 NY-,-- N 462.2 463.3 2.99 HN
S-NaCF3 H N-\I, N
76-42 N~N 448.1 449.2 3.33 S-N
H
N-~ N \
76-43 N~N 398.1 399.2 2.41 HN~
S-N N
F
H
N-e N
76-44 Ny),- N 378.1 379.2 2.43 HN~
S-N
H
N-N
76-45 N~N 430.1 431.2 2.45 HN~
S-N~a F
F
H
N-\I, N
N)-)-- N 462.2 463.3 2.62 HN~
S-N~- N
- \
H
N-~
\
N
76-47 N)--1- N 416.1 417.2 2.37 HN
S-N N F
a F
H
N-N
76-48 NY)--- N 424.2 425.2 1.105 HN,~^
, S-N
O
H
N-~
\
N
76-49 N 412.2 413.2 2.48 ~ N
HN~
S~-N~-QF
H
a N 422.1 391.2 2.27 T N
HN
TS-N~HN-\-C F3 H
\i-NT~N
76-51 N)-,-- N 390.1 391.2 2.27 HN
S-NHN-\
r F
F
H
a N
Y _ 76-52 N N 518.1 519.3 3.32 HN
S-N~-\~N-\_CF3 N-N
76-53 NY-,-- N 402.1 403.2 2.39 HN
5-N~- N
~F
F
H
N-~
\
N
76-54 N Y~-- N 398.1 399.2 2.37 HN
S-N
N
H
N-A' \I, N
76-55 NY-1--- N 398.1 399.2 2.37 HN
S-N~- N
F
H
N-N
76-56 Ni-)-- N 444.2 445.2 2.61 HN~ F
'S'-N~HN--&F
H
N-^I
"e'N
76-57 NY-,-- N 448.1 449.2 3.27 HN ~
;CF3 S-N N
"-r \
~N \
N~N
76-58 467.2 468.4 3.90 HN~
S-N N~\
(\_N
H
N-N
N~N
76-59 HN~\ 466.2 467.4 3.59 S-N
S N O
~
/
N
H
N-~N
NY
76-60 N 473.1 474.2 3.67 HN
S-N ~I~\
(\-N). S .O
c~
H
N-\I7~N \
N~
76-61 N 535.2 536.3 4.42 HN~
S-N ON, .O
0 Ph H
N-\
~N \
76-62 N~N 409.1 410.4 3.31 HN~
~S~-N~--~
NH
H
N-\I, ~N
N~
76-63 N 423.2 424.1 3.24 HN
NO
>
N
"-r \
~N \
NN
76-64 HN489.2 490.4 4.64 S-N C) N
F
H
N`
~N \
76-65 N 437.2 438.2 3.45 HN
S-N CN
11--o H
N-N
NY N
76-66 HNy 462.2 463.3 3.17 iI~
S-N N~
~
F O-F
H
N-'-T~N
N)-)-- N
76-67 HN466.2 467.2 3.56 S-N C N HN, H
N-~N \
NY _N
76-68 HN467.2 468.1 3.44 S-N ~1~
-N~
O
~O
H
4N-~
\
~N \
NY _N
76-69 HN473.2 474.3 3.92 ~
S-N ~-~
N
H
\ I.
~N \
76-70 N-)-- N 423.2 424.2 3.38 HN~
S-N C--o N
N-~N \
NY N
76-71 HN477.2 478.2 3.56 S-N N-\-N) ~D
H
"`
~N \
NY
7g_72 N 499.2 500.5 3.91 HN
S-N CN
Ph H
"`
~N \
"Y N
76-73 439.2 440.6 3.14 HN~
S-N CN
OH
H
N-76-74 ~N \
N 384.1 385.1 0.981 HN~
S-NHN-\
`-\OH
H
"`I
\
~N \
76-75 "N 412.2 413.2 0.932 HN~
S-NHN
\ OH
H
"`
370.1 371.2 0.788 76-76 N` N
HN~
1S'-NI HN--\-OH
H
N-~N \
76-77 "~N 422.2 423.3 1.224 HN~
~S-N~-H
N-N
\ I
~N \
"Y)-- N 419.2 420.3 3.69 HN~
S-N~-~
CN
H
N-~N \
"Yl-- N 451.2 452.3 3.46 HN~
S-N
N HAc H
N-~
\
"T~N
"~" 444.1 445.5 3.65 HN~
S-N
(\-~ O
H
N-N
"r)-- " 495.2 496.8 4.63 HN~
~~ /~--~
S-N
qPh NC
H
N-N
NYl-- N
76-82 HN~ 451.2 452.4 3.48 S-N
O
H
H
N-~N \
NY
76-83 N 450.2 451.2 2.81 HN
S-N
H
N-",T~N
N~
76-84 N 437.2 438.2 1.76 HN~
S-N
N-/
H
N-N
\ I
~N \
76-85 N -)'N 452.1 453.2 2.97 HN, S-N I-OH
H
N,N
~N
76-86 N~N 411.5 411.2 2.38 HN~
S-N N
H
N'N
N
76-87 NY-1- N 424.1 425.2 1.09 HN\ ^
~S/-N~HN
HO
H
N'N
I
Nl\
NY`N
76-88 HN 453.2 454.3 0.86 S_N a OH
H
N'N
N
NY`N
76_89 432.1 433.1 1.05 HN
Y~S-- \N
N-N
/
H
N'N
N
76-90 N 429.1 430.2 0.99 HN~ ^
~S~-N~- \N
N
N-N
I
N
76-91 N~N 438.1 439.1 0.97 HN\ ^
S/-~N~
/ N
OH
H
N-N
76-92 NYl-- N 448.1 HN
S- N~N
~/ -CF3 N-N
H3C~
76-93 Nlrt'N 480.2 481.3 3.33 HN
S-N j --\__ \ OEt N-N
NI_ 76-94 N ~ N 462.2 HN
~--~ F3 S-nj H
\ ~r H3C~I N
N'Y N
76-95 HN 444.2 S-N N
\~ F
F
H
a H3C~I N
N'Y
76-96 N 426.2 HN
S-N~aF
H
a N
H3C e INY N
~ 476.2 S-N aCF3 H
N-N
76-98 N yl-- N 436.1 HN
S-N~- N-\
( CF3 H
N-~
\
N
76_99 N N 404.1 Y
HN
S-NHN
F F
H
N-~
\
N
NY N
76-100 HN~ 448.2 S-N
F
HO
H
N-~
\
76-101 N I 490.1 HN
S-N N-\
(\ CF3 H
N-~
\
~N \
76-102 N~ N 478.2 HN\^ OH
~S/-N~N CF3 H
N-~
\
N
NY N
76-103 HN477.2 478.3 1.85 S-N Q
N
H
N
N \
76-104 N N 546.3 Y
HN~
S- N~N
Ph Ph H
N-~
\
N
NY N
76-105 HN ~ 463.2 S-N N
~ N
H
N-~
N
N~N 468.2 HN
S-N~- N
OH
Ph N-~
N
"Y N
76-107 HN -r 476.2 S-N N
N
H
N-N
"yl-- N 423.2 HN
S-N~Q,--NH
H
N-~
~N \
N Y _N
76-109 ""~ 554.2 S-N
OH
H
a N
76-110 N~ N 378.1 379.2 2.43 HN
S-N ~
/
N-N
N
76-111 N~ 408.1 409.2 2.59 T N
HN
S-NHN-\
H
N-N
I N
Nl,'I--N 506.2 507.3 2.59 HN~
S-N N
N-N
H3C"
"yl-- " 484.2 485.3 2.54 HN~
S-N N
COZEt F
H
N-N
\I
H3C\ ^N
76-114 7N::;~- N 382.1 HN\ ^
'S~/-N~N
OH
H
N-N
H3C\ ^N
76-115 ~NYl- N 391.1 392.2 2.01 HN`
S- NN
q CN
H
N- N
H3C\ N
76-116 NYl- N
HN\ ^
~S/-N~N
~q F
N-N
H3C\ ^N
TNY N
HN
S-N N~
L_ I\OMe N-N
\ I
H3C~N
NY'N
76-118 ~ ~~
HN`
S-N N
~q OiPr H
N-H3C\~N
76-119 N 1"\--- N 366.1 HN\^
S-N N
D
N-H3C\^
N 'N
TY N
76-120 h0''467.2 S-N N
CN
H
N
N
Y
76-121 N N 442.2 HN~
~S~- N~- ~N
POH
F
H
N-76-122 NN 380.2 HN~^ =
S- N~- N
~
H
N-~
~
N \
76-123 NN 394.2 HN
S- N~-\N
Et H
N-H3C~N
76-124 "'IY)- N 400.1 HN
S- N~ N
CI
H
N-H3C~N
76-125 "N 444.1 HN
S-N~N
Br H
N-H3C-r,7~N
" N
76-126 HNr-,~~ 467.2 S-N N
F
H
N-H3C~N ~
I"'~N 450.1 HN
S-N~N
OH
H
N-H3C Yl~N
NY N
76-128 HN451.2 S-N N
q QO
Example 76-1: 'H NMR (400 MHz, CD3OD) b 8.24 (s, 1 H), 8.23 (s, 2H), 8.07 (s, 1 H), 7.35 (s, 1 H), 4.57 (d, J = 12.8 Hz, 2H), 3.81 (t, J = 4.8, 2H), 3.57 (q, J =
14.0, 6.8 Hz, 2H), 3.52 (m, 2H), 3.41 (m, 2H), 2.60 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 6.8 Hz, 3H). HPLC-MS tR = 2.28 min (UV 254nm). Mass calculated for formula 426.2; observed MH+ (LCMS) 427.2 (m/z).
Example 76-2: 'H NMR (400 MHz, CD3OD) 6 8.31 (s, 1 H), 8.29 (s, 2H), 7.32 (s, 1 H), 4.88 (d, 1 H), 4.46 (d, J= 16.1 Hz, 1 H), 3.82 (d, J= 12.3 Hz, 1 H), 3.71 (d, J= 12.3 Hz, 1 H), 3.64 (m, 1 H), 2.65 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.31 (t, J =
7.1 Hz, 3H).
HPLC-MS tR = 2.26 min (UV 254nm).
Example 76-3: 'H NMR (400 MHz, CD3OD) 6 8.16 (s, 2H), 8.13 (s, 1H), 7.99 (s, 1H), 7.25 (s, 1 H), 4.72 (d, J = 15.6 Hz, 1 H), 4.53 (t, J = 15.6, 1 H), 3.66 (s, 2H), 3.61 (m, 1 H), 3.40 (m, 1 H), 2.57 (s, 3H), 1.33-0.95 (8H), 1.17 (t, J= 6.8 Hz, 3H).
HPLC-MS tR =
2.26 min (UV 254nm). Mass calculated for formula C20H26N80S 452.2; observed MH+
(LCMS) 453.2 (m/z).
Example 76-4: 'H NMR (400 MHz, CD3OD) 6 8.16 (s, 2H), 8.15 (s, 1H), 8.00 (s, 1H), 7.21 (s, 1 H), 4.95 (d, J= 16.0 Hz, 1 H), 4.35 (d, J= 16.8 Hz, 1 H), 4.07 (d, J= 12.4 Hz 1 H), 3.82 (d, J = 12.8 Hz 1 H), 3.52 (m, 2H), 2.57 (s, 3H), 1.96-1.58 (10H), 1.26 (t, J =
6.8 Hz, 3H). HPLC-MS tR = 2.48 min (UV 254nm). Mass calculated for formula C20H26N80S 466.3; observed MH+ (LCMS) 467.3 (m/z).
Example 76-5: 'H NMR (400 MHz, CD3OD) b 8.28 (s, 1 H), 8.25 (s, 2H), 8.10 (s, 1 H), 7.39 (s, 1 H), 4.65 (d, J = 14.0 Hz, 1 H), 4.52 (d, J = 10.8 Hz, 1 H), 4.24 (d, J = 14.0 Hz 1 H), 3.85 (d, J = 18.0 Hz 1 H), 3.65-3.44 (4H), 2.65 (s, 3H), 1.97-1.58 (6H), 1.29 (t, J =
7.2 Hz, 3H). HPLC-MS tR = 2.35 min (UV 254nm). Mass calculated for formula C20H26N80S 452.2; observed MH+ (LCMS) 453.2 (m/z).
Example 76-6 'H NMR (400 MHz, CD3OD) 6 8.21 (s, 3H), 8.03 (s, 1 H), 7.23 (s, 1 H), 4.38 (d, J = 5.6 Hz, 1 H), 3.79 (d, J = 5.4 Hz, 1 H), 3.63 (d, J = 12.4 Hz 1 H), 3.53 (m, 1H), 3.10 (m, 1H), 2.58 (s, 3H), 1.34 (s, 6H), 0.87 (t, J = 6.2 Hz, 3H). HPLC-MS tR =
2.39 min (UV 254nm). Mass calculated for formula C20H26N80S 440.2; observed MH+
(LCMS) 441.2 (m/z).
Example 76-7: 'H-NMR (400 MHz, CD3OD ) 6 8.33 m (3H), 8.15 s (1H), 7.41 s (1H), 4.80 (d, 2H), 4.15 (d, 2H), 4.06 (d, 2H), 3.62 (d, 2H), 3.58 (m, 1 H), 2.68 (d, 3H), 2.21 (m, 1 H), 1.81 (m , 6H) and 1.45 (s, 3H). HPLC-MS tR =1.80Min (UV 254nm). Mass calculated for formula C21 H26N80S 438.55, observed LC/MS m/z 439.1 (M+H).
Example 76-8: 'H-NMR (400 MHz, DMSO-d6) 6 12.73 bs (1H), 9.2 bs (1H), 8.28 s (2H), 8.09 s (1 H), 8.08 s (1 H), 7.36 s (1 H), 4.71 m (1 H), 4.05 m (1 H), 3.82 m (1 H), 3.63 m (1 H), 3.25 m (2H), 1.97 m (1 H), 1.65 m (6H) and 1.30 s (3H).
Example 76-9: 'H-NMR (400 MHz, DMSO-d6) S 8.28 (1H), 8.25 (2H), 8.08 (1 H), 7.32 (1 H), 4.71 (1 H), 4.08 (1 H), 3.84 (1 H), 3.52 (3 H), 3.46 (1 H), 2.63 (3 H), 2.17 (2 H), 1.87-1.73 (6 H), 1.45 (3 H).
Example 76-10: 'H-NMR (400 MHz, DMSO-d6 ) S 8.28 (1H), 8.25 (2H), 8.08 (1 H), 7.32 (1 H), 4.71 (1 H),4.08(1 H),3.84(1 H), 3.52 (3 H), 3.46 (1 H), 2.63 (3 H), 2.17 (2 H), 1.87-1.73 (6 H), 1.45 (3 H).
Example 76-11: 'HNMR (400 MHz, CD3OD) S 8.20 (s, 2H), 8.14 (s, 1 H), 8.03 (s, 1 H), 7.25 (s, 1 H), 4.48 (d, 1 H), 4.37 (d, 1 H), 3.46 (s, 3H), 2.91-3.60 (m, 6H), 2.62 (s, 3H), 1.40 - 1.89 (m, 4H), 0.92 (s, 3H).
Example 76-12: 'HNMR (400 MHz, CD3OD) S 8.20 (s, 2H), 8.14 (s, 1 H), 8.03 (s, 1 H), 7.25 (s, 1 H), 4.48 (d, 1 H), 4.37 (d, 1 H), 3.46 (s, 3H), 2.91-3.60 (m, 6H), 2.62 (s, 3H), 1.40 - 1.89 (m, 4H), 0.92 (s, 3H).
Example 76-40:1 H NMR (400 MHz, CD3OD) S 8.28 (s, 1 H), 8.25 (s, 2H), 8.10 (s, 1 H), 7.38 (s, 1 H), 4.59 (s, 2H), 3.3-3.9 (m, 4H), 2.64 (s, 3H), 2.3-2.5 (m, 4H).
Example 76-42: 'H NMR (400 MHz, CD3OD) b 8.13 (broad s, 2H), 7.85 (s, 1 H), 7.78 (s, 1 H), 7.15 (s, 1 H), 4.10 (d, J - 14 Hz, 1 H), 3.96 (d, J -14 Hz, 1 H), 3.54-3.66 (m, 1 H), 3.07-3.17 (m, 1 H), 2.62-2.72 (m, 1 H), 2.53 (s, 3H), 1.82-2.21 (m, 4H).
~OH OH
A mixture of iodoethane (52.5 g, 336.5 mmol) and 2-amino-2-methyl-l-propanol (30.0 g, 336.5 mmol) was stirred at 60 C for 15 min. It was diluted with 500 mL of ether, and basified by adding 5 N aqueous NaOH until it reaches pH =10. The organic layer was separated. The aqueous layer was extracted with ether (500 mL X 3). The combined organic was washed sequentially with 100 mL of water, and 100 mL of brine, then dried over anhydrous Na2SO4. The solvent was removed to provide 20 g of the crude product, which was purified by recrystallization in 150 mL of hexanes to give 13 g of a white solid. The solid was further purified by sublimation under reduced pressure to give 12 g of the title compound. 'H NMR (400 MHz, CDCI3) b 3.28 (s, 2H), 2.54 (qt, J = 7.1 Hz, 2H), 1.09 (t, J = 7.0 Hz, 3H), 1.07 (s, 6H).
1. LiAIHa +
HCI. H 2. CbzCI, K2CO3 Cbz Cbz 3. Chiral Separation Peak 1 Peak 2 Step A
Pd(OH)2, H2 C>--O
OH
O
Cbz Step B Cbz Step C H
Peak 1 or Peak 2 Step A: The substrate (10 g) was suspended in THF (200 mL). Then lithium aluminum hydride solution (110 mL, 2M in THF) was slowly added. The mixture was stirred at room temperature for 12 h. The solution was cooled to 0 C, and saturated aqueous Na2SO4 (200 mL) was slowly added. The mixture was filtered through Celite, and filtercake was washed with ethyl acetate (400 mL). The organic layer was washed with water (200 mL) and brine (200 mL). The organic layer was dried (anhydrous Na2SO4), filtered and evaporated to give the amino alcohol (6.9g). The amino alcohol (6.9 g) was dissolved in THF (80 mL) and water (80 mL) at room temperature. The potassium carbonate (14.76 g) was added. Then benzyl chloroformate (8.28 mL) in THF (40 mL) was added dropwise. The mixture was stirred at room temperature for 30 min.
Solvent was evaporated off under reduced pressure, and ethyl acetate (100 mL) was added.
Two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with brine (200 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography. The racemic aminoalcohol was chirally separated by SFC HPCL method. Then enatiomers corresponding to peak 1 and peak 2 were separately taken forward to prepare the corresponding building blocks.
Step B: The alcohol from Step A (1.936 g) was dissolved in dichloromethane (80 mL), and treated with proton sponge (8.32 g) at room temperature. Then trimethyloxonium tetrafluoroborate (5.69 g) was added. The mixture was stirred for 1 h. The reaction was quenched with saturated aqueous ammonium chloride solution (100 mL). The two layers were separated, and the aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layer was washed sequentially with hydrochloric acid (200 mL, 1 N), saturated sodium bicarbonate solution (200 mL), brine (200 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography.
Step C: The enantiomerically pure methyl ether from Step B in EtOH was treated with Pd(OH)2 on carbon (20% wt) and stirred in hydrogen atmosphere at atmospheric pressure at room temperature for 2 h. The mixture was filtered off, and the filtrate was evaporated under reduced pressure to give the amine.
1. LDA, THF; Mel 1. NaH, Mel, DMF
JOEt OH O
N 2. LiBHEt3 N 2. 20% TFA/DCM N
i i Boc Step A Boc Step B
1. CBZCI, K2CO3 20% Pd(OH)2 2. Chiral Separation N,, O N O- N O-~ Step D H
Step C Cbz Cbz Step A: At -78 C, ester (6359 mg, 24.7 mmol) in THF (50m1) was added dropwise to LDA (1.8 M in THF, 27.5 ml, 49.4 mmol) in THF (200m1). The reaction mixture was slowly warmed up to room temperature and stirred at that temperature overnight. The reaction was cooled to 0 C and quenched with saturated NH4CI solution. The mixture was diluted with H20 and extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (6221 mg, 93%). LCMS tR =2.27 Min.
Mass calculated for, M+ 271.1, observed LC/MS m/z 216.1 (M+H-C4H8). To a solution of ester (4659 mg, 17.2 mmol) in THF (300 ml) was added LiBHEt3 (69 ml, 1 M in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding saturated NH4CI. The mixture was extracted with CH2CI2. The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (3032mg, 77%). LCMS tR =1.82 Min. Mass calculated for, M+ 229.1, observed LC/MS m/z 174.1 (M+H-C4H8).
Step B: NaH (1324 mg, 60% dispersion in mineral oil, 33.1 mmol) was added portion wise to a mixture of compound from Step A and Mel (3.3 ml, 52.9 mmol) in DMF
(66 mL) at 0 C. The reaction mixture was slowly warmed up to room temperature and stirred at that temperature ovemight. The reaction was cooled to 0 C and quenched with saturated NH4CI solution. The mixture was diluted with H20 and extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the title compound (2633 mg, 82%). LCMS tR =2.32 Min. Mass calculated for, M+ 243.1, observed LC/MS m/z 188.1 (M+H-C4H8). A solution of compound 4 (901 mg, 3.71 mmol) was stirred in 20 % TFA in CH2CI2 (20 mL) at 0 C for 30 min and then room temperature for 15 min. The reaction mixture was concentrated. The crude residue was used for example without further purification. LCMS tR =0.26 Min. Mass calculated for, M+
143.1, observed LC/MS m/z 144.1 (M+H).
Step C: CbzCl (604 ul, 4.08 mmol) in THF (1 ml) was added to a mixture of compound from Step B and K2CO3 (1125 mg, 8.15 mmol) in THF (20 ml) and H20 (20 ml) at 0 C.
After stirring at room temperature for 30 min, the reaction mixture was extracted with EtOAc (x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. Purification by column chromatography afforded the titlte compound (965mg, 94%). LCMS tR =2.28 Min (UV 254nm). Mass calculated for, M+ 277.1, observed LC/MS m/z 278.1 (M+H). The title amines were chirally separated utilizing a Gilson GX-281 liquid handling system with HPLC capabilities. Separation was accomplished with the following conditions: Chiral Technologies Chiral PAK AD
column (5 x 50 cm; 20 p); flow = 50 mUmin; 7.5% isopropanol in hexanes (isocratic);
observed at 210 nm.
Step D: The enatiomerically pure isomers from Step C were dissolved in (1 mmol, 277 mg) in EtOH (6 ml) was mixed with 20% Pd(OH)2 (51 mg) and stirred under H2 balloon at room temperature for 2h. Filtration through celite and concentration afforded the title compound, which was used for next step without further purification.
LCMS tR
=0.26 Min. Mass calculated for, M+ 143.1, observed LC/MS m/z 144.1 (M+H).
SEM SEM H
- N,N
-" \N \~
N N 2N HCI, dioxane N
N N\~N N~N
StepA
T Step B HN SHN SHN SI/ O`R
~OH ~ ~OR ~
N\-- N~
\--Step A: The parent compounds were prepared from Example 76-2 using acid chlorides, acids, ureas and isocyanates using standard reaction conditions.
Step B: Sem-protected material from Step A was dissolved in 1,4-dioxane (1 mL) and treated with 4 N HCI in 1,4-dioxane (1 mL). then heated at 60C for 1 hr.. The mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC and conversion to the hydrochloride salt afforded the title compound as a colorless solid.
Using essentially the same procedures as described for Example 80, the following compounds were prepared.
LCMS
HPLC
Example Column 2 MW MH MS tR
m/z H
N-N
80-1 N N 468.2 469.3 2.62 HN , I /
N ~
~O 0 H
N-N
80_2 N N 510.3 511.3 3.12 HN g~
N
-rO O
H
N-AI
\ I , N
Y
80-3 N N f 496.2 497.3 2.98 HN S, /
N
~O O
H
\ `I
N
N Y N
80-4 496.2 497.3 2.98 HN S, y L /
N
-rO O
H
N-AI
~N \
80-5 N N 482.2 483.3 2.82 Y
HN S.
/
N ~
rO O
H
N-AI
\ , N
NY N
80-6 ' 494.2 495.3 2.83 HN S~
I
N
~O O
H
N -\ , N
Y
80-7 N N f 530.2 531.3 3.34 HN S~
i N
~O O
H
N-AI
N
N Y N
80-8 I 508.2 509.3 3.03 HN gI
N
-rO O
H
N-\I, N
N~
N 510.3 511.3 3.08 HN gI
N
C o H
N-\I' N
N~
N
80-10 525.3 526.3 2.21 HN S~
N
~O O
H
a N
~
80-11 N N 508.2 509.3 2.87 HN g~
I
N
-rO 0 H
N-~
\
N
80-12 N N 509.2 510.3 1.85 HN gI
-rO O
H
a ~N \
80-13 N N 525.3 526.3 2.37 HN g~
,,,NH2 I /
N
-rO 0 H
N-~
\
N
80-14 N N 539.3 540.3 2.86 Y
HN SI
,,,NH2 N
~O O
H
N
\
N
N~N 550.3 551.3 3.56 HN gI /
N
-rO O
H
N-^I
\ I , N
80-16 N N 497.2 498.3 2.65 Y
HN gI
\N~
N
~O O
H
a N
Nll)'-N 536.3 537.3 3.27 HN gI /
N
--rO 0 H
N-N
~
80-18 N N 522.3 523.3 2.98 HN SI
N
-rO O
H
N-N
80-19 N N 483.2 484.2 2.25 Y
HN SI
~NH2 N
,rO
H
N'N
~N \
N N
80-20 HN ~_\ 539.3 540.3 2.65 S-N
ol-~~
H
N-I N
~N \
NY N
80-21 HN` 557.2 558.2 2.53 S-N
O
SMe H
N'N
N
N Y _N
yf- -~ 573.3 574.2 2.74 i S-N
Ph H
N
N \
N N
80-23 HN 523.2 524.2 2.38 S-N
N
H
N-N
~N \
NY N
80-24 HN 497.2 498.3 2.29 S-Nl~
H
'N
N
NN
80-25 HN ~ 511.2 512.3 2.28 ~N~
S~-O
H
N
~N \
NY N
80-26 HN 484.2 485.3 2.77 S-N
~
Olp I
H
N-N
~N \
NY N
80-27 HN 512.2 513.3 3.03 S-Nh H
N-N
~N \
NY N
498.2 499.3 2.65 'S-NI~ ~
Ol H
N-N
N
NY N
HN 551.3 554.3 1.98 80-29 ~ /
S-N
N
c ) O
H
N-\f.
N
N Y _N
HN S 540.3 541.3 3.21 S-N \ O~
H
N-N
~N \
NY N
\ 511.2 512.2 3.32 80-31 HN Yl S-N
pINH
~
H
~N \
NY _N
HN
80-32 S_ N 563.2 564.2 3.36 pINH
F
H
N-N
~N \
N Y _N
80-33 HN S 583.3 584.2 3.52 o HN o O
O
H
N'N
N
NY N
80-34 HN531.2 532.2 2.99 S-N
p I ~N
H
N-~N \
N Y N
80-35 HN s, 569.2 570.2 3.16 iN `
N/\ O
~OH
~N
O ' O ~
H
N'N
N
NY
80-36 HN N 664.4 665.3 6.22 S-Nl~
p )14 H
N-N
N
NY N
80-37 HN 497.2 498.2 3.09 S-Nh pINH
H
~N \
NY N
80-38 HN r ~/ 511.2 512.2 3.32 S-N
pINH
H
N \
N Y N
HN
80-39 S N 525.3 526.2 3.56 pINH
H
N-~N \
NY N
80-40 HN 525.3 526.2 3.53 S-Nl~
pl NH
H
'N
\ I
N
NY N
80-41 HN 576.2 577.3 3.29 S-N
CF
SEM
SEM N' N
H2N N NaH / DMF/ RT ~N \
N
~
NY'~-N O O Step A HN S,0==0 \ ~ ~N
I O
O\
SEM H
N- -1) LAH, THF N 1) amine, K2CO3 / 80 C 5:P'N
NN NN
2) MsCI / Et3N
HN S2) 2N HCI, dioxane HN S.
Step ' p Step C
C0Ms NRZ
Step A: The starting sulfone was prepared by essentially the same procedure described in Example 6 except that ethylboronic acid or cyclopropylboronic acid was used. Final products listed in Table 17 were obtained by using the procedures described for Example 76.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N-\I' N
81-1 N N 440.2 441.2 1.21 Y
HN
I
N
/r0H
H
N-\ I, N
N ~ _N
81 _2 HN 440.2 441.2 1.29 I/
N
O --\
H
N-\ I , N
81-3 N Y~- N 422.2 423.1 1.26 HN g~
/
N
H
N-\ I, N
NY
81-4 N I 424.2 425.2 1.29 HN g~
~ k N
H
\ `I
N \
81-5 NY-,-- N 436.2 437.2 1.34 HN g~
~ N
N
H
\~r N
81-6 N~N 492.2 493.3 3.34 HN
, /N
N OH
H
\~r N \
81-7 N~N 478.2 479.3 3.17 H N
, /N
N OH
H
N`
N \
81-8 NYl-- N 494.2 495.3 2.93 HN IgO
/N
N OH
H
N`
N
81-9 NY-1--- N 434.2 435.3 3.08 H N g~
, /N
N
H
\ `I
N
81-10 N~N 408.2 409.3 2.86 HN g~ N
N
~
H
N-N
81-11 N N 422.2 423.3 2.97 HN g~
N
N
H
N-~ f.
N
81-12 N N 434.2 435.3 3.07 Y `
HN g, N
N
H
N-N
81-13 N N 436.2 437.3 3.12 ~
HN
/N
N
-A~
H
N'N
~ N \
~
81-14 N N 432.2 433.3 2.98 HN S~
, /
N
H
\~r N
81-15 N N 452.2 453.3 2.97 HN S~
E / N
N
HO\~
H " \
N-\ f' N
N Y _ 81-16 N 452.2 453.3 3.15 HN g~
T N - /O
N
H
N-N
81-17 NY-1- N 434.2 435.3 3.07 HN S~ / N
N
H
\~r N \
81-18 N Y ' N 448.2 449.3 3.29 HN gI N
N
~
H
N`
N
NY_ 81-19 N 478.2 479.3 3.35 HN g~
t N
N
<N. ,SEM N, ,SEM <JNH
N N Step A ~N \ Step B ~N \
NY-1--- N NN --~ N` N
HN N~T SNHNY S~
~ ~N ~ ~N y ~N
R
OMs NH
Step A: The title compound was prepared using as described for Example 7 except that t-butylamine was used.
Step B: To a solution of the product of Step A (1 equivalent) in THF (3 mL) was added DIEA (3 equivalents), and the respective trifilate (1.2 equivalents) at room temperature. The reaction was heated at reflux until consumption of starting material was observed by LC-MS analysis. The solution was cooled to room temperature and concentrated under reduced pressure. Purification by column chromatography (Si02, 30% ethyl acetate/dichloromethane) afforded the desired coupled intermediate.
This material was dissolved in 1,4-dioxane, HCI (4N in dioxane) was added and the mixture was sonicated until such time that HPLC indicated no starting material remained. The mixture was concentrated under reduced pressure, purified by prep-HPLC, and conversion to the hydrochloride salt afforded the title compounds as off-white solids in Table 18.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
tNH
H3C\ ^N
101-1 N 464.2 465.1 5.22 HN S
f IN
N
k N'NH
H3C\
N
101-2 S 446.2 447.2 4.09 HNT IN
N, , SEM N, , SEM N-~ N N NH
N Step A 5:;'N \ Step B N
NY-- N NY-`N NY N
HN ' H N ' HN SI IN I IN N
OMs SCH3 S02CH3 Step A: Sodium thiomethoxide (39 mg, 3.00 equiv) was added to a stirring mixture of mesylate prepared in example 7(100 mg, 1.00 equiv) and sodium iodide (14 mg, 0.50 equiv) in DMF (6 mL) at room temperature. The resulting mixture was allowed to stir for 2.5 hours at which time LC-MS analysis indicated the reaction was complete. The reaction was quenched with saturated aqueous sodium bicarbonate (30 mL) and then extracted with dichloromethane (2 x 70 mL). The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford the title compound as a yellow solid, 100 mg (>99%).
Step B: m-Chloroperbenzoic acid (66 mg, 2.05 equiv) was added to a stirring solution of compound from Step A (91 mg, 1.00 equiv) in dichloromethane (3 mL) at room temperature. The mixture was allowed to stir for 2 hours at which time thin layer chromatography indicated the reaction was complete. The mixture was diluted with ethyl acetate (40 mL) and then washed with saturated aqueous sodium bicarbonate (15 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. This material was dissolved in 1,4-dioxane, HCI (4N in dioxane) was added and the mixture was sonicated until such time that HPLC indicated no starting material remained. The mixture was concentrated under reduced pressure, purified by prep-HPLC, and conversion to the hydrochloride salt afforded the title compound as an off-white solid, 18 mg (27%). 'H NMR (300 MHz, DMSO-d6) S 12.19 (s, 1 H), 8.24 (s, 2H), 7.96 (s, 1 H), 7.83 (s, 1 H), 7.28 (s, 1 H), 4.61 (s, 2H), 3.01 (s, 3H), 2.53 (s, 3H). HPLC tr = 4.04 min (UV 254nm). Mass calculated for C15H15N702S2 389.1; observed MH+ (MS) 390.7 (m/z).
/ F Step A c(0,N11IIII) F Step BO / I F S~p C F
--' ~ S N -~ H2N S I N
SEM SEM H
SEM \ -\~r 1 Step D~N \ Step E N Step F~N
N_ 1\N N
+ ~N \ -- N~N NN N
Y ` HN ~ HN
S02Me S/ F S/ F HN ~/ F
NNo S No Step A: EtN(iPr)2 (10.55 mL, 60.69 mmol) was added at 0 C to acid (2953 mg, 20.23 mmol, prepared according to Bioorganic & Medicinal Chemistry, 11(20), 4333-4340;
2003), EDCI (5817 mg, 30.34 mmol), HOBT (4100 mg, 30.34 mmol) and piperidine (2398 uL, 24.28 mmol) in DMF (100 mL). After stirring at room temperature overnight, the crude reaction material was diluted with EtOAc and washed with brine (2X).
The organic layer was dried over Na2SO4, filtered, and concentrated to give the crude product which was chromatographed to give the product amide. HPLC-MS tR =1.57 Min (UV 254nm)=Mass calculated for formula, M+ 213.0, observed LC/MS m/z 214.1 (M+H).
Step B: Powdered KNO3 (1100.8 mg, 10.89 mmol) was added portionwise to a stirred solution of amide (927.6 mg, 4.356 mmol) in conc. H2SO4 (20 mL) at 0 C. After stirring at 0 C for 30 min, the reaction mixture was poured onto ice. Extraction with and the combined organic lawyer was washed with H20, dried over Na2SO4 and concentrated. Purification by column chromatography afforded first the undesired nitration product 545.5 mg (48.5%), HPLC-MS tR = 1.79 Min (UV 254nm)= Mass calculated for M+ 258.0, observed LC/MS m/z 259.1(M+H),'HNMR (400 MHz, CDCI3) 6 7.58 (d, 1 H, J = 0.4 Hz), 3.67 (m, 4H), 1.73 (m, 6H), then the desired nitration product 435.6 mg (38.8%), HPLC-MS tR = 1.68 Min (UV 254nm). Mass calculated for M+
258.0, observed LC/MS m/z 259.1(M+H).1 H NMR (400 MHz, CDC13) 6 8.37 (d, 1H, J
= 3.2 Hz), 3.67 (m, 4H), 1.71 (m, 6H).
Step C: To a solution of nitroamide (435.6 mg, 1.69 mmol) in HOAc (20 mL) was added iron powder (471.5 mg, 8.44 mmol). The reaction mixture was heated at 70 C
for 30 min. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added 30mL of 20% MeOH/CH2CI2 followed by 20 mL of saturated aqueous NaHCO3. The mixture was stirred until it stoped bobbling.
The mixture was extracted by EtOAc (x 2), dried over Na2SO4, and then concentrated. The crude amine was used for displacement reaction without further purification.
HPLC-MS tR = 1.32 Min (UV 254nm). Mass calculated for M+ 228.0, observed LC/MS m/z 229.1(M+H).
Step D: A solution of crude amine from Step C (491.5 mg, 2.156 mmol) and sulfone (292 mg, 0.719 mmol) in DMSO (10 mL) was treated with NaH (60% dispersion in oil, 172.5 mg, 4.312 mmol) at room temperature. The mixture was stirred until LCMS
indicated the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated to afford crude product 4. Purification afforded compound 4. HPLC-MS tR = 2.503 Min (UV 254nm). Mass calculated for M+ 555.2, observed LC/MS m/z 556.3(M+H).
Step E: To a solution of the amide from Step D (120 mg, 0.216 mmol) in dichloromethane (12 mL) was added lithium aluminum hydride (86.4 mg, 2.162 mmol) and ethyl ether (3 mL) at 0 C. The reaction mixture was stirred at room temperature until LCMS indicate the reaction was complete. The reaction was quenched with (86 uL), 3N NaOH (86 uL) and H20 (264 uL). The reaction was filtered and concentrated to afford crude compound 5. HPLC-MS tR = 1.738 Min (UV 254nm).
Mass calculated for M+ 541.2, observed LC/MS m/z 542.2 (M+H).
Step F: 4N HCI in dioxane (3mL) was added to crude product from Step E at 0 C.
The mixture was stirred at room temperature until LCMS indicated the reaction was complete. Concentration afforded crude product. Purification by Prep-LC and conversion to a hydrochloric salt afforded the title compound. HPLC-MS tR =
0.923 Min (UV 254nm). Mass calculated for M+ 411.1, observed LC/MS m/z 412.2 (M+H).
H
N-\
N
N~/ N
HN -~/
S
N
By essentially the same procedure given in Example 84, the title compound can be prepared. HPLC-MS tR = 1.005 Min (UV 254nm). Mass calculated for M+ 425.1, observed LC/MS m/z 426.2 (M+H).
SEM
N-NEM
~ IJV /N
A / ~ I+ B c OZN I IO HZN _O N ~ -- N\~N
II S~ T
SO2Me O
O
SEM SEM NEM
N-D I` F
N N
~ ---- N~N E - NY-,--N - N
H N ~ H N HN _ N~N
S/ S HN ~
OH O Na F S / ^
}-F
Step A: To a solution of nitroester (2285 mg, 12.22 mmol) in HOAc (55 mL) was added iron powder (6825 mg, 122.20 mmol). The reaction mixture was heated at 75 C for 10 min. The mixture was cooled to room temperature and then added 200 mL of MeOH. The resulting mixture was filtered through celite (the celite was rinsed with additional amount MeOH). The filtrate was concentrated to remove most of AcOH. To the residue was added 50 mL of 20% MeOH/CH2CI2 followed by saturated aqueous NaHCO3 until it stoped bubbling. The mixture was extracted by EtOAc (x 2), dried over Na2SO4, and then concentrated. The crude amine was used without further purification. HPLC-MS tR = 1.07 Min (UV 254,m). Mass calculated for M+
157Ø0, observed LC/MS m/z 158.1(M+H).
Step B: To a solution of the aminoester (850 mg, 5.414 mmol)) and sulfone from Example 1 (1 equivalent, 1469 mg, 3.609 mmol) in DMSO (36 mL) was treated with NaH (60% dispersion in oil, 14.43 mmol, 577 mg) at room temperature portionwise.
After 10 min, LC-MS analysis of the reaction indicated the reaction was complete.
While cooling by water bath, the reaction was quenched with sat. NH4C1 dropwise (5 ml) and then added H20 (160 ml) extracted with ethyl acetate (2x). The combined organic layers were washed with brine and dried (sodium sulfate). Evaporation and purification by column chromatography (0 to 100% EtOAc/Hexane) afforded title compound (1492 mg, 85%). HPLC-MS tR = 2.41 Min (UV 254nm). Mass calculated for M+ 484.1, observed LC/MS m/z 485.2 (M+H).
Step C: To a solution of the product of Step B (206 mg, 0.4271 mmol) in THF (8 mL) was treated with DIBAL (1.0 M in CH2C12, 2.56 mL) at -78 C dropwise. After stirring at -78 C for 4.5h, LCMS indicated the existence of small amount of starting material..
Two more equivalents DIBAL (0.85 mL) were added. After stirring at -78 C for another 0.5 h, brine (6 mL) was added portionwise at -78 C to quench the excess reagents.
The reaction mixture was extracted with CH2CI2 (3X). Evaporation of solvent and purification by column chromatography (0 -> 100% 2% MeOH in EtOAc/Hexane) afforded alcohol (153 mg, 79%). HPLC-MS tR = 2.01 Min (UV 254nm). Mass calculated for M+ 456.1, observed LC/MS m/z 457.1 (M+H).
Step D: To a solution of alcohol from Step C (537 mg, 1.17 mmol) in THF (26 mL), was added H20 (0.078 mL) followed by Dess-Martin periodinane (599 mg, 1.41 mmol) at 0 C. The reaction was stirred at room temperature until LCMS
indicated the reaction was complete. The reaction mixture was diluted with CH2CI2, and washed with saturated aqueous NH4CI solution. The organic was dried over anhydrous Na2SO4 and then concentrated. Purification by column chromatography afforded aldehyde (237.1 mg, 44%). HPLC-MS tR = 2.15 Min (UV 254nm). Mass calculated for M+ 454.1, observed LC/MS m/z 455.1 (M+H).
Step E: To a mixture of aldehyde (94 mg, 0.21 mmol) and 4-fluoropiperidine hydrochloride (58 mg, 0.41 mmol) in DCE (10 mL) was added DIEA (144 uL, 0.828 mmol), followed by NaBH(OAc)3 (139 mg, 0.62 mmol). The reaction mixture was stirred at room temperature ovemight and then diluted with CH2CI2, and washed with saturated NaHCO3 solution. The organic was dried over anhydrous Na2SO4 and then concentrated. The crude product was used without purification for next step.
HPLC-MS tR = 1.57 Min (UV 254,1m). Mass calculated for M+ 541.2, observed LC/MS m/z 542.2 (M+H).
Step F: 4N HCI in dioxane (5mL) was added to crude amine at 0 C. The mixture was stirred at room temperature until LCMS indicated the reaction was complete.
Concentration and purification by Prep-LC the title compound. HPLC-MS tR =
0.89 Min (UV 254nm). Mass calculated for M+ 411.1, observed LC/MS m/z 412.1 (M+H).
H
N -\ I , N
NY _N
HN ~
S ~
Na F
F
By essentially the same procedure as Example 86, the title compound can be prepared. HPLC-MS tR = 0.97 Min (UV 254nm). Mass calculated for M+ 429.1, observed LC/MS m/z 430.1 (M+H).
H
N- N
N
NY N
HNI l S F N F
By essentially the same procedure as Example 86, the title compound can be prepared. HPLC-MS tR = 0.99 Min (UV 254nm). Mass calculated for M+ 443.1, observed LC/MS m/z 444.1 (M+H).
SEM SEM SEM SEM
-~' Br B
~/~N N c F / N
T~` l- N N -)- N N N N Y-,-- N
N Y
SMe SMe SMe SOZMe SEM SEM
N-~ F
a N F
+ H2N ~ D N` ~ E - F NN ---S~COZMe ~ N HN
N HN
-COZMe ~
S-N S_N OH
SEM H
F a F F N \ G N
N\/ N N~N
HiN HN
S-N OMs S N N
Part A: A mixture of 6-bromo compound (4562 mg, 10.39 mmol), PdCl2dppf (424.3 mg, 0.519 mmoL), Cul (296.9 mg, 1.56 mmol) and tributyl(1-ethoxyvinyl)tin (5617 uL, 16.627 mmol) in CH3CN (100 mL) was refluxing until LCMS indicate the reaction was complete. 1 N HCI (15 mL) was added and the mixture was stirred until LCMS
indicate the conversion to ketone. The reaction mixture was diluted with EtOAc, washed with sat NH4C1, dried with Na2SO4, and concentrated. Purification afforded ketone (3200 mg, 76%). HPLC-MS tR = 2.32 Min (UV 254nm)= Mass calculated for M+ 403.1, observed LC/MS m/z 404.2 (M+H).
Part B: Bis(2-methoxyethyl)aminosulfur trifluoride (2745 uL, 14.89 mmoL) was added dropwise to ketone from Part A (600 mg, 1.489 mmoL) in CH2CI2 (1 mL) at 0 C.
The mixture was stirred at room temperature for 1 week and then carefully added dropeise to Sat NaHCO3 solution. The mixture was extracted with CH2CI2 and the organic layer was dried over Na2SO4, and concentrated. Purification afforded di-fluoro compound.
HPLC-MS tR = 2.52 Min (UV 254nm). Mass calculated for M+ 425.1, observed LC/MS
m/z 426.2 (M+H).
Part C: m-CPBA (1515.7 mg, 6.76 mmoL) was added to a solution the product of Part B (1307 mg, 3.07 mmoL) in CH2CI2 (31 mL). After stirring at room temperature for 2h, the reaction mixture was diluted with EtOAc, washed with sat NaHCO3, dried with Na2SO4, and concentrated. The sulfone (5-A) was used directly without further purification. HPLC-MS tR = 2.17 Min (UV 254nm). Mass calculated for M+ 457.1, observed LC/MS m/z 458.0 (M+H).
Part D: To a solution of the aminoisothiazole (400 mg, 2.53 mmol) and sulfone from Part C (964 mg, 2.11 mmol) in DMF (13 mL) was treated with NaH (60% dispersion in oil, 4.64 mmol, 186 mg) at room temperature. The mixture was stirred until LCMS
indicate the reaction was complete. The reaction mixture was diluted with EtOAc, washed with sat NH4CI, dried with Na2SO4, and concentrated. Purification afforded the displacement product (438.5 mg, 39%). HPLC-MS tR = 2.22 Min (UV 254nm).
Mass calculated for M+ 535.1, observed LC/MS m/z 536.1 (M+H).
Part E: To the solution of ester (406.5 mg, 0.759 mmol) in THF (39 mL) was added LiBHEt3 (3.79 mL, 1 M solution in THF). The reaction was stirred at room temperature for 30 min. It was quenched by adding saturated aqueous NH4CI (15 mL). The mixture was extracted by 30 mL of CH2CI2. The organic was concentrated and the crude alcohol was used for next step without further purification. HPLC-MS tR
= 1.99 Min (UV 254nm). Mass calculated for M+ 507.1, observed LC/MS m/z 508.1 (M+H).
Part F: To a solution of crude alcohol from Part E in THF (40 mL), was added triethylamine (365 uL, 2.62 mmol) and methanesulfonylchloride (173 uL, 2.23 mmol).
The reaction was stirred at room temperature for 30 min. It was quenched by adding MeOH. The solution was diluted by 30 mL of CH2CI2, washed consecutively with mL of 2 N aqueous HCI, water, and brine. The solvent was removed under vacuum to give crude mesylate which was used in next transformations without further purification. HPLC-MS tR = 2.35 Min (UV 254nm)= Mass calculated for M+ 585.1, observed LC/MS m/z 586.1 (M+H).
Part G: A mixture of crude compound (30mg, 0.051 mmol), 3-methyl piperidine (24 uL, 0.205 mmol), EtN(iPr)2 (54 uL, 0.307 mmol) and Nal (1 mg) in THF (2ml) was heated at 80 C for 1 h and 10 min. The mixture was cooled dot room temperature and then concentrated. 4N HCI in dioxane (3mL) was added to crude displacement product at 0 C. The mixture was stirred at room temperature until LCMS indicated the reaction was complete. Concentration and purification afforded compound 5-1. HPLC-MS tR
=
1.27 Min (UV 254nm). Mass calculated for M+ 458.1, observed LC/MS m/z 459.1 (M+H).
By essentially the same procedure given in Example 89, the compounds listed in Table 19 can be prepared.
Table 19 LCMS MH+ HPLC
Example Column 2 MW m/z MS tR
H
N'N
F F
N_ \
89-2 N~IN 444.1 445.1 1.20 HN~ ^ ~
'(S~-N~- 0 H
N'N
F F
i I N_ 89-3 N~IN 458.1 459.1 1.26 HN S-N
N- I N
F F
~N
89-4 NY-,-- N 502.2 503.2 1.18 HN` ^
S-NN
OH
H
N' I N
F
N
89_5 Nl,)'-N 516.2 517.2 1.23 HN` ^
NQ OH
H
N' I N
F F
~N
89_6 NY-,-- N 502.2 503.2 1.36 HN S-N ~~J -O-l H
N'N
F F
NI_ 89-7 N~N 432.1 433.1 1.19 HN~ ^
S(~ N~- \N--\
H
N'N
F F
N
89-8 NY-1- N 518.1 519.1 1.20 HN O
i S-N N
\ HO
H
N' I N
F F
i I N
89-9 N~ N 446.1 447.1 1.22 HN~
S`N N-~
H
N' ~ N
F F
~ I N
NY-1--- N 472.1 43.2 1.34 HN
S-N~--\N
N-N
F F
, N
NN 476.1 477.1 1.19 HN~
S N N-~
p \,-H
N' I N
F F
N
89-12 NY-1--- N 456.1 457.1 1.13 HN~ ^
~S~-Nk-\N
H
N' I N
F F
~N
89-13 N~N 476.1 477.1 1.06 HN~ pH
S NN-Y
H
N' I N
F F
j~N
89-14 N~N 460.1 461.2 1.13 HN~ ^
S(~~N~N4L
H
N'N
F F
N
89-15 NN 458.1 459.2 1.26 HN\ ^
~S/-N~N
SEM SEM SEM SEM
- N-r `~' \ -N
~
N Step A ~N \ Step B ~N \ Step C- N
I _ -- - 1/
NN NY'L-- N N~N NN
SEM"N 1/ SEMN SEM"N i SEM"N
~S-NOMs S-N CN S_NH2 S-OH
Step A: To a solution of mesylate (1.1 g, 1.65 mmol) in DMSO (20 mL) at room temperature was added Nal (280 mg, 1.88 mmol) and NaCN (300 mg, 6.12 mmol).
The mixture was stirred at 60 C for 1 h. It was diluted with 200 mL of EtOAc and washed with water (200 mL X 2). The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 60% EtOAc/hexanes) to afford 980 mg of the title compound. 'H NMR (400 MHz, CDCI3) b 7.90 (s, 1 H), 7.82 (s, 1 H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.20 (s, 1 H), 6.61 (brs, 2H), 5.56 (s, 2H), 3.88 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 2.53 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.07 (s, 9H).
Step B: A solution of compound from Step A (530 mg, 0.889 mmol) in 30 mL of CH2CI2 was cooled to 0 C. To this was slowly added DIBAL-H solution (1 M in CH2CI2, 3.56 mL, 3.56 mmol). The reaction was stirred at 0 C for 20 min. It was quenched with 1 mL of MeOH, and the resulting solution was stirred at room temperature with 50 mL of saturated Rochelle salt solution for 2 h. The organic layer was isolated and the solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 10% 7N NH3 in MeOH/ CH2CI2) to give 450 mg of the title compound. 'H NMR (400 MHz, CDCI3) 6 7.90 (s, 1H), 7:83 (s, 1H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.05 (s, 1 H), 6.65 (brs, 2H), 5.55 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 3.16 (t, 2H), 2.95 (t, 2H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step C: A solution of compound from Step B (400 mg, 0.667 mmol) and NaOAc (400 mg, 4.88 mmol) in 20 mL of AcOH was stirred at 60 C. To this was slowly added t-butyl nitrite (1.40 mL, 11.8 mmol). The reaction was stirred at 60 C for 20 min. It was cooled to room temperature and added 20 mL of CH2CI2. The solid was filtered off, and the solvent in the filtrate was removed under vacuum. The residue was diluted with 100 mL of CH2CI2 and washed with 50 mL of saturated NaHCO3 aqueous solution. The organic portion was concentrated. The residuw was dissolved in 10 mL
of MeOH. To this solution was added a solution of NaOH (200 mg) in 1 mL of water.
After stirred at room temperature for 30 min, it was diluted with 100 mL of CH2CI2 and washed with 100 mL of brine. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 75% EtOAc/hexanes) to give 240 mg of the title compound. ' H NMR (400 MHz, CDCI3) b 7.90 (s, 1 H), 7.81 (s, 1 H), 7.63 (s, 1 H), 7.58 (s, 1 H), 7.05 (s, 1 H), 6.65 (brs, 2H), 5.57 (s, 2H), 4.03 (t, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 3.01(t, 2H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
SEM SEM SEM H
, \ , N, \ -N- r N St--~~N Step Step N \ ~N NN
N N N~ ~ N
HN
SEM"N SEM i/ SEM"N
S'N OH S-N OMs 1-N N S SN
S
Step A: To a solution of Example 90 (200 mg, 0.333 mol) in 10 mL of THF, was added NEt3 (84 mg, 0.830 mmol) followed by methanesulfonyl chloride (76.4 mg, 0.667 mmol). The reaction was stirred at room temperature for 20 min. It was quenched by adding 10 mL of water and diluted with 50 mL of CH2CI2. The mixture was washed with 20 mL of 0.5 N aqueous HCI solution. The organic was dried over anhydrous Na2SO4. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 70% EtOAc/hexanes) to give 180 mg of the title compound.
Step B: A mixture of mesylate from Step A (42 mg, 0.062 mmol), thiomorpholine (16 mg, 0.16 mmol), K2CO3 (8.5 mg, 0.062 mmol) and a trace amount of Nal in 1.5 mL
of THF was stirred at 80 C for 24 h. It was cooled to room temperature. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 5% 7 N NH3 in MeOH/CH2CI2) to give 37 mg of the title compound. 'H NMR
(400 MHz, CDCI3) b 7.88 (s, 1 H), 7.81 (s, 1 H), 7.64 (s, 1 H), 7.57 (s, 1 H), 7.05 (s, 1 H), 6.64 (brs, 2H), 5.55 (s, 2H), 3.75 (t, 2H), 3.65 (t, 2H), 2.64-3.08(m, 8H), 2.52 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
Step C: To a solution of product from Step B (37 mg, 0.054 mmol) in 2 mL of THF/MeOH (1:1) stirred at 80 C, was added 0.5 mL of 4 N HCI in dioxane solution.
The reaction was stirred at 80 C for 30 min. It was cooled to room temperature and diluted with 2 mL of THF and 1 mL of ether. The solid was collected by filtration and washed with ether to give 26 mg of the title compound as its HCI salt form.
HPLC-MS
tR = 2.21 min (UV 254nm). Mass calculated for formula C19H2ON$OS 426.1;
observed MH+ (LCMS) 427.2 (m/z).
By essentially the same procedure set forth in Example 91 only replacing thiomorpholine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 20 were prepared.
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z H
N' I N
\
91-1 NN 410.5 411.2 1.95 N
HN ~
S N
N \-j N-N
91-2 N\ N 396.5 397.2 2.38 ~N
HN ~
S-N N
H
N' I N
91-3 N N 408.5 409.2 2.51 N
HN
N No N- I N
\
N
91-4 NY-,-- N 426.5 427.2 2.29 HN
NNo N' I N
~N \
91-5 Yl- N OEt 440.6 441.2 2.52 HN
S- N ~NJ
/
H
NV
~N \
91-6 NY-,-- N 424.6 425.2 2.60 HN
S-NJJJ
N, I N
N
91-7 NY-1-- N 422.5 423.2 2.46 HN ~
S- N
H
N' ~ N
~N \
91-8 N~N 476.5 477.3 2.62 HN ~~_ /~ \_N~CF
SN
SEM SEM H
SEM
% N, Y Y
'r \ N Step AN Step B N N
"
N St ~
N _~
- N ~ " " N
NyL- N
" SEM~N SEM-" HN Y
SEM" Z CHO S_ N Br SN O S-N O
S-" Br ON N
Step A: To a solution of carbon tetrabromide (170 mg, 0.512 mmol) in 4 mL of stirred at 0 C, was added PPh3 (267 mg, 1.02 mmol). The reaction was stirred at 0 C for 15 min when the aidehyde (200 mg, 0.341 mmol) was added. The resulting solution was further stirred at 0 C for 15 min. It was quenched with 10 mL of saturated NaHCO3 aqueous solution. The mixture was extracted by 20 mL of CH2CI2.
The aqueous phase was further extracted by CH2CI2 (10 mL X 2). The combined organics were concentrated and further purified by column chromatography (Si02, 50% EtOAc/hexanes) to give 150 mg of the title compound.
Step B: A stirred solution of compound from Step A (40 mg, 0.054 mmol) and pyrrolidine (30 mg, 0.43 mmol) in 0.6 mL of DMSO and 0.15 mL of water was stirred at 100 C for 3 h. It was cooled to room temperature and diluted with 15 mL of CH2CI2. The content was washed with water, saturated aqueous NaHCO3 and brine sequentially. The organic was concentrated and purified by column chromatography (Si02, 3.5% 7 N NH3 in MeOH/ CH2CI2) to give 20 mg of the title compound. 'H
NMR
(400 MHz, CDCI3) b 7.88 (s, 1 H), 7.81 (s, 1 H), 7.64 (s, 1 H), 7.57 (s, 1 H), 7.18 (s, 1 H), 6.62 (brs, 2H), 5.55 (s, 2H), 3.90 (s, 2H), 3.75 (t, 2H), 3.67 (t, 2H), 3.45-3.62 (m, 4H), 2.52 (s, 3H), 1.35-1.63 (m, 6H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step C: A solution of compound from Part B (20 mg, 0.029 mmol) in 1 mL of THF
and 2 mL of TFA was stirred at 60 C for 2 h. The solvent was removed under vacuum.
The residue was dissolved in 2 mL of THF. To the stirred solution was added 1 mL of 1 M HCI in ether.The solid was collected by filtration and washed with ether to give 10 mg of the title compound as its HCI salt form. HPLC-MS tR = 2.55 min (UV
254nm).
Mass calculated for formula C19H2ON80S 408.2; observed MH+ (LCMS) 409.2 (m/z).
By essentially the same procedure set forth in Example 92, only replacing pyrrolidine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 21 were prepared.
LCMS
HPLC
Example Column 2 MW MH+
MS tR
m/z N- I N
N
92-1 N`~N 422.5 423.2 2.83 H~N' n S N No H
N-I N
N
92-2 Nyj'-N 436.5 437.2 3.15 HN
S N N~
O
N-I N
N
92-3 NN 410.5 411.2 2.82 HN
S-N N
O
H
N-I N
~N \
92-4 N\ ~N 440.5 441.2 2.92 H~N' ~
_ S
S N N
O
H
N
92-5 N \ ~ \ 424.1 N
HN 5:
SN
SE
H
SEM
%
SE N, \ '~1 `
N'~v ~ ~N N
N Step A I N Step B' N, Step C N\~N
N~ ~ -- N Y_ N `r ~N I I
SEM"N i HN ~
SEM"N1/\ SEMN1/\ /
S_N
S'N N
/
S'N Br bo S'N OMs .
Step A: To a solution of mesylate (560 mg, 0.841 mmol) in 16 mL of acetone was added LiBr (730 mg, 8.41 mmol). The mixture was stirred at room temperature for 1.5 h. It was diluted with 100 mL of CH2CI2 and washed with brine (100 mL). The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 506 mg of the title compound. 6 7.88 (s, 1 H), 7.81 (s, 1 H), 7.65 (s, 1 H), 7.58 (s, 1 H), 7.30 (s, 1 H), 6.70 (brs, 2H), 5.57 (s, 2H), 4.55 (s, 2H), 3.78 (t, 2H), 3.68 (t, 2H), 2.56 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step B: To a solution of compound from Step A (40 mg, 0.061 mmol) in 1.5 mL of THF, was added 2-tri-n-butylstannylpyridine (45 mg, 0.12 mmol), and Pd(PPh3)4 (17 mg, 0.015 mmol). The reaction was stirred at 80 C in a sealed vial for 16 h.
The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 3% 7 N NH3 in MeOH/ CH2CI2) to give 32 mg of crude title compound contaminated by triphenylphosphine oxide. This material was used in Step C without further purification.
Step C: The product of Step B was dissolved in 2 mL of MeOH/THF (1:1) at 80 C. To this solution was added 0.5 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 30 min. It was cooled to room temperature and diluted with 1 mL of THF.
The solid was collected by filtration and washed with THF and ether to give 15 mg of the title compound as its HCI salt form. 6 8.8(d, 1 H), 8.86 (t, 1 H), 8.10 (s, 3H), 7.92-8.08 (m, 3H), 7.22 (s, 1 H), 4.60 (s, 2H), 2.58 (s, 3H). HPLC-MS tR = 2.00 min (UV
254nm).
Mass calculated for formula C19H16N8S 388.1; observed MH+ (LCMS) 389.2 (m/z).
By essentially the same procedure set forth in Example 93, only replacing 2-tri-n-butylstannylpyridine with other respective stannyl reagents in Step B, compounds shown in column 2 of Table 22 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N' I N
N
93-1 NY-,-- N 402.1 HN TN, N
H
N' ~ N
N
93-2 NY-,-- N 402.1 HN ~
/
S-N
N
H
N' I N
N
93-3 NY-,-- N 402.1 HN
S-N
N
H
N' ~ N
N
93-4 N N 402.1 HN
S-N
N
H
N-N
93-5 Nl,),-N 418.1 HN ~
/ OMe S-N N/ ~
H
N' I N
\
N
93-6 N N 418.1 HN ~
/
S-N N/
OMe H
N-N
~N \
93-7 N~N 418.1 HN
/
S-N
OMe H
N' I N
N
93-8 N N 418.1 HN
S-N
N
MeO
H
N-N
93-9 N~N 406.1 HN
/
S-N N/ \
F
H
N'N
\ I
N
93-10 N~N 466.1 HN
/
S-N
Br H
N'N
~N \
93-11 N~N 422.1 HN
/
S-N
CI
H
N' N
N
93-12 Nyl-- N 406.1 HN ~N/ F
S- / ~
N
H
N'N
N
93-13 NN 466.1 HNS-~
/ r N
N
H
N'N
N
93-14 N 422.1 / CI
HNS-~
N
N
H
N'N
N
93-15 N ~ N 431.2 HN ~
/
S-N N/ ~
NMe H
N-I N
N
93-16 NY-1-- N 404.1 HN ~
S-N O +~ \
~-N
SEM SEM SEM
\~r N-r N-r N Step A ~N Step B N
~
N
NY-L--N N)--1-N N
SEM"N SEM"N SEM"N ~ OH
CHO S- ~ S- /
N N N
MeS
SEM SEM H
N-N ~
o I
N Step C ~N \ Step D N
I' NN
NN NN
T 7 HN SMe SEMN OH SEM"N i SMe r /
S- / S_ S'N N
N N N
MeS
Step A: To a mixture of 10 mL of THF/DMF (1:1)was added NaH (39.3 mg, 1.64 mmol). It was cooled to -10 C and a solution of trimethylsulfonium iodide (334 mg, 1.64 mmol) in 5 mL of DMSO was then slowly added. To the resulting mixture was added aldehyde. The reaction was stirred at room temperature for 40 min. It was quenched with ice water, and diluted with 50 mL of CH2CI2. The mixture was washed with water and brine. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 390 mg of the title compound. 6 7.90 (s, 1 H), 7.82 (s, 1 H), 7.67 (s, 1 H), 7.59 (s, 1 H), 7.10 (s, 1 H), 6.80 (brd, 1 H), 6.56 (brd, 1 H), 5.57 (s, 2H), 4.02-4.10 (m, 1 H), 3.78 (t, 2H), 3.69 (t, 2H), 3.07-3.25 (m, 2H), 2.58 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.08 (s, 9H).
Step B: A solution of compound from Step A (270 mg, 0.450 mmol) in 4 mL of DMF
was treated with sodium methanethiolate (100 mg, 1.43 mmol). The reaction was stirred at room temperature for 30 min. It was diluted with 15 mL of water.
The mixture was extracted with EtOAc (20 mL x 3). The combined organics were washed with brine (20 mL) and then concentrated. The residue was purified by column chromatography (Si02, 70% EtOAc/hexanes) to give 220 mg of the title compound.
7.90 (s, 1 H), 7.82 (s, 1 H), 7.65 (s, 1 H), 7.58 (s, 1 H), 7.21 (s, 1 H), 6.76 (brd, 1 H), 6.56 (brd, 1 H), 5.57 (s, 2H), 4.94 (m, 1 H), 3.40-3.80 (m, 5H), 2.80-3.15 (m, 2H), 2.58 (s, 3H), 2.12 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
Step C: To a solution of compound from Step B (30 mg, 0.046 mol) in 1 mL of THF, was added NEt3 (14 mg, 0.14 mmol) followed by methanesulfonyl chloride (16 mg, 0.14 mmol). The reaction was stirred at room temperature for 15 min. It was quenched by adding 2 mL of water and diluted with 15 mL of CH2CI2. The mixture was washed with 10 mL of 0.2 N aqueous HCI solution. The organic was dried over anhydrous Na2SO4 and then concentrated. The residue was treated with Nal (10 mg, 0.071 mmol) and piperidine (13 mg, 0.15 mmol) in 1 mL of THF. The resulting mixture was stirred at 80 C for 12 h. It was diluted with 15 mL of CH2CI2 and washed with 15 mL of saturated aqueous NaHCO3 solution. The solvent was removed under vacuum, and the residue was purified by column chromatography (Si02, 3% 7 N NH3 in MeOH/
CH2CI2) to give 12 mg of the title compound.
Step D: To a solution of compound from Step C (12 mg, 0.017 mmol) in 1 mL of THF/MeOH (1:1), was added 0.5 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C for 1 h. It was cooled to room temperature and diluted with 10 mL of ether.
The solid was collected by filtration and washed with ether to give 8 mg of the title compound as its HCI salt form. HPLC-MS tR = 2.88 min (UV 254nm). Mass calculated for formula C21H26N$S2 454.2; observed MH+ (LCMS) 455.3 (m/z).
By essentially the same procedure set forth in Example 94, only replacing piperidine with other respective aliphatic amines in Step B, compounds shown in column 2 of Table 23 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
N- N
94-1 N 440.6 441.2 2.57 N T\l-- N
HN ~
S_\' N ~--SMe N- N
94-2 N 468.6 469.3 2.83 N\~N
HTN N
S N SMe By essentially the same procedure set forth in Example 94, only replacing sodium methanethiolate with sodium benzenethiolate in Step A, and employing the respective aliphatic amines to replace piperidine in Step B, compounds shown in column 2 of Table 24 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MStR
H
N' N
95-1 N ^ 516.7 517.3 3.23 NN ~ 1 HTN ` J
S_ N SPh H
N' I N
95-2 N 502.6 503.3 3.09 N T\'t-- N ~
HN ~
S_\~ N ~SPh H
N' ~ N
95-3 N 530.7 531.3 3.23 YN
HN N
S N SPh SEM SEM
N \`r `
N
N \ ~ ~ \
NyL-- N NY~'-N
SEM-N SEM-N OH
~CHO
S'N S'N SO2Me A stirred solution of dimethylsulfone (281 mg, 2.99 mmol) in 5 mL of DMF was treated with sodium t-butoxide (287 mg, 2.99 mmol) at room temperature for 5 min.
Aldehyde was then added. The reaction was stirred at room temperature for 15 min.
It was quenched with saturated aqueous NH4CI solution (5 mL). The mixture was diluted with 50 mL of water and extracted with 50 mL of EtOAc/hexanes (1:1), followed by 25 mL of EtOAc. The combined organic phase was washed with brine and then concentrated. The residue was purified by column chromatography (Si02, 50% EtOAc/hexanes) to give 270 mg of the title compound. b 7.90 (s, 1 H), 7.82 (s, 1 H), 7.68 (s, 1 H), 7.60 (s, 1 H), 7.20 (s, 1 H), 6.67 (brs, 2H), 5.55 (s, 2H), 5.34-5.47 (brs, 1 H), 3.90-3.98 (brs, 1 H), 3.78 (t, 2H), 3.68 (t, 2H), 3.10 (s, 3H), 2.58 (s, 3H), 0.95 (m, 4H), 0.02 (s, 9H), -0.10 (s, 9H).
By essentially the same procedure set forth in Step B and Step C in Example 96, compounds shown in column 2 of Table 25 were prepared.
LCMS
Example Column 2 MW MH+ HPLC
m/z MS tR
H
N' N
N
96-1 N~N 472.6 473.3 2.23 HN N
Me S N SO
O
N'N
N
96-2 N` ~N 0 486.6 487.3 2.62 HN N
Me S_N S O
O
N' N
N
"N ~ 500.6 501.3 2.75 96-3 N\' N
HN
Me S_N SO
SEM SEM SEM H
`~' -~' ` ~~ `N
ci ci N Step A N Step B N Step N
N N N N NN N~N
HN
SEMN SEM"N~, I CHO SEM'N i/ _ / /r S
S-N OH S-N S-N RN-R2 N R`~-R2 , ~
The compounds shown in column 2 of Table 24 were prepared according to the above reaction scheme and employing the following general procedures.
Step A: To a stirred solution of compound alcohol (1.00 g, 1.70 mmol) in 20 mL
of THF, was added Dess-Martin periodinane (1.84 g, 4.26 mmol) and a trace amount of water. The reaction was stirred at room temperature for 40 min. It was diluted with 200 mL of-CH2CI2, and washed with water and brine. The organic was dried over anhydrous Na2SO4. The solvent was removed under vacuum. The residue was purified by column chromatography (Si02, 40% EtOAc/hexanes) to give 250 mg of the title compound.
Step B: To a solution of compound from Step A (0.05 mmol) in 1 mL of CH2CI2/MeOH
(1:1) was added the respective amine (5 equivalent) and a trace amount of trifluoroacetic acid. The mixture was stirred at room temperature for 30 min when NaBH4 (10 equivalent) was added. The stirring was continued for additional 10 min.
The reaction was quenched with saturated aqueous NH4CI solution. The mixture was extracted with CH2CI2. The organic was concentrated and the residue was purified by column chromatography (Si02, 5% 7 N NH3 in MeOH/ CH2CI2) to give title compound.
Step C: To a solution of compound from Step B(0.05 mmol) in 1 mL of THF/MeOH
(1:1), was added 1 mL of 4 N HCI in dioxane. The reaction was stirred at 80 C
for 30 min. It was cooled to room temperature and diluted with 10 mL of ether. The solid was collected by filtration to afford compound 97-1 and 97-2, respectively.
LCMS
Example Column 2 MW MH+ HPLC
MS tR
m/z H
N'N
CI \ I
N
97-1 N~N 428.9 429.2 2.63 HN~
S-N~-~N
H
N'N
CI \ I
N
97-2 NY-1- N 446.9 447.2 2.68 HN\
~S/-NN
F
SEM SEM
N CH3MgBr N Et3N / MsCI
~ THF/RT N THF
SEMN H Part A SEMN ~/
Part B
R
SEM Part C N`
\~r \
1)R1R2N/THF/A N
N
2) 4N-HCI- Dioxane NY N
RN
SEMN~~^ Part D 10-3 (R = SEM) ~
S,N N.R
S-N OMs YX (R = H) R2 Part A: To a solution of the isothiazole-aldehyde (534 mg; 0.9 mmol) in anhydrous THF (9 mL) was added methyl magnesium bromide (3M; 1.8 mL) at room temperature. After stirring for 20 min, the reaction mixture was quenched with 5 mL of saturated aqueous NH4CI solution and diluted with CH2CI2. The organic layer was washed with water and brine. The aqueous layer was back extracted with CH2CI2.
The combined organic layers were dried over sodium sulfate and concentrated to obtain the crude product. Flash silica gel chromatography (EtOAc: CH2CI2 = 2:1) gave the desired carbinol as a white solid (460 mg; 84%) along with unreacted aidehyde (50 mg). 'H-NMR (CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H); 7.55 (s, 1 H);
7.1 (s, 1 H);
6.75-6.65 (br-dd, 2H); 5.55 (s, 2H); 4.95 (t, J = 3 Hz, 1 H); 3.8 (t, J = 6 Hz, 2H); 3.7 (t, J
= 6 Hz, 2H); 2.55 (s, 3H); 1.6 (d, J = 3 Hz, 3H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part B: Triethylamine (136mg; 1.35mmol) and methanesulfonyl chloride (88 mg;
0.77 mmol) were added to a solution of the carbinol from Part A (232 mg; 0.39 mmol) in 12 mL of THF at room temperature. After 10 min, the reaction was quenched with water and diluted with CH2CI2. The organic layer was washed with water and brine, dried over Na2SO4_and concentrated to obtain crude product. Rapid elution with CH2CI2:
EtOAc (2:1) from a flash silica gel column gave the desired mesylate as white solid (268 mg; 100%). 'H-NMR (CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H);
7.55 (s, 1 H);
7.3 (s, 1 H); 6.7 (br-s, 2H); 5.85 (q, J = 4 Hz, 1 H); 5.55 (s, 2H); 3.8 (t, J
= 6 Hz, 2H); 3.7 (t, J = 6 Hz, 2H); 2.95 (s, 3H); 2.6 (s, 3H); 1.85 (d, J = 4 Hz, 3H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part C: A solution of the mesylate (40 mg; 0.06 mmol) in 2 mL of anhydrous THF
was treated with hexamethyleneimine (15 mg; 0.15 mmol) plus a catalytic amount of Nal and the mixture was heated at reflux in an oil bath (80 C; 20 h). The reaction mixture was cooled to room temperature and diluted with water and CH2CI2. The organic layer was washed with water, brine and dried over Na2SO4. Concentration in vacuo gave the crude product. Purification was carried out on flash silica gel column, eluting the product with CH2CI2 containing 2-4% of 7N-Ammonia in methanol. The desired di-SEM protected amine product was obtained as a colorless film (31 mg; 75%).1H-NMR
(CDCI3): 7.9 (s, 1 H); 7.8 (s, 1 H); 7.65 (s, 1 H); 7.55 (s, 1 H); 7.3 (s, 1 H); 6.6 (br-s, 2H);
5.55 (s, 2H); 4.0 (br-s, 1 H); 3.8 (t, J = 6 Hz, 2H); 3.7 (t, J = 6 Hz, 2H);
2.8 (br-s, 4H);
2.6 (s, 3H); 1.75-1.5 (m, 11 H); 1.0 (m, 2H); 0.05 (s, 9H); -0.05 (s, 9H).
Part D: To a solution of the above di-SEM protected amine from Part C (31 mg;
0.045 mmol) in 0.2 mL of THF and 0.2 mL of CH3OH was added 4N-HCI in dioxane (0.2 mL). The resulting mixture was heated at 80 C in an oil bath for 30 min and then allowed to cool to room temperature. THF (2 mL) was added to the reaction mixture and the precipitated product was collected by filtration. The filer cake was washed with THF and ether and dried under vacuum to obtain the title product as white solid (23 mg)-By using appropriate Grignard reagents in the first step and appropriate amine in the third step in the procedures described above, all the target compounds listed in Table 1 were prepared and characterized.
LCMS
HPLC
Example Structure EM MH+
MS tR
m/z H
\ `I
N
98-1 N-?- N 422.2 423.2 2.46 HN~ ,~
~~ /~--~
S'N N
H
I
N
98-2 NY-1- N 398.2 399.2 2.06 HN~
S-N HN
HO
H
\ `I
N
N~N 426.2 427.2 2.13 S'N N
~ HO
H
N-~ N \
98-4 N~N 396.2 397.2 2.57 HN~
S-N N--\
H
\ `I
98-5 '-T~N 422.2 423.2 2.74 N~N
HN
S'N N
H
\ `I
N
98-6 N,N 436.2 437.2 2.86 HN ~
S'N N
H
\ `I
N
98-7 N- -N 470.3 471.3 3.01 HN
H
ci N \
98-8 NYl- N 440.2 441.2 2.39 HN~
/
S-N N
EtO
H
\ `I
~N \
98-9 N N 426.5 427.2 2.25 HN~ ~+
~~ /--~
S'N N
F
H
\ `I
N \
~
98-9 Ny N 440.2 441.2 2.35 HN~
S'N N
F
HO DPPA, Et3N, t-BuOH ~ ~
S BocHN
O O O
The substrate (500 mg) was suspended in t-BuOH (30 mL), and Et3N (0.45 mL) and DPPA (0.73 mL) was added sequentially at room temperature. Then the mixture was heated at 85 C overnight. The reaction mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The residue was taken up in ethyl acetate (50 mL) and water (50 mL) was added. The biphasic mixture was stirred for 15 min. Then two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with brine (50 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (SiO2). HPLC-MS tR =
1.70. Mass calculated for CjjH15N03S 241.08; observed MH+ (LCMS) 242.2 (m/z) (UV254nm).
HO ~~ OH ~TU' Et3N HO ~ NQ DPPA, Et3N
S Me(Me0)NH.HCI 'BuOH BOcHN S 11 O O O O O
Part A Part B
MgBr ~ ~ 30% TFA in CH2CI~
BocHN S TFA.HZN
THF-Et20 O
Part D s 0 Part C
N-NSEM N-NSEM N'NH
, DMF 1). Ti(OiPr)4, NaBH4, pip N
NaH
+ \~N \ N Part F
~ ~ N N
_`~
NY N Part E N Y N
I 2). HCI (PartG) HN
SOZMe HN
Part A: Diacid (3 g) was suspended in CH2CI2 (50 mL), and N,O-dimethylhydroxylamine hydrochloride (1.69 g), HATU (6.6 g) and diisopropylethylamine (12.12 mL) was added sequentially at room temperature.
The reaction mixture was stirred overnight, and quenched by addition of water (100 mL).
The two layers were separated. The aqueous layer was acidified to pH 4.0, and extracted with CHCI3 (5 x 100 mL). The organic layers were combined, and dried (Na2SO4), filtered and evaporated under reduced pressure to give the product.
HPLC-MS tR = 1.14. Mass calculated for C$H9NO4S 215.03; observed MH+ (LCMS) 216.1 (m/Z) (UV254nm).
Part B: The substrate from Part A (3.2 g) was suspended in t-BuOH (100 mL), and Et3N (2.27 mL) and DPPA (3.64 mL) was added sequentially at room temperature.
Then the mixture was heated at 85 C overnight. The reaction mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The residue was taken up in ethyl acetate (100 mL) and water (100 mL) was added.
The biphasic mixture was stirred for 15 min. Then two layers were separated, and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with brine (150 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02). HPLC-MS tR = 1.55. Mass calculated for C12H18N204S
286.1;
observed MH+ (LCMS) 287.2 (m/z) (UV254nm).
Part C: The substrate from Part B (191 mg) was dissolved in THF/Et20 (3mU6mL) and cooled to 0 C. Then methylmagnesium bromide (0.83 mL, 2.0 M solution) was added dropwise. The reaction mixture was warmed to room temperature, and stirred for 12 h and quenched by addition of saturated ammonium chloride (10 mL). The two layers were separated and the aqueous layer was extracted with ethyl acetate (10 mL). The combined organic layer was washed with brine (30 mL), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02).
Part D: The substrate from Part C (10 mg) was dissolved in 30% TFA in CH2CI2 (2 mL), and the mixture was stirred for 30 min. Then the solvent was evaporated under reduced pressure and the residue was dried in vacuum. The crude product was used in the next step without further purification.
Part E: The sulfone (574.19 mg) and amine trifluoroacetic acid salt (514 mg) was dissolved in DMF (15 mL) under argon and treated with NaH (432 mg, 60%
dispersion in oil). After LCMS indicated complete conversion of starting material to product, the reaction mixture was quenched with saturated ammonium chloride solution (15 mL).
Then ethyl acetate (25 mL) was added. The two layers were separated, and the aqueous layer was extracted with ethyl acetate (25 mL). The combined organic layer was washed with brine (30 ml), dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was purified by column chromatography (Si02). HPLC-MS tR = 2.31. Mass calculated for C22H28N6O2SSi 468.2; observed MH+
(LCMS) 469.1 (m/z) (UV254nm).
Part F: Ketone (25 mg) was suspended in Ti(O-i-Pr)4 (1 mL) and treated with piperidine (0.2 mL) under argon. The mixture was stirred at room temperature overnight. Then methanol (2 mL) was added followed by NaBH4 (10 mg). The reaction mixture was stirred for additional 30 min. and quenched by addition of 2M
aqueous NaOH (5 mL). It was filtered, and ethyl acetate (5 ml) was added to the filtrate. The two layers were separated, and the aqueous layer was extracted with ethyl acetate (5 ml). The combined organic layer was dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product which was taken to the next step without further purification.
Part G: The substrate was dissolved in 4N HCI in dioxane and stirred for 30 min.
LCMS indicated complete conversion of starting material to the product. Then solvent was evaporated under reduced pressure, and the crude material was purified by reverse phase HPLC. HPLC-MS tR = 1.28. Mass calculated for C21H25N7S 407.2;
observed (M-84)+ (LCMS) 323 (m/z) (UV254nm)=
The compounds in Table 28 were prepared following similar procedure.
LCMS
Example Column 2 MW (M- HPLC
84)+ MS tR
m/z N-NH
N
NY lN
100-1 HN 407.2 323 1.28 ~
N-NH
N
NY N
100-2 H INs 421.2 337.1 1.34 ~
TFAA / Et2O; H
H2N,_,-\OEt K2C03 (36%) F3CyN ~~OEt LAH / EtZO (36%) F3Cv N
Step A O Step B ,,~ OEt Step A: To a solution of 2-ethoxyethylamine (2.0 g, 22.4 mmol) in diethyl ether (40 mL) at 0 C was added trifluoroacetic anhydride (4.7 g, 22.4 mmol) dropwise.
The reaction was stirred at room temperature for 1 hr. Potassium carbonate (10 g) was added to the reaction solution. The reaction was stirred at room temperature for 1 hr.
The mixture was filtered through Celite and the organic filtrate was concentrated to give 1.5 g (36% yield) of the title compound.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (1.5 g, 8.1 mmol) in Et20 (20 mL) was added to a flask charged with lithium aluminum hydride (0.92 g, 24.3 mmol) in Et20 (20 mL). The reaction was stirred at room temperature for 30 min, then at reflux for 12 hr. The reaction was cooled to room temperature and quenched with MeOH until the bubbling ceased. The reaction was diluted with Et20 (30 mL) and filtered through a pad of Celite. The filtrate was concentrated by distillation to give 0.5 g (36% yield) of title compound as a colorless liquid. The amine was used without further purification.
F F F
F
F O F+ F~N~\OEt pYr/CHppy(55%) F~N'-'-\OEt LAH/Et20(83%) _ O 0 StepA O Step B F OEt Step A: To a solution of 2-ethoxyethylamine (1.0 g, 11.2 mmol) in dichloromethane (50 mL) at 0 C was added pyridine (2.2 g, 28.1 mmol). Difluoroacetic anhydride (2.3 g, 13.5 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 2.5 hr. The reaction was diluted with dichloromethane (50 mL) and H20 (20 mL). The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 1.03 g (55%
yield) of the (difluoromethyl)acetamide as a colorless liquid.
Step B: A solution of the (difluoromethyl)acetamide from Step A (1.04 g, 6.20 mmol) in Et20 (21 mL) was added to a flask charged with lithium aluminum hydride (0.47 g, 12.39 mmol) in Et20 (25 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at room temperature for 2 hr. The reaction was quenched by the sequential addition of 0.47 mL of H20; 0.47 mL of 15 % NaOH
(aq) solution; 1.4 mL H20. The reaction was stirred at room temperature for 15 min then filtered through a pad of Celite. The filtrate was concentrated by distillation to give 0.79 g (83% yield) of the title compound as a colorless liquid. The amine was used without further purification.
H2N OH TFAA / pyr / CH2q2 (60%) F3Cy N
H OH LAH / Et20 (65%0) F3 ~N OH
A 0~ Step B 5 Step A: To a solution of 1-amino-l-cyclopentane methanol (1.0 g, 8.68 mmol) in dichloromethane (35 mL) at 0 C was added pyridine (2.4 g, 30.4 mmol).
Trifluoroacetic anhydride (4.6 g, 21.7 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 16 hr. The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 1.07 g (60% yield) of the title compound as a light brown liquid. The title compound was used directly in the next reaction (Step B) without further purification.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (0.64 g, 3.06 mmol) in Et20 (10 mL) was added to a flask charged with lithium aluminum hydride (0.35 g, 9.1 mmol) in Et20 (30 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at 0 C for 30 min, then at room temperature for 19 hr.
The reaction was cooled to room temperature and stirred for 3 days. The reaction was then cooled to 0 C and quenched by the sequential addition of 0.35 mL of H20;
0.35 mL of 15 % NaOH (aq) solution; 1.05 mL H20. The reaction was stirred at room temperature for 20 min then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 0.39 g (65% yield) of the title compound as a white solid. The amine was used without further purification.
~OH TFAA / pyr / CHpCIp (38%) ~ u OH LAH / Et20 (92%) F C^N "OH
H2N Step A F3C H' ~/ Step B 3 H
Step A: To a solution of 2-amino-2-methyl-l-propanol (1.0 g, 11.2 mmol) in dichloromethane (100 mL) at 0 C was added pyridine (3.1 g, 39.6 mmol).
Trifluoroacetic anhydride (5.9 g, 28.1 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 16 hr. The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq); brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 0.79 g (38% yield) of the title compound as a white solid.
Step B: A solution of the (trifluoromethyl)acetamide from Step A (0.79 g, 4.29 mmol) in Et20 (43 mL) was added to a flask charged with lithium aluminum hydride (0.49 g, 12.91 mmol) in Et20 (13 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at 0 C for 30 min, then at reflux for 4 hr. The reaction was cooled to room temperature and stirred for 3 days. The reaction was then cooled to 0 C and quenched by the sequential addition of 0.49 mL of H20; 0.49 mL of 15 %
NaOH (aq) solution; 1.47 mL H20. The reaction was stirred at room temperature for 20 min, then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 0.67 g (92% yield) of the title compound as a white solid. The amine was used without further purification.
O F ~
F~ ~F ~OH pyr/CHZCIp(74%) F` ~O~ LAH/Et20(97%) F~N OH
0 0 +HN Step A 7F H O Step B F H
Step A: To a solution of 2-amino-2-methyl-l-propanol (1.0 g, 11.2 mmol) in dichloromethane (50 mL) at 0 C was added pyridine (2.7 g, 33.7 mmol).
Difluoroacetic anhydride (3.9 g, 22.4 mmol) was then slowly added to the reaction solution. The reaction was further stirred at 0 C for 15 min, then at room temperature for 2 hr. The reaction was diluted with dichloromethane (50 mL) and H20 (20 mL).
The reaction was sequentially washed with 1 N HCI (aq); saturated NaHCO3 (aq);
brine. The organic phase was dried over NaSO4 and concentrated in vacuo to give 2.04 g (74% yield) of the title compound as a colorless liquid.
Step B: A solution of the (difluoromethyl)acetamide from Step A (2.04 g, 8.31 mmol) in Et20 (17 mL) was added to a flask charged with lithium aluminum hydride (0.95 g, 24.92 mmol) in Et20 (50 mL) at 0 C while under a N2 atmosphere. The reaction was stirred under a N2 atmosphere at room temperature for 2 hr. The reaction was quenched by the sequential addition of 0.95 mL of H20; 0.95 mL of 15 % NaOH
(aq) solution; 2.85 mL H20. The reaction was stirred at room temperature for 15 min then filtered through a pad of Celite. The filtercake was washed with Et20 and concentrated in vacuo to give 1.23 g (97% yield) of the title compound as white needles.
The amine was used without further purification.
N SteP A N Step 6 N
N~ N Me3SI / NaH N
~ N Dess-Martin 1 SEMN Oxidation SEMN DMSO / RT SEMN
~ ~-CHO
/
S-N OH S-N S-N
Step C N N
NaOMe / CH3OH N~N 4) MsCI / Et3N (Step D) N - \
N
SEMN, OCH3 5) 4-F-Piperidine (Step E) SEMN OCH3 N
/l \
S-N OH 6) 4N-HCI-Dioxane (Step F) S-N
F
Step A: Dess-Martin periodinane reagent (1.3 g; 3.1 mmol) was added to a solution of the isothiazole-alcohol (450 mg; 1 mmol) in 30 mL of THF containing 0.06 mL of water and the reaction mixture was stirred at room temperature for 45 min. The reaction was diluted with ether and filtered and washed with more ether. The filtrate was washed with saturated NaHCO3 solution, brine and dried. Concentration in vacuo gave the isothiazole aldehyde (418 mg; 93%). 1H-NMR (CDCI3): 10 (s, 1H); 7.68 (s, 1H);
7.65 (s, 1 H); 7.4 (s, 1 H); 7.3 (s, 1 H); 6.65 (s, 2H); 3.7 (t, J = 6 Hz, 2H); 2.6 (s, 3H); 1.95 (m,1 H); 1.1 (q, J = 2, 6 Hz, 2H); 1.0 (t, J = 6 Hz, 2H); 0.8 (q, J = 2, 6 Hz, 2H); -0.05 (s, 9H).
Step B: To a solution of sodium hydride (60% in mineral oil; 169 mg; 4.2 mmol) in a mixture of 3.6 mL of DMSO and 3.6 mL of THF cooled to -10 C, was added a solution of trimethyl sulfonium iodide (863 mg; 4.2 mmol) in 3.6 mL of DMSO drop wise.
This was followed by the addition of a solution of the aldyhyde (363 mg; 0.84 mmol) in 5.6 mL of anhydrous THF, added in one portion. After stirring at room temperature for one hour, the reaction mixture was quenched with ice water. The organic products were extracted with EtOAc. The combined aqueous layers were back extracted with ethyl acetate. All the organic extracts were pooled and washed with water, brine and dried over Na2SO4 and concentrated to obtain the crude product. Elution of the major spot from Flash silica gel using 25% EtOAc in hexanes gave the desired isothiazole epoxide (316 mg; 85%). 1 H-NMR (CDCI3): 7.7 (s, 1 H); 7.35 (s, 1 H); 7.05 (s, 1 H); 6.8 (d,J=4Hz, 1 H); 6.5 (d, J = 4 Hz, 1 H); 4.05 (t, J = 2 Hz, 1 H); 3.7 (t, J = 6 Hz, 2 H); 3.2 (t, J 4 Hz, 1 H); 3.05 (t, J = 2 Hz, 1 H); 2.6 (s, 3H); 1.95 (m,1 H); 1.1 (q, J = 2, 6 Hz, 2H); 0.95 (t, J = 6 Hz, 2H); 0.8 (q, J = 2, 6 Hz, 2H); -0.05 (s, 9H).
Step C: A solution of sodium methoxide in methanol (25% by wt; 4.5 mmol; 1 mL) was added to a solution of the epoxide (201 mg; 0.45 mmol) in a 1:1 mixture of DMF-methanol (4 mL). The resulting solution was heated at 60 C for 3.5 hr, then cooled to room temperature and quenched with water. Extracted the organic product with EtOAc, washed the organic extract with water and brine and dried over Na2SO4.
Concentration gave the crude product. Purification by flash silica gel chromatography using 1:1 mixture of CH2CI2 and EtOAc provided the desired methoxymethyl carbinol (180 mg; 84%) as colorless oil. 'H-NMR (CDCI3): 7.7 (s, 1 H); 7.35 (s, 1 H);
7.2 (s, 1 H);
6.7 (d, J = 4 Hz, 1 H); 6.58 (d, J = 4 Hz, 1 H); 5.0 (d, J = 2 Hz, 1 H); 3.7 (m, 3H); 3.5 (s, 3H); 2.95 (d, J = 14 Hz, 1 H); 2.6 (s, 3H); 1.95 (m,1 H); 1.05 (d, J = 4 Hz, 2H); 0.95 (t, J
= 6 Hz, 2H); 0.8 (d, J = 4 Hz, 2H), -0.05 (s, 9H).
Step D-F: This sequence of steps was carried out as described for Example 76 in 64%
overall yield for the 3 step sequence. HPLC. HPLC-MS tR = 2.85. Mass calculated for C21H27FN60S = 430.2; observed (M-H)+ (LCMS) 431.2 (m/z) (UV25anm)=
ASSAYS:
Aurora Enzyme Assay An in vitro assay was developed that utilizes recombinant Aurora A or Aurora B
as an enzyme source and a peptide based on PKA as the substrate.
Aurora A Assay:
Aurora A kinase assays were performed in low protein binding 384-well plates (Coming Inc). All reagents were thawed on ice. Compounds were diluted in 100%
DMSO to desirable concentrations. Each reaction consisted of 8 nM enzyme (Aurora A, Upstate cat#14-511), 100 nM Tamra-PKAtide (Molecular Devices, 5TAMRA-GRTGRRNSICOOH ), 25 M ATP (Roche), 1 mM DTT (Pierce), and kinase buffer (10 mM Tris, 10 mM MgCI2, 0.01 % Tween 20). For each reaction, 14 l containing TAMRA-PKAtide, ATP, DTT and kinase buffer were combined with 1 pl diluted compound. The kinase reaction was started by the addition of 5 l diluted enzyme.
The reaction was allowed to run for 2 hours at room temperature. The reaction was stopped by adding 60 l IMAP beads (1:400 beads in progressive (94.7% buffer A:
5.3% buffer B) 1X buffer, 24 mM NaCI). After an additional 2 hours, fluorescent polarization was measured using an Analyst AD (Molecular devices).
Aurora B Assay:
Aurora B kinase assays were performed in low protein binding 384-well plates (Corning Inc). All reagents were thawed on ice. Compounds were diluted in 100%
DMSO to desirable concentrations. Each reaction consisted of 26 nM enzyme (Aurora B, Invitrogen cat#pv3970), 100 nM Tamra-PKAtide (Molecular Devices, 5TAMRA-GRTGRRNSICOOH ), 50 M ATP (Roche), 1 mM DTT (Pierce), and kinase buffer (10 mM Tris, 10 mM MgC12, 0.01 % Tween 20). For each reaction, 14 i containing TAMRA-PKAtide, ATP, DTT and kinase buffer were combined with 1 l diluted compound. The kinase reaction was started by the addition of 5 l diluted enzyme. The reaction was allowed to run for 2 hours at room temperature. The reaction was stopped by adding 60 l IMAP beads (1:400 beads in progressive (94.7% buffer A: 5.3% buffer B) 1 X buffer, 24 mM NaCI). After an additional 2 hours, fluorescent polarization was measured using an Analyst AD (Molecular devices).
IC50 Determinations:
Dose-response curves were plotted from inhibition data generated each in duplicate, from 8 point serial dilutions of inhibitory compounds.
Concentration of compound was plotted against kinase activity, calculated by degree of fluorescent polarization. To generate IC50 values, the dose-response curves were then fitted to a standard sigmoidal curve and IC50 values were derived by nonlinear regression analysis.
Compounds of the present invention exhibit Aurora A IC50 values of about 4 nm to about 3000 nM, Aurora B IC50 values of about 13 nM to about 3000 nM, and p-IC50 values of about 1 nM to about 10,000 nM.
While the present invention has been described in conjunction with the specific embodiments set forth above, many altematives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.
Claims (45)
1. A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, -C(O)NR5R6, -N(R5)C(O)R6, heterocyclyl, heteroaryl substituted with (CH2)1-3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6;
R1 is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CH2OR5, -C(O)NR5R6, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5 and -OR5;
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR7R8)n-X, heterocyclenyl-(CR7R8)n-X, heteroaryl-(CR7R8)n-X or aryl-(CR7R8)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONR5R6, -OR5 and alkyl, n is 1-6, X is selected from the group consisting of -NR5R6, -OR5, -SO-R5, -SR5, SO2R5, heteroaryl, heterocyclyl and aryl, wherein said heteroaryl or aryl can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -O-alkyl, alkyl, halo, or NR5R6;
R7 and R8 are each independently hydrogen, alkyl, heterocyclyl, aryl, heteroaryl or cycloalkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl, wherein each of said alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl,can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, amino, aminodialkyl, aminocycloalkyl, halo, trihaloalkyl, dihaloalkyl, and monohaloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -CO2-alkyl, -CO2-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, heterocyclenyl, halo, trihaloalkyl, dihaloalkyl, CN and monohaloalkyl.
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, wherein:
R is H, CN, -NR5R6, cycloalkyl, cycloalkenyl, heterocyclenyl, heteroaryl, -C(O)NR5R6, -N(R5)C(O)R6, heterocyclyl, heteroaryl substituted with (CH2)1-3 NR5R6, unsubstituted alkyl, or alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR5, heterocyclyl, -N(R5)C(O)N(R5R6), -N(R5)-C(O)OR6, -(CH2)1-3-N(R5R6) and -NR5R6;
R1 is H, halo, aryl or heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CH2OR5, -C(O)NR5R6, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5 and -OR5;
R2 is H, halo, aryl, arylalkyl or heteroaryl, wherein each of said aryl, arylalkyl and heteroaryl can be unsubstituted or optionally independently be substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of halo, amide, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -C(O)OH, -C(O)NH2, -NR5R6 (wherein the R5 and R6, together with the N of said -NR5R6, form a heterocyclyl ring), -CN, arylalkyl, -CH2OR5, -S(O)R5, -S(O2)R5, -CN, -CHO, -SR5, -C(O)OR5, -C(O)R5, heteroaryl and heterocyclyl;
R3 is heterocyclyl-(CR7R8)n-X, heterocyclenyl-(CR7R8)n-X, heteroaryl-(CR7R8)n-X or aryl-(CR7R8)n-X wherein each of the heterocyclyl-, heterocyclenyl-, heteroaryl-or aryl- moieties of said R3 can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -CONR5R6, -OR5 and alkyl, n is 1-6, X is selected from the group consisting of -NR5R6, -OR5, -SO-R5, -SR5, SO2R5, heteroaryl, heterocyclyl and aryl, wherein said heteroaryl or aryl can be unsubstituted or substituted with one or more moieties, independently selected from the group consisting of -O-alkyl, alkyl, halo, or NR5R6;
R7 and R8 are each independently hydrogen, alkyl, heterocyclyl, aryl, heteroaryl or cycloalkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl, wherein each of said alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH, hydroxyalkyl, trihaloalkyl, dihaloalkyl, monohaloalkyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, -alkyl-OC(O)alkyl, -alkylOC(O)cycloalkyl, -alkylOC(O)aryl, -alkylOC(O)aralkyl, -alkylOC(O)NR5aryl, -alkylOC(O)NR5alkyl, -alkylOC(O)NR5heterocyclyl, -alkylOC(O)NR5heteroaryl -alkylOC(O)NR5cycloalkyl, -alkylOC(O)heterocyclyl, alkylC(O)OH, alkylC(O)Oalkyl, -alkylC(O)Ocycloalkyl, -alkylC(O)Oaryl, -alkylC(O)Oaralkyl, -alkylC(O)ONR5aryl, -alkylC(O)ONR5alkyl, -alkylC(O)ONR5heterocyclyl, -alkylC(O)ONR5heteroaryl -alkylC(O)ONR5cycloalkyl, -alkylC(O)Oheterocyclyl, alkylC(O)OH, and alkylC(O)Oalkyl,can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, aminoalkyl, amino, aminodialkyl, aminocycloalkyl, halo, trihaloalkyl, dihaloalkyl, and monohaloalkyl;
further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or more moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -CO2-alkyl, -CO2-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, heterocyclenyl, halo, trihaloalkyl, dihaloalkyl, CN and monohaloalkyl.
2. The compound of claim 1, wherein R2 is unsubstituted heteroaryl or heteroaryl substituted with alkyl.
3. The compound of claim 1, wherein R2 is heteroaryl substituted with alkyl.
4. The compound of claim 1, wherein R2 is pyrazolyl.
5. The compound of claim 1, wherein R2 is pyrazolyl substituted with alkyl.
6. The compound of claim 1, wherein R2 is 1-methyl-pyrazol-4-yl.
7. The compound of claim 1, wherein R is H.
8. The compound of claim 1, wherein R is CN.
9. The compound of claim 1, wherein R is -C(O)NR5R6.
10. The compound of claim 1, wherein R is -C(O)NH2.
11. The compound of claim 1, wherein R is heterocyclenyl.
12. The compound of claim 1, wherein R is tetrahydropyridinyl.
13. The compound of claim 1, wherein R is 1,2,3,6-tetrahydropyridinyl.
14. The compound of claim 1, wherein R is alkyl substituted with one or more moieties which can be the same or different each moiety being independently selected from the group consisting of -OR1 and -NR5R6.
15. The compound of claim 1, wherein R is alkyl substituted with one or more -NR5R6.
16. The compound of claim 1, wherein R is alkyl substituted with -NH2.
17. The compound of claim 1, wherein R is alkyl substituted with -NH(methyl).
18. The compound of claim 1, wherein R3 is heteroaryl substituted with heterocyclylmethyl.
19. The compound of claim 1, wherein R3 is heteroaryl-CH2-X, wherein X is -OR5, -SOR5, -NR5R6, or -SR5; R5 is hydrogen, -alkylN(alkyl)2, heterocyclylalkyl or heterocyclenylalkyl; R6 is or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
20. The compound of claim 1, wherein R3 is heteroaryl-CH2-X or heteroaryl-CHMethyl-X, wherein X is -NR5R6, R5 is -alkylN(alkyl)2, alkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, or -alkylSH, wherein each of said arylalkyl, heterocyclenylalkyl, cycloalkyl, cycloalkylalkyl or heteroarylalkyl can be unsubstituted or substituted with hydroxyalkyl, alkoxyalkyl, alkyl, or hydroxyl; R6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or -alkylN(alkyl)2; or R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein said cyclic ring or bridged cyclic ring can be unsubstituted or substituted one or more moities, which can be the same or different, independently selected from the group consisting of hydroxyl, alkyl, alkoxyl, alkoxylalkyl, hydroxyalkyl, arylalkyl, aryl, heterospirocyclyl, heterospirocyclenyl, heterospiroaryl and -CO2alkyl.
21. The compound of claim 1, wherein R3 is heteroaryl-CH2-X , wherein the heteroaryl of said heteroaryl-CH2-X is substituted with alkyl or -CONR5R6, wherein X
is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form a cyclic ring.
is -NR5R6, R5 is alkyl, R6 is alkyl, or R5 and R6 are optionally joined together with the N
of said -NR5R6 to form a cyclic ring.
22. The compound of claim 1, wherein R3 is aryl-CH2-X, wherein the aryl of said aryl-CH2-X can be unsubsituted or substituted with alkyl, wherein X is heterocyclyl.
23. The compound of claim 1, wherein R3 is isothiazole, thiophene or pyrimidine substituted with:
24. The compound of claim 1, wherein R3 is wherein X is selected from the group consisting of, -NR5R6, -OR5 -SO-R5 and -SR5, R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxyalkyl, -alkyl-S-alkyl, aminoalkyl, aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl, heterocyclenyl, alkylN(alkyl)2, alkylNH(alkyl), alkylN(alkenyl)2, -alkylN(alkoxyl)2, -alkyl-SH and hydroxyalkyl, wherein each of said aryl, heteroaryl, heterocyclenyl, heterocycloalkyl, cycloalkyl, cyclenyl, heterocyclylalkoxyl, -S-alkylheterocyclyl, heterocyclyl and heterocyclenyl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of alkyl, alkoxyalkyl, and hydroxyalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl and heterocycloalkylalkyl can be unsubstituted or substituted with one or more alkyl, further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -CO2-alkyl, -CO2-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
R6 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, alkoxyalkyl, -alkyl-S-alkyl, -alkylSH, alkoxyl, -S-alkyl, hydroxyalkyl, and aminoalkyl, wherein each of said aryl, cyclenyl, cycloalkyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroaryl, heterocyclenyl, heterocyclyl, heteroarylalkyl, heterocyclenylalkyl and heterocycloalkylalkyl can be unsubstituted or substituted with one or more alkyl, further wherein in any -NR5R6 in Formula I, said R5 and R6 can optionally be joined together with the N of said -NR5R6 to form a cyclic ring or bridged cyclic ring, wherein each of said cyclic ring or bridged cyclic ring, can be unsubstituted or substituted with one or moieties, which can be the same or different, independently selected from the group consisting of hydroxyl, -SH, alkyl, alkenyl, hydroxyalkyl, -alkyl-SH, alkoxyl, -S-alkyl, -CO2-alkyl, -CO2-alkenyl, arylalkyl, cyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclenylalkyl, heterocycloalkylalkyl, heteroaryl, aryl, cyclenyl, cycloalkyl, spiroheterocyclyl, spiroheterocyclenyl, spiroheteroaryl, spirocyclyl, spirocyclenyl, spiroaryl, alkoxyalkyl, -alkyl-S-alkyl, heterocyclyl, and heterocyclenyl.
25. A compound represented by the formula:
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
26. A compound according to claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, in purified form.
27. A compound according to claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, in isolated form.
28. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, in combination with at least one pharmaceutically acceptable carrier.
29. The pharmaceutical composition according to claim 28, further comprising one or more anti-cancer agents different from the compound of claim 2.
30. The pharmaceutical composition according to claim 29, wherein the one or more anti-cancer agents are selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin (e.g., Caely)®, Myocet®, Doxil®), taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH
66336, R115777®, L778,123®, BMS 214662®, Iressa®, Tarceva®, antibodies to EGFR, antibodies to IGFR (including, for example, those published in US 2005/0136063 published June 23, 2005), KSP inhibitors (such as, for example, those published in WO 2006/098962 and WO 2006/098961; ispinesib, SB-743921 from Cytokinetics), centrosome associated protein E ("CENP-E") inhibitors (e.g., GSK-923295), Gleevec®, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN.TM., Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, bortezomib ("Velcade"), Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225®, satriplatin, mylotarg, Avastin, Rituxan, panitubimab, Sutent, sorafinib, Sprycel (dastinib), nilotinib, Tykerb (lapatinib) and Campath.
66336, R115777®, L778,123®, BMS 214662®, Iressa®, Tarceva®, antibodies to EGFR, antibodies to IGFR (including, for example, those published in US 2005/0136063 published June 23, 2005), KSP inhibitors (such as, for example, those published in WO 2006/098962 and WO 2006/098961; ispinesib, SB-743921 from Cytokinetics), centrosome associated protein E ("CENP-E") inhibitors (e.g., GSK-923295), Gleevec®, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN.TM., Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, bortezomib ("Velcade"), Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225®, satriplatin, mylotarg, Avastin, Rituxan, panitubimab, Sutent, sorafinib, Sprycel (dastinib), nilotinib, Tykerb (lapatinib) and Campath.
31. A method of inhibiting one or more Aurora kinases, comprising administering a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, to a patient.
32. A method of treating one or more diseases by inhibiting an Aurora kinase, comprising administering a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, to a patient.
33. A method of treating one or more diseases by inhibiting an Aurora kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of claim 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of claim 1;
wherein the amounts of the first compound and the second compound result in a therapeutic effect.
and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of claim 1;
wherein the amounts of the first compound and the second compound result in a therapeutic effect.
34. The method according to any of claims 31, 32, or 33, wherein the Aurora kinase is Aurora A.
35. The method according to any of claims 31,32, or 33, wherein the Aurora kinase is Aurora B.
36. The method according to any of claims 32 or 33, wherein the disease is selected from the group consisting of:
tumor of the bladder, breast (including BRCA-mutated breast cancer, colorectal, colon, kidney, liver, lung, small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, bladder, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma and Burkett's lymphoma;
chronic lymphocytic leukemia ("CLL"), acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;
fibrosarcoma, rhabdomyosarcoma;
head and neck, mantle cell lymphoma, myeloma;
astrocytoma, neuroblastoma, glioma, glioblastoma, malignant glial tumors, astrocytoma, hepatocellular carcinoma, gastrointestinal stromal tumors ("GIST") and schwannomas;
melanoma, multiple myeloma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
tumor of the bladder, breast (including BRCA-mutated breast cancer, colorectal, colon, kidney, liver, lung, small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, bladder, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma and Burkett's lymphoma;
chronic lymphocytic leukemia ("CLL"), acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;
fibrosarcoma, rhabdomyosarcoma;
head and neck, mantle cell lymphoma, myeloma;
astrocytoma, neuroblastoma, glioma, glioblastoma, malignant glial tumors, astrocytoma, hepatocellular carcinoma, gastrointestinal stromal tumors ("GIST") and schwannomas;
melanoma, multiple myeloma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
37. The method according to any of claims 31, 32, or 33, further comprising radiation therapy.
38. The method according to claim 33, wherein the anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH
66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN.TM., Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin,.
herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225, Campath, Clofarabine, cladribine, aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.
66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN.TM., Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin,.
herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225, Campath, Clofarabine, cladribine, aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.
39. A method of inhibiting one or more kinases wherein said kinases are selected from the group consisting of cyclin dependent kinases, Checkpoint kinases, tyrosine kinases and Pim-1 kinases, comprising administering a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof to a patient in need of such inhibition.
40. A method of treating one or more diseases by inhibiting one or more kinases, wherein said kinases are selected from the group consisting of cyclin dependent kinases, Checkpoint kinases, tyrosine kinases and Pim-1 kinases, comprising administering a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof to a patient in need of such treatment.
41. The method of claim 39 or claim 40, wherein said cyclin dependent kinases are selected from CDK1 or CDK2, said Checkpoint kinases are selected from CHK-1 or CHK-2, and said tyrosine kinases are selected from the group consisting of VEGF-R2, EGFR, HER2, SRC, JAK and TEK.
42. A method of treating a cancer comprising administering a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof.
43. A method of inhibiting one or more kinases wherein said kinases are selected from the group consisting of cyclin dependent kinases, Checkpoint kinases, tyrosine kinases and Pim-1 kinases, comprising administering a therapeutically effective amount of at least one compound of claim 25 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof to a patient in need of such inhibition.
44. A method of treating one or more diseases by inhibiting an Aurora kinase, comprising administering to a mammal in need of such treatment an amount of a first compound, which is a compound of claim 25, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof;
and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of claim 25;
wherein the amounts of the first compound and the second compound result in a therapeutic effect.
and an amount of at least one second compound, the second compound being an anti-cancer agent different from the compound of claim 25;
wherein the amounts of the first compound and the second compound result in a therapeutic effect.
45. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 25 or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, in combination with at least one pharmaceutically acceptable carrier.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94399907P | 2007-06-14 | 2007-06-14 | |
US60/943,999 | 2007-06-14 | ||
US98793207P | 2007-11-14 | 2007-11-14 | |
US60/987,932 | 2007-11-14 | ||
PCT/US2008/007295 WO2008156614A2 (en) | 2007-06-14 | 2008-06-11 | Imidazopyrazines as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2690557A1 true CA2690557A1 (en) | 2008-12-24 |
Family
ID=40002934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2690557A Abandoned CA2690557A1 (en) | 2007-06-14 | 2008-06-11 | Imidazopyrazines as protein kinase inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2170892A2 (en) |
JP (1) | JP2010529195A (en) |
CN (1) | CN101772500A (en) |
AR (1) | AR066958A1 (en) |
CA (1) | CA2690557A1 (en) |
CL (1) | CL2008001745A1 (en) |
MX (1) | MX2009013729A (en) |
PE (1) | PE20090365A1 (en) |
TW (1) | TW200911811A (en) |
WO (1) | WO2008156614A2 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2756759C (en) | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines for use as kinase inhibitors |
TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
US8993535B2 (en) | 2009-09-04 | 2015-03-31 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (en) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS |
EP2576560B1 (en) * | 2010-06-01 | 2015-09-30 | Bayer Intellectual Property GmbH | Substituted imidazopyrazines |
DK2630259T3 (en) * | 2010-10-20 | 2015-07-06 | Univ Bordeaux | SIGNATURES OF CLINICAL OUTCOME In gastrointestinal stromal tumors AND METHOD FOR THE TREATMENT OF gastrointestinal stromal tumors |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
US20140187548A1 (en) * | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
CN103732589B (en) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor |
MX344600B (en) | 2011-06-27 | 2016-12-20 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES. |
RU2657540C2 (en) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4]triazolo[4,3-a]quinoxaline compounds and pde 10 inhibitors for use in treatment of neurological or metabolic disorders |
RU2667058C2 (en) | 2012-07-09 | 2018-09-14 | Янссен Фармацевтика Нв | Inhibitors of phosphodiesterase 10 enzyme |
CU24389B1 (en) | 2014-01-13 | 2019-04-04 | Aurigene Discovery Tech Ltd | BICYCLIC HETEROCICLYL COMPOUNDS AS IRAK4 INHIBITORS |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
PL3105218T3 (en) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
LT3105226T (en) | 2014-02-13 | 2019-11-11 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
PE20190377A1 (en) | 2016-04-22 | 2019-03-08 | Incyte Corp | FORMULATIONS OF AN LSD INHIBITOR 1 |
EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
KR102633530B1 (en) * | 2017-03-31 | 2024-02-02 | 오리진 온콜로지 리미티드 | Compounds and compositions for treating blood disorders |
CN107954977A (en) * | 2017-12-15 | 2018-04-24 | 上海鼎雅药物化学科技有限公司 | The synthetic method of Raltitrexed intermediate |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
TW202304911A (en) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | Pyridinamide compound |
WO2023169438A1 (en) * | 2022-03-07 | 2023-09-14 | 上海凌达生物医药有限公司 | Nitrogen-containing heterocyclic cell cycle inhibitor compounds as well as preparation method therefor and use thereof |
WO2024088192A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | An aurora a inhibitor for use in treatments of cancers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
WO2004026877A1 (en) * | 2002-09-23 | 2004-04-01 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
KR20070119606A (en) * | 2004-11-10 | 2007-12-20 | 씨지아이 파마슈티칼스, 인크. | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
EP1945644A2 (en) * | 2005-11-10 | 2008-07-23 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
-
2008
- 2008-06-11 EP EP08768351A patent/EP2170892A2/en not_active Withdrawn
- 2008-06-11 CN CN200880101960A patent/CN101772500A/en active Pending
- 2008-06-11 CA CA2690557A patent/CA2690557A1/en not_active Abandoned
- 2008-06-11 JP JP2010512177A patent/JP2010529195A/en not_active Withdrawn
- 2008-06-11 WO PCT/US2008/007295 patent/WO2008156614A2/en active Application Filing
- 2008-06-11 MX MX2009013729A patent/MX2009013729A/en not_active Application Discontinuation
- 2008-06-11 AR ARP080102481A patent/AR066958A1/en not_active Application Discontinuation
- 2008-06-11 PE PE2008001001A patent/PE20090365A1/en not_active Application Discontinuation
- 2008-06-12 TW TW097121942A patent/TW200911811A/en unknown
- 2008-06-12 CL CL2008001745A patent/CL2008001745A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2170892A2 (en) | 2010-04-07 |
AR066958A1 (en) | 2009-09-23 |
WO2008156614A2 (en) | 2008-12-24 |
MX2009013729A (en) | 2010-01-25 |
CN101772500A (en) | 2010-07-07 |
WO2008156614A3 (en) | 2009-02-12 |
JP2010529195A (en) | 2010-08-26 |
PE20090365A1 (en) | 2009-04-04 |
CL2008001745A1 (en) | 2008-12-05 |
TW200911811A (en) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2690557A1 (en) | Imidazopyrazines as protein kinase inhibitors | |
AU2008279776B2 (en) | Heterocyclic amide compounds as protein kinase inhibitors | |
AU2006315718B2 (en) | Imidazopyrazines as protein kinase inhibitors | |
CA2627623C (en) | Methods for inhibiting protein kinases | |
US7511040B2 (en) | Imidazopyrazines as protein kinase inhibitors | |
JP5052518B2 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
US7557104B2 (en) | Imidazopyrazines as protein kinase inhibitors | |
US7642266B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | |
US20090175852A1 (en) | Imidazopyrazines as protein kinase inhibitors | |
WO2009097233A9 (en) | Imidazopyrazines as protein kinase inhibitors | |
CA2628534A1 (en) | Methods for inhibiting protein kinases | |
CA2665127A1 (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
AU2006302435B2 (en) | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases | |
AU2013200310A1 (en) | Pyrazolopyrimidines as Protein Kinase Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |